Datasets:

chuyin0321

/

news-stocks

like 1

Follow

chuyin0321 2

DTF

CHICAGO, May 02, 2023--(BUSINESS WIRE)--DTF Tax-Free Income 2028 Term Fund Inc. (NYSE: DTF) (the "Fund"), a closed-end fund advised by Duff & Phelps Investment Management Co. (the "Investment Adviser"), today announced that Dusty L. Self will become the sole portfolio manager of the Fund when co-portfolio manager Ronald H. Schwartz, CFA, retires effective on June 15, 2023.Ms. Self, co-portfolio manager of the Fund since June 30, 2022, has more than 30 years of experience focused on investment grade municipal strategies, including 12 years as a co-portfolio manager with Mr. Schwartz. She is a "dual hatted" employee of Duff & Phelps Investment Management Co. and Seix Investment Advisors1, each of which is a subsidiary and affiliated manager of Virtus Investment Partners.David D. Grumhaus, Jr., president and chief executive officer of the Fund, said, "Dusty’s extensive track record as a manager of investment grade municipal securities will continue to benefit the Fund’s shareholders. On behalf of management and the Board, I want to thank Ron for his service with the Fund and wish him well in his retirement."About the FundDTF Tax-Free Income 2028 Term Fund Inc. is a diversified closed-end investment management company whose investment objective is current income exempt from regular federal income tax consistent with preservation of capital. The Fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations. For more information, visit www.dpimc.com/dtf or call (800) 338-8214.About the Investment AdviserDuff & Phelps Investment Management Co., an affiliated manager of Virtus Investment Partners, Inc., began in 1932 as a fundamental research firm and has been managing assets since 1979. The firm seeks to provide specialty investment strategies that enhance client outcomes through active portfolio management and customized solutions, utilizing a process with values that include quality, reliability, and specialization. Investment strategies include U.S. and global real estate securities, global listed infrastructure, energy infrastructure, water, and clean energy.Story continuesSource: DTF Tax-Free Income 2028 Term Fund Inc.1 Seix Investment Advisors is a division of Virtus Fixed Income Advisers, LLCView source version on businesswire.com: https://www.businesswire.com/news/home/20230502006094/en/ContactsClayton J. Minor or Timothy P. Riordan, (833) 604-3163

Business Wire

DTF Tax-Free Income 2028 Term Fund Inc. Announces Retirement of Co-Portfolio Manager

https://finance.yahoo.com/news/dtf-tax-free-income-2028-201500625.html

233f9a96-20bc-3184-b041-6cfcbd48471e

DTF

CHICAGO, June 15, 2023--(BUSINESS WIRE)--The Board of Directors of DTF Tax-Free Income 2028 Term Fund Inc. (NYSE: DTF) (the "Fund"), a closed-end fund advised by Duff & Phelps Investment Management Co., today authorized the payment of dividends on the Fund’s common stock as follows:Cents Per ShareEx-Dividend DateRecord DatePayable Date3.25July 14, 2023July 17, 2023July 31, 20233.25August 14, 2023August 15, 2023August 31, 20233.25September 14, 2023September 15, 2023September 29, 2023The Fund estimates that the above dividends are likely to exceed the Fund’s net income and net realized capital gains; therefore, a portion of these dividends is likely to result in a return of capital. A return of capital may occur, for example, when some or all of the money that you invested is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with "yield" or "income." The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of the fiscal year and may be subject to changes based on tax regulations. The Fund or your broker will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.About the FundDTF Tax-Free Income 2028 Term Fund Inc. is a closed-end diversified investment management company whose investment objective is current income exempt from regular federal income tax consistent with preservation of capital. The Fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations. For more information, visit dpimc.com/dtf or call (800) 338-8214.About the Investment AdviserDuff & Phelps Investment Management Co., an affiliated manager of Virtus Investment Partners, Inc., began in 1932 as a fundamental research firm and has been managing assets since 1979. The firm seeks to provide specialty investment strategies that enhance client outcomes through active portfolio management and customized solutions, utilizing a process with values that include quality, reliability, and specialization. Investment strategies include U.S. and global real estate securities, global listed infrastructure, energy infrastructure, water, and clean energy.Story continuesView source version on businesswire.com: https://www.businesswire.com/news/home/20230615563425/en/ContactsClayton J. Minor or Timothy P. Riordan, (833) 604-3163

Business Wire

DTF Tax-Free Income 2028 Term Fund Inc. Announces Dividends

https://finance.yahoo.com/news/dtf-tax-free-income-2028-210200543.html

2e7fe8f3-a2e0-3063-836a-0572dcf054cd

DUK

Duke Energy (DUK) closed at $91.02 in the latest trading session, marking a +1.81% move from the prior day. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow gained 0.22%, while the tech-heavy Nasdaq added 0.09%.Coming into today, shares of the electric utility had lost 3.78% in the past month. In that same time, the Utilities sector lost 2.52%, while the S&P 500 lost 1.27%.Investors will be hoping for strength from Duke Energy as it approaches its next earnings release. The company is expected to report EPS of $2.04, up 14.61% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.2 billion, up 2.97% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.61 per share and revenue of $29.52 billion. These totals would mark changes of +6.45% and +1.33%, respectively, from last year.Investors should also note any recent changes to analyst estimates for Duke Energy. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Duke Energy is currently sporting a Zacks Rank of #3 (Hold).Valuation is also important, so investors should note that Duke Energy has a Forward P/E ratio of 15.94 right now. This represents a premium compared to its industry's average Forward P/E of 15.69.Story continuesInvestors should also note that DUK has a PEG ratio of 2.62 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DUK's industry had an average PEG ratio of 2.72 as of yesterday's close.The Utility - Electric Power industry is part of the Utilities sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDuke Energy Corporation (DUK) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Duke Energy (DUK) Outpaces Stock Market Gains: What You Should Know

https://finance.yahoo.com/news/duke-energy-duk-outpaces-stock-220017155.html

59cfe3b2-7719-3b93-8c17-825aef47783b

DUK

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to examine Duke Energy Corporation (NYSE:DUK), by way of a worked example.Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. View our latest analysis for Duke Energy How Is ROE Calculated?ROE can be calculated by using the formula:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for Duke Energy is:7.4% = US$3.8b ÷ US$51b (Based on the trailing twelve months to June 2023).The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.07.Does Duke Energy Have A Good Return On Equity?Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. You can see in the graphic below that Duke Energy has an ROE that is fairly close to the average for the Electric Utilities industry (8.3%).roeThat isn't amazing, but it is respectable. Even if the ROE is respectable when compared to the industry, its worth checking if the firm's ROE is being aided by high debt levels. If a company takes on too much debt, it is at higher risk of defaulting on interest payments. Our risks dashboardshould have the 2 risks we have identified for Duke Energy.How Does Debt Impact Return On Equity?Most companies need money -- from somewhere -- to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. Thus the use of debt can improve ROE, albeit along with extra risk in the case of stormy weather, metaphorically speaking.Story continuesDuke Energy's Debt And Its 7.4% ROEDuke Energy does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.53. With a fairly low ROE, and significant use of debt, it's hard to get excited about this business at the moment. Investors should think carefully about how a company might perform if it was unable to borrow so easily, because credit markets do change over time.ConclusionReturn on equity is one way we can compare its business quality of different companies. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE.But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So I think it may be worth checking this free report on analyst forecasts for the company.But note: Duke Energy may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Does Duke Energy Corporation (NYSE:DUK) Create Value For Shareholders?

https://finance.yahoo.com/news/does-duke-energy-corporation-nyse-120026465.html

441fb1c9-401d-3e24-b225-ee2c66fc7bf4

DUNE

Dune Acquisition CorporationGlobal Hydrogen is a Pure Play Hydrogen and Carbon Recovery Project Developer and Industrial Gas Supplier WEST PALM BEACH, Fla. & NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- Global Hydrogen Energy LLC (“Global Hydrogen”), which seeks to be a leader in the sustainable energy transition as a next-generation industrial gas supplier, today announced that Carter Glatt, CEO and Director of Dune Acquisition Corporation (Nasdaq: DUNEU, DUNE, DUNEW) (“Dune”), will serve as Chairman Nominee of its post-closing Board. On May 15, 2023, Dune, a special purpose acquisition company, and Global Hydrogen announced that they have entered into a definitive agreement for a business combination, which would result in Global Hydrogen becoming a publicly listed company.  The combined company will be called Global Gas Corporation upon the closing of the business combination and its common stock is expected to be listed on Nasdaq under the new ticker symbol “HGAS”.“We are privileged to have Carter accept our nomination to serve as Chairman of the post-closing company He brings a track record of excellence in executing complex transactions and capital formation in the public markets. Coupled with his background in energy and energy transition, Carter’s history of scaling assets as a public company operating executive will deeply serve us as a resource at Global Hydrogen,” said William B. Nance, Founder and Chief Executive Officer of Global Hydrogen.“Global Hydrogen is at the nexus of the decarbonization movement, with the push towards a zero emission transportation future serving as an impetus to spur a decades long tailwind in the growth of clean hydrogen infrastructure. By continuing to partner with William and his team at the Board level, I look forward to Global Hydrogen establishing itself as a pre-eminent resource for all customers supporting the clean economy,” said Mr. Glatt.Mr. Glatt holds a B.A. with Honors from Dartmouth College and has served as Founder and CEO of Dune Acquisition Corporation since 2020. Prior to that, his other public company executive roles included serving as the Head of Corporate Development and Senior Vice President of GTY Technology Holdings Inc., or GTY (Nasdaq: GTYH), a SaaS company that offers a cloud-based suite of solutions for the public sector which was formerly a SPAC founded by the former chairmen of EMC Corporation, VMware, Inc. and Accenture PLC. In such role, Mr. Glatt oversaw or was directly involved in all M&A, joint venture, capital raising, investor relations and strategic alternatives efforts for GTY.Story continuesAbout Global HydrogenHeadquartered in New York and founded in 2023, Global Hydrogen seeks to be a leader in the sustainable energy transition as a next-generation industrial gas supplier. Global Hydrogen is a 100% minority-owned business that targets both privately and publicly-funded hydrogen development and carbon recovery projects, including projects supported by local, county, state, and national-level governments. Global Hydrogen primarily targets renewable waste as feedstock to generate the industrial gases it sells, and seeks arrangements with owners of wastewater treatment plants, food waste processing facilities, agricultural farms, and landfills as well as producers and distributors of renewable natural gas. For additional information, visit globalhydrogen.co.About Dune Acquisition CorporationDune Acquisition Corporation was founded by its Chief Executive Officer, Carter Glatt, to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.Additional Information and Where to Find It The proposed business combination with Global Energy (the “Business Combination”) will be submitted to Dune’s stockholders for their consideration. Dune intends to file a proxy statement (the “Proxy Statement”) that will be sent to all holders of Dune’s common stock in connection with the Business Combination. This press release does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Dune’s stockholders, Global Hydrogen’s unitholders and other interested persons are advised to read, when available, the preliminary Proxy Statement and the amendments thereto and the definitive Proxy Statement and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Global Hydrogen, Dune and the Business Combination. When available, the definitive Proxy Statement and other relevant materials for the proposed Business Combination will be mailed to stockholders of Dune as of a record date to be established for voting on the proposed Business Combination. Dune stockholders and Global Hydrogen unitholders will also be able to obtain copies of the preliminary Proxy Statement, the definitive Proxy Statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Dune’s secretary at 700 S. Rosemary Avenue, Suite 204, West Palm Beach, FL 33401, (917) 742-1904.Participants in Solicitation Dune and its directors and executive officers may be deemed participants in the solicitation of proxies from Dune’s stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Dune is contained in Dune’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on April 10, 2023 and is available free of charge at the SEC’s website at www.sec.gov. To the extent such holdings of Dune’s securities may have changed since that time, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants will be contained in the Proxy Statement for the proposed Business Combination when available. These documents can be obtained free of charge from the sources indicated above.Global Hydrogen and its managers and executive officers may also be deemed to be participants in the solicitation of proxies from Dune’s stockholders with respect to the proposed Business Combination. A list of the names of such managers and executive officers and information regarding their interests in the proposed Business Combination will be included in the Proxy Statement for the proposed Business Combination when available. Cautionary Note Regarding Forward-Looking Statements This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” “will,” “shall,” “seek,” “result,” “become,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean a statement is not forward looking. Indications of, and guidance or outlook on, future earnings, dividends or financial position or performance are also forward-looking statements. These forward-looking statements include, but are not limited to: (1) references with respect to the anticipated benefits of the proposed Business Combination and anticipated closing timing; (2) the anticipated capitalization and enterprise value of the combined company following the consummation of the proposed Business Combination; (3) current and future potential commercial and customer relationships; and (4) anticipated demand for the combined company’s product and service offerings. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Dune’s and Global Hydrogen’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Most of these factors are outside Dune’s and Global Hydrogen’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (i) the occurrence of any event, change, or other circumstances that could give rise to the termination of the purchase agreement; (ii) the outcome of any legal proceedings that may be instituted against Dune and Global Hydrogen following the announcement of the purchase agreement and the transactions contemplated thereby; (iii) the inability of the parties to timely or successfully complete the proposed Business Combination, including due to failure to obtain approval of the stockholders of Dune, redemptions by Dune’s stockholders, certain regulatory approvals or the satisfaction of other conditions to closing in the purchase agreement; (iv) risks relating to the uncertainty of the projected financial information with respect to Global Hydrogen; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase agreement or could otherwise cause the transaction to fail to close; (vi) the impact of the COVID-19 pandemic on Global Hydrogen’s business and/or the ability of the parties to complete the proposed Business Combination; (vii) the inability to maintain the listing of Dune’s shares on the Nasdaq Stock Market following the proposed Business Combination; (viii) the risk that the proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the proposed Business Combination; (ix) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of Global Hydrogen to grow and manage growth profitably, sell and expand its product and service offerings, implement its growth strategy and retain its key employees; (x) risks relating to Global Hydrogen’s operations and business, including the combined company’s ability to raise financing, hire employees, secure supplier, customer and other commercial contracts, obtain licenses and information technology and protect itself against cybersecurity risks; (xi) intense competition and competitive pressures from other companies worldwide in the industries in which the combined company will operate; (xii) litigation and the ability to adequately protect the combined company’s intellectual property rights; (xiii) costs related to the proposed Business Combination; (xiv) changes in applicable laws or regulations; and (xv) the possibility that Global Hydrogen or Dune may be adversely affected by other economic, business and/or competitive factors. The foregoing list of factors is not exhaustive, and there may be additional risks that neither Dune nor Global Hydrogen presently know or that Dune and Global Hydrogen currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Additional information concerning certain of these and other risk factors is contained in Dune’s most recent filings with the SEC, including Dune’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in those documents that Dune has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained herein. In addition, forward-looking statements reflect Dune’s and Global Hydrogen’s expectations, plans or forecasts of future events and views as of the date of this press release. Dune and Global Hydrogen anticipate that subsequent events and developments will cause Dune’s and Global Hydrogen’s assessments to change. All subsequent written and oral forward-looking statements concerning Dune and Global Hydrogen, the Transactions or other matters attributable to Dune, Global Hydrogen or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. While Dune and Global Hydrogen may elect to update these forward-looking statements at some point in the future, each of Dune or Global Hydrogen expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Dune’s and Global Hydrogen’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.ContactsDune Acquisition [email protected] (917) 742-1904Global Hydrogen Energy [email protected]

GlobeNewswire

Carter Glatt to be Chairman Nominee of Global Hydrogen Energy LLC's Post-Closing Board

https://finance.yahoo.com/news/carter-glatt-chairman-nominee-global-201500802.html

3ddba945-cfc1-3f76-b296-b9cdf89f9726

DUNE

Dune Acquisition CorporationGlobal Hydrogen is a Pure Play Hydrogen and Carbon Recovery Project Developer and Industrial Gas SupplierWEST PALM BEACH, FL & NEW YORK, NY, July 20, 2023 (GLOBE NEWSWIRE) -- The Port of Brownsville, Texas, the largest land-owning public port authority in the United States, last month submitted an application seeking $15 million in funding under the U.S. Department of Transportation’s (“DOT”) Charging and Fueling Infrastructure Discretionary Grant Program (“CFI”).  Global Hydrogen Energy LLC (“Global Hydrogen”) was selected as the Port’s private hydrogen project development partner. Grant award decisions are expected later this summer.If selected by DOT for this competitive grant, the Port and Global Hydrogen will work with a team of experienced local partners to construct hydrogen infrastructure, capable of generating and dispensing tons of hydrogen per day, which will be made available to the Port’s tenants, to commercial businesses and to the public.  The low-carbon hydrogen produced by this project has the potential to reduce net carbon dioxide (CO2) emissions of the Port and end users of the hydrogen by up to several thousand tons per year through its use as an energy carrier for fleets of fuel-cell electric heavy duty vehicles, such as long-haul trucks, transit buses, locomotive rail and refuse collection trucks, which are transitioning to zero emission powertrains.The DOT’s competitive CFI program, created by the Infrastructure Investment and Jobs Act, passed in 2021, provides $2.5 billion over five years to deploy alternative fueling infrastructure, such as hydrogen infrastructure, in publicly accessible locations near population centers.The Port of Brownsville, officially known as the Brownsville Navigation District (the “BND”), holds the distinction of being both the largest land-owning public port authority in the United States and the nation’s only deep-water seaport located on the U.S.-Mexico border.  The BND is also a significant truck and rail destination, as the nation’s 11th and 12th most-trafficked port when measured by truck and commercial rail border crossings, respectively. In 2021, the BND processed approximately 8.9 million short tons of domestic and foreign cargo.Story continues“Global Hydrogen is pleased to have been selected as the Brownsville Navigation District’s private hydrogen development partner and we look forward to continuing to work with the Port’s Commissioners and executive leadership. If the BND is selected for this grant, we believe establishing hydrogen infrastructure in Brownsville will provide significant opportunities for the public and other key constituents as we seek to accelerate towards a zero emission transportation future,” said William B. Nance, Founder and Chief Executive Officer of Global Hydrogen.Global Hydrogen, which seeks to be a leader in the sustainable energy transition as a next-generation industrial gas supplier, previously announced on May 15, 2023 that it had entered into a definitive agreement for a business combination with Dune Acquisition Corporation (Nasdaq: DUNEU, DUNE, DUNEW) (“Dune”), a special purpose acquisition company, which would result in Global Hydrogen becoming a publicly listed company.  The combined company will be called Global Gas Corporation upon the closing of the business combination and its common stock is expected to be listed on The Nasdaq Capital Market under the new ticker symbol “HGAS”.About Global HydrogenHeadquartered in New York and founded in 2023, Global Hydrogen seeks to be a leader in the sustainable energy transition as a next-generation industrial gas supplier. Global Hydrogen is a 100% minority-owned business that targets both privately and publicly-funded hydrogen development and carbon recovery projects, including projects supported by local, county, state, and national-level governments. Global Hydrogen primarily targets renewable waste as feedstock to generate the industrial gases it sells, and seeks arrangements with owners of wastewater treatment plants, food waste processing facilities, agricultural farms, and landfills as well as producers and distributors of renewable natural gas. For additional information, visit globalhydrogen.co.About Dune Acquisition CorporationDune Acquisition Corporation was founded by its Chief Executive Officer, Carter Glatt, to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.Additional Information and Where to Find It The proposed business combination with Global Hydrogen (the “Business Combination”) will be submitted to Dune’s stockholders for their consideration. On July 17, 2023, Dune filed with the Securities and Exchange Commission (the “SEC”) a revised preliminary proxy statement (the “Revised Preliminary Proxy Statement”) in connection with the proposed Business Combination. This document does not contain all the information that should be considered in regard to the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. Dune’s stockholders, Global Hydrogen’s unitholders and other interested persons are advised to read the Revised Preliminary Proxy Statement and any further amendments thereto and the definitive proxy statement and other documents filed in connection with the proposed Business Combination, when available, as these materials contain, and will contain, as applicable, important information about Global Hydrogen, Dune and the proposed Business Combination. When available, the definitive proxy statement and other relevant materials for the proposed Business Combination will be mailed to stockholders of Dune as of a record date to be established for voting on the proposed Business Combination. Dune stockholders and Global Hydrogen unitholders are also able to obtain copies of the Revised Preliminary Proxy Statement, and will be able to obtain copies of the definitive proxy statement and other documents filed with the SEC, when available, without charge, at the SEC’s website at www.sec.gov, or by directing a request to Dune’s secretary at 700 S. Rosemary Avenue, Suite 204, West Palm Beach, FL 33401, (917) 742-1904.Participants in Solicitation Dune and its directors and executive officers may be deemed participants in the solicitation of proxies from Dune’s stockholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in Dune is contained in Dune’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on April 10, 2023, as amended by Amendment No. 1 to Dune’s Annual Report on Form 10-K/A, which was filed with the SEC on July 17, 2023, each of which is available free of charge at the SEC’s website at www.sec.gov. To the extent such holdings of Dune’s securities may have changed since that time, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants is contained in the Revised Preliminary Proxy Statement, and will be contained in any further amendments to the Revised Preliminary Proxy Statement and the definitive proxy statement and other documents filed in connection with the proposed Business Combination, when available. These documents can be obtained free of charge from the sources indicated above.Global Hydrogen and its managers and executive officers may also be deemed to be participants in the solicitation of proxies from Dune’s stockholders with respect to the proposed Business Combination. A list of the names of such managers and executive officers and information regarding their interests in the proposed Business Combination are contained in the Revised Preliminary Proxy Statement, and will be contained in any further amendments to the Revised Preliminary Proxy Statement and the definitive proxy statement and other documents filed in connection with the proposed Business Combination, when available.Cautionary Note Regarding Forward-Looking StatementsThis press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” “will,” “shall,” “seek,” “result,” “become,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean a statement is not forward looking. Indications of, and guidance or outlook on, future earnings, dividends or financial position or performance are also forward-looking statements. These forward-looking statements include, but are not limited to: (1) references with respect to the anticipated benefits of the proposed Business Combination and inferences of closing timing; (2) the anticipated benefits and expected timing of the grant award decisions in connection with the BND’s funding application to DOT; (3) current and future potential commercial and customer relationships; and (4) anticipated demand for the combined company’s product and service offerings. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Dune’s and Global Hydrogen’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Most of these factors are outside Dune’s and Global Hydrogen’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive Unit Purchase Agreement dated May 14, 2023 governing the Business Combination between Dune and Global Hydrogen (the “Purchase Agreement”); (ii) the outcome of any legal proceedings that may be instituted against Dune and Global Hydrogen following the announcement of the Purchase Agreement and the transactions contemplated thereby; (iii) the inability of the parties to timely or successfully complete the proposed Business Combination, including due to failure to obtain approval of the stockholders of Dune, redemptions by Dune’s stockholders, certain regulatory approvals or the satisfaction of other conditions to closing in the Purchase Agreement; (iv) risks relating to the uncertainty of the projected financial information with respect to Global Hydrogen; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Purchase Agreement or could otherwise cause the transaction to fail to close; (vi) the impact of the COVID-19 pandemic on Global Hydrogen’s business and/or the ability of the parties to complete the proposed Business Combination; (vii) the inability to maintain the listing of Dune’s shares on The Nasdaq Capital Market following the proposed Business Combination; (viii) the risk that the proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the proposed Business Combination; (ix) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of Global Hydrogen to grow and manage growth profitably, sell and expand its product and service offerings, implement its growth strategy and retain its key employees; (x) risks relating to Global Hydrogen’s operations and business, including the combined company’s ability to raise financing, hire employees, secure supplier, customer and other commercial contracts, obtain licenses and information technology and protect itself against cybersecurity risks; (xi) intense competition and competitive pressures from other companies worldwide in the industries in which the combined company will operate; (xii) litigation and the ability to adequately protect the combined company’s intellectual property rights; (xiii) costs related to the proposed Business Combination; (xiv) changes in applicable laws or regulations; and (xv) the possibility that Global Hydrogen or Dune may be adversely affected by other economic, business and/or competitive factors. The foregoing list of factors is not exhaustive, and there may be additional risks that neither Dune nor Global Hydrogen presently know or that Dune and Global Hydrogen currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Additional information concerning certain of these and other risk factors is contained in Dune’s most recent filings with the SEC, including Dune’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on April 10, 2023, as amended by Amendment No. 1 to Dune’s Annual Report on Form 10-K/A, which was filed with the SEC on July 17, 2023, and in those documents that Dune has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained herein. In addition, forward-looking statements reflect Dune’s and Global Hydrogen’s expectations, plans or forecasts of future events and views as of the date of this press release. Dune and Global Hydrogen anticipate that subsequent events and developments will cause Dune’s and Global Hydrogen’s assessments to change. All subsequent written and oral forward-looking statements concerning Dune and Global Hydrogen, the transactions related to the proposed Business Combination or other matters attributable to Dune, Global Hydrogen or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. While Dune and Global Hydrogen may elect to update these forward-looking statements at some point in the future, each of Dune and Global Hydrogen expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Dune’s and Global Hydrogen’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.ContactsDune Acquisition [email protected](917) 742-1904William B. NanceGlobal Hydrogen Energy [email protected]

GlobeNewswire

Global Hydrogen Energy Selected by Port of Brownsville as Private Development Partner in $15 Million Federal Funding Application

https://finance.yahoo.com/news/global-hydrogen-energy-selected-port-201700677.html

bed04176-317b-3b73-9cc3-69f9404a6a0a

DUOL

In this article, we will be looking at a brief overview of the American education system, the basis of US illiteracy as well as the 25 most illiterate states in America. If you wish to skip our detailed analysis, you can go directly to the 5 Most Illiterate States in America.A National Literacy CrisisThe United States is in a state of a literary crisis as it labels many adults in the country as being ‘functionally illiterate’. This term refers to a literacy level where an individual understands basic vocabulary but is not able to comprehend anything beyond simple words. This equates to a below-average literacy level.State-Level Literacy DynamicsThe Gallop analysis of data acquired from the United States Department of Education reports that almost 130 million adults in the US have low literacy. This implies that the country has a significant adult population whose reading skills are equivalent to those of a sixth grader.The national literacy situation narrows down to the states. The United States comprises 50 states. The literacy statistics tend to vary among the states. On one extreme of the country are states like Massachusetts and New Hampshire which have high literacy rates. Children and adult education are promoted here and the government also significantly funds public schools. On the other extreme, there are states like New Mexico and Texas. These states have been struggling with their low literacy numbers. Some other factors also play a role here since these two cities are home to most immigrants whose first language is not English and hence, the literacy rates are low. Poverty worsens the scenario as New Mexico being highly poverty-ridden, is also the most illiterate state in the US. Hence, we notice the disparity in literacy among states.Companies that are Changing the Literacy ScenarioTechnology is the force that has transformed many conventional sectors of life, especially education. The technology adoption rates have been high since the pandemic hit the world. This is evident from the popularity of edtech firms. In the case of the United States, there are several edtech firms that enhance the accessibility and quality of education in the country. Some of these edtech giants include Chegg, Inc. (NYSE:CHGG), Coursera, Inc. (NYSE:COUR) and Duolingo, Inc. (NASDAQ:DUOL).Story continuesChegg, Inc. (NYSE:CHGG) is one of the notable names among American students. It provides help with homework, textbook rentals, and an opportunity to learn online. One of its major developments this year was CheggMate, an AI-powered chatbot for answering student queries.On August 7, Chegg, Inc. (NYSE:CHGG) reported earnings for the fiscal second quarter of 2023. The company reported an EPS of $0.28 and generated a revenue of $182.85 million, outperforming market consensus by $6.34 million. Shortly after its earnings release, Piper Sandler analyst Arvind Ramnani raised his price target on Chegg, Inc. (NYSE:CHGG) to $13 from $11 and maintained a Neutral rating on the shares, citing improved retention rate and subscriber growth.Another edtech company which contributes to education in the US is Coursera, Inc. (NYSE:COUR). It is an online course provider. Other than courses, it also offers professional certificates and master's degrees in subjects related to data science and entrepreneurship. Since the demand for learning skills related to AI has been on the rise, the company recently took a relevant initiative. On July 18, the company reported that they have launched their plugin on ChatGPT Pro where users can find content related to what they've searched for on the AI platform as the plugin displays a list of Coursera, Inc. (NYSE:COUR) courses, their links and descriptions.Duolingo, Inc. (NASDAQ:DUOL) is known for its language certifications. It also offers a standardized English test known as Duolingo English Test, similar to IELTS. On March 14, the company reported the launch of its new product 'Duolingo Max'. This product has been powered by Open AI and it provides exceptional features for language learners. These new features include practicing language with Duolingo, Inc. (NASDAQ:DUOL) characters or simply asking AI to know about the mistakes users have made while learning languages.On August 8, Duolingo, Inc. (NASDAQ:DUOL) reported strong earnings for the fiscal second quarter of 2023. The company reported earnings per share of $0.08 and outperformed EPS estimates by $0.28. The company's revenue for the quarter amounted to $126.84 million, up 43.51% year over year and ahead of revenue consensus by $3.14 million.Socioeconomic Factors Contributing to IlliteracySocioeconomic factors do not explicitly mean income since they cover other aspects such as social status, living conditions, and exposure to opportunities. All of these factors play a role in literacy. The American Psychological Association reported that children from a low socioeconomic background have less cognitive abilities which restricts their learning process. Most of these students join school with a 5-year gap as compared to those from middle-income households. Thus, children living a less privileged life tend to develop fewer aspirations related to their careers and hence drop out of college at a higher rate, contributing to illiteracy in the country. Despite the prevailing situation, Chegg, Inc. (NYSE:CHGG), Coursera, Inc. (NYSE:COUR), and Duolingo, Inc. (NASDAQ:DUOL) continue to transform the educational landscape across the country.Now that we have reviewed illiteracy and its disparate outcomes in the United States, we can analyze the 25 most illiterate states in America.25 Most Illiterate States in AmericaMonkey Business Images/Shutterstock.comMethodologyIn order to create a list of the 25 most illiterate states in America, we utilized data from the US Census Bureau. This data was taken from the Education Attainment database. The data has been taken for a uniform age group between 18 to 24 years. We used three metrics as a measure of literacy. The metrics chosen include the number of high school graduates, college degree holders, and bachelor’s or higher degree holders. Further, we considered that the high school graduate number should be our first priority while college degree holders and bachelor’s degree holders will follow. Please note that a college degree refers to an associate degree or a certification and hence is different from a bachelor's degree.We calculated weighted scores on a priority basis for the metrics. Please note that the weighted score is a measure of literacy and hence, the states with higher weighted scores are less illiterate and ranked lower in the list. For every state, we assigned a weight of 3 to the high school graduates, 2 to the college degree holders, and 1 to the bachelor’s or higher degree holders to calculate the overall weighted score which reflects the priority of the metrics we assumed for the purpose of this research. Finally, we ranked the states in descending order of their weighted scores as follows:25. KentuckyHigh School Graduates: 161,223      College Degree Holders: 164,290Bachelor’s Or Higher Degree Holders: 47,557Weighted Score: 34.42Kentucky state is located in the Southeastern part of the United States. It is one of the most illiterate states in the country as illiteracy among adults is common with many of them not being able to read anything above basic reading material.24. TennesseeHigh School Graduates: 239,537      College Degree Holders: 241,908     Bachelor’s Or Higher Degree Holders: 74,275Weighted Score: 34.12The US state of Tennessee also struggles with its illiteracy issue. Since the numbers are low for those who attend high school, college, and university, the state becomes one of the most illiterate American states.23. VirginiaHigh School Graduates: 97,952        College Degree Holders: 149,572Bachelor’s Or Higher Degree Holders: 36,675Weighted Score: 34.03The US state of Virginia also makes it to the top US illiterate states. The Virginia Literacy Foundation works to reduce adult literacy however there are many adults who have never even completed high school.22. CaliforniaHigh School Graduates: 1,215,035   College Degree Holders: 1,568,917Bachelor’s Or Higher Degree Holders: 434,774Weighted Score: 33.78Reading proficiency is significantly low in California. This puts the state behind other progressive states in the US. The school dropout rates are high, ranking the state as one of the least literate US states.Chegg, Inc. (NYSE:CHGG), Coursera, Inc. (NYSE:COUR) and Duolingo Inc (NASDAQ:DUOL) are among the most notable companies making strides to promote the growth of literacy rates in America.21. OklahomaHigh School Graduates: 156,286College Degree Holders: 143,648Bachelor’s Or Higher Degree Holders: 30,687Weighted Score: 33.72Oklahoma is one of the 25 most illiterate states in the United States. Some portion of the state population hasn’t even passed high school while many adults have below-average or average literacy.20. DelawareHigh School Graduates: 30,317        College Degree Holders: 35,184Bachelor’s Or Higher Degree Holders: 7,890Weighted Score: 33.67Illiteracy is a concern for the US state of Delaware where many adults are functionally illiterate, Children in the state also struggle with reading, making it one of the most illiterate American states.19. OhioHigh School Graduates: 396,138      College Degree Holders: 407,343Bachelor’s Or Higher Degree Holders: 131,320Weighted Score: 33.60Another least educated state in the US is Ohio. Functional level of illiteracy is very common in the state and needs to be addressed.18. LouisianaHigh School Graduates: 163,451      College Degree Holders: 161,712Bachelor’s Or Higher Degree Holders: 36,431Weighted Score: 33.38The literacy figures are not adequate for the US state of Louisiana either. Less than half of the students in the public schools of the state read at their grade level. Hence, Louisiana is one of the most less educated states in the country.17. North CarolinaHigh School Graduates: 344,120      College Degree Holders: 428,964Bachelor’s Or Higher Degree Holders: 125,122Weighted Score: 33.37The issue of illiteracy is also common in the US state of North Carolina. Those who drop out of school are not even proficient at the grade level they were studying at. The adverse literary situation makes the state a highly illiterate state in the country.16. PennsylvaniaHigh School Graduates: 414,582      College Degree Holders: 426,998Bachelor’s Or Higher Degree Holders: 155,459Weighted Score: 33.33The literacy situation in Pennsylvania is concerning. The lack of basic literary skills among adults is evident from the fact that some of them cannot even read newspapers or brochures. Thus, Pennsylvania is one of the most illiterate states in the country.15. MichiganHigh School Graduates: 318,898      College Degree Holders: 386,921Bachelor’s Or Higher Degree Holders: 112,790Weighted Score: 33.13The city of Detroit in the US state of Michigan is subject to high illiteracy as many adults are functionally illiterate. Children are underperforming in their grades making the state one of the 25 most illiterate American states.14. MississippiHigh School Graduates: 99,518        College Degree Holders: 125,586Bachelor’s Or Higher Degree Holders: 24,818Weighted Score: 33.02Mississippi has a significant number of adults who have just passed nine years of school. The high school graduation rate is also low. All of this makes Mississippi one of the most illiterate cities in America.Investors who wish to increase their exposure to the edtech industry can look up Chegg, Inc.(NYSE:CHGG), Coursera, Inc.(NYSE:COUR), and Duolingo Inc (NASDAQ:DUOL).13. IndianaHigh School Graduates: 241,977      College Degree Holders: 252,407Bachelor’s Or Higher Degree Holders: 77,970Weighted Score: 33.00With a comparatively lower number of people who tend to be a part of a school, college, or university, Indiana has low literacy. Adults in the state struggle with reading and comprehending complex things, making it one of the most illiterate states in America.12. GeorgiaHigh School Graduates: 389,938College Degree Holders: 389,304Bachelor’s Or Higher Degree Holders: 115,177Weighted Score: 32.97Georgia is ranked as one of the US states where people tend to be illiterate. Many of these people lack basic literacy skills and hence experience unemployment and low wages.11. TexasHigh School Graduates: 1,040,301College Degree Holders: 1,097,853Bachelor’s Or Higher Degree Holders: 311,171Weighted Score: 32.93Texas is one of the 25 most illiterate states in America. Adult literacy is low and a problem for the state. Furthermore, there are many students who fail to perform at their grade levels.10. South CarolinaHigh School Graduates: 166,475      College Degree Holders: 192,507Bachelor’s Or Higher Degree Holders: 54,260Weighted Score: 32.87South Carolina is another American state which fails to have adequate literacy. The literacy rate is lower than the national average literacy. Children fail to read at their grade level, adding to the literacy crisis in the state.9. MissouriHigh School Graduates: 187,113                  College Degree Holders: 233,565Bachelor’s Or Higher Degree Holders: 71,365Weighted Score: 32.85Thus, Missouri ranks as one of the 25 most illiterate states in the United States. With average or below-average reading skills, many adults in the state are unable to advance in life.8. ArizonaHigh School Graduates: 244,573      College Degree Holders: 265,391Bachelor’s Or Higher Degree Holders: 71,571Weighted Score: 32.67Arizona is one of the 25 most illiterate states in America. Children in the state become a victim of a literacy crisis at an early age. Hence these students continue to struggle with reading.7. FloridaHigh School Graduates: 586,777College Degree Holders: 715,710     Bachelor’s Or Higher Degree Holders: 199,597Weighted Score: 32.63Florida is one of the most illiterate American states. Many children fail their reading tests while some adults can’t read things as basic as food labels. Thus, the literacy rate is low.6. IllinoisHigh School Graduates: 370,612College Degree Holders: 463,253Bachelor’s Or Higher Degree Holders: 185,926Weighted Score: 32.50Another state that makes it to the list of the most illiterate states in America is Illinois. Basic reading, writing, math, and language skills are common among only a few adults. Hence, the literacy rate of the city keeps on declining.Click to continue reading and see 5 Most Illiterate States in America.Suggested articles:10 Stocks Receiving a Massive Vote of Approval from Wall Street Analysts15 Highest Paying Countries for Economists17 Highest Paying Countries for PilotsDisclosure: None. 25 Most Illiterate States in America is published on Insider Monkey.

Insider Monkey

25 Most Illiterate States in America

https://finance.yahoo.com/news/25-most-illiterate-states-america-131357884.html

bd0539e5-41e7-3250-b0c5-7a95d78bc93f

DUOL

This year's rally in technology stocks might still have legs, and Duolingo and Splunk could be among the stocks that keep running upward.Continue reading

Motley Fool

History Suggests the Nasdaq-100 Will Soar for the Rest of 2023 -- 2 Super Stocks to Buy Right Now

https://finance.yahoo.com/m/357242db-8e3f-3483-b996-7c31b1ce78c8/history-suggests-the.html

357242db-8e3f-3483-b996-7c31b1ce78c8

DVA

Align Technology, Inc. ALGN recently introduced a new SmartForce feature, attachment-free aligner activation. The new SmartForce attachment-free aligner activation feature, which builds on Align Technology’s foundational biomechanics for clear aligners and its database of Invisalign patients, is expected to aid in minimizing the number of attachments while maintaining predictable treatment outcomes.The new SmartForce attachment-free aligner activation feature is the latest of Align Technology’s many biomechanical innovations that enhance experiences for patients in Invisalign treatment.The attachment-free aligner activation feature is built into the Align Digital Platform and is the newest innovation as part of the Align digital workflow. A related update to ClinCheck treatment planning will include Live Update for 3D Controls that includes an attachment-free aligner activation selection.The introduction of the latest feature is expected to significantly boost Align Technology’s Invisalign sales across the globe.Significance of the FeatureThe SmartForce features, which include optimized attachments that are small tooth-colored shapes attached to teeth, are designed to deliver precise forces when and where needed to achieve more predictable tooth movements. Double attachments are often needed on upper central (front) teeth to achieve desired mesiodistal root movements.Although optimized attachments are critical for successful Invisalign treatment, with this new release, certain movements are now likely to be achieved using a similar force system via aligner activation. This is expected to reduce the need for double attachments on the centrals. If an attachment is still needed for certain scenarios, aligner activation will be present with a single optimized root control attachment as with other teeth, such as canines and premolars.Per management, via the innovation, Align Technology is expected to address the needs of doctors and their patients without compromising Invisalign treatment outcomes. Management also added that in cases where attachments are still necessary to ensure the optimal force systems, a single optimized root control attachment with SmartForce aligner activation has been designed to achieve the same movement instead of the more visible double attachment.Story continuesIndustry ProspectsPer a report by Allied Market Research, the global clear aligners market was valued at $3.8 billion in 2021 and is anticipated to reach $32.4 billion by 2031 at a CAGR of 24%. Factors like the increase in the trend of cosmetic dentistry, the rising number of people going for dental aesthetics and the prevalence of malocclusion are expected to drive the market.Given the market potential, the introduction of the latest feature is likely to significantly solidify Align Technology’s foothold in the niche space.Recent DevelopmentsThis month, Align Technology introduced the Invisalign Palatal Expander System, a modern and innovative direct 3D printed device based on a proprietary and patented technology.The same month, Align Technology introduced Plan Editor in ClinCheck treatment planning software, a new tool in the Align digital workflow built into the Align Digital Platform.Also, in September, Align Technology entered into a definitive agreement to acquire privately-held Cubicure GmbH. Per management, the acquisition of Cubicure will strengthen Align Technology’s existing intellectual property portfolio and know-how in direct 3D printing of appliances. Integration with Cubicure will also extend and scale Align Technology’s printing, materials and manufacturing capabilities for its 3D-printed product portfolio.Price PerformanceShares of Align Technology have gained 43.7% in the past year compared with the industry’s 7.8% rise and the S&P 500’s 11.6% growth.Zacks Investment ResearchImage Source: Zacks Investment ResearchZacks Rank & Other Key PicksCurrently, Align Technology carries a Zacks Rank #2 (Buy).A few other top-ranked stocks in the broader medical space are DaVita Inc. DVA, HealthEquity, Inc. HQY and Integer Holdings Corporation ITGR.DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.DaVita has gained 8.7% against the industry’s 9.1% decline over the past year.HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 9.1%.HealthEquity has gained 6.5% against the industry’s 7.4% decline over the past year.Integer Holdings, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.Integer Holdings has gained 29.2% compared with the industry’s 4.8% rise over the past year.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDaVita Inc. (DVA) : Free Stock Analysis ReportAlign Technology, Inc. (ALGN) : Free Stock Analysis ReportHealthEquity, Inc. (HQY) : Free Stock Analysis ReportInteger Holdings Corporation (ITGR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Align Technology's (ALGN) New Feature to Boost Patient Experience

https://finance.yahoo.com/news/align-technologys-algn-feature-boost-152900544.html

e1723022-a57f-301f-84b7-78a20bca8ea8

DVA

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a strategic collaboration with Navigate BioPharma Services, Inc. The tie-up is aimed at exploring opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.Navigate BioPharma Services, Inc., a provider of innovative biomarker and specialty bioanalytic solutions for clinical development and companion diagnostic applications, is an independently operating subsidiary within the Novartis group of companies.The latest partnership is expected to significantly strengthen BD’s foothold in the global Biosciences (BDB) business, which is part of its broader Life Sciences arm.Rationale Behind the CollaborationThe collaboration is expected to leverage the expertise and capabilities of both companies to provide end-to-end solutions for pharmaceutical and biotechnology companies. These companies are developing novel therapies that require companion diagnostics, tests intended to match patients with advanced treatments and critical clinical trial applications that use flow cytometry. The partnership also aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.Per BD’s management, the partnership will likely combine Navigate BioPharma's experience in designing and validating biomarker assays for clinical trials and regulatory submissions with the broad BD portfolio of flow cytometry instruments, reagents, software and in vitro diagnostics (IVD) development services. This, in turn, is expected to potentially accelerate the delivery of innovative personalized therapies to patients who need them.Navigate BioPharma's management believes that flow cytometry-based companion diagnostics can aid in identifying patients who are most likely to benefit from a specific therapy, monitor their response to treatment and optimize dosing and safety from a patient sample. Hence, advances in flow cytometry technology made by BD will likely enable IVD testing to be executed with accuracy, automation and standardization across all elements of the workflow.Story continuesIndustry ProspectsPer a report by BCC Research, the global market for flow cytometry was valued at $5.2 billion in 2022 and is expected to reach $7.6 billion in 2027 at a CAGR of 8%. Factors like technological advancements, the increasing trend toward single-cell analysis and the growing adoption of flow cytometry in clinical applications are likely to drive the market.Given the market potential, the latest association is expected to significantly strengthen BD’s business worldwide.Notable Developments in Life Sciences ArmLast month, BD reported its third-quarter fiscal 2023 results, wherein it registered a solid uptick in its top-line and bottom-line results, along with improvements in the overall base revenues. Robust performances by its BDB business unit reflected double-digit growth in Cancer reagents leveraging BD’s growing installed base of FACSLyric analyzers, adoption of FACSDuet sample preparation automation and continued strong growth in research reagents enabled by its BD Horizon dyes.The same month, BD received the FDA’s 510(k) clearance for the BD Respiratory Viral Panel for the BD MAX System.In June, BD announced the worldwide commercial launch of a new automated instrument, BD FACSDuet Premium Sample Preparation System.Price PerformanceShares of BD have gained 2.5% in the past year compared with the industry’s 7.4% rise and the S&P 500's 11.3% growth.Zacks Investment ResearchImage Source: Zacks Investment ResearchZacks Rank & Key PicksCurrently, BD carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, HealthEquity, Inc. HQY and Integer Holdings Corporation ITGR.DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.DaVita has gained 4.5% against the industry’s 9.9% decline over the past year.HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.2%. HQY’s earnings surpassed estimates in all the trailing four quarters, with an average of 13%.HealthEquity has gained 8.2% against the industry’s 7.2% decline over the past year.Integer Holdings, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.Integer Holdings has gained 26.8% compared with the industry’s 3.4% rise over the past year.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBecton, Dickinson and Company (BDX) : Free Stock Analysis ReportDaVita Inc. (DVA) : Free Stock Analysis ReportHealthEquity, Inc. (HQY) : Free Stock Analysis ReportInteger Holdings Corporation (ITGR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

https://finance.yahoo.com/news/bds-bdx-tie-explore-flow-171900910.html

e8658099-a5e0-38a1-87df-ba6f10027fc5

DVN

It looks like Devon Energy Corporation (NYSE:DVN) is about to go ex-dividend in the next four days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. Therefore, if you purchase Devon Energy's shares on or after the 14th of September, you won't be eligible to receive the dividend, when it is paid on the 29th of September.The company's upcoming dividend is US$0.49 a share, following on from the last 12 months, when the company distributed a total of US$3.47 per share to shareholders. Based on the last year's worth of payments, Devon Energy has a trailing yield of 6.6% on the current stock price of $52.66. If you buy this business for its dividend, you should have an idea of whether Devon Energy's dividend is reliable and sustainable. So we need to investigate whether Devon Energy can afford its dividend, and if the dividend could grow. Check out our latest analysis for Devon Energy Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Devon Energy paid out 61% of its earnings to investors last year, a normal payout level for most businesses. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. It distributed 47% of its free cash flow as dividends, a comfortable payout level for most companies.It's positive to see that Devon Energy's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.Story continuesClick here to see the company's payout ratio, plus analyst estimates of its future dividends.historic-dividendHave Earnings And Dividends Been Growing?Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. That's why it's comforting to see Devon Energy's earnings have been skyrocketing, up 49% per annum for the past five years. The current payout ratio suggests a good balance between rewarding shareholders with dividends, and reinvesting in growth. With a reasonable payout ratio, profits being reinvested, and some earnings growth, Devon Energy could have strong prospects for future increases to the dividend.The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Devon Energy has delivered an average of 16% per year annual increase in its dividend, based on the past 10 years of dividend payments. Both per-share earnings and dividends have both been growing rapidly in recent times, which is great to see.The Bottom LineHas Devon Energy got what it takes to maintain its dividend payments? We like Devon Energy's growing earnings per share and the fact that - while its payout ratio is around average - it paid out a lower percentage of its cash flow. Overall we think this is an attractive combination and worthy of further research.So while Devon Energy looks good from a dividend perspective, it's always worthwhile being up to date with the risks involved in this stock. Our analysis shows 4 warning signs for Devon Energy that we strongly recommend you have a look at before investing in the company.A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Devon Energy (NYSE:DVN) Could Be A Buy For Its Upcoming Dividend

https://finance.yahoo.com/news/devon-energy-nyse-dvn-could-121600975.html

256a3c11-f82a-34ce-bdd9-09a4739f967c

DVN

Oil prices had been stuck in a rut over the past year, bouncing between $65 and $80 a barrel. Higher oil prices would be a boon for all oil stocks. Pioneer Natural Resources (NYSE: PXD), ConocoPhillips (NYSE: COP), and Devon Energy (NYSE: DVN) stand out to a few Fool.com contributors for their oil-fueled dividends.Continue reading

Motley Fool

Oil Prices Are on the Rise: 3 Dividend Stocks to Play the Energy Rally

https://finance.yahoo.com/m/b5cf922a-a0cb-3b93-a44f-996320f10433/oil-prices-are-on-the-rise-3.html

b5cf922a-a0cb-3b93-a44f-996320f10433

DWAC

Donald Trump is one of the world's most famous businessmen. Now investors can throw in their lot with the former President with DWAC stock.Continue reading

Investor's Business Daily

This Is The Ultimate Donald Trump Stock: Is DWAC A Buy Amid Legal Woes, SEC Settlement?

https://finance.yahoo.com/m/4f0fc7b0-09f7-3f0a-9ef6-fca209ceac29/this-is-the-ultimate-donald.html

4f0fc7b0-09f7-3f0a-9ef6-fca209ceac29

DWAC

Trump’s return to mainstream social-media platforms Facebook and X has erased a key strength of the smaller platform popular with conservatives.Continue reading

The Wall Street Journal

Trump’s Truth Social Challenge Now Is to Get a Deal Done

https://finance.yahoo.com/m/bda67adc-354c-37ab-acdf-6dedd19f12bb/trump%E2%80%99s-truth-social.html

bda67adc-354c-37ab-acdf-6dedd19f12bb

DX

In this article, we discuss 15 highest yielding dividend stocks you can buy today. You can skip our detailed analysis of dividend stocks and high yields, and go directly to read 5 Highest Yielding Dividend Stocks You Can Buy Today. The performance of high-yielding stocks can vary significantly over time and is influenced by various economic, market, and company-specific factors. In one of our articles, we referred to research by Columbia Business School to analyze the performance of high-yielding dividend stocks. According to the report, between January 2000 and May 2010, the High Dividend Index showed an average yearly gain of 6.16%. In contrast, the S&P 500 had a decline of 4.75% during that time. In addition to this, Morgan Stanley conducted a study that looked at how high-dividend stocks performed during inflationary periods. The report mentioned these stocks typically do well when inflation is higher than usual but on a downward trend. The report also mentioned that their stability and dependable income make high-yielding stocks a relatively secure choice, especially appealing when economic conditions are uncertain.That said, not all dividends are the same. Going for the stock with the highest yield can be riskier. Analysts advise that investors should look for companies that are reliable and have a history of increasing their dividends each year. However, companies must use their funds wisely to sustain returns for their shareholders. Max Wasserman, founder and senior portfolio manager at Miramar Capital, spoke with the Wall Street Journal about the payout ratios in his interview earlier this year. He said that a lot of the recent halts and reductions in dividend payments happened because companies made bad decisions about how they use their money. Here are some comments from the analyst:“Some companies have been stretching their balance sheets to remain dividend ‘aristocrats’ or to stay on the radar of mutual funds and dividend investors, and it’s hit their cash flows. With higher debt costs, inflation and uncertainty, they’ve made the decision to cut the dividend in response.”Story continuesThe Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL), and PepsiCo, Inc. (NASDAQ:PEP) have raised their dividends consecutively for decades which shows that these companies have solid balance sheets with strong cash flows. In this article, we will explore dividend stocks with the highest yields.15 Highest Yielding Dividend Stocks You Can Buy TodayOur Methodology:For this list, we selected dividend stocks with yields ranging from 10% to 19%, as of September 7. The majority of these stocks belong to the REIT sector, as these companies are required to pay approximately 90% of their income to shareholders as a distribution. As these stocks have exceptionally high yields, a lot of the companies on the list don't have a consistent record of paying dividends. They've either stopped or reduced their dividend payments in 2020 due to the pandemic or because they were facing financial difficulties.15. Cal-Maine Foods, Inc. (NASDAQ:CALM)Dividend Yield as of September 7: 10.84%Cal-Maine Foods, Inc. (NASDAQ:CALM) is an American company that specializes in the production and marketing of shell eggs. The company operates multiple farms and facilities where they raise laying hens to produce eggs. On August 3, the company declared a quarterly dividend of $0.76 per share, which was in line with its previous dividend. Its dividend growth history remained somewhat unstable after the pandemic but the company paid regular dividends to shareholders. As of September 7, the stock has a dividend yield of 10.84%.The Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL), and PepsiCo, Inc. (NASDAQ:PEP) are some other dividend stocks that have regularly raised their dividends over the years.At the end of Q2 2023, 26 hedge funds tracked by Insider Monkey reported having stakes in Cal-Maine Foods, Inc. (NASDAQ:CALM), compared with 28 in the previous quarter. The collective value of these stakes is over $126.6 million.Diamond Hill Capital mentioned Cal-Maine Foods, Inc. (NASDAQ:CALM) in its Q2 2023 investor letter. Here is what the firm has to say:“Our bottom contributors in Q2 included Ashland and Cal-Maine Foods, Inc. (NASDAQ:CALM). Cal-Maine Foods is the largest producer and marketer of shell eggs in the US. During Q2, wholesale commodities and caged egg prices normalized in the US, helped by the country having seemingly averted an avian flu outbreak — a combination which, though positive for the industry, pressured shares during the quarter. We maintain our positive outlook on Cal-Maine given the company’s significant investment in specialty and cage-free egg production, which we expect should benefit from a secular tailwind in the period ahead.”14. Blackstone Mortgage Trust, Inc. (NYSE:BXMT)Dividend Yield as of September 7: 10.85%Blackstone Mortgage Trust, Inc. (NYSE:BXMT) is an American real estate investment trust company that primarily focuses on real estate finance and investment activities. It is one of the best dividend stocks on our list with high yields as the company neither slashed nor ceased its dividend payments during the pandemic. It currently pays a quarterly dividend of $0.62 per share and has a dividend yield of 10.85%, as recorded on September 7.At the end of June 2023, 18 hedge funds in Insider Monkey's database reported having stakes in Blackstone Mortgage Trust, Inc. (NYSE:BXMT), worth collectively over $101.6 million. With roughly 2 million shares, Citadel Investment Group was the company's leading stakeholder in Q2.13. OUTFRONT Media Inc. (NYSE:OUT)Dividend Yield as of September 7: 10.92%OUTFRONT Media Inc. (NYSE:OUT) is a New York-based company that operates in the outdoor advertising industry. It specializes in providing advertising space and solutions on various outdoor media platforms. The company temporarily stopped paying dividends to shareholders in 2020 in the face of the pandemic and resumed its payouts a year later. It currently pays a quarterly dividend of $0.30 per share for a dividend yield of 10.92%, as of September 7.OUTFRONT Media Inc. (NYSE:OUT) was a part of 24 hedge fund portfolios at the end of Q2 2023, according to Insider Monkey's database. The stakes owned by these hedge funds have a total value of nearly $231 million.12. Hawaiian Electric Industries, Inc. (NYSE:HE)Dividend Yield as of September 7: 11.75%Hawaiian Electric Industries, Inc. (NYSE:HE) is a holding company based in Hawaii that mainly provides electric utility and banking services to its consumers. Though the stock has a high dividend yield of 11.75%, it managed to raise its dividends for five consecutive years, which makes it one of the best dividend stocks on our list. The company currently pays a quarterly dividend of $0.36 per share.The number of hedge funds tracked by Insider Monkey reported having stakes in Hawaiian Electric Industries, Inc. (NYSE:HE) grew to 18 in Q2 2023, from 15 in the previous quarter. The consolidated value of these stakes is roughly $50 million.11. Dynex Capital, Inc. (NYSE:DX)Dividend Yield as of September 7: 12.17%Dynex Capital, Inc. (NYSE:DX) is a Virginia-based real estate investment trust company that primarily focuses on investments in mortgage-backed securities and other real estate-related assets. It is one of the best dividend stocks on our list as it pays monthly dividends to shareholders. On August 11, the company announced a monthly dividend of $0.13 per share, which was consistent with its previous dividend. The stock's dividend yield on September 7 came in at 12.17%.As of the close of the June quarter of 2023, 12 hedge funds in Insider Monkey's database held investments in Dynex Capital, Inc. (NYSE:DX), up from 11 in the previous quarter. The consolidated value of these stakes is over $57.7 million.10. Ares Commercial Real Estate Corporation (NYSE:ACRE)Dividend Yield as of September 7: 12.83%An American real estate investment trust company, Ares Commercial Real Estate Corporation (NYSE:ACRE) is next on our list of the best dividend stocks. The company currently pays a quarterly dividend of $0.33 per share and has a dividend yield of 12.83%, as recorded on September 7.The number of hedge funds tracked by Insider Monkey owning stakes in Ares Commercial Real Estate Corporation (NYSE:ACRE) stood at 4 at the end of Q2 2023, which remained unchanged from the previous quarter. The consolidated value of these stakes is over $11.5 million. Among these hedge funds, Millennium Management was the company's leading stakeholder in Q2.9. Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI)Dividend Yield as of September 7: 13.26%Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI) is an American real estate investment trust company that primarily focuses on financing and investing in commercial real estate assets. The company was a part of 9 hedge fund portfolios at the end of Q2 2023, according to Insider Monkey's database. The total value of stakes owned by these hedge funds is over $4.15 million.Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI) reduced its quarterly dividend due to the pandemic. However, it continued to provide its shareholders with consistent dividend payments during that challenging period. The company currently pays a quarterly dividend of $0.35 per share and has a dividend yield of 13.26%, as of September 7.8. Big 5 Sporting Goods Corporation (NASDAQ:BGFV)Dividend Yield as of September 7: 13.59%Big 5 Sporting Goods Corporation (NASDAQ:BGFV) is a California-based sporting goods company that offers a diverse array of products, including athletic footwear, apparel, sporting equipment, and accessories for various sports and outdoor activities.Big 5 Sporting Goods Corporation (NASDAQ:BGFV), one of the best dividend stocks on our list, currently pays a quarterly dividend of $0.30 per share. The company raised its dividends three times after the pandemic and also holds a strong history of paying special dividends to shareholders. As of September 7, the stock has a dividend yield of 13.59%.As of the close of Q2 2023, 5 hedge funds tracked by Insider Monkey held stakes in Big 5 Sporting Goods Corporation (NASDAQ:BGFV), the same as in the previous quarter. The collective value of these stakes is over $2.44 million.7. Ellington Financial Inc. (NYSE:EFC)Dividend Yield as of September 7: 13.68%Ellington Financial Inc. (NYSE:EFC) is a specialty finance company that primarily focuses on investing in a wide range of financial assets, including mortgage-backed securities, mortgage-related derivatives, and other structured finance products. The company offers monthly dividends to shareholders and currently pays a per-share dividend of $0.15 every month. As of September 7, the stock has a dividend yield of 13.68%.Insider Monkey's database of Q2 2023 showed that 6 hedge funds owned stakes in the company, compared with 5 in the previous quarter. The collective value of these stakes is roughly $17 million.6. KKR Real Estate Finance Trust Inc. (NYSE:KREF)Dividend Yield as of September 7: 14.04%KKR Real Estate Finance Trust Inc. (NYSE:KREF) ranks sixth on our list of the best dividend stocks to buy with high yields. The real estate investment trust company currently offers a quarterly dividend of $0.43 per share and has a dividend yield of 14.04%, as of September 7. The company has been making regular dividend payments to shareholders since 2017.KREF can be a good addition to dividend portfolios alongside some of the best dividend stocks like The Procter & Gamble Company (NYSE:PG), Colgate-Palmolive Company (NYSE:CL), and PepsiCo, Inc. (NASDAQ:PEP).At the end of the second quarter of 2023, 5 hedge funds in Insider Monkey's database reported having stakes in KKR Real Estate Finance Trust Inc. (NYSE:KREF), compared with 7 in the previous quarter. The total value of these stakes is nearly $18 million. Click to continue reading and see 5 Highest Yielding Dividend Stocks You Can Buy Today. Suggested articles:12 Best Healthcare ETFs To Buy10 Undervalued Stocks to Buy According to Goldman SachsJim Cramer and Billionaire Ken Fisher Love These 10 StocksDisclosure. None. 15 Highest Yielding Dividend Stocks You Can Buy Today is originally published on Insider Monkey.

Insider Monkey

15 Highest Yielding Dividend Stocks You Can Buy Today

https://finance.yahoo.com/news/15-highest-yielding-dividend-stocks-142403215.html

28e1005c-2ad2-3614-8a42-bac0d36af4a5

DX

Investing.com-- Oil prices fell from a near 10-month high on Monday, seeing a measure of profit taking after a stellar rally over the past month, although bets on tightening supplies still kept Brent above key levels.Markets turned cautious before key U.S. inflation data due later this week, which is largely expected to factor into interest rates. A Federal Reserve meeting is also on tap later in September.Oil prices saw a strong run-up last week after Saudi Arabia and Russia announced deeper-than-expected supply cuts for the remainder of the year, spurring bets that market tightness will help offset any potential demand headwinds from rising interest rates.But prices now appeared to have paused amid some profit taking, while uncertainty over interest rates and fears of a potential drop-off in U.S. demand also kept markets uncertain.Brent oil futures fell 0.5% to $90.25 a barrel, while West Texas Intermediate crude futures fell 0.8% to $86.85 a barrel by 20:47 ET (00:47 GMT).IEA, OPEC reports on tap this weekFocus this week is on monthly reports from the Organization of Petroleum Exporting Countries (OPEC) and the International Energy Agency (IEA) for their respective forecasts for oil markets.Both groups expect tighter supplies to lift oil prices this year, and have also reiterated that crude demand is expected to remain relatively strong thanks to a recovery in China.But a swathe of recent data showed that China’s economy was cooling despite the lifting of anti-COVID restrictions earlier this year. While the country’s oil imports have remained steady, doubts have risen over its appetite for fuel, especially amid deteriorating economic conditions.Recent data showed that Chinese consumer inflation crept back into positive territory in August, while producer inflation remained in deflation territory.Dollar strong with inflation, Fed in focusStrength in the dollar also stemmed further gains in crude, as the greenback rose for eight straight weeks to a near six-month high.Story continuesRecent signs of resilience in the U.S. economy- particularly in inflation and the labor market- pushed up concerns that the Federal Reserve will have enough headroom to keep interest rates higher for longer.Markets fear that this trend could spur more cooling in the U.S. economy, potentially denting crude demand. U.S. fuel demand is also expected to cool in the coming months, with the end of the travel-heavy summer season.A stronger dollar also weighs on oil demand by making crude more expensive for international buyers.Related ArticlesOil prices slip from near 10-month high, Brent holds $90Island states seek climate protection from Law of the SeaFactbox-Iranian-American prisoners involved in swap, fund release

Investing.com

Oil prices slip from near 10-month high, Brent holds $90

https://finance.yahoo.com/news/oil-prices-slip-near-10-211057110.html

9db0b723-5e64-362d-a85d-b1bcb55af228

DXC

Getting booted out of the S&P 500 is a mark of shame most companies try to avoid. But it's a harsh possibility several face.Continue reading

Investor's Business Daily

8 Stocks Are Most At Risk Of Getting Booted Out Of The S&P 500

https://finance.yahoo.com/m/ba111cf2-1b54-38ca-b7de-7f3abf725649/8-stocks-are-most-at-risk-of.html

ba111cf2-1b54-38ca-b7de-7f3abf725649

DXC

DXC Assure Cede Excels in both Advanced Technology and Breadth of FunctionalityASHBURN, Va., Sept. 7, 2023 /PRNewswire/ - DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services and insurance software provider, was ranked as a Luminary in Celent's report for insurers on reinsurance administration.DXC Technology Logo (CNW Group/DXC Technology Company)"Increasingly, reinsurance administration impacts the overall success of an insurance company," said Donald Light, Director, North America Property/Casualty Insurance Practice, Celent. "Where the administration of a reinsurance program is often managed in worksheets and word processing programs, solutions like DXC Assure Cede can help insurers track and recover what otherwise could amount to hundreds of millions of dollars in unrecovered reinsurance payments."Celent's report, Ceded Reinsurance Solutions—Global Edition, profiles 13 standalone ceded reinsurance solutions, and includes information about specific features and functionalities available, coverage of Property & Casualty (P&C) and Life ceded reinsurance, and technology. DXC Assure Cede was categorized as a Luminary based on offering both advanced technology and breadth of functionality within its solution."We are honored to be recognized by Celent as being one of the top two most sophisticated ceded reinsurance solutions in the market," said Ray August, Global Lead, Insurance Software & BPS, DXC Technology. "As the number one provider of core technology to the insurance industry globally, DXC combines deep domain expertise with a mission to innovate. DXC Assure Cede provides unrivaled functional coverage for end-to-end ceded reinsurance administration, hosted on the DXC Assure Digital Platform, helping customers manage risk effectively."Catering to both the P&C and Life Insurance businesses, and supporting complex protection arrangements, DXC Assure Cede helps insurers effectively manage their reinsurance arrangements. With a focus on automation and data analytics, including AI insights, DXC Assure Cede streamlines reinsurance with minimal manual interventions, at increased speed and accuracy. Each year, more insurers and reinsurers choose DXC's software for ceded and assumed reinsurance, which currently serves more than 150 customers across 45 countries.Story continuesRead Celent's full report, Ceded Reinsurance Solutions—Global Edition, here.Forward Looking StatementsAll statements in this press release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled "Risk Factors" in DXC's upcoming Annual Report on Form 10-K for the fiscal year ended March 31, 2023, and any updating information in subsequent SEC filings. No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this report or to reflect the occurrence of unanticipated events except as required by law.About DXC TechnologyDXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world's largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/dxc-technology-ranked-as-a-luminary-among-reinsurance-administrators-by-celent-301920454.htmlSOURCE DXC Technology Company

PR Newswire

DXC Technology Ranked as a Luminary Among Reinsurance Administrators by Celent

https://finance.yahoo.com/news/dxc-technology-ranked-luminary-among-123000814.html

eee18853-f547-3e39-896d-e3bdc50d67e8

DXCM

U.S. equities fell for a second straight session on Sept. 6, 2023, with the S&P 500 Index losing 0.7% amid investors' concerns the Federal Reserve isn't done with raising interest rates yet.Continue reading

Investopedia

S&P 500 Gains and Losses Today: Index Drops Amid Renewed Fears of More Fed Rate Hikes

https://finance.yahoo.com/m/25539601-57b3-3c75-b425-a726656a0553/s-p-500-gains-and-losses.html

25539601-57b3-3c75-b425-a726656a0553

DXCM

DexCom DXCM shares soared 6.5% in the last trading session to close at $106.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9% loss over the past four weeks.DexCom recorded a strong price increase after it allayed concerns that popular weight-loss drugs, like Wegovy, would tamp down usage of its diabetes devices. Per a company presentation on Sep 5, Dexcom confirmed that across all segments of patients with type 2 diabetes, use of continuous glucose monitors increased after beginning treatment with GLP-1 drugs.This medical device company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of +21.4%. Revenues are expected to be $936.02 million, up 21.6% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For DexCom, the consensus EPS estimate for the quarter has been revised 4.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DXCM going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>DexCom belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Integer ITGR, closed the last trading session 0.7% lower at $80.74. Over the past month, ITGR has returned -8.5%.For Integer , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.07. This represents a change of +12.6% from what the company reported a year ago. Integer currently has a Zacks Rank of #2 (Buy).Story continuesWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDexCom, Inc. (DXCM) : Free Stock Analysis ReportInteger Holdings Corporation (ITGR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Strength Seen in DexCom (DXCM): Can Its 6.5% Jump Turn into More Strength?

https://finance.yahoo.com/news/strength-seen-dexcom-dxcm-6-134300254.html

d6ded63e-6ba4-3bfd-baee-81170a6e3548

DXCM

DexCom (DXCM) closed the most recent trading day at $104.91, moving -1.84% from the previous trading session. This change lagged the S&P 500's 0.32% loss on the day. At the same time, the Dow added 0.17%, and the tech-heavy Nasdaq lost 0.89%.Coming into today, shares of the medical device company had lost 3.68% in the past month. In that same time, the Medical sector gained 2.04%, while the S&P 500 lost 0.12%.Investors will be hoping for strength from DexCom as it approaches its next earnings release. In that report, analysts expect DexCom to post earnings of $0.34 per share. This would mark year-over-year growth of 21.43%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $936.02 million, up 21.62% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.23 per share and revenue of $3.54 billion. These totals would mark changes of +41.38% and +21.74%, respectively, from last year.Investors might also notice recent changes to analyst estimates for DexCom. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.83% higher. DexCom currently has a Zacks Rank of #3 (Hold).In terms of valuation, DexCom is currently trading at a Forward P/E ratio of 86.83. Its industry sports an average Forward P/E of 27.9, so we one might conclude that DexCom is trading at a premium comparatively.Story continuesAlso, we should mention that DXCM has a PEG ratio of 2.02. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments was holding an average PEG ratio of 2.1 at yesterday's closing price.The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 43% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDexCom, Inc. (DXCM) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

https://finance.yahoo.com/news/dexcom-dxcm-dips-more-broader-220020943.html

594a5617-248a-3dd6-bd40-109e500ebf15

DXPE

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine DXP Enterprises, Inc. (NASDAQ:DXPE), by way of a worked example.Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. Put another way, it reveals the company's success at turning shareholder investments into profits. Check out our latest analysis for DXP Enterprises How To Calculate Return On Equity?ROE can be calculated by using the formula:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for DXP Enterprises is:16% = US$58m ÷ US$369m (Based on the trailing twelve months to June 2023).The 'return' is the income the business earned over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.16.Does DXP Enterprises Have A Good ROE?Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. You can see in the graphic below that DXP Enterprises has an ROE that is fairly close to the average for the Trade Distributors industry (18%).roeSo while the ROE is not exceptional, at least its acceptable. Even if the ROE is respectable when compared to the industry, its worth checking if the firm's ROE is being aided by high debt levels. If so, this increases its exposure to financial risk. Our risks dashboardshould have the 2 risks we have identified for DXP Enterprises.How Does Debt Impact Return On Equity?Virtually all companies need money to invest in the business, to grow profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first and second cases, the ROE will reflect this use of cash for investment in the business. In the latter case, the use of debt will improve the returns, but will not change the equity. That will make the ROE look better than if no debt was used.Story continuesDXP Enterprises' Debt And Its 16% ROEDXP Enterprises does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.12. There's no doubt its ROE is decent, but the very high debt the company carries is not too exciting to see. Debt does bring extra risk, so it's only really worthwhile when a company generates some decent returns from it.SummaryReturn on equity is useful for comparing the quality of different businesses. Companies that can achieve high returns on equity without too much debt are generally of good quality. All else being equal, a higher ROE is better.But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So I think it may be worth checking this free report on analyst forecasts for the company.Of course DXP Enterprises may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

How Did DXP Enterprises, Inc.'s (NASDAQ:DXPE) 16% ROE Fare Against The Industry?

https://finance.yahoo.com/news/did-dxp-enterprises-inc-nasdaq-113149657.html

1e6a3804-2c46-3470-9d5c-48f980bf2315

DXPE

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. So on that note, DXP Enterprises (NASDAQ:DXPE) looks quite promising in regards to its trends of return on capital.Return On Capital Employed (ROCE): What Is It?Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on DXP Enterprises is:Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)0.15 = US$124m ÷ (US$1.0b - US$208m) (Based on the trailing twelve months to June 2023).Thus, DXP Enterprises has an ROCE of 15%. In absolute terms, that's a pretty normal return, and it's somewhat close to the Trade Distributors industry average of 14%. View our latest analysis for DXP Enterprises roceIn the above chart we have measured DXP Enterprises' prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free report for DXP Enterprises.So How Is DXP Enterprises' ROCE Trending?The trends we've noticed at DXP Enterprises are quite reassuring. The data shows that returns on capital have increased substantially over the last five years to 15%. Basically the business is earning more per dollar of capital invested and in addition to that, 55% more capital is being employed now too. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.The Key TakeawayTo sum it up, DXP Enterprises has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific. Astute investors may have an opportunity here because the stock has declined 18% in the last five years. That being the case, research into the company's current valuation metrics and future prospects seems fitting.Story continuesOn a separate note, we've found 1 warning sign for DXP Enterprises you'll probably want to know about.If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Returns Are Gaining Momentum At DXP Enterprises (NASDAQ:DXPE)

https://finance.yahoo.com/news/returns-gaining-momentum-dxp-enterprises-123003078.html

9625606c-2fce-3db3-94d7-4afe0971079b

DYAI

Dyadic International, Inc.Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited (EDCL) in Bangladesh Progress in developing animal-free recombinant serum albumin with initial positive analytical results and casein proteins with Dapibus™ cell lines New C1 ferritin nanoparticle antigens; initiated infectious disease animal studies to combat bird flu, encephalitis and meningitisMultiple new fully funded research collaborations with:A Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human health in a large infectious disease segmentA new animal health company to use C1 platform for livestock application Fermbox to use Dapibus™ platform to co-develop and commercialize animal free alternative proteins and biomaterial productsExpanded licensing agreement with Rubic One Health Expanded collaboration with Phibro animal health/Abic Biological LaboratoriesU.S. Patent granted for manufacturing seasonal and pandemic influenza vaccines from proprietary C1 protein production platformCash and investment grade securities of $10.2 million as of June 30, 2023Financial results and business update conference call scheduled for 5:00 pm ET todayJUPITER, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human and animal health, today announced its financial results for the second quarter of 2023, and highlighted recent company developments.“As announced last month, we are excited to report the interim analysis of Day 29 data from our first in human Phase 1 clinical trial, in which no major vaccine related safety issues were observed. DYAI-100, the vaccine candidate produced from our proprietary and patented C1-cell protein production platform has been shown to produce an immune response at both the low and high dosing levels,” said Mark Emalfarb, President and Chief Executive Officer of Dyadic. “We believe this important milestone is a pivotal point in the evolution from our commercial success in industrial biotech to broadening our capability as a life-science biotechnology company. As demonstrated by our recently announced fully funded collaboration with a top five pharmaceutical company in a large infectious disease segment, we believe that our Phase 1 data will provide the biopharmaceutical industry, academia, and governmental agencies with the confidence that our C1-cell microbial protein production platform offers the safety, speed, cost, and quality needed to gain market share in the competitive industry,” concluded Mr. Emalfarb.Story continuesJoe Hazelton, Chief Business Officer of Dyadic, also commented, “In addition to the expansion of our pharmaceutical licensing programs, Dyadic is working toward the development of near-term commercialization opportunities such as our non-animal derived serum albumin projects, where we recently reported positive results from third party analytical testing of the company’s animal-free recombinant bovine serum albumin. We believe demonstrating that Dyadic’s recombinant albumin is comparable to currently marketed products has brought us a step closer to commercialization opportunities in the rapidly expanding global serum albumin market as well as helping us to initiate several other projects for non-pharmaceutical enzyme and protein applications. We believe the successful expression of a stable casein protein in our Dapibus™ expression system further demonstrates the broad applicability of our technology in large and growing segments such as non-animal dairy proteins.” Mr. Hazelton continued, “We are expanding both our C1 licensing and DapibusTM programs for strain engineering and production services with a focus on customers interested in creating high performance microbial strains for their vaccine antigens, monoclonal antibodies, other therapeutic proteins, as well as enzymes and proteins for food, nutrition, and wellness.”Recent Company ProgressDYAI-100 SARS-CoV-2 RBD (Receptor Binding Domain) Booster Vaccine CandidateNo major vaccine-related safety concerns based on the interim analysis of the Day 29 data for both low and high dose groups reviewed by the Data Safety Monitoring Board (DSMB).To date, no serious adverse events or local and systemic side effects have been observed.Booster vaccine produced immune response at both dose levels.The Last Patient Last Visit (LPLV) is scheduled for August 25, 2023, and the full clinical study report (CSR) is expected in Q4 2023.Vaccine CollaborationsEssential Drugs Company Limited (EDCL) in Bangladesh – On June 21, 2023, the Company announced that it entered a Memorandum of Understanding with EDCL, the state-owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh, to facilitate biopharmaceutical research, pre-clinical development, cGMP production, and clinical development for the prevention and control of diseases and improvement of public health programs in Bangladesh.Top 5 Pharma – In April 2023, the Company entered a new fully funded research collaboration, with a top 5 pharmaceutical company, to express a vaccine antigen from C1 for human health in a large infectious disease segment. The agreement also grants an option for a future commercialization license in the designated field.Rubic One Health (“Rubic”) – On April 12, 2023, the Company expanded its initial 2021 license agreement with Rubic to include vaccines and therapeutic proteins beyond COVID-19 vaccines, for both human animal health markets. The expanded license agreement will help Rubic prepare for the development and manufacture of affordable vaccines and drugs for the African continent.Virovax Bio (“Virovax”) – Currently, four new animal studies are ongoing with C1 produced ferritin nanoparticle antigens combined with Virovax’s adjuvants for influenza (H5N1/Bird Flu), West Nile and Powassan, to protect against encephalitis and meningitis.Uvax Bio (“Uvax”) – In June 2023, the Company has renewed and expanded its research collaboration with Uvax, a spin-off vaccine company from Scripps Research. Uvax is developing prophylactic vaccines for the most challenging infectious diseases, and our research collaboration is expected to help Uvax overcome gene expression challenges using the Company’s C1-cell protein production platform.Antibody CollaborationsNIIMBL – During the NIIMBL annual meeting in June 2023, the Company presented data and research results generated from the NIIMBL Grant received by the Company under the previously announced White House’s American Rescue Plan, which ended successfully.EU 87G7 COVID-19 Antibody Collaboration – In June 2023, a manuscript was submitted to a peer-reviewed scientific journal titled “Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models” in collaboration with Dr. Albert Osterhaus and several other authors. The manuscript describes the safety and efficacy results with a C1-cell produced monoclonal antibody obtained from studies in hamsters and non-human primates.Fondazione Biotecnopolo di Siena (“FBS”) – On May 24, 2023, the Company entered a Memorandum of Understanding with the FBS, which performs the functions of an anti-pandemic hub with a particular focus on the development and production of vaccines and monoclonal antibodies for the treatment of emerging epidemic-pandemic pathologies.   We expect FBS to conduct research and development, clinical study, regulatory approval, manufacture and commercialization of vaccines and therapeutic proteins using the Company’s C1 protein production platform.Animal HealthNew Animal Health Partner – In June 2023, the Company entered a fully funded collaboration with a new animal health company to develop an antigen for livestock animals.Rubic One Health (“Rubic”) – On April 12, 2023, the Company expanded its initial 2021 license agreement with Rubic to include vaccines and therapeutic proteins beyond COVID-19 vaccines for both human animal health markets. The expanded license agreement is expected to help Rubic prepare for the development and manufacture of affordable vaccines and drugs for the African continent.Phibro Animal Health/Abic Biological Laboratories – In the first quarter of 2023, the Company extended its research collaboration with Abic Biological Laboratories Ltd. (“Abic”), an affiliate of Phibro Animal Health Corporation (“Phibro”) to apply newly developed techniques and methods to further increase the expression level of a recombinant livestock antigen using C1. The Company and Abic have expanded the collaboration to include the development of additional antigens for use in livestock animal health applications.Alternative Proteins and Dapibus™ Platform Commercial Product Portfolio Pipeline – On August 7, 2023, the Company announced that it has successfully developed stable cell lines to produce recombinant serum albumin products. The Company initiated animal-free recombinant serum albumin projects in late 2022 for use in potential therapeutic, product development, research, and/or diagnostic human and animal pharmaceutical applications. We have started sampling potential customers who have expressed interest in Dyadic’s C1 serum albumin products. Initial independent analytical assessment of the Company’s recombinant bovine serum albumin demonstrated that it is structurally equivalent to the commercially available animal derived product. In non-pharmaceutical applications, the Company initiated the development of non-animal derived recombinant dairy proteins and enzymes for use in food and nutrition to support its Dapibus™ platform.Fermbox Bio (“Fermbox”) – On May 7, 2023, the Company entered a fully funded co-development and marketing agreement with Fermbox to help accelerate our ability to exploit the Dapibus™ platform and expand Dyadic’s product offerings for non-pharmaceutical alternative proteins applications, such as food, nutrition, wellness and other bioproducts.Other EventsBARDA and FDA Workshop – On April 27, 2023, the Company presented at Recombinant Protein-Based COVID-19 Vaccines Workshop, a virtual event hosted by the Biomedical Advanced Research and Development Authority (BARDA) and FDA. The goals of the workshop were to provide: 1) a forum for product sponsors to discuss progress and technical challenges in the manufacturing when changing strain composition to currently circulating variants of SARS-CoV-2; and 2) an open forum for collaborative discussions to facilitate advancement of recombinant protein-based COVID-19 vaccines.Patent Update – On April 18, 2023, the Company announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office for patent application 16/640,483, titled “Production of Flu Vaccine in Myceliophthora thermophila”, which will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company’s C1 protein production platform. The Company has developed several influenza antigens and in collaboration with scientists in the EU and USA various animal studies have been completed, with both hemagglutinin (HA) and neuraminidase (NA) antigens expressed from the Company’s C1 protein production platform. Additional pandemic influenza (H5N1/bird flu) animal trials are currently in process.Financial HighlightsCash Position: As of June 30, 2023, cash, cash equivalents, and the carrying value of investment grade securities, including accrued interest, were approximately $10.2 million compared to $12.7 million as of December 31, 2022.Revenue: Research and development revenue and license revenue for the quarter ended June 30, 2023, increased to approximately $837,000 compared to $659,000 for the same period a year ago. Research and development revenue and license revenue for the six months ended June 30, 2023, increased to approximately $1,815,000 compared to $1,307,000 for the same period a year ago. The increase is primarily attributed to higher individual contract amounts on certain research funding compared to the same period a year ago.Cost of Revenue: Cost of research and development revenue for the quarter ended June 30, 2023, increased to approximately $793,000 compared to $411,000 for the same period a year ago. Cost of research and development revenue for the six months ended June 30, 2023, increased to approximately $1,520,000 compared to $815,000 for the same period a year ago.R&D Expenses: Research and development expenses for the quarter ended June 30, 2023, decreased by 49.9% to approximately $918,000 compared to $1,831,000 for the same period a year ago. Research and development expenses for the six months ended June 30, 2023, decreased by 45.6% to approximately $1,728,000 compared to $3,174,000 for the same period a year ago.The decrease in research and development expenses for the quarter and six months ended June 30, 2023 versus the same periods in 2022 was due to the winding down of activities of contract research organization and consultants to manage and support the pre-clinical and clinical development as well as a decrease in cGMP manufacturing costs as the Company completed the dosing of Phase 1 clinical trial of its DYAI-100 RBD COVID-19 booster vaccine candidate in February 2023.G&A Expenses: General and administrative expenses for the quarter ended June 30, 2023, decreased by 18.1% to approximately $1,403,000 compared to $1,714,000 for the same period a year ago. The decrease in G&A expenses for the quarter ended June 30, 2023 compared to the same period in 2022 includes decreases in legal expenses of $103,000, incentives of approximately $81,000, business development and investor relations expenses of $75,000, insurance expenses of $37,000, and other decreases of $15,000. General and administrative expenses for the six months ended June 30, 2023, decreased by 14.5% to approximately $2,883,000 compared to $3,370,000 for the same period a year ago. The decrease in G&A expenses for the six months ended June 30, 2023 compared to the same period in 2022 includes decreases in incentives of approximately $215,000, business development and investor relations expenses of $137,000, insurance expenses of $72,000, legal expenses of $48,000 and other decreases of $15,000.Other Income: Other income for the three and six months ended June 30, 2023, was primarily from the sale of the equity interest in Alphazyme, LLC.Net Loss: Net loss for the quarter ended June 30, 2023, was approximately $2,153,000 or $(0.07) per share compared to $3,288,000 or $(0.12) per share for the same period a year ago. Net loss for the six months ended June 30, 2023, was approximately $3,109,000 or $(0.11) per share compared to $5,780,000 or $(0.20) per share for the same period a year ago.Conference Call InformationDate: Wednesday, August 9, 2023Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 1-877-407-0784International: 1-201-689-8560Conference ID: 13735362Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1593531&tp_key=0b0ed46180An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.About Dyadic International, Inc.Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the DapibusTM filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com.Safe Harbor Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.Contact:Dyadic International, Inc.Ping W. RawsonChief Financial OfficerPhone: 561-743-8333Email: [email protected]     DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS              Three Months Ended June 30,Six Months Ended June 30,  2023  2022  2023  2022 Revenues:    Research and development revenue$793,042 $614,435 $1,726,976 $1,148,156 License revenue 44,117  44,118  88,235  158,824 Total revenue 837,159  658,553  1,815,211  1,306,980      Costs and expenses:    Costs of research and development revenue 792,944  411,109  1,519,862  815,855 Research and development 917,552  1,830,798  1,728,118  3,173,660 General and administrative 1,402,569  1,714,029  2,882,609  3,369,729 Foreign currency exchange loss 14,521  20,621  25,543  10,373 Total costs and expenses 3,127,586  3,976,557  6,156,132  7,369,617      Loss from operations (2,290,427) (3,318,004) (4,340,921) (6,062,637)     Other income:    Interest income 109,194  30,009  213,925  32,977 Other income 28,273  —  1,017,592  250,000 Total other income 137,467  30,009  1,231,517  282,977      Net loss$(2,152,960)$(3,287,995)$(3,109,404)$(5,779,660)     Basic and diluted net loss per common share$(0.07)$(0.12)$(0.11)$(0.20)     Basic and diluted weighted-average common shares outstanding 28,811,061  28,264,157  28,786,402  28,257,776 See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2023. DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS    June 30, 2023 December 31, 2022 (Unaudited) (Audited)Assets      Current assets:      Cash and cash equivalents$5,841,591  $5,794,272 Short-term investment securities 4,287,325   6,847,270 Interest receivable 36,053   58,285 Accounts receivable 767,597   330,001 Prepaid expenses and other current assets 136,152   392,236 Total current assets 11,068,718   13,422,064       Non-current assets:     Investment in Alphazyme —   284,709 Other assets 5,822   6,045 Total assets$11,074,540  $13,712,818       Liabilities and stockholders’ equity     Current liabilities:     Accounts payable$905,876  $1,276,313 Accrued expenses 909,482   955,081 Deferred research and development obligations 9,000   40,743 Deferred license revenue, current portion 176,471   176,471 Total current liabilities 2,000,829   2,448,608        Deferred license revenue, net of current portion 88,235   176,471 Total liabilities 2,089,064   2,625,079        Commitments and contingencies (Note 4)             Stockholders’ equity:      Preferred stock, $.0001 par value:      Authorized shares - 5,000,000; none issued and outstanding —   — Common stock, $.001 par value:      Authorized shares - 100,000,000; issued shares - 41,064,563 and 40,816,602, outstanding shares - 28,811,061 and28,563,100 as of June 30, 2023, and December 31, 2022, respectively 41,065   40,817 Additional paid-in capital 104,465,590   103,458,697 Treasury stock, shares held at cost - 12,253,502 (18,929,915)  (18,929,915)Accumulated deficit (76,591,264)  (73,481,860)Total stockholders’ equity 8,985,476   11,087,739 Total liabilities and stockholders’ equity$11,074,540  $13,712,818 See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2023.

GlobeNewswire

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

https://finance.yahoo.com/news/dyadic-announces-second-quarter-2023-200000150.html

b35e9109-1b07-3d64-a7d8-ba2241ac708e

DYAI

By John Vandermosten, CFANASDAQ:DYAIREAD THE FULL DYAI RESEARCH REPORTSecond Quarter 2023 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided 2Q:23 operational and financial results in a press release on August 9, 2023, filed its Form 10-Q with the SEC and held a conference call with investors.1 Dyadic announced several new collaborations and expanded agreements since its first quarter report. It has also completed its first in-human trial where DYAI-100 was used as a booster vaccine. No serious adverse events were reported and a safety assessment was provided in June.A few new collaborations were announced including Uvax Bio for an infectious disease vaccine, Fondazione Fondazione Biotecnopolo di Siena to develop epidemic related vaccines and antibodies and an unidentified animal health company in a fully funded livestock antigen program. A memorandum of understanding was signed with the Bangladesh state-owned pharmaceutical company which is seeking to develop a biopharmaceutical program to support improvement of public health. Work on the Janssen monoclonal antibody and bispecific continues.Highlights for 2023 to date include:➢ Sale of Alphazyme interest – January 2023➢ Dosing initiated in DYAI-100 COVID trial – January 2023➢ Dosing completed in DYAI-100 COVID trial – February 2023➢ Participation in FDA Vaccine Workshop – April 2023➢ Presentation at World Vaccine Congress – April 2023➢ Patent Notice of Allowance awarded from USPTO – April 2023➢ Fermbox Bio animal free protein collaboration – May 2023➢ MoU with Bangladesh State-Owned Pharmaceutical Company – June 2023Financial results for the quarter ending June 30, 2023, compared to the same prior year period:➢ Revenues were $0.8 million, up 27% from $0.7 million and cost of revenues was $0.8 million vs. $0.4 million. The revenue and cost of research increase was attributable to activity related to the Janssen license agreements and other collaboration programs in the pipeline;Story continues➢ Research and development expenses totaled $0.9 million, down 50% from $1.8 million. The decrease was attributable to the reduction in contract research organization activities and cost of pharmaceutical quality and regulatory consultants to manage and support the pre-clinical and clinical development. A decrease in current good manufacturing practice (cGMP) manufacturing costs also contributed to the change;➢ General and administrative expenses were $1.4 million, down 18% over prior year period amounts. Lower incentives, insurance expenses, business development, investor relation and legal expenses contributed to the change;➢ Interest income increased to $109,000 from $30,000 due to higher yields on securities held;➢ Other income was $28,000 compared to $0 and reflected true-ups related to the Alphazyme sale;➢ Net loss amounted to ($2.2) million compared to ($3.3) million. On a per share basis, net loss was ($0.07) vs. ($0.12).As of June 30, 2023, cash, equivalents and short-term securities totaled $10.1 million compared to $12.6 million at the end of 2022. 2Q:23 cash burn was ($1.6) million compared with ($1.8) million in 2Q:22. Financing cash flows were zero. Dyadic holds no debt on its balance sheet. Cash burn guidance for 2023 is maintained at $6 to $7 million.Bangladesh Memorandum of UnderstandingDyadic has entered into a Memorandum of Understanding (MoU) with Essential Drugs Company Limited (EDCL) the state-owned pharmaceutical company in Bangladesh. Details were provided in a June 21 press release. The purpose of the MoU is to help build the infrastructure to increase access and affordability of biomanufactured vaccines and drugs for underserved diseases. Dyadic hopes a collaboration will enable the acceleration of adoption of its microbial platform to manufacture vaccines and biologics faster. The government of Bangladesh seeks to expand collaborations with global partners in an effort to innovate critical therapies. The collaboration with Dyadic is intended to advance research, develop drugs and vaccines, facilitate current good manufacturing practices (cGMP) production and conduct clinical trials.The relationship traces back to 2021, when Dyadic and Bangladesh began to work on a strategic plan to address the country’s bio-security interests and to promote research training and dissemination of knowledge of health technology. This effort is particularly important as Bangladesh recently reported over 1,600 cases of dengue fever in a day and a 2023 total of almost 20,000 cases as of mid-July. More than 170 people have died. There is only one vaccine in the US and it is recommended only for people who have had dengue in the past. The vaccine does not work in all types of the fever and new medicines are needed. For those with severe disease, hospitalization is required; however, there is no antiviral treatment for dengue. The prevalence of the mosquito-transmitted disease in Bangladesh highlights the need for internal development of vaccines and treatment.Serum AlbuminDyadic announced continued progress toward commercialization of animal-free recombinant serum albumin in an August 7th press release. The results of third-party clinical testing showed that C1 produced serum albumin is structurally equivalent to commercial animal derived product. C1 produced serum albumin has the additional advantage of providing more consistent product that does not include any animal-related contaminants and can be produced efficiently and at low-cost relative to the alternative now in use.Dyadic is developing bovine and human animal-free serum albumin and has identified a market size of $5.7 billion in 2022 that is growing at a high single digit rate per annum. The product has both pharmaceutical and non-pharmaceutical applications. These include use of albumin to increase blood volume to treat various conditions such as surgical blood loss, hemorrhage, or trauma. Additionally, recombinant serum albumin is being used as an alternative to plasma-derived albumin in human therapeutics, cell culture media, diagnostic test kits and research & development. Serum albumin also has non-pharmaceutical applications as a component of cell culture media in the alternative protein segment. Bovine serum albumin is frequently used as a component of the cell culture media to grow animal cells for the production of cultivated meat.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.________________________1. A transcript is also available here.

Zacks Small Cap Research

DYAI: MoUs Highlight C1 Vaccine Potential

https://finance.yahoo.com/news/dyai-mous-highlight-c1-vaccine-131400425.html

070e2338-ae7d-36ab-96fe-4342f686d991

DYN

In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts. If you want to skip our introduction to short selling, then jump ahead to 5 Most Shorted Stocks That Are Loved By Analysts. Short selling is a tricky game. Rapid share price appreciations can stretch a short seller's budget to the limit and lead to losses that are twice, thrice, or even more higher than the initial investment.To understand this consider a simple example. Imagine you go short on the shares of Firm A. The stock is currently trading for $10, and you borrow shares at this price and sell them on the market in hopes that the price will fall. Ten shares sold short will be worth $100. However, the firm announces a breakthrough technology and the shares soar to $30. Now, you have to spend $300 to buy back the ten shares and return all of these to book a loss that is three times the original borrowed amount. On the flip side, if you had bought the ten shares with the hope that the share price would appreciate but the shares tanked to $0, then you'd have lost $100 only.Yet, despite this, shorting stocks is still an important part of the U.S. market. In fact, shorting has helped discover some massive frauds recently. One of the biggest examples is the story of Nikola Corporation (NASDAQ:NKLA). While its shares currently trade for $1.31, they were actually soaring to high levels around $66 in 2020. So, what happened? Well, short seller Hindenburg Research released a report in September 2020 which accused Nikola of manipulating its vehicle tests and engaging in investor fraud. The firm's shares, which were trading at around $34, tanked and have been unable to recover since then. The report also made Nikola's founder and chief executive officer Trevor Milton resign, and the firm has never been the same.Hindenburg was back earlier this year when it targeted one of India's biggest business groups, the Adani Group. It alleged improper financial practices at the firm, and Adani along with associated companies ended up losing $104 billion in market value. The report also knocked down the group's founder Mr. Gautam Adani several places down the world's rich list, and Adani's shares have still to recover despite 2023 nearing its end.Story continuesHowever, as we mentioned above, short selling is a risky endeavor. A short position going wrong, i.e. the share price appreciating instead of falling is called a short squeeze. A short squeeze causes billions of dollars in losses, and we took a look at some notable squeezes in our coverage of 10 Biggest Short Squeezes of All Time. It shows that one of the biggest short squeezes in history is the one that took place in the shares of Volkswagen AG (OTC: VWAGY), which ended up causing hedge funds $30 billion in losses. Other notable short squeezes include the close to $40 billion in losses that short sellers incurred when going against Tesla, Inc. (NASDAQ: TSLA) - whose chief Mr. Elon Musk is known for engaging the short sellers on the social media platform X (formerly Twitter).Today we've decided to take a look at some latest stocks that are on short sellers' radar but with a twist that compares their positions with Wall Street analysts. As a primer, short interest shares are those that have been sold short on the market, and some top picks in today's piece are Microvast Holdings, Inc. (NASDAQ:MVST), BioVie Inc. (NASDAQ:BIVI), and Bionano Genomics, Inc. (NASDAQ:BNGO). Most Shorted Stocks That Are Loved By AnalystsPhoto by Marga Santoso on UnsplashOur Methodology To make our list of the most shorted stocks that are loved by Wall Street analysts, we compiled the list of stocks that had more than 8% of their float shorted, had Strong Buy recommendations from analysts, and have significant share price upside based on the average analyst share price. The stocks with the highest upside are chosen as the most shorted stocks loved by analysts.Most Shorted Stocks That Are Loved by Analysts15. INmune Bio, Inc. (NASDAQ:INMB)Short Interest Percentage: 9.75%Average Share Price Target: $17.33 Share Price Upside: 119% INmune Bio, Inc. (NASDAQ:INMB) is a small biotechnology company focusing on developing cancer and tumor treatments. Baird rated its shares as Outperform in June 2023 and the firm narrowed its loss per share in its second quarter.During Q2 2023, four out of the 910 hedge funds part of Insider Monkey's database had held a stake in INmune Bio, Inc. (NASDAQ:INMB). Out of these, the firm's biggest investor is Henrik Rhenman's Rhenman & Partners Asset Management since it owns 178,284 shares that are worth $1.6 million.INmune Bio, Inc. (NASDAQ:INMB) joins BioVie Inc. (NASDAQ:BIVI), Microvast Holdings, Inc. (NASDAQ:MVST), and Bionano Genomics, Inc. (NASDAQ:BNGO) in our list of most shorted stocks that are loved by analysts.14. Ardelyx, Inc. (NASDAQ:ARDX)Short Interest Percentage: 12.96%Average Share Price Target: $8.64 Share Price Upside: 119%Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to Overweight from Neutral in August 2023.As of June 2023, 14 out of the 910 hedge funds polled by Insider Monkey had invested in the company. Ardelyx, Inc. (NASDAQ:ARDX)'s largest hedge fund stakeholder is Israel Englander's Millennium Management through its $23.6 million investment.13. 89bio, Inc. (NASDAQ:ETNB)Short Interest Percentage: 11.73%Average Share Price Target: $37 Share Price Upside: 124%Another biotechnology company, 89bio, Inc. (NASDAQ:ETNB) makes treatments for liver diseases. Cantor Fitzgerald and RBC Capital kept Overweight and Outperform share ratings for its stock in August 2023 despite the fact that the firm had missed analyst EPS estimates for its second quarter.Insider Monkey scoured through 910 hedge fund portfolios for their second quarter of 2023 shareholdings and discovered that 39 had bought and invested in 89bio, Inc. (NASDAQ:ETNB)'s shares. Peter Kolchinsky's RA Capital Management is the company's biggest shareholder since it owns a $216 million stake.12. The Lovesac Company (NASDAQ:LOVE)Short Interest Percentage: 30.85%Average Share Price Target: $52.67 Share Price Upside: 136%The Lovesac Company (NASDAQ:LOVE) is a furniture company. A consumer cyclical firm, its performance is quite dependent on consumer spending power. Naturally, the shares have see sawed this year, and are up by a marginal 1.32% year to date.During 2023's June quarter, 17 among the 910 hedge funds surveyed by Insider Monkey had held the firm's shares. The Lovesac Company (NASDAQ:LOVE)'s largest stakeholder among these is Paul Marshall and Ian Wace's Marshall Wace LLP through its $15.8 million investment.11. Dyne Therapeutics, Inc. (NASDAQ:DYN)Short Interest Percentage: 9.44%Average Share Price Target: $29.50 Share Price Upside: 148%Dyne Therapeutics, Inc. (NASDAQ:DYN) is an American firm that develops treatments for muscular diseases such as dystrophy. It's unsurprising that nearly 10% of the firm's float has been shorted, since its cash burn rate of $178 million per year is quite high when compared to $208 million of cash reserves as of June 2023.Insider Monkey surveyed 910 hedge funds and discovered 22 Dyne Therapeutics, Inc. (NASDAQ:DYN) investors as of June 2023. Out of these, the biggest shareholder is Ken Griffin's Citadel Investment Group since it owns 2.7 million shares that are worth $30.4 million.Microvast Holdings, Inc. (NASDAQ:MVST), Dyne Therapeutics, Inc. (NASDAQ:DYN), BioVie Inc. (NASDAQ:BIVI), and Bionano Genomics, Inc. (NASDAQ:BNGO) are some highly shorted stocks on the analyst radar.10. Viking Therapeutics, Inc. (NASDAQ:VKTX)Short Interest Percentage: 14.50%Average Share Price Target: $33.8 Share Price Upside: 148%Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, the firm's shares are up by nearly 60% year to date and the stock is rated Strong Buy on average.As of Q2 2023 end, 28 out of the 910 hedge funds polled by Insider Monkey had invested in the company. Viking Therapeutics, Inc. (NASDAQ:VKTX)'s largest hedge fund investor is Andreas Halvorsen's Viking Global through a stake worth $57.4 million.9. Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Short Interest Percentage: 15.76%Average Share Price Target: $45.57 Share Price Upside: 162%Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) makes treatments for eye diseases. The firm scored a win in July when the Food and Drug Administration (FDA) approved its treatment for an eyelid disease that is thought to affect 25 million Americans. The stock soared after the announcement and the shares have gained 20% year to date.Insider Monkey's second quarter of 2023 survey of 910 hedge funds saw 13 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) investors. Albert Cha and Frank Kung's Vivo Capital is the company's biggest stakeholder due to its $40.8 million investment.8. Ebix, Inc. (NASDAQ:EBIX)Short Interest Percentage: 24.54%Average Share Price Target: $39.88 Share Price Upside: 162%Ebix, Inc. (NASDAQ:EBIX) is a software company that provides platforms to insurance, remittance, and other firms in the U.S. to manage customer relationship and run other functions. Its shares tanked in August right around the same time Ebix, Inc. (NASDAQ:EBIX) reported its June quarter earnings that saw a hefty EPS drop and a miss of analyst revenue growth estimates.By the end of June 2023, 16 hedge funds out of the 910 polled by Insider Monkey had held the firm's shares. Out of these, Ebix, Inc. (NASDAQ:EBIX)'s largest investor is D. E. Shaw's D E Shaw since it owns $17.8 million worth of shares.7. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Short Interest Percentage: 24.54%Average Share Price Target: $20.38 Share Price Upside: 169%Another biotechnology firm, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) develops treatments for immune system disorders. The firm's been having a good financial time lately, as it has beaten analyst EPS estimates in all four of its latest quarters.Insider Monkey scoured through 910 hedge funds for their investors during this year's second quarter and found 17 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investors. Joseph Edelman's Perceptive Advisors is the biggest stakeholder among these since it owns 11.3 million shares that are worth $95.2 million.6. Pliant Therapeutics, Inc. (NASDAQ:PLRX)Short Interest Percentage: 11%Average Share Price Target: $46.33 Share Price Upside: 185%Pliant Therapeutics, Inc. (NASDAQ:PLRX) is an American company making treatments for liver diseases. The firm beat analyst EPS estimates for its second quarter, and Cantor Fitzgerald, JP Morgan, Oppenheimer, and RBC Capital maintained Outperform or Overweight ratings for the shares in August 2023.28 out of the 910 hedge funds part of Insider Monkey's Q2 2023 database had held a stake in the company. Out of these, the firm's largest investor is David Kroin's Deep Track Capital through a stake worth $73.3 million.Microvast Holdings, Inc. (NASDAQ:MVST), Pliant Therapeutics, Inc. (NASDAQ:PLRX), BioVie Inc. (NASDAQ:BIVI), and Bionano Genomics, Inc. (NASDAQ:BNGO) are most shorted stocks loved by analysts. Click to continue reading and see 5 Most Shorted Stocks That Are Loved by Analysts.  Suggested Articles:Ken Fisher’s Top 15 Growth Stock PicksKen Fisher’s Top 15 Stock Picks13 NASDAQ Stocks with Lowest PE RatiosDisclosure: None. 15 Most Shorted Stocks That Are Loved by Analysts is originally published on Insider Monkey.

Insider Monkey

15 Most Shorted Stocks That Are Loved By Analysts

https://finance.yahoo.com/news/15-most-shorted-stocks-loved-142218926.html

43d73e99-d3cb-35b5-8848-a778a2bf4281

DYN

Dyne Therapeutics, Inc.WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference being held in New York on Monday, September 11, 2023 at 4:15 p.m. ET.A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.About Dyne TherapeuticsDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.Contact:Dyne TherapeuticsAmy [email protected] 857-341-1203

GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

https://finance.yahoo.com/news/dyne-therapeutics-present-morgan-stanley-113000604.html

75a31bbd-fc44-3a1e-a26d-e1231e52d1e6

DZSI

DZSAs event Platinum Sponsor, DZS experts will share deep insights and experience across last-mile and middle-mile best practices, AI-driven efficiencies and regulatory strategiesDALLAS, Aug. 15, 2023 (GLOBE NEWSWIRE) --  DZS (Nasdaq: DZSI), a global leader of access, optical and cloud-controlled software-defined solutions, will be showcasing many of its latest innovations and expert insights at Fiber Connect 2023, the world’s leading optical fiber business technology event, hosted by the Fiber Broadband Association and taking place in Orlando, Florida, August 20 - 23.With bridging the digital divide being a pervasive theme on most attendees minds, DZS will highlight on the show floor a variety of disruptive and Build America, Buy America (BABA)-ready Access EDGE, Subscriber EDGE, Optical EDGE and Cloud EDGE solutions targeting this challenge and opportunity, including its recently launched DZS FiberWay solutions, the industry’s first comprehensive hardened edge broadband offering designed to address the needs of reaching unserved and underserved markets. A Platinum Sponsor of the event, DZS leaders will also be providing fresh perspectives across a wide array of speaking topics at the event, including a keynote panel on the influence of “AI on In-Home Experience” as well as breakouts focused on last-mile and middle-mile technologies and regulatory insights.“DZS is excited about Fiber Connect 2023 and the potential it offers for us to increase the market’s awareness of our game-changing vision and technology,” said Miguel Alonso, Chief Product Officer, DZS. “We have enhanced our existing solutions and continue to bring to market new innovations designed to meet the challenges of bridging the digital divide in the short term while reimagining how to meet the emerging requirements across both access and transport while keeping OPEX to a minimum. Our breakthroughs are giving our customers clear competitive advantages, including: significantly lowering deployment and operating costs minimizing total cost of ownership (TCO); the proven ability to deliver exceptional customer experiences; reducing churn and improving Net Promoter Scores (NPS); and increasing Average Revenue Per User (ARPU).”Story continuesDZS will demonstrate many of its recent pioneering advancements at Fiber Connect 2023 booth #403, such as:DZS Xtreme, which leverages proven AI for automated, cross-domain network and service orchestration. With access, transport, and mobile components to knit all network domains into a coherent whole, DZS Xtreme empowers operators to create services tailored to subscribers’ specific requirements—from content streaming to telehealth to virtual reality.DZS Saber 4400, an environmentally hardened platform that redefines the economics of coherent optical metro and edge transport and supports the industry’s smallest form factor multi-degree CDC Flex-Grid ROADM functionality. Ready to support BABA requirements, the Saber 4400 is ideal for US middle mile broadband programs.DZS Velocity V1, V2, and V6 optical line terminal (OLT) solutions come in a range of form factors from 1RU to 6RU, supporting up to 25,000 subscribers in a non-blocking architecture with the capacity to allow in-place upgradeability from 10G (Gigabit) Passive Optical Networking (PON) to 50G PON and beyond. The award-winning DZS Velocity portfolio, which also has 14- and 16-slot chassis-based form factors, provides industry-leading density, can be deployed in centralized and disaggregated architectures featuring advanced software-defined networking support.DZS CloudCheck and Expresse, AI-enabled, cloud-based software solutions that enable operators to monitor, manage, and optimize both home WiFi networks with support for the market’s widest array of customer premise equipment (CPE), as well as provide extensive service assurance across the entire network. Leveraging contextual analytics and machine learning (ML) algorithms to proactively optimize subscriber WiFi networks and end-to-end quality of experience, these two solutions help operators deliver the ultimate subscriber experience while significantly reducing truck rolls and overall support costs.DZS FiberWay, the industry’s first comprehensive, hardened edge broadband solution designed to bridge the digital divide drawing from our DZS Cloud, Velocity, and Saber portfolios and complemented by key industry partners.Stay alert for additional new DZS platforms and partnerships to be announced during Fiber Connect 2023.DZS offers a market-leading portfolio of network edge and cloud-based solutions architected to enable extraordinary performance at the lowest total cost of ownership. DZS platforms and software are standards-based, proven interoperable with diverse equipment, and designed to be managed in multi-vendor environments. As a pioneer in disaggregated platforms, SDN and virtualization, communications leaders look to DZS for innovation that delivers differentiating quality of experience and future-proof network investments.Gunter Reiss, Chief Customer Officer for Americas, Europe, Middle East and Africa (AEMEA) will participate in the moderated discussion, “In Home Experience Panel”, taking place from 10:20 to 11:00 a.m. ET on Monday, August 21. This marquee session, which will attract up to 3,000 attendees, will explore how operators can optimize customer experience when residential users require diverse, bandwidth-intensive services simultaneously over the network. Mr. Reiss will also participate in the “Innovations in Passive Optical Infrastructure – Enabling the Future” session from 1:30 – 2:20 p.m. on Monday, August 21.“With our strong presence at this annual broadband community gathering and preeminent fiber industry event for the Americas, DZS is focused on enhancing the profitability and growth of our customers,” said Mr. Reiss. “Specifically, our new DZS FiberWay solution gives rural operators simplified deployment and turnkey management of gigabit and multi-gigabit fiber networks with fully auto-provisioned, AI- and cloud-enabled operations infrastructure, while meeting Build America Buy America (BABA) requirements to receive U.S. government program funding.”Other DZS presenters at Fiber Connect 2023 include:Geoff Burke, Senior Vice President of Marketing, who will participate in the panel discussion, “Fiber Expansion: When Fiber Gets Everywhere, It Means It Can Go Anywhere” from 1:30 p.m. to 2:20 p.m. on Tuesday, August 22.Sanjay Bhatia, Vice President of Product Marketing, who will participate in multiple panel discussions including “Middle Mile and Future Demands: Drivers, Case Studies, Technologies, Strategies” from 12:40 to 1:30 p.m. on Sunday, August 20 and “Infrastructure Innovation in the Middle Mile,” from 1:30 p.m. to 2:20 p.m. on Tuesday, August 22.Keith Nauman, Senior Vice President, Access Edge Solutions, who will participate in the panel discussion “Fiber Access Technologies Deep Dive” from 12:30 to 1:50 p.m. on Monday, August 21.Jason Lauzon, Director, Strategic Sales and Customer Engineering, who will participate in the panel discussion “The Middle Mile Technology Deep Dive” from 12:30 to 1:50 p.m. on Tuesday, August 22.William Marx, Government Affairs Manager, who will participate in the “Understanding the Political Landscape” session from 12:40 to 1:30 p.m. on Sunday, August 20.Visit DZS at Fiber Connect 2023 at booth #403.To learn more about DZS, visit https://www.dzsi.com.About DZSDZS Inc. (Nasdaq: DZSI) is a global leader of access, optical and cloud-controlled software defined solutions.DZS, the DZS logo, and all DZS product names are trademarks of DZS Inc. Other brand and product names are trademarks of their respective holders. Specifications, products, and/or product names are all subject to change.This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” variations of such words, and similar expressions are intended to identify forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings.  In addition, additional or unforeseen affects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. DZS undertakes no obligation to update or revise any forward-looking statements for any reason.For further information see: www.DZSi.com.DZS on Twitter: https://twitter.com/dzs_innovationDZS on LinkedIn: https://www.linkedin.com/company/DZSi/CONTACT: Press Inquiries: Kenny Vesey, Thatcher+Co. Phone: +1.973.518.3644 Email: [email protected]

GlobeNewswire

DZS to Debut Multiple BABA-Ready Network Edge Innovations at Fiber Connect 2023 to Accelerate Bridging the Digital Divide

https://finance.yahoo.com/news/dzs-debut-multiple-baba-ready-120000703.html

fd319271-5a17-367e-982c-61f8228f2009

DZSI

DZSDALLAS, Aug. 18, 2023 (GLOBE NEWSWIRE) -- DZS Inc. (“DZS” or the “Company”) (Nasdaq: DZSI), a global leader of access, optical and cloud-controlled software defined solutions, announced today that on August 15, 2023, it received a delinquency notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Form 10-Q”). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market.The Company filed a Notification of Late Filing on Form 12b-25 on August 9, 2023, indicating, among other things, that the filing of the Form 10-Q would be delayed principally due to the ongoing review by the Audit Committee of the Company’s Board of Directors of the Company’s accounting for revenue recognition and the extent to which these matters affect the Company’s internal controls over financial reporting in connection with the need to restate the Company’s previously issued unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2023.Nasdaq has informed the Company that the Company must submit a plan of compliance (the “Plan”) within 60 calendar days, or no later than October 16, 2023, addressing how it intends to regain compliance with Nasdaq’s listing rules and, if Nasdaq accepts the Plan, it may grant an extension of up to 180 calendar days from the Form 10-Q original filing due date, or until February 5, 2024, to regain compliance.The Company plans to file the Form 10-Q as soon as reasonably practicable following the completion of the Audit Committee’s review and the restatement.About DZS Inc.DZS Inc. (Nasdaq: DZSI) is a global leader of access, optical and cloud-controlled software defined solutions.Story continuesDZS, the DZS logo, and all DZS product names are trademarks of DZS Inc. Other brand and product names are trademarks of their respective holders. Specifications, products, and/or product names are all subject to change.This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” variations of such words, and similar expressions are intended to identify forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings. In addition, additional or unforeseen affects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. DZS undertakes no obligation to update or revise any forward-looking statements for any reason.For further information see: www.DZSi.com.DZS on Twitter: https://twitter.com/dzs_innovationDZS on LinkedIn: https://www.linkedin.com/company/DZSi/CONTACT: Press Inquiries: Kenny Vesey, Thatcher+Co. Phone: +1.973.518.3644 Email: [email protected]

GlobeNewswire

DZS Inc. Receives Nasdaq Notice Regarding Late Form 10-Q Filing

https://finance.yahoo.com/news/dzs-inc-receives-nasdaq-notice-210000757.html

c8bed9d1-e4f9-3010-b05a-29b300c9f5d1

E

Baker Hughes Company BKR entered into an agreement with Tellurian Inc. TELL to supply refrigerant compression packages for the Driftwood Liquefied Natural Gas (“LNG”) project in Louisiana.Baker Hughes will supply eight LM6000PF+ gas turbines, main refrigerant compressors and control units for the first phase of the Driftwood LNG project.Upon completion, Driftwood’s Phase 1 will involve two LNG facilities with a combined export capacity of 11 million tons per year. Baker Hughes’ technology will help Driftwood LNG achieve initial LNG production in 2027.Driftwood LNG will have the capacity to export up to 27.6 million tons of LNG per annum. Once online, Driftwood LNG is expected to become one of the low-cost LNG production projects globally.Baker Hughes is expected to complete fabricating the electric-powered integrated compressor line (ICL) packages and other turbomachinery equipment for the Driftwood Pipeline’s Line 200 by early 2024. This marks the first time Baker Hughes would install its ICL decarbonization technology for pipeline compression in North America.Bechtel Energy is the engineering, procurement and construction contractor for the first phase of the Driftwood LNG terminal. Bechtel completed the piling and compressor foundations for Plant 1 of the Driftwood LNG project.Tellurian develops low-cost LNG projects. The company owns and operates natural gas liquefaction and storage facilities and loading terminals. Notably, the firm expects the development costs for the first phase of its Driftwood LNG export plant to reach $14.5 billion.Baker Hughes is recognized as an industry leader in the LNG space. BKR expects growth in LNG demand to extend for several years, with a pipeline of international opportunities expanding project visibility out to 2026 and beyond. Notably, BKR’s reliable technology solution will support LNG production in the United States.Price PerformanceShares of Baker Hughes have outperformed the industry in the past six months. The stock has gained 23.7% compared with the industry’s 17.7% growth.Story continuesZacks Investment ResearchImage Source: Zacks Investment ResearchZacks Rank & Stocks to ConsiderBKR currently carries a Zack Rank #3 (Hold).Some better-ranked players in the energy sector are USA Compression Partners, LP USAC and Eni SpA E. Each of these companies currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.USA Compression Partners is one of the largest independent natural gas compression services providers across the United States in terms of fleet horsepower.USA Compression Partners has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days. The consensus estimate for USAC’s 2023 and 2024 earnings per share is pegged at 30 cents and 58 cents, respectively.Eni SpA, based in Rome, Italy, is among the leading integrated energy players in the world.The company announced a share buyback plan of €2.2 billion for the year, which commenced in May. It intends to return 25-30% of annual cash flow to shareholders.Eni has witnessed upward earnings estimate revision for 2023 and 2024 in the past 30 days. The consensus estimate for E’s 2023 and 2024 earnings per share is pegged at $5.19 and $4.99, respectively.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEni SpA (E) : Free Stock Analysis ReportUSA Compression Partners, LP (USAC) : Free Stock Analysis ReportBaker Hughes Company (BKR) : Free Stock Analysis ReportTellurian Inc. (TELL) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Baker Hughes (BKR) to Supply Equipment for Driftwood Project

https://finance.yahoo.com/news/baker-hughes-bkr-supply-equipment-165100447.html

ee510195-0d79-3b0a-9786-f4ce1aa793fe

E

Antero Resources Corporation AR has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days.The company, with a Zacks Rank #3 (Hold), has gained 25.1% over the past three months compared with 15.6% growth of the composite stocks belonging to the industry.Zacks Investment ResearchImage Source: Zacks Investment ResearchFactors Working in FavorNatural gas is trading at more than $2.61 per MMBtu, highlighting a handsome commodity pricing environment. Being a leading natural gas producer, Antero Resources is well-positioned to capitalize on the favorable commodity price.Antero Resources’ strategic acreage position in the low-risk/long reserve-life properties of the Appalachian Basin is a major positive. Its core acreage position allows for significant long-lateral drilling opportunities and capital efficiencies. The company boasts that in the prolific basin, it has more than two decades of premium low-cost drilling inventory, representing a solid production outlook.Looking at financial strength, Antero Resources has a strong and sustainable balance sheet. Compared to composite stocks of the industry, the company has significantly lower debt exposure, as reflected in the lower debt-to-capitalization ratio over the past few years.AR is targeting a capital return program of 25-50% of free cash flow per year, beginning with the implementation of share repurchase program. Since the inception of the buyback plan in the first quarter of 2022, the company has repurchased 31.1 million shares for roughly $1 billion. The company currently has $1 billion of remaining capacity under the buyback program.Demand for natural gas is expected to surpass supply growth over the next two years, driven by significant LNG export growth. AR is well-positioned to benefit from its leading firm transportation portfolio, which delivers the majority of its gas to the growing LNG demand markets. Also, the firm emits lower greenhouse gases than other major fossil fuel players.Story continuesThus, Antero Resources, the fast-growing natural gas producer in the United States, is poised for an upside in the coming days.Risks Responsible to Limit GrowthAs an upstream energy firm, Antero Resources is highly exposed to volatility in commodity prices. Also, the company’s lack of geographic diversification adds to the concern since its entire asset base is located in the Appalachian region.Key PicksSome better-ranked players in the energy sector are USA Compression Partners, LP USAC, Enerplus Corporation ERF and Eni SpA E. Each of these companies currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.USA Compression Partners is one of the largest independent natural gas compression services providers across the United States in terms of fleet horsepower.USA Compression Partners has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days. The consensus estimate for USAC’s 2023 and 2024 earnings per share is pegged at 30 cents and 58 cents, respectively.Enerplus Corporation is an independent oil and gas production company with resources across Western Canada and the United States.Enerplus Corporation has witnessed upward earnings estimate revisions for 2023 and 2024 in the past 30 days. The consensus estimate for ERF’s 2023 and 2024 earnings per share is pegged at $2.26 and $2.66, respectively.Eni SpA, based in Rome, Italy, is among the leading integrated energy players in the world.The company announced a share buyback plan of €2.2 billion for the year, which commenced in May. It intends to return 25-30% of annual cash flow to shareholders.Eni has witnessed upward earnings estimate revision for 2023 and 2024 in the past 30 days. The consensus estimate for E’s 2023 and 2024 earnings per share is pegged at $5.19 and $4.99, respectively.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEni SpA (E) : Free Stock Analysis ReportEnerplus Corporation (ERF) : Free Stock Analysis ReportUSA Compression Partners, LP (USAC) : Free Stock Analysis ReportAntero Resources Corporation (AR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why Hold Strategy is Apt for Antero Resources (AR) Stock Now

https://finance.yahoo.com/news/why-hold-strategy-apt-antero-171400738.html

6c03ac1c-bef7-3955-a6e8-ceb8e632397d

EA

Madden NFL 24 Sees More Players and Games Played in Launch Week Year-over-Year and Now Welcomes PlayStation® and Xbox Players to Participate in Free Trial This WeekendEA SPORTS™ Offers New Madden NFL 24 NFL+ Edition Making it Even Easier for Fans to Play and Watch the Sport They LoveREDWOOD CITY, Calif., September 07, 2023--(BUSINESS WIRE)--Electronic Arts Inc. (NASDAQ: EA) is celebrating the 2023 NFL Season kickoff by inviting football fans everywhere to play EA SPORTS™ Madden NFL 24 via a global trial, during a Free Play Weekend,* September 7 through September 10 on Xbox One, Xbox Series X|S, PlayStation®4 and PlayStation®5. Players on Xbox Series X|S and PS5™ platforms can experience the new levels of control and realism delivered through elevated gameplay along with the fun of mini-games and depth of Superstar Mode, Franchise Mode and more. NFL fans looking to jump headfirst into the season kickoff can enjoy the new Madden NFL 24 NFL+ Edition** (available until October 10), which gives fans a unique opportunity to play and watch all of the NFL action by accessing Madden NFL 24 and 3 months of NFL+ Premium, the NFL’s direct-to-consumer service.†This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907825819/en/Madden NFL 24 NFL Kickoff Infographic - Cover athlete Josh Allen is the top quarterback according to Madden NFL 24 players (Graphic: Business Wire)Madden NFL continues to welcome more football fans into the game – Madden NFL 24 set a single-week franchise record for digital units sold, saw a 36 percent increase in games played and drew more players during week one of launch compared to Madden NFL 23. Through the increased play, several trends emerged that project who fans think might make the biggest impact this season:Cover athlete Josh Allen was the top quarterback for a second consecutive year and totaled more than double the passing touchdowns of runner-up Patrick MahomesThe Ravens vaulted to the most used team behind a 180 percent increase in year-over-year usage; newly added Odell Beckham Jr. tallied the most touchdown catches and Lamar Jackson (#4) landed in the top-five quarterbacksPlayers pegged the AFC North as a division to watch, with three teams among the most popular in the game (Ravens #1, Bengals #2, Steelers #4) and two intra-division clashes (Ravens-Steelers #1, Bengals-Ravens #4) among the most common matchupsJonathan Taylor was the game’s top running back, newly traded Jalen Ramsey led in interceptions and Aaron Donald racked up the most sacksStory continues"We love seeing more players enjoying Madden NFL 24, and looking at all the ways they are exploring the new gameplay, new modes, and everything about this year’s experience," said Mike Mahar, Senior Production Director, EA SPORTS Madden NFL. "NFL Kickoff means a brand new season of world class football competition is upon us, and alongside the big hits and game changing plays each week, our team will be hard at work bringing new content, experiences and improvements based on player feedback via live service updates all season long."New content in Madden NFL 24 this week includes the release of the six-song EP, CROWD CONTROL, also available on all DSPs. CROWD CONTROL features Pro Bowler Darren Waller (N.Y. Giants), four-time Pro Bowler Terron Armstead (Miami Dolphins), Ray-Ray McCloud (S.F. 49ers), three-time Pro Bowler Melvin Ingram and Pro Bowler DJ Chark (Carolina Panthers). The players perform alongside hip-hop stars Rob49, Jay Rock, That Mexican OT, and Lebra Jolie, and the album features production from EST Gee and Turbo while GRAMMY Award winner Derrick Milano serves as the executive producer.The Madden NFL 24 NFL+ Edition, available now through October 10, includes the Madden NFL 24 Standard Edition, 3 monthly Ultimate Team packs (1 per month Sept-Nov), and 3 months of NFL+ Premium content. NFL+ Premium gives fans access to live local and primetime games on mobile, NFL RedZone, NFL Network, Game Replays and more so they never miss a play.To stay up-to-date on all-things Madden NFL 24 follow Instagram, Twitter and TikTok or visit the Madden NFL website.Visit: EAPressPortal.com for Madden NFL 24 assetsMadden NFL 24 is developed in Orlando, Florida and Madrid, Spain by EA Tiburon for Xbox Series X|S, PlayStation®5, Xbox One, PlayStation®4, and PC via EA app for Windows, Steam® and Epic Games Store. Download Madden NFL 24 Mobile Football from the Apple App Store® or Google Play™ store now.About Electronic ArtsElectronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company develops and delivers games, content and online services for Internet-connected consoles, mobile devices and personal computers.In fiscal year 2023, EA posted GAAP net revenue of approximately $7.4 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality brands such as EA SPORTS FC™, Battlefield™, Apex Legends™, The Sims™, Madden NFL, Need for Speed™, Titanfall™, Plants vs. Zombies™ and F1®. More information about EA is available at www.ea.com/news.EA, EA SPORTS, EA SPORTS FC, Battlefield, Need for Speed, Apex Legends, The Sims, Titanfall and Plants vs. Zombies are trademarks of Electronic Arts Inc. John Madden, NFL, and F1 are the property of their respective owners and used with permission.*Conditions apply. See https://ea.com/games/madden-nfl/madden-nfl-24/free-trial for details. Trial period may vary based on platform, see retailer for details.**Limited time offer only available in U.S. Conditions & restrictions apply. See www.ea.com/madden-24-disclaimers & www.nfl.com/legal/subscriptions_terms for details.†NFL+ Terms: Offer only available in U.S. to new & qualified returning NFL+ subscribers. To redeem NFL+ subscription offer, you must create an NFL account and provide a valid credit card number. Subscription must be redeemed within ninety (90) days from date of purchase. NFL+ is $14.99/month after 3-month promotional period. Subscription automatically renews until canceled. Terms and conditions apply. See www.nfl.com/legal/subscriptions_terms for details. Madden NFL 24: NFL+ Edition offer ends on 10/10/23.Category: EA SportsView source version on businesswire.com: https://www.businesswire.com/news/home/20230907825819/en/ContactsNathan EdwardsPR [email protected]

Business Wire

EA SPORTS™ Madden NFL 24 Sets Single-Week Franchise Record for Digital Units Sold and Brings More Ways to Play and Watch Ahead of NFL Kickoff Weekend

https://finance.yahoo.com/news/ea-sports-madden-nfl-24-160000388.html

a63f5c79-fdad-3132-ad5f-5f153943117e

EA

On Wednesday, GameStop Corporation (NYSE: GME) exceeded Wall Street estimates with its top and bottom line second quarter results. GameStop shares rose almost 6% in extended trading as the reported quarter showed signs that efforts under the leadership of Ryan Cohen to boost the company’s digital presence are working as intended as Game Stop reported a narrower than expected loss amid increased gaming demand as gamers splurged on F1 23 from Electronic Arts (NASDAQ: EA) and Diablo IV published by Activision Blizzard (NASDAQ: ATVI) that should soon get acquired by no other than Microsoft Corporation (NASDAQ: MSFT).Second Quarter HighlightsDuring the quarter that ended on July 29th, Game Stop reported its revenue rose about 2% to $1.16 billion, topping $1.14 billion that three analysts polled by LSEG estimated. The Texas-based company attributed the rise in revenue to "significant software release" along with increased sales of new gaming hardware in several international segments. Software and collectibles sales made about 49% of total revenue, while the remaining half was made of hardware sales that remained flat. However, software sales rose 25% but they were offset by a 24% decline in collectibles.With efficient cost-cutting efforts, Game Stop reduced its selling, general and administrative expenses to $322.5 million, making 27.7% of net sales while during last year’s comparable quarter, these expenses amounted to $387.5 million, making up about 34.1% of net sales. But Game Stop also had transition costs $4.3 million from its store closures in Europe where it has been lowering its footprint as Cohen steered the company away from physical stores to an increased digital presence in an effort to rebound from the recent sales slump caused by console users and gamers downloading games over the internet instead of buying hard copies that GameStop sells. Also, publishers have been releasing more free games to attract smartphone and tablet gamers and altered their revenue models to rely more on advertising and sales of virtual goods.Story continuesIntense Dynamics Is In The Air At The Gaming WorldGaming has even taken center stage at Microsoft that is trying to finalize its $68.7 billion acquisition of Activision Blizzard. Although the deal has encountered several regulatory setbacks, it is getting closer to a close. Together, Microsoft and Activision Blizzard agreed to push the deadline to complete the deal to October 18th. Last month, Microsoft submitted a proposal to the U.K.’s Competition and Markets Authority with which it agrees to transfer cloud streaming rights to PC and console games that Activision Blizzard published to Ubisoft for 15 years, in case the acquisition goes through.Meanwhile, one of the world’s largest publishers, Electronic Arts, is focusing on growing its existing franchises and disproportionately invest in its successful IPs to create a new world that generates more engagement. Electronic Arts CEO Andrew Wilson spoke at a recent conference, and although many of its franchises like The Sims, Madden and Battlefield already boast substantial communities, Wilson expressed particular enthusiasm around the FIFA franchise that is in for rebranding with the launch of EA Sports FC 24. The purpose of this move is to empower Electronic Arts to go beyond the game as the rebranding is expected to open new collaboration and expansion opportunities: from welcoming commercial partners to expanding into football-related ventures, as well as operating at a faster pace.FIFA 23 already achieved impressive engagement levels that resulted in record-breaking sales and increased playtime.Meanwhile, GameStop’s Corporate Structure Is Still In The WorksAs a result of the shake up in the gaming universe, GameStop CFO stepped down last month after the board ousted the fifth CEO in five years back in June. But Ryan Cohen, now executive chairman and company’s largest shareholder, seems to have a good game plan in the works. Mark H. Robinson, general counsel and secretary, took on additional roles of general manager and principal executive director and Daniel Moore has been appointed as principal accounting officer and interim principal financial officer. Back in January, GameStop came back to quarterly profit after seven straight quarter of losses, and now it continues its turnaround journey without a CEO and CFO as no new executive appointments have been announced during the quarterly report and there won’t be a conference call.DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.This article Game Stop's Second Quarter Report Shows It Is Getting Its Game Back originally appeared on Benzinga.com.© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga

Game Stop's Second Quarter Report Shows It Is Getting Its Game Back

https://finance.yahoo.com/news/game-stops-second-quarter-report-162052051.html

9e13d510-c2a9-32d1-895b-065b2dddbfae

EAF

In this article we present the list of Mohnish Pabrai's 10 Biggest Investments in 10 Years. Click to skip our detailed analysis of Mohnish Pabrai’s background and investing history and jump right to Mohnish Pabrai's 5 Biggest Investments in 10 Years.Micron Technology, Inc. (NASDAQ:MU), General Motors Company (NYSE:GM), and Bank of America Corporation (NYSE:BAC) are a few of the stocks that Mohnish Pabrai has built substantial stakes in over the last ten years, with those companies delivering varied performance in the years since.Mohnish Pabrai is the founder of Pabrai Investment Funds, and one of the most successful value investors in the world, with a net worth estimated at $1.8 billion as of May 2022. He is an unabashed admirer and copycat of Warren Buffett, having paid just over $650,000 to have lunch with the legendary investor back in 2007, which he later said was worth every penny.While Pabrai doesn’t have the track record outstanding returns that Buffett has, he is by no means a slouch when it comes to successful value investing. From his fund’s inception in 1999, it has delivered 25% annualized returns, easily beating the market most years and massively outperforming it on several occasions, including 2009, when his fund returned 120%.One of the key philosophies that Pabrai sticks to is to find extremely undervalued companies that could deliver returns of up to 5x over the course of a few years and then wait. As he told Forbes in 2013, he has no interest in stocks that look 10% undervalued. He bets on only the most obvious investments he can find and has said that if he can find a couple of great investment ideas every year, he’s more than happy.Rather than just single stocks, Pabrai has frequently focused on a few stocks at a time within specific sectors. He bet heavily on finance stocks in the early 2010’s before shifting his focus to consumer discretionary stocks (namely automakers) through the latter half of the decade. He then shifted heavily into tech stocks, before his latest shift out of tech and into the materials sector.Story continuesAs evidenced by his current 13F portfolio, Pabrai is not an easy investor to emulate for those focused on stocks that trade on the major U.S. exchanges. He currently has just two 13F holdings, both of which were just added to his portfolio during the second quarter. Instead, the bulk of his focus is on emerging markets, where he believes there are far more highly undervalued stocks for him to unearth.However, given his highly concentrated 13F portfolio, it is quite easy to emulate just his U.S. stock picks, assuming you’re willing to display the patience that Pabrai knows is extremely challenging, but also vital to being a successful value investor.That said, emulating Pabrai’s stock picks and holding on to them for several years may not be a winning strategy, as evidenced by the long-term performance of his ten biggest holdings from the past decade, which we’ll look at below. Rather, Insider Monkey has found that it’s far more lucrative to emulate the consensus stock picks of a select group of top performing hedge funds each quarter.Note that the stock performance figures of Pabrai’s top stock picks listed below are not indicative of Pabrai’s personal returns on these stocks, many of which he sold out of years ago. Rather, it’s to judge the long-term performance of stocks that he once deemed highly undervalued and likely to deliver massive returns in the coming years. In many cases, those returns never materialized.Mohnish Pabrai's 10 Biggest Investments in 10 YearsOur MethodologyThe following data is gathered from Pabrai Investment Funds’ 13F filings with the SEC dating back to the third quarter of 2013. We follow hedge funds like Pabrai Investment Funds because Insider Monkey’s research has uncovered that their consensus stock picks can deliver outstanding returns.All hedge fund data is based on the exclusive group of 900+ funds tracked by Insider Monkey that filed 13Fs for the Q1 2023 reporting period.Mohnish Pabrai's 10 Biggest Investments in 10 Years10. Alphabet Inc. (NASDAQ:GOOG)Value of Pabrai Investment Funds’ 13F Position: $63.5 million (Q3 2017) Stock Performance Since Q3 2017: +155% Number of Hedge Fund Shareholders (Q1 2023): 155 (GOOG), 204 (GOOGL) Bank of America Corporation (NYSE:BAC), Micron Technology, Inc. (NASDAQ:MU), and General Motors Company (NYSE:GM) are three of Mohnish Pabrai’s biggest investments in 10 years, though none of them have performed as well as Alphabet Inc. (NASDAQ:GOOG) in recent years, which has been one of Pabrai’s top performing stock picks since he built a $63.5 million position in the company in the third quarter of 2017, the tenth-largest position he’s held in a stock over the past ten years. GOOG shares have gained 155% since Q3 2017, though Pabrai sold off his stake in Alphabet in the first quarter of 2018, personally missing out on most of those gains.Alphabet Inc. (NASDAQ:GOOG) has been focusing heavily on its AI capabilities dating back to just before Pabrai’s largest position in the company, which should quell any concerns about AI chatbots overthrowing its advertising dominance. Those fears have gone unrealized thus far, as Google search and advertising revenue both rose during Q2. Those investments are poised to pay off further in the years to come as Alphabet integrates AI capabilities into its search engine and other products.Alphabet Inc. (NASDAQ:GOOG) has been a top performer for the Weitz Partners III Opportunity Fund this year, as outlined in the fund’s Q2 2023 investor letter:“The year-to-date’s top contributors Microsoft Corp. (MSFT) and Google parent Alphabet Inc. (NASDAQ:GOOG) (also a top quarterly contributor) have generated an enormous volume of AI-centric headlines. Both are at the vanguard of introducing AI-powered technologies into consumer-facing products, most notably their respective search engine. We trimmed several of the year’s winners on strength, including Meta, Microsoft, Alphabet, CoStar Group, Inc. (CSGP), and CarMax.”9. POSCO Holdings Inc. (NYSE:PKX)Value of Pabrai Investment Funds’ 13F Position: $72.8 million (Q2 2014) Stock Performance Since Q2 2014: +44.7% Number of Hedge Fund Shareholders (Q1 2023): 6 Mohnish Pabrai unloaded his stake in POSCO Holdings Inc. (NYSE:PKX) in the final quarter of 2015 after several years of owning PKX shares. His stake in the company reached its peak (dating back to Q3 2013) in the second quarter of 2014, being valued at $72.8 million. The stock has gained a modest 44.7% in the nine years since, or about 5% per year on average.While POSCO Holdings Inc. (NYSE:PKX)’s returns have been underwhelming, especially up until its recent rally, investors and analysts are intrigued by the company’s proposed shift away from being a pure play steelmaker. Posco plans to invest more than $90 billion over the next seven years into renewable energy technologies like batteries and hydrogen fuel cells, as well as further investments into its core business.The investment will surge Posco’s annual capital spending by about 75% on average over the next seven years, which will challenge POSCO Holdings Inc. (NYSE:PKX)’s bottom line and almost certainly require the company to raise money and/or take on a major debt burden. There are also questions about the company’s bullish lithium price expectations by 2030, with the company forecasting lithium at $30,000 per ton, while UBS forecasts lithium to sell for $22,500 per ton.8. GrafTech International Ltd. (NYSE:EAF)Value of Pabrai Investment Funds’ 13F Position: $73.6 million (Q3 2019) Stock Performance Since Q3 2019: -66.4% Number of Hedge Fund Shareholders (Q1 2023): 14 Pabrai’s opened a position in GrafTech International Ltd. (NYSE:EAF) during the second quarter of 2019 and raised it by 35% during the following quarter, during which it reached $73.6 million in value. He began unloaded the position in Q4 of that year and had sold out of it completely by the first quarter of 2020. GrafTech has been one of the worst performers that Pabrai latched onto, losing two-thirds of its value since the third quarter of 2019.GrafTech International Ltd. (NYSE:EAF) has grappled with both slowing demand for its graphite electrodes in recent quarters, as well as the temporary shutdown of its production facility in Mexico last year. The company’s Monterrey operations, which account for about 25% of GrafTech’s total production capacity, are back in business, but demand is likely to remain sluggish throughout 2023. As the largest supplier of graphite electrodes, GrafTech is well positioned longer-term to capitalize on the steel industry’s pivot to electric arc steel furnaces.The Black Bear Value Fund was bullish on GrafTech International Ltd. (NYSE:EAF)’s future top-line and margin growth in its Q2 2022 investor letter:“GrafTech manufactures graphite electrodes in North America and Europe. The electrodes are necessary to produce electric arc furnace steel, a more environmental process than blast furnace production. EAF benefits from a global push to decarbonize steelmaking which is driving new capacity in electric arc steelmaking. EAF can self-source their main input, pet-needle coke, through their Seadrift subsidiary. Pet-needle coke is increasingly going to be in short supply as it is an important input commodity for electric vehicle battery production. Owning your own input commodity is a strategic advantage as others cannot guarantee production nor guarantee a profit on an order.EAF is in a unique position. Their product helps steelmakers emit less greenhouse gases which helps drive the topline. They can guarantee their product as they know 2/3 of their capacity can be covered by Seadrift. The market is worried about recession which could result in some short-term pain to the industry. Another area of concern are long-term-agreements (LTA’s) which are starting to roll off. Bears are concerned that as the business shifts to the spot market, the margins will decline. I will concede that historical margins are unlikely to be repeated but it seems likely new LTA’s will be signed.Recall our earlier discussion on scarcity. Their competitors DO NOT have control of their input costs…this advantage will become more pronounced as pet needle coke becomes scarcer as EV production ramps up. That should lead to higher top-line prices and healthy margins for EAF. I conservatively think we own this business at 11-16% FCF yield and presume no new long-term contracts are signed. In time new LTA’s will be signed and the business should achieve a more appropriate valuation.”7. Citigroup Inc. (NYSE:C)Value of Pabrai Investment Funds’ 13F Position: $81.3 million (Q4 2013) Stock Performance Since Q4 2013: -15.5% Number of Hedge Fund Shareholders (Q1 2023): 81 Financial institutions were a favorite investment of Mohnish Pabrai’s for nearly a decade, up until the beginning of 2015. Citigroup Inc. (NYSE:C) was added to his portfolio in the final quarter of 2011 and occupied a prominent place in it until the end of 2014. He unloaded the majority of his Citi position in the first quarter of 2015 and finished the job the following quarter. Citigroup’s shares have fallen by 15.5% in the nearly ten years since Pabrai held an $81.3 million position in the company in the final quarter of 2013.Citigroup Inc. (NYSE:C) has been undertaking a broad transformation initiative since early 2021 that includes divesting some of the investment bank’s smaller and less profitable operations, particularly its overseas consumer banks, with the goal of simplifying its corporate structure and making the company more attractive to investors.Citigroup Inc. (NYSE:C) currently trades at a P/E of just 6.36x. By comparison, Citi shares were trading at a P/E of 11.3x on June 30 2015, by which point Pabrai had sold off his position. While the shares are relatively cheap historically, it’s also true that Citigroup has been underperforming some of its rivals like Bank of America Corporation (NYSE:BAC). In the first quarter, Citi’s ROE was just 9.5%, while its ROTCE was 10.9%, well off Bank of America’s 12.5% and 17.4% figures respectively.6. Seritage Growth Properties (NYSE:SRG)Value of Pabrai Investment Funds’ 13F Position: $87.1 million (Q2 2021) Stock Performance Since Q2 2021: -52.6% Number of Hedge Fund Shareholders (Q1 2023): 18 Seritage Growth Properties (NYSE:SRG) appears to be another disappointing investment for Mohnish Pabrai, and also stands as one of his most recent investments. He held on to a small stake in the retail REIT up until the first quarter of this year, though the bulk of his former position was sold off in the first quarter of 2020, during which SRG shares cratered from $40 to $8. They rebounded to as much as $23 a year later but are back down to less than $9 today.Seritage Growth Properties (NYSE:SRG) is currently in the process of liquidating its assets, which the company believed could amount to between $18.50 and $29.00 per share being distributed to shareholders. However, with real estate valuations having since fallen, it looks more likely that Seritage will come up short of its lowest estimate, which has dragged down the stock. Seritage anticipates selling over 80 of its remaining assets this year, of which more than half have already been sold despite the challenging market conditions.O’keefe Stevens Advisory took a deep dive into some of what went wrong with Seritage Growth Properties (NYSE:SRG) in its Q3 2022 investor letter:“Seritage Growth Properties (NYSE:SRG) – A good idea on paper, hard to execute in practice. When we made our initial purchase in 2018, we thought the idea of repurposing existing Sears and Kmart properties at below-market rents into modern spaces, enabling the company to charge multiples of the prior rent, made sense. Increasing rents from $5 to $20 PSF with a 10-11% ROI seemed like a nobrainer. The return profile made sense, and applying moderate leverage to stabilized properties improved end economics. Multiple changes at the management level and a $1.44B loan from Berkshire with a 7% interest rate and covenants (yes, those still exist) made this an impossible endeavor. We thought partnering with Eddie Lampert would align our interests and prove an intelligent decision, given the capital and brain power he has put into this situation.On paper, selling non-core assets and using the proceeds to fund Capex plans and ongoing corporate expenses makes sense. The problem is the number of properties the company needed to sell for this business model to work. Every year that went by materially lowered the company’s value as the interest expense proved to be a heavy burden. The company essentially turned into a death spiral where they were merely selling properties to meet the interest expense and having little remaining for the core part of the business plan. Compiling all this with the lockdowns in 2020 and 2021 and the supply chain mess still being worked through has further delayed this turnaround.Today the company is much smaller. Seritage once owned 253 properties totaling 39m SF compared to today, where they own161 properties and 19m SF. During this time, they only paid down $100m of the term loan. The turnaround has taken too long, and the company has put itself up for sale. Again, on paper, this seems like a good idea; however, going through a sale of this proportion will take a long time in a calm environment. The rise in interest rates, tight credit markets, and equity market volatility make this a monumental task. I suspect the number of buyers for these properties, which was once small to begin with, is down to a handful. A critical issue with the SRG portfolio is that the assets are spread out across the country. One player is not going to purchase all these assets. Real Estate Developers and owners tend to concentrate their efforts on a single region (excluding the global players such as Blackstone, Simon, and other private equity groups). Seritage may be able to sell some nearby properties as a package but would likely take a discount to FV, or it has to sell each property one by one…(Click here to read the full text) See where General Motors Company (NYSE:GM), Bank of America Corporation (NYSE:BAC), and Micron Technology, Inc. (NASDAQ:MU) rank among Mohnish Pabrai’s biggest investments over the past decade by clicking the link below. Click to continue reading and see the Mohnish Pabrai's 5 Biggest Investments in 10 Years. Suggested articles:Goldman Sachs Tech Stocks: Top 12 Stock Picks10 Most Promising Penny Stocks According to Analysts13 Best Wide Moat Stocks To Buy According To Hedge FundsDisclosure: None. Mohnish Pabrai's 10 Biggest Investments in 10 Years is originally published at Insider Monkey.

Insider Monkey

Mohnish Pabrai’s 10 Biggest Investments in 10 Years

https://finance.yahoo.com/news/mohnish-pabrai-10-biggest-investments-230416410.html

4815fa4a-3986-337e-ab8b-43e7abddffe6

EAF

Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase? A business that's potentially in decline often shows two trends, a return on capital employed (ROCE) that's declining, and a base of capital employed that's also declining. This indicates the company is producing less profit from its investments and its total assets are decreasing. So after we looked into GrafTech International (NYSE:EAF), the trends above didn't look too great.What Is Return On Capital Employed (ROCE)?If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for GrafTech International:Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)0.15 = US$199m ÷ (US$1.5b - US$180m) (Based on the trailing twelve months to June 2023).Thus, GrafTech International has an ROCE of 15%. In absolute terms, that's a pretty normal return, and it's somewhat close to the Electrical industry average of 13%. Check out our latest analysis for GrafTech International roceAbove you can see how the current ROCE for GrafTech International compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free report for GrafTech International.The Trend Of ROCEWe are a bit worried about the trend of returns on capital at GrafTech International. To be more specific, the ROCE was 47% five years ago, but since then it has dropped noticeably. On top of that, it's worth noting that the amount of capital employed within the business has remained relatively steady. Companies that exhibit these attributes tend to not be shrinking, but they can be mature and facing pressure on their margins from competition. So because these trends aren't typically conducive to creating a multi-bagger, we wouldn't hold our breath on GrafTech International becoming one if things continue as they have.Story continuesIn Conclusion...All in all, the lower returns from the same amount of capital employed aren't exactly signs of a compounding machine. Unsurprisingly then, the stock has dived 77% over the last five years, so investors are recognizing these changes and don't like the company's prospects. With underlying trends that aren't great in these areas, we'd consider looking elsewhere.If you'd like to know more about GrafTech International, we've spotted 3 warning signs, and 1 of them is a bit unpleasant.While GrafTech International isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Some Investors May Be Worried About GrafTech International's (NYSE:EAF) Returns On Capital

https://finance.yahoo.com/news/investors-may-worried-graftech-internationals-132050100.html

b9120de2-946e-35a7-9865-e92a7453a757

EAR

ParticipantsAdam Laponis; CFO; Eargo, Inc.Christian Gormsen; CEO, President & Director; Eargo, Inc.Nicholas S. Laudico; Chief Retail Officer; Eargo, Inc.Malgorzata Maria Kaczor Andrew; Partner & Research Analyst; William Blair & Company L.L.C., Research DivisionPresentationOperatorLadies and gentlemen, good afternoon. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eargo First Quarter 2023 Earnings Conference Call. Today's conference is being recorded (Operator Instructions)And I will now turn the conference over to Nick Laudico, Chief Retail Officer. You may begin.Nicholas S. LaudicoThanks, operator. Good afternoon, everyone, and welcome to the Eargo First Quarter 2023 Earnings Conference Call. As a reminder, this call is being broadcast live and a digital replay will be available on our IR website. Joining me on today's call are Christian Gormsen, President and Chief Executive Officer; and Adam Laponis, Chief Financial Officer.Before we begin, I'd like to remind you that some of the matters discussed in the conference call will contain forward-looking statements regarding future events as outlined in our press release today. We wish to caution you that such statements are based on management's current expectations and beliefs, are forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ include, but are not limited to, factors referenced in our press release today as well as our filings with the SEC.Before turning the call over to Christian, I want to make note that we have posted a historical GAAP to non-GAAP reconciliation table on our IR website in the Events & Presentations section.With that said, I will now turn the call over to Christian.Christian GormsenThank you, Nick, and thank you, everyone, for joining us today. Through the first quarter of 2023, we continued to make progress on evolving Eargo into a true omnichannel business. Retail once again led the way in our efforts to diversify our business growth with our direct-to-consumer cash-pay business seeing increased efficiency as we continue to refine our media spend. While still early, we also continue to pursue opportunities to expand our presence in the insurance market.Our first quarter volume growth, combined with our continued capital efficiency initiatives, led to increased gross margins, reduced operating expenses and a lower net operating loss. We believe the worst of the uncertainty impacting our business is behind us, enabling us to make incremental steps in the right direction each quarter. As such, we believe that quarterly net operating cash burn will continue to see modest sequential improvements in the remaining quarters of 2023.Moving to a summary of our first quarter business performance. First quarter net revenue was $11.8 million, up approximately 29% year-over-year and slightly down on a sequential basis. As a reminder, Q1 is typically a sequentially down quarter following the end of heightened holiday promotional activity in Q4.First quarter gross shipment growth was primarily driven by sales to Victra, our largest retail partner. In the first quarter, Victra submitted an initial stocking order of Eargo 7 hearing aid devices in addition to subsequent replenishment orders. Since announcing our nationwide partnership with Victra last fall, we have been pleased with the early progress in this new channel. Importantly, Victra reports that Eargo devices continue to sell through Victra's approximately 1,500 retail locations. This positive trend gives us confidence in the future growth potential of the partnership.We continue to support our retail partners by training and educating their sales staff on how to communicate with consumers about key differentiators of Eargo devices. With respect to our partnership with Victra, our focus for the remainder of 2023 is the continued training and education of the Victra sales force, gathering customer feedback and improving the overall customer experience.From a direct-to-consumer cash-pay perspective, our focus has been on media spend efficiency. And we continue to make incremental improvements to the cost of acquiring a customer as we refine our strategy and continue to optimize our media channel spend.Turning to a brief update on insurance access. As we shared on our last call, we're currently accepting both FEHB and non-FEHB insurance as a method of direct payment in certain limited circumstances, in particular when customers have undergone additional testing by a licensed health care provider to establish medical necessity with supporting clinical documentation. In the meantime, we expect to continue to operate at low insurance volumes and believe meaningful volume lift will take some time.Before turning it to Adam, let me touch on Eargo 7, our seventh generation device and an example of our long-standing commitment to innovation. We were thrilled to announce Eargo 7 earlier this year at CES, followed by a full commercial launch in mid-February. Since then, the device has been available for purchase across all channels. We have been pleased with both the initial device uptake so far, which has tracked well to our expectations and the customer -- positive customer feedback. Specifically, Eargo 7 has received better overall customer reviews and reduced connectivity complaints versus prior Eargo devices.Following received -- receipt of 510(k) clearance from the FDA last quarter, Eargo 5, Eargo 6 and Eargo 7 can each be marketed as self-fitting hearing aids with the use of Sound Match via our mobile app, and each is currently marketed as over-the-counter pursuant to the FDA's new OTC regulatory requirements.With our self-fit technology, Eargo 7 does not require traditional in-office visits for fitting or adjustments like other hearing aids. This benefit has really resonated with customers so far in our retail and direct-to-consumer settings as they are able to get set up and personalize their devices at home quickly and easily.We're incredibly proud of our first quarter results, especially in the context of an evolving hearing aid industry. We believe that the distribution of hearing aids in the U.S. through the physical retail channel will continue to grow and believe we are one of the leaders in this market evolution.Let me now turn it over to Adam for a more detailed summary of our first quarter financial and operating results.Story continuesAdam LaponisThanks, Christian. Given Christian's summary of net revenues, I will begin my commentary at the gross shipment line. First quarter gross systems shipped were 8,705, up approximately 51% year-over-year and roughly flat sequentially. The year-over-year increase in gross systems shipped was primarily driven by sales to Victra.As Christian noted, first quarter net revenue was $11.8 million, up approximately 29% year-over-year and slightly down on a sequential basis. We derived approximately 22% of our net revenue in Q1 2023 from sales to Victra. It is important to note that our shipment volume in both the fourth quarter of 2022 and the first quarter of 2023 were impacted by large stocking orders through Victra as they made significant purchase to build and maintain inventory levels at their approximately 1,500 retail locations.Going forward, we may not be able to accurately predict the timing or size of any future Victra orders, which may impact our net revenue and the consistency of our results on a sequential basis.The first quarter 2023 sales return rate was 37.4%, up 3.5 percentage points year-over-year and 2.5 percentage points sequentially. The increase in the sales return rate was primarily driven by a sales channel mix shift given the larger percentage of sales attributed to our retail partner, Victra, where we have only recently implemented sales return-reduction initiatives.These initiatives are similar to those implemented in our direct-to-consumer cash-pay channel years ago, which ultimately reduced and stabilized our sales return rate into the mid-30s. We hope to achieve similar benefits from these initiatives in the retail channel over the coming quarters and therefore believe the higher actual sales return rate experienced in the first quarter is transient.Moving to non-GAAP gross margin and non-GAAP operating expenses. Our discussion of financial metrics in the gross margin line below will be on a non-GAAP basis, which excludes stock-based compensation expense. Please refer to our GAAP to non-GAAP reconciliation included in today's earnings release and the historical GAAP to non-GAAP reconciliation table on our IR website in the Events & Presentations section.First quarter non-GAAP gross margin was 43.8% compared to 40.5% in the first quarter of 2022. We are pleased with our ability to expand gross margins consistently as we continue to scale volumes.Moving to operating expenses. While we continue to refine our op cost structure, we have invested selectively in areas we believe will be the future drivers of our business, including insurance and retail as well as the supporting compliance infrastructure. First quarter non-GAAP sales and marketing expenses were $12.5 million or 100.5% of net revenues compared to $12.6 million or 137.9% of revenues in the first quarter of 2022.Non-GAAP research and development expenses were $3.9 million or 33.5% of net revenues compared to $4.9 million or 53% of net revenues in the first quarter of 2022. The decrease is primarily due to lower personnel-related costs and lower third-party costs.Non-GAAP general and administrative expenses were $8.1 million or 68.5% of net revenues compared to $13.6 million or 148.1% of net revenues in the first quarter of 2022. This decrease was primarily due to a reduction in professional fees, partially offset by an increase in personnel and personnel-related costs. Non-GAAP net operating loss for the first quarter of 2023 was $19.4 million compared to a non-GAAP net operating loss of $27.4 million for the first quarter of 2022.Moving to the balance sheet. We had cash and cash equivalents of $79.8 million at March 31, 2023. This compares to $101.2 million as of December 31, 2022. Our net operating cash burn, which we define as cash used in operating and investment activities, in the first quarter of 2023 was approximately $21.5 million.Now turning to cash burn guidance. The company expects modest sequential improvement to net operating cash burn in the remaining quarters of 2023. We are not providing any further financial guidance at this time.I will now turn it back to Christian for closing commentary.Christian GormsenThanks, Adam. When we last spoke with you in March, we ended on a note of optimism with a belief that we were well positioned to capitalize on our recent progress in 2023 as we work to return Eargo to growth mode. Standing here today with the first quarter of 2023 now behind us, I'm pleased to report we have even greater confidence in our ability to transform our business and execute our omnichannel strategy. We believe that the first quarter demonstrated momentum in our business, laying the groundwork for further Eargo success.While we clearly have work to do, we do believe the worst of the uncertainty impacting our business is behind us, enabling us to make incremental steps in the right direction each quarter. Most importantly, we remain steadfast in our belief that Eargo is driving a revolutionary change in the hearing industry, backed by innovative technology and robust remote customer care. There remains a very large and unpenetrated market opportunity for us to capitalize on, particular in direct-to-consumer, and we look forward to providing future updates on our progress over the course of 2023.We I will now turn the call over to the operator for Q&A.Question and Answer SessionOperator(Operator Instructions) And we will take our first question from Margaret Kaczor with William Blair.Malgorzata Maria Kaczor AndrewI wanted to start with Victra. And I apologize, I've got a series of questions. But can you give us a sense of, I guess, how many Victra stores at this point have an Eargo device given the stocking dynamic? So is that largely behind us? And then you mentioned that most of the sales were stocking, but you're clearly seeing an increase in return rates, meaning that they seem to be selling some of these devices, and hopefully, replacing some of the sales. So I guess, can you give us a sense, at least based on the return rate, how much that may suggest for sell-through, either as a percentage or the number versus the sell-in?Christian GormsenThanks, Margaret. Let me start here, and I'll see if Adam has some more details that you're looking for. But at the highest level, we've sold into all Victra stores. All 1,500 have inventory of Eargo, so you can get Eargo 7 at any Victra Verizon store, assuming they haven't just recently sold out. But there is also a replenishment system set in place. So that is completely behind us in terms of getting that initial stocking there.We've also seen -- in terms of development, we've clearly seen more sell-through in Q1 than what we saw in Q4. So we are seeing over to improvements in the sell-through. Obviously, it's being masked to that level about the actual sell-in of inventory, which is what we're reporting on financially.Adam, anything -- any further color? I don't think we have further color to give, right?Adam LaponisNo. I think Christian said it well, Margaret. We did see sequential improvement in the sell-in -- sell-through, but the sell-in still exceeded the sell-through even in Q1.Christian GormsenYes.Malgorzata Maria Kaczor AndrewAnd was that true in maybe March? Is that...Adam LaponisI'd say -- well, again, the orders don't come in on a week to week. They came in, in pretty big months, so it's kind of lumpy in that regard. But I'd say the average orders in March and the total sell-in -- the average order of sell-in in Q3, we're getting closer, but we're still not there yet. But we're -- so we're still in that dynamic of building up inventory in Q1.But to your question of, is it done, at this point, we're at a steady state now, where we've got inventory in every store and we are seeing continued momentum in sell-through.In terms of RFC dynamics, yes, we are seeing a increase in RFC. So we are seeing that sell-through, but we're also now implementing the trainings across the country that -- and the other actions that we think we did back in the 2018, 2019 that can positively impact that RFC rate over time.Malgorzata Maria Kaczor AndrewOkay. So moving to that return rate, can you give us a sense of how quickly those initiatives maybe did help the DTC business? Was it a matter of quarters or years? And if you could remind us as well the current generation of Eargo devices. I believe that despite the high return rate, you can still reuse those devices, so the impact on gross margins maybe a little bit less than in the past. Is that true?Adam LaponisYes. So let me give you kind of 2 parts there, Margaret. So the first part is when we did this back in 2018 to 2019 over the course of 4 quarters, we saw a 10-point reduction in return rates, in the mid-40s to the mid-30s, in that time range. So I think that's probably a decent proxy for the kind of time we're expecting things to move here. So it will take quarters, but it won't take years.In terms of the, we call it refurbishment capabilities of our products, we are able to refurbish all of the Eargo 5, 6 and 7 lines that get returned to us. So it does minimize that impact to gross margin when there is a higher return. But we're still sensitive to it from both the customer experience as well as there is still some costs associated with that rework.Malgorzata Maria Kaczor AndrewOkay. Yes. Two more questions. So number one, on the Victra experience, obviously, you're seeing some success there. So does that suggest you may want to expand these types of partnerships? And so if so, why? And then if not, what metrics do you need to see to want to expand any further?Christian GormsenYes. No, let me grab that. Clearly, we believe that the best way to grow hearing penetration, which is the overall goal and the mission of Eargo, helping more people hear better, is to meet people where they are. And I think we're getting strong feedback that those people are in locations like Victra Verizon stores. So that basically is the whole strategy that we're building on.It's also clear that it's a new location. People are not walking into a Verizon store expecting to buy a hearing aid. So it is that journey of educating consumers that you can actually now get a health product in such a location. And I think that's part of driving, obviously, the sell-through, not the sell-in, and also managing the return rate and managing people's expectations.So as we've always said, this is a long-term initiative. It's a long-term strategy for us. But it's something we are as committed to. As Adam also mentioned, it's an area that we are actively investing in our organization's capability to support into. And then we've continued investing through the quarter here, and we'll continue to do so through the rest of the year.So absolutely -- and the KPIs we'll be looking for is ultimately not the sell-in, it's the sell-throughs combined with the return rates. And ultimately, the most important is the customer experience. And so far, what we're learning is customers did not expect it, but they appreciate that opportunity. So it's a journey that we have literally just embarked on but we're excited about for the future.Malgorzata Maria Kaczor AndrewOkay. Last question. You mentioned most of the increase in sales seems to be from Victra, but can you give us a sense around DTC growth on a year-over-year basis and then how that might change with the latest Eargo 7 launch? And any potential marketing expense you may have?Adam LaponisYes. So Margaret, when you look at the 20% of revenue coming from retail, you can kind of back into it if that -- year-on-year, we're essentially between the repeat business and our existing DTC business. We're roughly flat, even slightly down, depending on how you cut it. So to me, there's -- we are focused on optimizing it, and that's really where we're seeing the improvement in sales and marketing and driving that first and then building off on the growth from there.We are seeing, though, that there is cross-pollination effect. A customer goes into Victra and creates a lead that they can convert online or the phone and vice versa. A customer that goes on the phone can then go into Victra. So the 2 are commingling each other as well. And that's a phenomena we want to see, but we expect to see more of that as we go forward.OperatorAnd ladies and gentlemen, this concludes today's conference call, and we thank you for your participation. You may now disconnect.

Thomson Reuters StreetEvents

Q1 2023 Eargo Inc Earnings Call

https://finance.yahoo.com/news/q1-2023-eargo-inc-earnings-092238794.html

92bc36f6-a639-30e0-9722-f48809a1ac93

EAR

Eargo IncRecent Highlights:Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023.William Brownie, Interim CEO and COO, said, “Through the first half of 2023, we made incremental progress on our key retail, insurance, and innovation initiatives as we continue to evolve Eargo into a true omni-channel business. While each of these initiatives will take time to fully implement and refine, we are pleased that with each quarter we have made progress on that evolution.”“Our core direct-to-consumer cash-pay segment has been stable through 2023 as compared to 2022. We continue to focus on lowering customer acquisition costs through further optimizing media spend and maintaining an efficient inside sales force. Meanwhile, demand from consumers interested in purchasing Eargo devices through our evolving retail channel continues to develop following our launch in Victra’s approximately 1,500 retail locations nationwide and the FDA’s over-the-counter final rule. As expected, retail shipment volume was lower sequentially in the second quarter, following the large stocking order by Victra following the launch of Eargo 7 in the first quarter. We see continued value in our partnership and are committed to this important sales channel as part of our omni-channel strategy. We anticipate that our insurance channels will be a priority of the Company as we continue to work with payors to establish coverage for Eargo and to establish relationships with health plans, benefits managers, and managed care providers following the OTC final rule.”Story continuesMr. Brownie concluded, “As part of our previously announced cost reduction plan, we are taking steps to further streamline our business and significantly reduce cash burn to provide an extended runway to execute our omni-channel strategy. While this difficult decision will result in a reduced overall workforce, we plan to maintain top talent across key functions, which we believe will allow us to continue to satisfy consumer demand across our omni-channel and support existing customers as well as support our insurance channel strategy and innovation priorities. The cost reduction plan is expected to reduce our go-forward cash burn estimates, and we anticipate this reduced burn rate will extend our net operating cash runway into the second half of 2024. Lastly, Christian Gormsen, Eargo’s CEO for seven years, departed from the Company in June. On behalf of the entire Eargo organization, I want to thank Christian for his many contributions over the years and wish him well in his new endeavors.”Second Quarter 2023 Financial and Operating ResultsDuring the second quarter of 2023, we announced a cost reduction plan intended to optimize our cost structure and operating model. We currently expect the cost reduction plan to be substantially implemented through the end of fiscal 2023 and estimate that we will incur one-time charges of approximately $3.5 million to $5.0 million in connection with the plan. The majority of the costs we expect to incur in connection with the cost reduction plan will be recorded as they are incurred and are therefore not reflected in the discussion below.Gross systems shipped for the second quarter of 2023 were 5,098, compared to 4,455 during the second quarter of 2022. The year-over-year increase in shipment volume was largely driven by sales of our Eargo hearing aids to Victra, our largest retail partner, for in-person customer sales at its approximately 1,500 store locations across the United States. We are currently unable to predict the timing or size of any future Victra orders, which may impact our net revenue and the consistency of our results on a sequential and quarterly basis.The sales returns rate for the second quarter of 2023 was 34.2%, compared to 33.3% in the second quarter of 2022. The year-over-year increase in the sales returns rate in the second quarter of 2023 was primarily due to a higher sales returns rate for systems sold to Victra.Net revenue was $8.1 million for the second quarter of 2023, compared to $7.2 million for the second quarter of 2022. The year-over-year increase was driven by the increase in gross systems shipped.Gross profit for the second quarter of 2023 was $1.6 million, compared to gross profit of $2.5 million for the second quarter of 2022. Gross margin was 20.1% for the second quarter of 2023, compared with 34.7% for the second quarter of 2022. The year-over-year decrease in gross margin was primarily due to rework costs of $0.8 million to address loss of charging capacity in certain of our hearing aids in inventory and impairment charges of $0.8 million related to previously capitalized software costs, which, when combined, reduced gross margins in the second quarter of 2023 by approximately 20%.Total operating expenses were $27.4 million, or 338.4% of net revenues, for the second quarter of 2023, compared with $34.0 million, or 468.6%, for the second quarter of 2022.Sales and marketing expenses were $12.6 million, or 155.7% of net revenues, for the second quarter of 2023, compared with $12.7 million, or 175.7%, for the second quarter of 2022. Lower media spend in the second quarter of 2023 compared to the corresponding prior-year period was offset by increases in personnel and personnel-related costs.Research and development expenses were $5.4 million, or 66.2% of net revenues, for the second quarter of 2023, compared with $3.9 million, or 53.5%, for the second quarter of 2022. The year-over-year increase was primarily driven by higher personnel-related costs, partially offset by lower third-party costs.General and administrative expenses were $9.4 million, or 116.5% of net revenues, for the second quarter of 2023, compared with $17.3 million, or 239.3%, for the second quarter of 2022. The year-over-year decrease was primarily driven by a reduction in general corporate costs related to legal, consulting and other professional fees that were driven by activities related to litigation, financing and compliance matters in the second quarter of 2022. The decrease in general and administrative expense also includes a net increase in personnel and personnel-related costs of $1.1 million, which includes a $0.5 million increase in headcount and a $1.6 million increase related to employee workforce reduction costs for severance and related benefits, partially offset by a $1.0 million credit related to the reversal of previously expensed stock-based compensation associated with forfeited equity awards.Excluding stock-based compensation expense, non-GAAP operating expenses for the second quarter of 2023 were $24.9 million, including research and development expenses of $4.7 million, sales and marketing expenses of $11.6 million, and general and administrative expenses of $8.7 million. Please refer to the section below titled “Use of Non-GAAP Financial Measures” and the non-GAAP reconciliation tables at the end of this press release.GAAP loss from operations was $25.8 million, or 318.3% of net revenues, for the second quarter of 2023, compared with $31.4 million, or 433.9% of net revenues, for the second quarter of 2022. The year-over-year decrease in GAAP loss from operations was primarily due to factors described in the above paragraphs. Excluding stock-based compensation expense, non-GAAP loss from operations losses for the second quarter of 2023 were $23.2 million, compared with $30.0 million in the second quarter of 2022.Net loss attributable to common stockholders for the second quarter of 2023 was $25.2 million, or $1.21 per share, compared to a net loss attributable to common stockholders of $32.4 million, or $16.48 per share, for the second quarter of 2022. Excluding stock-based compensation expense, non-GAAP net loss attributable to common stockholders for the second quarter of 2023 was $22.5 million, or $1.08 per share, compared to a non-GAAP net loss of $30.9 million, or $15.71 per share, for the same period in 2022. The year-over-year decrease in both GAAP and non-GAAP net loss per share attributable to common stockholders was primarily driven by a reduction in GAAP and non-GAAP net loss, respectively, and the Company’s rights offering and related conversion of senior secured convertible notes completed in November 2022, which resulted in the issuance of 18.75 million additional shares of our common stock.Net operating cash burn, defined as cash used in operating and investment activities, for the second quarter of 2023 was approximately $19.0 million.Cash and cash equivalents were $60.8 million as of June 30, 2023, compared to $101.2 million as of December 31, 2022.2023 Financial GuidanceThe Company is not providing financial guidance at this time.Conference Call and Webcast InformationThe Company will not be hosting a conference call and webcast to discuss second quarter 2023 results.About EargoEargo is a medical device company on a mission to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, completely-in-canal, FDA-regulated devices indicated to compensate for mild to moderate hearing loss. Our differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online, at retail locations or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, email or video chat. Eargo hearing aids are offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.Eargo’s seventh generation device, Eargo 7, is an FDA 510(k) cleared, self-fitting over-the-counter hearing aid featuring Sound Adjust+ with Comfort and Clarity Modes, which focuses on noise reduction and adapting to the user’s environment and needs. Eargo 7 is available for purchase here.Related Linkshttp://eargo.comForward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including but not limited to statements regarding the continued evolution of our omni-channel business; consumer demand for our products and our ability to satisfy demand; the efficiency of our customer acquisition and media spend; our partnerships with Victra and other third-party partners; our work with payors to establish insurance coverage for our products and to establish relationships with health plans, benefits managers, and managed care providers; the effects, timing and costs of our cost reduction plans; our ability to support our customers; our strategy and innovation priorities; and our expected net operating cash runway. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks, uncertainties and assumptions related to: our expectations regarding our omni-channel business, including partnerships with retailers, resellers and other distributors (whether brick and mortar or online); the extent to which we may be able to validate and establish processes to support the submission of claims for reimbursement from third-party payors or to otherwise establish relationships with health plans, benefits managers, and managed care providers, and our ability to maintain or increase insurance coverage of our hearing aids; the timing or results of ongoing claims audits and medical records reviews by third-party payors; estimates of our future capital needs and our ability to raise capital on favorable terms, if at all, including the timing of future capital requirements and the terms or timing of any future financings; the effects, timing and costs of our cost reduction plans; the impact of the regulatory landscape for hearing aid devices on our business and results of operations; our expectations concerning additional orders by existing customers; our expectations regarding the potential market size and size of the potential consumer populations for our products and any future products, including insurance coverage of our hearing aids; our ability to release new hearing aids and the anticipated features of any such hearing aids; the performance, differentiation and attractiveness to consumers of our products; developments and projections relating to our competitors and our industry, including competing products; our ability to maintain our competitive technological advantages against new entrants in our industry; the pricing of our hearing aids; our expectations regarding the ability to make certain claims related to the performance of our hearing aids relative to competitive products; our expectations with regard to changes in the regulatory landscape for hearing aid devices and related opportunities, including the implementation and effects of the new over-the-counter hearing aid regulatory framework; and our expectations regarding macroeconomic conditions, including but not limited to the impact of COVID-19, inflationary trends, uncertainty or volatility in the market (including recent and potential disruption in the banking system and financial markets and geopolitical events (such as the conflict in Ukraine and tensions across the Taiwan Strait)) on our business and results of operations. These and other risks are described in greater detail in the sections titled “Risk Factors” contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in our other filings with the Securities and Exchange Commission. Any forward-looking statements in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, are based on current expectations, forecasts and assumptions, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Use of Non-GAAP Financial MeasuresThe Company reports non-GAAP results for gross profit, gross margin, total operating expenses, sales and marketing expenses, research & development expenses, general & administrative expenses, total operating loss, net loss, and net loss per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include charges such as stock-based compensation, as listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of stock-based compensation in its non-GAAP financial measures to assist investors in analyzing and assessing the Company’s operating performance. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, and they may not be comparable with similarly named financial measures of other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial measures and the reconciliation between these presentations, to more fully understand its business.Investor ContactAdam LaponisChief Financial [email protected] Eargo, Inc.Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share amounts)  June 30, December 31,   2023   2022 ASSETS    Current assets:    Cash and cash equivalents $60,779  $101,238 Accounts receivable, net  961   1,910 Inventories  5,360   5,036 Prepaid expenses and other current assets  5,835   7,846 Total current assets  72,935   116,030 Operating lease right-of-use assets  7,582   5,765 Property and equipment, net  4,586   7,441 Intangible assets, net  850   1,063 Goodwill  873   873 Other assets  724   906 Total assets $87,550  $132,078 LIABILITIES AND STOCKHOLDERS’ EQUITY    Current liabilities:    Accounts payable $3,729  $6,504 Accrued expenses  9,665   12,715 Sales returns reserve  5,070   3,942 Other current liabilities  1,457   1,462 Lease liability, current portion  602   628 Total current liabilities  20,523   25,251 Lease liability, noncurrent portion  7,210   5,973 Total liabilities  27,733   31,224 Stockholders’ equity:    Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; zero shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively  —   — Common stock; $0.0001 par value; 450,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 20,749,579 and 20,726,965 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively  2   2 Additional paid-in capital  621,188   615,151 Accumulated deficit  (561,373)  (514,299)Total stockholders’ equity  59,817   100,854 Total liabilities and stockholders’ equity $87,550  $132,078       Eargo, Inc.Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts)  Three months ended June 30, Six Months Ended June 30,   2023   2022   2023   2022 Revenue, net $8,108  $7,247  $19,921  $16,423 Cost of revenue  6,477   4,733   13,168   10,224 Gross profit (loss)  1,631   2,514   6,753   6,199 Operating expenses:        Research and development  5,364   3,879   9,969   9,726 Sales and marketing  12,627   12,734   26,028   26,024 General and administrative  9,446   17,344   19,354   32,278 Total operating expenses  27,437   33,957   55,351   68,028 Loss from operations  (25,806)  (31,443)  (48,598)  (61,829)Other income (expense), net:        Interest income  654   56   1,524   61 Interest expense  —   (285)  —   (549)Loss on extinguishment of debt  —   (772)  —   (772)Total other income (expense), net  654   (1,001)  1,524   (1,260)Loss before income taxes  (25,152)  (32,444)  (47,074)  (63,089)Income tax provision  —   —   —   — Net loss and comprehensive loss $(25,152) $(32,444) $(47,074) $(63,089)Net income (loss) attributable to common stockholders, basic and diluted $(25,152) $(32,444) $(47,074) $(63,089)Net income (loss) per share attributable to common stockholders, basic and diluted $(1.21) $(16.48) $(2.27) $(32.07)Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic and diluted  20,745,838   1,968,201   20,740,152   1,967,175           Eargo, Inc. Results of Operations – Reconciliation between GAAP and Non-GAAP (Unaudited) (In thousands, except per share amounts)         Reconciliation between GAAP and non-GAAP net loss per share attributable to common stockholders: Three months ended June 30, Six Months Ended June 30,  2023   2022   2023   2022 GAAP net loss per share to common stockholders, basic and diluted$(1.21) $(16.48) $(2.27) $(32.07)Stock-based compensation 0.13   0.77   0.29   2.31 Non-GAAP net loss per share to common stockholders, basic and diluted$(1.08) $(15.71) $(1.98) $(29.76)                Reconciliation between GAAP and non-GAAP net loss attributable to common stockholders: Three months ended June 30, Six Months Ended June 30,  2023   2022   2023   2022 GAAP net loss attributable to common stockholders, basic and diluted$(25,152) $(32,444) $(47,074) $(63,089)Stock-based compensation 2,629   1,511   6,037   4,535 Non-GAAP net loss attributable to common stockholders, basic and diluted$(22,523) $(30,933) $(41,037) $(58,554)                Reconciliation between GAAP and non-GAAP gross profit and gross margin: Three months ended June 30, Six Months Ended June 30,  2023   2022   2023   2022 GAAP gross profit$1,631  $2,514  $6,753  $6,199 Stock-based compensation 48   37   90   59 Non-GAAP gross profit$1,679  $2,551  $6,843  $6,258         GAAP gross margin 20.1%  34.7%  33.9%  37.7%Stock-based compensation 0.6%  0.6%  0.5%  0.4%Non-GAAP gross margin 20.7%  35.3%  34.4%  38.1%                Reconciliation between GAAP and non-GAAP operating expenses and operating loss: Three months ended June 30, Six Months Ended June 30, 2023 2022 2023 2022GAAP research and development expense$5,364  $3,879  $9,969  $9,726 Stock-based compensation (714)  585   (1,366)  (435)Non-GAAP research and development expense$4,650  $4,464  $8,603  $9,291         GAAP sales and marketing expense$12,627  $12,734  $26,028  $26,024 Stock-based compensation (1,075)  (693)  (1,965)  (1,333)Non-GAAP sales and marketing expense$11,552  $12,041  $24,063  $24,691         GAAP general and administrative expense$9,446  $17,344  $19,354  $32,278 Stock-based compensation (792)  (1,366)  (2,616)  (2,708)Non-GAAP general and administrative expense$8,654  $15,978  $16,738  $29,570         GAAP total operating expense$27,437  $33,957  $55,351  $68,028 Stock-based compensation (2,581)  (1,474)  (5,947)  (4,476)Non-GAAP total operating expense$24,856  $32,483  $49,404  $63,552         GAAP operating loss$(25,806) $(31,443) $(48,598) $(61,829)Stock-based compensation 2,629   1,511   6,037   4,535 Non-GAAP operating loss$(23,177) $(29,932) $(42,561) $(57,294)        

GlobeNewswire

Eargo Reports Second Quarter 2023 Financial Results

https://finance.yahoo.com/news/eargo-reports-second-quarter-2023-200500491.html

bb58ec6e-37e1-387a-8ed9-20939e9fd02e

EB

Key InsightsThe projected fair value for Eventbrite is US$21.82 based on 2 Stage Free Cash Flow to EquityCurrent share price of US$11.36 suggests Eventbrite is potentially 48% undervalued Analyst price target for EB is US$13.40 which is 39% below our fair value estimateToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Eventbrite, Inc. (NYSE:EB) as an investment opportunity by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. View our latest analysis for Eventbrite The MethodWe are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:Story continues10-year free cash flow (FCF) estimate2024202520262027202820292030203120322033 Levered FCF ($, Millions) US$95.0mUS$120.0mUS$138.7mUS$154.8mUS$168.3mUS$179.7mUS$189.3mUS$197.6mUS$204.9mUS$211.5mGrowth Rate Estimate SourceAnalyst x1Analyst x1Est @ 15.62%Est @ 11.57%Est @ 8.73%Est @ 6.74%Est @ 5.35%Est @ 4.38%Est @ 3.70%Est @ 3.22% Present Value ($, Millions) Discounted @ 9.4% US$86.8US$100US$106US$108US$107US$105US$101US$96.1US$91.1US$85.9("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$987mThe second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.1%. We discount the terminal cash flows to today's value at a cost of equity of 9.4%.Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = US$211m× (1 + 2.1%) ÷ (9.4%– 2.1%) = US$3.0bPresent Value of Terminal Value (PVTV)= TV / (1 + r)10= US$3.0b÷ ( 1 + 9.4%)10= US$1.2bThe total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$2.2b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of US$11.4, the company appears quite undervalued at a 48% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.dcfThe AssumptionsWe would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Eventbrite as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.4%, which is based on a levered beta of 1.232. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.SWOT Analysis for EventbriteStrengthCash in surplus of total debt.WeaknessNo major weaknesses identified for EB.OpportunityForecast to reduce losses next year.Has sufficient cash runway for more than 3 years based on current free cash flows.Trading below our estimate of fair value by more than 20%.ThreatDebt is not well covered by operating cash flow.Looking Ahead:Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. What is the reason for the share price sitting below the intrinsic value? For Eventbrite, we've compiled three relevant elements you should assess:Risks: Take risks, for example - Eventbrite has 1 warning sign we think you should be aware of.Future Earnings: How does EB's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Is There An Opportunity With Eventbrite, Inc.'s (NYSE:EB) 48% Undervaluation?

https://finance.yahoo.com/news/opportunity-eventbrite-inc-nyse-eb-113544372.html

3c9b3da8-c37d-3abe-86a7-e7fe2ec497cd

EB

SAN FRANCISCO, August 31, 2023--(BUSINESS WIRE)--Eventbrite, Inc. (NYSE: EB), a global events marketplace, today announced that it will present at the Truist Securities Internet Growth Summit and the Piper Sandler Growth Frontiers Conference.Julia Hartz, Co-Founder and Chief Executive Officer and Lanny Baker, Chief Financial Officer, will present at the Truist Securities Internet Growth Summit on Tuesday, September 12th, at 8:00 a.m. ET / 5:00 a.m. PT.Mr. Baker will present at the Piper Sandler Growth Frontiers Conference on Wednesday, September 13th at 2:00 p.m. CT / 12:00 p.m. PT.A live webcast and replay of the fireside chats will be available on the company’s investor relations website at https://investor.eventbrite.com.About EventbriteEventbrite is a global events marketplace that serves event creators and event goers in nearly 180 countries. Since inception, Eventbrite has been at the center of the experience economy, transforming the way people organize and attend events. The company was founded by Julia Hartz, Kevin Hartz and Renaud Visage, with a vision to build a self-service platform that would make it possible for anyone to create and sell tickets to live experiences. With over 280 million tickets distributed for over 5 million total events in 2022, Eventbrite is where people all over the world discover new things to do or new ways to do more of what they love. Eventbrite has also earned industry recognition as a top employer with special designations that include a coveted spot on Fast Company’s prestigious The World’s 50 Most Innovative Companies and Fast Company’s Brands That Matter lists, the Great Place to Work® Award in the U.S., and Inc.’s Best-Led Companies honor. Learn more at www.eventbrite.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230831952813/en/ContactsEventbrite Investor [email protected]

Business Wire

Eventbrite to Participate in the Truist Securities Internet Growth Summit and Piper Sandler Growth Frontiers Conference

https://finance.yahoo.com/news/eventbrite-participate-truist-securities-internet-200500884.html

58c7a106-3ed3-3155-9482-ba69a5bad9e2

EBAY

History is messy, our cultural legacy is diverse and messy, and what the curators select for posterity, let alone for display, poses innumerable questions about priorities. What does the public visiting the British Museum want to see of a global culture lasting thousands of years; what does the museum want to tell visitors and what language should it use to describe what it does, as a curator of “culture”? Can we even convince a modern public, drunk on simple messages gleaned from TikTok and Instagram and X, that there is any point in culture and history.Continue reading

Financial Times

Letter: Spare a thought for the British Museum’s curators

https://finance.yahoo.com/m/54e05ee0-7f44-32fa-871b-a340e8d93100/letter-spare-a-thought-for.html

54e05ee0-7f44-32fa-871b-a340e8d93100

EBAY

One person’s rubbish is another person’s treasure, as they say, so you could make a chunk of cash by selling unwanted items cluttering your attic and cupboards.Coins, retro toys and games, old tech, books and magazines can all be sold, with some items possibly worth a lot more than you may think.Dig out old toysToys don’t have to be 50 or 100 years old to be worth money. For example, Beanie Babies became a big collectible in the 1990s, and while the vast majority of these stuffed toys will not be worth much at all, some can fetch a high price – so it’s worth checking your collection and seeing whether you have any hidden gems.Some of the Beanie Babies that had limited production runs may be valuable, say experts, for example, the original royal blue Peanut the Elephant, which was launched in 1995 but quickly withdrawn and replaced by a light blue version. There are claims that it could earn you a four-figure sum.The website Beaniepedia says: “The Royal Blue version is one of the most rare and valuable Beanie Babies in existence, fetching high prices when sold.” A Beanie Babies Halo the Bear sold via an eBay auction for £800 in June. Job lots of toys can sometimes sell for a decent-ish sum if you don’t have any particularly rare ones in your collection.The same rules apply to Lego. Limited-edition, vintage sets in mint condition can sell for hundreds, or sometimes thousands, of pounds.Chris Wharfe, the editor of Brick Fanatics, a website dedicated to all things Lego, says: “The most valuable sets tend to be those that have a limited run or are attached to a popular IP [intellectual property] like Star Wars.Related: How to save on food shopping: from discount apps and cashback to free stuff“Even regular sets often skyrocket in price if they are sealed – stuff that you wouldn’t necessarily expect, like an obscure Marvel set or a Castles or Pirates set from your childhood. Anything that’s part of a series usually increases in value, too.”Story continuesWharfe says some good examples of valuable older sets are 10143 Lego Star Wars UCS Death Star II from 2005, 10182 Lego Creator Expert Cafe Corner from 2007 (the first modular building), and 6399 Monorail Airport Shuttle from 1990, “all of which are worth four figures new and sealed”.Other toys that can be worth money include pre-1998 Polly Pockets (a range of dolls and accessories), some items in the My Little Pony range (for example, Mimic, a unicorn pony that was part of the Twinkle Eyed Ponies range), and certain Pokémon and Yu-Gi-Oh! cards, says the website Save the Student.Coins can be worth a mintA 1939 British farthing (¼ penny). Photograph: Ivan Vdovin/AlamyAgain, they don’t have to be hundreds of years old. Changechecker.org has a scarcity index, ranking the UK’s most sought-after 10p, 50p and £2 coins based on how rare they are. The higher a coin ranks on the index, the more valuable it is likely to be.Look out for coins with commemorative designs such as the Kew Gardens 50p, which has a score of 100 on the index. One of these recently sold on eBay for £147, attracting 24 bids. Other rare 50p coins include the London 2012 Olympics judo, triathlon and football designs.Meanwhile, the scarcest 10p coin is the robin design, released in 2018-19 as part of a series on quintessentially British icons. It features a robin inside the letter R, surrounded by snowflakes.Jewellery, medals, etcThe over-50s website Saga previously partnered with the BBC Antiques Roadshow expert Mark Hill to identify some of the most sought-after collectibles. Costume jewellery can be a big earner if it is the right item; they said popular names from the 1930s onwards were highly desirable, such as vintage Miriam Haskell designs. Her necklaces can go for thousands of pounds.With medals, they said that while condition played a role, “the greater the significance of its backstory, the more value it holds”. A Distinguished Service Cross sold for £120,000 in 2011.Hill said items to look out for included wristwatches and those related to key events, moments or people in history.Choose a reselling platformVinyl records are likely to attract higher prices than CDs. Photograph: Rawpixel/AlamyOnce you have a selection of items to sell, do your research to find out where to list them to get the best price. Start by checking what similar items have sold for on each platform.EBay, probably the best-known reselling site with millions of users worldwide, is simple to use. However, a specialist website may be worth considering for niche items.Vinted is a simple way to sell high street clothes but items are typically priced relatively low. If you are selling vintage or designer clothes, a specialist website such as Vestiaire Collective could be more effective.While vinyl records are likely to command higher prices, if you have a glut of old CDs, you could make some cash by flogging them on an app or site such as musicMagpie. Each individual CD typically is not going to be worth much but, depending on the size of the collection, it could add up to a worthwhile amount.There are also apps that specifically cater to people trying to offload unwanted items fast. These can be convenient to use but you are unlikely to secure high prices, so they may be better for those flogging a large quantity of lower-value items such as CDs and non-rare books.Bear in mind that platforms may charge listing fees or take a cut of the final price.In-person options include car boot sales but, again, shoppers are often after a bargain, so they are unlikely to pay top dollar, even if your item is worth it.Get your items verified and pricedThe better the item’s condition, the more money you are likely to make. Check the quality of your item and list it accurately on whichever platform you choose. Don’t list a record as being in mint condition if it has a scratch on it, for example.You could visit an expert to give you an authenticity verification and provide a valuation. This will cost money, so will eat into your profits, but a verification of authenticity could help you sell faster and for a higher price, so it is a balancing act for you to decide on a case-by-case basis.

The Guardian

Cash for clutter: how to make money from what’s in the attic

https://finance.yahoo.com/news/cash-clutter-money-attic-090047595.html

3c7fdd0e-f711-3581-b135-128e0b842e33

EBF

MIDLOTHIAN, Texas, June 19, 2023--(BUSINESS WIRE)--Ennis, Inc. (the "Company"), (NYSE: EBF), today reported financial results for the first quarter ended May 31, 2023. Highlights include:Revenues were $111.3 million for the quarter compared to $107.7 million for the same quarter last year, an increase of $3.6 million or 3.3%.Earnings per diluted share for the current quarter were $0.45 compared to $0.45 for the comparative quarter last year.Our gross profit margin for the quarter was 30.6% compared to 31.6% for the comparative quarter last year.Financial OverviewThe Company’s revenues for the first quarter ended May 31, 2023 were $111.3 million compared to $107.7 million for the same quarter last year, an increase of $3.6 million, or 3.3%. The increase includes revenue contributions of approximately $4.1 million from School Photo Marketing, an acquisition completed on November 30, 2022, and Stylecraft Printing Company, an acquisition completed on May 23, 2023. The increase from acquisitions was partially offset by an otherwise slight decline in sales volume as purchasing patterns have normalized since last year’s tight paper market. Gross profit margin was $34.0 million, or 30.6%, as compared to $34.0 million, or 31.6%, for the same quarter last year. Net earnings for the quarter remained flat at $11.6 million, or $0.45 per diluted share, as compared to $11.6 million, or $0.45 per diluted share, for the same quarter last year. Our recent acquisitions contributed $0.04 in diluted earnings per share for the quarter.Keith Walters, Chairman, Chief Executive Officer and President, commented by stating, "Our results for the quarter were within our expectations. Our gross profit margin for the quarter of 30.6% is within our target range and showed improvement of 300 basis points from 27.6% in the sequential quarter ending February 28, 2023 and declined 100 basis points to 30.6% compared to 31.6% in the same prior year quarter. Our EBITDA remained relatively stable at $20.5 million or 18.4% of sales compared to the sequential quarter, $20.5 million or 19.9% of sales and compared to the same quarter last year $20.5 million or 19.1% of sales.Story continues"We incurred additional expenses this quarter in which we anticipate the benefits to be recognized in future quarters. We relocated one of our leased facilities into an existing location with excess capacity. The lease renewal would have been an increase of 70% and the move to an existing location is anticipated to reduce future costs and improve our operational efficiency. We incurred additional legal expenses during the quarter related to a case against Wright Printing Company, its owner Mark Wright, and CEO Mardra Sikora. In April 2023, we were awarded $5.0 million in actual and punitive damages but the judgment award has not been recognized in our financials to date. These additional expenses for the quarter resulted in a decrease of $0.03 to our diluted earnings per share."Our recent acquisitions contributed $4.1 million in sales during the current quarter; however, the real impact of our latest acquisitions is expected to be seen in the remainder of fiscal year 2024. Stylecraft Printing Company in Canton, Michigan expands our product lines and geographical footprint, as well as adds a well-known brand that has been serving the distributor channel for more than 50 years. UMC Print, a leading trade-only printer acquired after the quarter close, June 2, 2023, will add strategic locations & capabilities to drive growth with our distributor partners. We will continue to explore acquisitions that make sense and hunt for new sales in new markets and new channels. As part of our regular course of business we continue to monitor incoming order volumes so that we can proactively adjust our costs accordingly."We believe we have one of the strongest balance sheets in the industry, with no debt and significant cash. Our profitability and strong financial condition will allow us to continue operations and fund acquisitions without incurring debt. Given those strengths, we also anticipate timely access to credit should larger acquisition opportunities materialize. We continue to focus on delivering profitability and returns to our shareholders."Non-GAAP ReconciliationsTo provide important supplemental information to both management and investors regarding financial and business trends used in assessing its results of operations, from time to time the Company reports the non-GAAP financial measure of EBITDA (EBITDA is calculated as net earnings before interest expense, tax expense, depreciation, and amortization). The Company may also report adjusted gross profit margin, adjusted earnings and adjusted diluted earnings per share, each of which is a non-GAAP financial measure.Management believes that these non-GAAP financial measures provide useful information to investors as a supplement to reported GAAP financial information. Management reviews these non-GAAP financial measures on a regular basis and uses them to evaluate and manage the performance of the Company’s operations. Other companies may calculate non-GAAP financial measures differently than the Company, which limits the usefulness of the Company’s non-GAAP measures for comparison with these other companies. While management believes the Company’s non-GAAP financial measures are useful in evaluating the Company, when this information is reported it should be considered as supplemental in nature and not as a substitute or an alternative for, or superior to, the related financial information prepared in accordance with GAAP. These measures should be evaluated only in conjunction with the Company’s comparable GAAP financial measures.The following table reconciles EBITDA, a non-GAAP financial measure, for the three months ended May 31, 2023 to the most comparable GAAP measure, net earnings (dollars in thousands).Three months endedMay 31,May 31,20232022Net earnings$11,635$11,627Income tax expense4,5254,523Interest expense——Depreciation and amortization4,3444,378EBITDA (non-GAAP)$20,504$20,528% of sales18.4%19.1%In Other NewsOn June 16, 2023 the Board of Directors declared a quarterly cash dividend of 25.0 cents per share on the Company’s common stock. The dividend is payable on August 7, 2023 to shareholders of record on July 7, 2023.About EnnisFounded in 1909, the Company is one of the largest private-label printed business product suppliers in the United States. Headquartered in Midlothian, Texas, Ennis has production and distribution facilities strategically located throughout the USA to serve the Company’s national network of distributors. Ennis manufactures and sells business forms, other printed business products, printed and electronic media, integrated forms and labels, presentation products, flex-o-graphic printing, advertising specialties and Post-it® Notes, internal bank forms, plastic cards, secure and negotiable documents, specialty packaging, direct mail, envelopes, tags and labels and other custom products. For more information, visit www.ennis.com.Safe Harbor under the Private Securities Litigation Reform Act of 1995Certain statements that may be contained in this press release that are not historical facts are forward-looking statements that involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward-looking statements. The words "anticipate," "preliminary," "expect," "believe," "intend" and similar expressions identify forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These statements are subject to numerous uncertainties, which include, but are not limited to, the severity and duration of the COVID-19 pandemic and related economic repercussions, the erosion of demand for our printer business documents as the result of digital technologies, risk or uncertainties related to the completion and integration of acquisitions, the limited number of available suppliers and variability in the prices of paper and other raw materials, and operational challenges relating to the COVID-19 pandemic and efforts to mitigate the spread of the virus, including logistical challenges, protecting the health and well-being of our employees and potential plant closures. Other important information regarding factors that may affect the Company’s future performance is included in the public reports that the Company files with the Securities and Exchange Commission, including but not limited to, its Annual Report on Form 10-K for the fiscal year ending February 28, 2023. The Company does not undertake, and hereby disclaims, any duty or obligation to update or otherwise revise any forward-looking statements to reflect events or circumstances occurring after the date of this release, or to reflect the occurrence of unanticipated events, although its situation and circumstances may change in the future. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The inclusion of any statement in this release does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.Ennis, Inc.Unaudited Condensed Consolidated Financial Information(In thousands, except share and per share amounts)Three months endedCondensed Consolidated Operating ResultsMay 31,20232022Net Sales$111,294$107,667Cost of goods sold77,25373,663Gross profit34,04134,004Operating expenses18,34317,682Income from operations15,69816,322Other (income) expense(462)172Earnings from operations before income taxes16,16016,150Income tax expense4,5254,523Net earnings$11,635$11,627Weighted average common shares outstandingBasic25,839,65125,820,639Diluted25,979,53325,959,448Earnings per shareBasic$0.45$0.45Diluted$0.45$0.45Cash dividends per share$0.25$0.25May 31,February 28,Condensed Consolidated Balance Sheet Information20232022AssetsCurrent AssetsCash$102,106$93,968Accounts receivable, net46,62753,507Inventories, net48,04846,834Prepaid expenses1,9332,317Total Current Assets198,714196,626Net property, plant & equipment50,60147,789Operating lease right-of-use assets, net11,87713,133Goodwill and intangible assets, net134,488135,907Other assets310380Total Assets$395,990$393,835Liabilities and Shareholders’ EquityCurrent liabilitiesAccounts payable$14,465$18,333Accrued expenses19,19518,067Current portion of operating lease liabilities4,7184,847Total Current Liabilities38,37841,247Other non-current liabilities19,93121,156Total liabilities58,30962,403Shareholders' Equity337,681331,432Total Liabilities and Shareholders' Equity$395,990$393,835Three months endedMay 31,Condensed Consolidated Cash Flow Information20232022Cash provided by operating activities$21,726$14,237Cash used in investing activities(7,129)(1,036)Cash used in financing activities(6,459)(7,586)Net change in cash8,1385,615Cash at beginning of period93,96885,606Cash at end of period$102,106$91,221View source version on businesswire.com: https://www.businesswire.com/news/home/20230619332858/en/ContactsMr. Keith S. Walters, Chairman, Chief Executive Officer and PresidentMs. Vera Burnett, Chief Financial OfficerMr. Dan Gus, General Counsel and SecretaryEnnis, Inc. 2441 Presidential ParkwayMidlothian, Texas 76065Phone: (972) 775-9801Fax: (972) 775-9820www.ennis.com

Business Wire

Ennis, Inc. Reports Results for the Quarter Ended May 31, 2023 and Declares Quarterly Dividend

https://finance.yahoo.com/news/ennis-inc-reports-results-quarter-100000974.html

5a86ef84-143b-358b-994b-8e228404690b

EBF

Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks that underperform the market. That's what has happened with the Ennis, Inc. (NYSE:EBF) share price. It's up 27% over three years, but that is below the market return. At least the stock price is up over the last year, albeit only by 4.2%.Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. See our latest analysis for Ennis To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.Ennis was able to grow its EPS at 13% per year over three years, sending the share price higher. The average annual share price increase of 8% is actually lower than the EPS growth. So it seems investors have become more cautious about the company, over time. We'd venture the lowish P/E ratio of 11.27 also reflects the negative sentiment around the stock.You can see below how EPS has changed over time (discover the exact values by clicking on the image).earnings-per-share-growthWe know that Ennis has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Ennis will grow revenue in the future.What About Dividends?It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Ennis, it has a TSR of 47% for the last 3 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence!Story continuesA Different PerspectiveEnnis provided a TSR of 9.3% over the last twelve months. Unfortunately this falls short of the market return. On the bright side, that's still a gain, and it's actually better than the average return of 5% over half a decade This could indicate that the company is winning over new investors, as it pursues its strategy. If you would like to research Ennis in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Simply Wall St.

Ennis' (NYSE:EBF) investors will be pleased with their respectable 47% return over the last three years

https://finance.yahoo.com/news/ennis-nyse-ebf-investors-pleased-115423499.html

ff3dcf4f-9fd6-39d8-9921-07fe1ef42fca

EBMT

In this piece, we will take a look at ten oversold bank stocks to buy. If you want to skip our overview of the banking sector and want to jump to the top five stocks, then take a look at 5 Oversold Bank Stocks To Buy. Deciding whether to buy a stock can invovle analyzing several data points and factors. These can include understanding a firm's balance sheet to gauge its financial performance and perhaps even project cash flows in the future to make a rough estimate of the future share price to determine whether the shares are overvalued or undervalued. Another approach, which takes a lighter look at business operations, or combines it with the market trends, is called technical trading. This way of investing in stocks takes a look at several indicators of a share price, such as moving averages over several time periods, high and low prices, the volume of shares being traded, and the relative strength index (RSI).Out of these, the RSI is used to measure whether a stock is facing an irrational investor reaction in the market. It does this by measuring the shift in share prices over a couple of weeks to determine whether the stock is oversold or if it overbought. There is no hard and fast rule for determining either of these. However, conventional wisdom says that an RSI reading below 30 indicates oversold while a reading above 50 indicates overbought. Of course, as is with any other financial indicator, such as the Price to Earnings ratio, one metric alone should never be used to make a trading decision. Instead, metrics for firms in an industry group, such as banking, have to be compared on a broader basis and then checked to see if any recent developments indicate longer term trends rather than short term dips or rises.Using the RSI to see if a stock is oversold to make a buying decision requires the same thinking. After all, some stocks might be seeing too much fear than their fundamentals might validate, but others could be sold for genuine reasons such as management incompetence. For instance, Nikola Corporation (NASDAQ:NKLA), whose shares were trading at $64 in 2020 is now down to $2.67 after revelations of fraud. However, back when Nikola's shares were at their peak, its RSI index might have told you that the stock is oversold when the shares first started to dip in the wake of Hindenberg Research's scathing report. Another stock to take a look in this regard is Territorial Bancorp Inc. (NASDAQ:TBNK). A regional bank, its shares first dropped during the banking crisis earlier this year and then fell at July end as it reported weak results for the second quarter. According to the RSI, Territorial Bancorp Inc. (NASDAQ:TBNK) is significantly oversold, and you'll find out by how much as you read ahead.Story continuesMoving ahead to the banking industry, the sector has been facing quite a bit of turmoil lately along with opportunities for making more money. The banking sector's upheaval is driven by the Federal Reserve's rapid interest rate hikes, which both benefit and have the potential to harm banks. On the former front, banks benefit from high interest rates since they can immediately increase the rate they charge borrowers while keeping the rates offered on deposit products lower for longer. This increases the money (or the spread) that the banks earn by taking money and lending it out. On the flip side, a higher interest rate might also mean that the bank's assets, such as any bonds that it might have bought during a low rate environment, are now worthless. This can lead to the bank taking heavy hits, losses, and even shutting down as was the case in America earlier this year during the banking crisis.As to what's happening in the banking world right now, July saw a number of banks report their earnings. The industry heavyweights, such as Bank of America Corporation (NYSE:BAC), Morgan Stanley (NYSE:MS), JPMorgan Chase & Co. (NYSE:JPM), and Wells Fargo & Company (NYSE:WFC) passed the earnings test with flying colors. However, at the same time, smaller and regional banks didn't do so well. Apart from Territorial Bancorp, others such as KeyCorp (NYSE:KEY) and Truist Financial Corporation (NYSE:TFC) also missed profit estimates.Therefore, given the weakness in the banking sector right now, it might be wise to take a look at the market and determine if any stocks are facing market exuberance on the downside. We've tried to do this today, and some names that have popped up are Territorial Bancorp Inc. (NASDAQ:TBNK), Waterstone Financial, Inc. (NASDAQ:WSBF), and Farmers & Merchants Bancorp, Inc. (NASDAQ:FMAO).Oversold Bank Stocks To BuyImage by Sergei Tokmakov, Esq. from PixabayOur Methodology To compile our list of oversold bank stocks, we first tried searching for bank stocks with an RSI reading below 30. However, this yielded little results. Therefore, all bank stocks that have an RSI of below 50 and a Hold or better rating from analysts were then selected. They were then ranked through their RSI scores, which for this list, range between 36 to 47. The final list of most oversold bank stocks is as follows. While removing the analyst rating parameter could have yielded more stocks, this was avoided to provide some quality to the collection instead of relying solely on a single metric.10 Oversold Bank Stocks To Buy10. Enterprise Financial Services Corp (NASDAQ:EFSC)Latest RSI Reading: 47.05Enterprise Financial Services Corp (NASDAQ:EFSC) is a Clayton, Missouri based bank that provides accounts, brokerage, and other services. Out of the five analysts covering the stock, two have rated the shares as a Buy, which is a shift from earlier trends when it had one Buy and one Strong Buy rating. On average, the rating is a Buy, and the latest rating came from Raymond James which maintained it at Market Perform.By the end of this year's first quarter, 13 of the 943 hedge funds part of Insider Monkey's database had held Enterprise Financial Services Corp (NASDAQ:EFSC)'s shares. Out of these, the firm's largest shareholder is Emanuel J. Friedman's EJF Capital with a stake of $5.8 million.Just like Waterstone Financial, Inc. (NASDAQ:WSBF), Territorial Bancorp Inc. (NASDAQ:TBNK), and Farmers & Merchants Bancorp, Inc. (NASDAQ:FMAO), Enterprise Financial Services Corp (NASDAQ:EFSC) is an oversold stock on the analyst radar.9. Columbia Financial, Inc. (NASDAQ:CLBK)Latest RSI Reading: 46.46Columbia Financial, Inc. (NASDAQ:CLBK) is a New Jersey based regional bank. The firm's Q2 earnings report was typical of what we're seeing from regional banks as it missed analyst EPS estimates by a wide margin.Seven of the 943 hedge funds polled by Insider Monkey had owned a stake in the bank as of Q1 2023. Columbia Financial, Inc. (NASDAQ:CLBK)'s biggest hedge fund investor is Jim Simons' Renaissance Technologies courtesy of an investment that is worth $14.5 million.8. Eagle Bancorp Montana, Inc. (NASDAQ:EBMT)Latest RSI Reading: 46.15Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) provides accounts, loans, and other banking products. The firm missed Q2 2023 earnings by a wide margin, but to keep shareholders happy, it promised a large dividend.After sifting through 943 hedge fund holdings for this year's first quarter, Insider Monkey discovered that three had bought Eagle Bancorp Montana, Inc. (NASDAQ:EBMT)'s shares. Jim Simons' Renaissance Technologies is the largest shareholder with a stake of $998,000.7. Shore Bancshares, Inc. (NASDAQ:SHBI)Latest RSI Reading: 45.89Shore Bancshares, Inc. (NASDAQ:SHBI) is a Maryland based bank that offers deposit and non deposit products. The shares are significantly down year to date as it has missed analyst EPS estimates in three out of its last four quarters. The last Overweight upgrade for the stock came a year back in August. However, a weaker analyst sentiment for the regional banking sector allowed it to beat revenue estimates for the second quarter even as it lagged the EPS estimates by quite a bit.Insider Monkey's first quarter of 2023 survey of 943 hedge funds revealed that eight had invested in the bank. Shore Bancshares, Inc. (NASDAQ:SHBI)'s largest hedge fund investor during this time period was Phil Stone's Fourthstone LLC with a $21 million investment.6. Citizens Financial Services, Inc. (NASDAQ:CZFS)Latest RSI Reading: 44.42Citizens Financial Services, Inc. (NASDAQ:CZFS) provides standard banking services such as deposit accounts along with trust administration, retirement planning, and consulting to oil and gas companies. Its performance across the previous three quarters has been strong particularly since it maintained EPS levels in Q2 2023 in line with previous quarters despite significantly low estimates by analysts. Therefore, the shares' losses year to date are significantly lower than the S&P Regional Banks Select Industry Index.Only two of the 943 hedge funds part of Insider Monkey's database had held a stake in S&P Regional Banks Select Industry Index as of Q1 2023.Territorial Bancorp Inc. (NASDAQ:TBNK), Citizens Financial Services, Inc. (NASDAQ:CZFS), Waterstone Financial, Inc. (NASDAQ:WSBF), and Farmers & Merchants Bancorp, Inc. (NASDAQ:FMAO) are some oversold bank stocks. Click to continue reading and see 5 Oversold Bank Stocks To Buy. Suggested Articles:15 Most Undervalued Growth Stocks To Buy25 Best Stocks for Dividends10 Best International Dividend Stocks To BuyDisclosure: None. 10 Oversold Bank Stocks To Buy is originally published on Insider Monkey.

Insider Monkey

10 Oversold Bank Stocks To Buy

https://finance.yahoo.com/news/10-oversold-bank-stocks-buy-230450875.html

ba1db552-2dc4-3fd3-9805-a69e04099e03

EBMT

Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is important as the process of settlement involves two full business days. So if you miss that date, you would not show up on the company's books on the record date. Meaning, you will need to purchase Eagle Bancorp Montana's shares before the 10th of August to receive the dividend, which will be paid on the 1st of September.The company's next dividend payment will be US$0.14 per share, and in the last 12 months, the company paid a total of US$0.56 per share. Calculating the last year's worth of payments shows that Eagle Bancorp Montana has a trailing yield of 4.2% on the current share price of $13.325. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. So we need to check whether the dividend payments are covered, and if earnings are growing. Check out our latest analysis for Eagle Bancorp Montana Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Fortunately Eagle Bancorp Montana's payout ratio is modest, at just 36% of profit.When a company paid out less in dividends than it earned in profit, this generally suggests its dividend is affordable. The lower the % of its profit that it pays out, the greater the margin of safety for the dividend if the business enters a downturn.Click here to see the company's payout ratio, plus analyst estimates of its future dividends.historic-dividendHave Earnings And Dividends Been Growing?Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. This is why it's a relief to see Eagle Bancorp Montana earnings per share are up 8.8% per annum over the last five years.Story continuesThe main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Eagle Bancorp Montana has delivered an average of 7.0% per year annual increase in its dividend, based on the past 10 years of dividend payments. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders.Final TakeawayIs Eagle Bancorp Montana worth buying for its dividend? Eagle Bancorp Montana has seen its earnings per share grow slowly in recent years, and the company reinvests more than half of its profits in the business, which generally bodes well for its future prospects. In summary, Eagle Bancorp Montana appears to have some promise as a dividend stock, and we'd suggest taking a closer look at it.While it's tempting to invest in Eagle Bancorp Montana for the dividends alone, you should always be mindful of the risks involved. For example, we've found 1 warning sign for Eagle Bancorp Montana that we recommend you consider before investing in the business.Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Here's What We Like About Eagle Bancorp Montana's (NASDAQ:EBMT) Upcoming Dividend

https://finance.yahoo.com/news/heres-eagle-bancorp-montanas-nasdaq-120105653.html

5186421a-eff5-3329-9b30-09338f2f802d

ECL

In this piece, we will take a look at the August updates of Bill Gates' stock portfolio. If you want to skip out an introduction to the well known technology billionaire, then head on over to Bill Gates Stock Portfolio Latest 2023 Update: Top 5 Stocks.Bill Gates really needs no introduction. His company, Microsoft Corporation (NASDAQ:MSFT) is one of the biggest technology companies in the world and one that sits at the heart of the computing revolution that has taken the planet by storm.Mr. Gates' story is one of a typical Silicon Valley entrepreneur. He attended the illustrious Harvard University for his undergraduate education, but sensing an opportunity in the computing market, dropped out and set up Microsoft in 1976. During the first decade of its existence, Microsoft would compete with Apple Inc (NASDAQ:AAPL) to take the personal computing crown and these years would signify the different approaches to a product that Gates and his rival Steve Jobs would take. While Jobs would stress the need to control the entire user experience through his product and pair the Macintosh operating system with the Mac computer, Gates would instead focus on developing software that could be used on any computer. As history shows, Gates won this war, and Microsoft is currently the world's largest computer operating system company. Apple, however, came back with the smartphone as it became the first company to capture a large market with the iPhone.After working at Microsoft for nearly four decades, Gates left the firm in 2014. However, due to his stature in the industry and his active approach towards charity, he is still a regular feature of news pieces despite nearly ten years having passed since his retirement. The Microsoft billionaire, who is worth $116 billion as of August 2023, donates to charitable causes and invests primarily through his Bill and Melinda Gates Foundation. Apart from the foundation, he also invests through his family office called Cascade Investment. If you're interested in his family office's investments, then check out Bill Gates’ Most Recent Portfolio: Top 15 Stock Picks. Story continuesMr. Gates' foundation is also one of the biggest charities in the world, and estimates suggest that through it, he has donated more than $50 billion to a variety of charitable causes over the past two decades. His friendship with another well-known charitable billionaire, Warren Buffett of Berkshire Hathaway, is also well known and so is Mr. Buffett's influence on Mr. Gates' investment philosophy. As opposed to Gates, who is a technology billionaire, Mr. Buffett is an old school investor who finds value in a variety of sectors such as energy and finance. These choices often hedge investment losses in a market downturn in growth stocks such as the one we witnessed last year, and Mr. Buffett has also influenced the Bill and Melinda Gates Foundation's investments by quite a bit. Like his friend, Mr. Gates has also pledged to give away nearly all of his wealth once he passes away.These days the billionaire is busy being a celebrity and focusing on his interests. In August, he interviewed Khan Academy's founder Sal Khan as part of his Unconfuse Me podcast where the pair discussed a variety of topics. For those out of the loop, Khan Academy is the world's premier online education platform that is made of countless free courses to make sure that children all over the world can access education for free. During the talk, Gates shared his experience around ChatGPT's early days and how OpenAI stunned him when it demonstrated its software to him. The Microsoft founder linked the demo to the time he was at Xerox PARC in the 1970s, which is a big claim if you're in the loop about computing history. If you're not, then consider the fact that the graphical user interface (GUI) developed by Xerox PARC is the precursor to the modern computing operating systems that we use today. It had a simple point and click interface, which had left both Mr. Gates and Mr. Jobs stunned when they first saw it - an understandable reaction considering how the software would become the backbone of the computer.Therefore, comparing the OpenAI demo with the Xerox demo is no short claim and it underscores the impact that Mr. Gates believes that OpenAI might have on the world. During his talk with Sal Khan, Mr. Gates recalled the two demonstrations and shared:In June, they kept showing me this thing, and I was like, "Yeah, it’s kind of an idiot savant. I don’t think it’s practical. Why don’t you see if it can do the AP Biology exam. And I’m not going to pay any attention until you can get a 5." And I thought, "Okay, that’ll give me three years to work on HIV and malaria." And then it was so bizarre because Sam Altman and Greg Brockman in late August said, "Hey, we want to come show you this thing." It was early September when there were like thirty people at my house. And I’ve said it’s the most stunning demo I’ve ever seen in my life. I mean, right up there with seeing the Xerox PARC graphics user interface that set the agenda for Microsoft for about fifteen years. This demo was so surprising to me, the emergent depth that as they scaled up the training set, its fluency, and you have to say understanding, that computers could not read in the sense humans do, and it couldn’t write in the sense humans do. And now, with lots of footnotes about hallucination and things like that, but I’m still personally in a state of shock at wow, it is so good, and okay, therefore, let’s see where we can put it to good use.So, with these details in mind, let's take a look at the August update for Bill Gates' stock portfolio. The top three Bill Gates stock picks are Berkshire Hathaway Inc. (NYSE:BRK-A), Microsoft Corporation (NASDAQ:MSFT), and Canadian National Railway Company (NYSE:CNI).Bill Gates Stock Portfolio: August 2023 UpdateOur Methodology To compile our list of stocks for the August update to Bill Gates' stock portfolio, we used the Bill and Melinda Gates Foundation's Q2 2023 SEC filings and picked top ten stocks from the portfolio. While not included in this list, the fund bought a new stake worth $96 million in Anheuser-Busch InBev SA/NV (NYSE:BUD) during the time period covered.Bill Gates Stock Portfolio: August 2023 Update: Top 10 Stocks10. FedEx Corporation (NYSE:FDX)Bill & Melinda Gates Foundation's Q2 2023 Stake: $380 million  FedEx Corporation (NYSE:FDX) is a courier and logistics services provider. The firm's stock has performed remarkably well on the stock market this year since it is up by nearly 50% year to date. Mr. Gates' foundation owned a $380 million stake in the company as of June 2023, making it the largest hedge fund investor.During the same time period, 62 of the 910 hedge funds polled by Insider Monkey had bought FedEx Corporation (NYSE:FDX)'s shares. Out of these, the firm's second largest shareholder is Ken Griffin's Citadel Investment Group with a $333 million stake.Along with Microsoft Corporation (NASDAQ:MSFT), Berkshire Hathaway Inc. (NYSE:BRK-A), and Canadian National Railway Company (NYSE:CNI), FedEx Corporation (NYSE:FDX) is part of Bill Gates' August stock portfolio update.9. Walmart Inc. (NYSE:WMT)Bill & Melinda Gates Foundation's Q2 2023 Stake: $474 million Walmart Inc. (NYSE:WMT) is the biggest brick and mortar retailer in the world. Its highly anticipated second quarter earnings were a positive bunch of figures, as the firm beat analyst EPS estimates and also increased its full year revenue growth guidance to a high end of 4.5%.During Q2 2023, 81 of the 910 hedge funds part of Insider Monkey's database had held a stake in the retailer. Walmart Inc. (NYSE:WMT)'s largest hedge fund investor is Ken Fisher's Fisher Asset Management since it owns 8.8 million shares that are worth $1.3 billion.8. Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:KOF)Bill & Melinda Gates Foundation's Q2 2023 Stake: $517 million Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:KOF) is the Mexican franchise of Coca-Cola. It produces and sells a variety of Coca-Cola's products. The firm's second quarter earnings saw it report $1.32 in earnings per share, which was seven cents higher than the analyst estimates.By the end of this year's second quarter, the Bill & Melinda Gates Foundation had held a hefty $517 million stake in Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:KOF), making it the largest hedge fund shareholder. Along with the firm, ten of the 910 hedge funds part of Insider Monkey's research had also invested in the company.7. Ecolab Inc. (NYSE:ECL)Bill & Melinda Gates Foundation's Q2 2023 Stake: $974 million Ecolab Inc. (NYSE:ECL) is an industrial water treatment and pest control products and services provider. Despite a general lag in the industrial sector, it reported an 8% sales growth and 21% operating income growth over the year during its second quarter.After digging through 910 hedge fund portfolios for their June quarter of 2023 shareholdings, Insider Monkey discovered that 56 had invested in the company. Ecolab Inc. (NYSE:ECL)'s biggest investor in our database is the Bill & Melinda Gates Foundation Trust with a stake worth $974 million.6. Deere & Company (NYSE:DE)Bill & Melinda Gates Foundation's Q2 2023 Stake: $1.5 billion Deere & Company (NYSE:DE) is another industrial company that sells tractors, crawlers, and other machines.Mr. Gates' foundation is Deere & Company (NYSE:DE)'s biggest shareholder since it owns 3.9 million shares that are worth $1.5 billion. As a whole, 56 of the 910 hedge funds part of Insider Monkey's Q2 2023 database had invested in the company.Berkshire Hathaway Inc. (NYSE:BRK-A), Deere & Company (NYSE:DE), Microsoft Corporation (NASDAQ:MSFT), and Canadian National Railway Company (NYSE:CNI) are some stocks that the Bill Gates Foundation invested in during 2023's second quarter. Click to continue reading and see Bill Gates Stock Portfolio Latest 2023 Update: Top 5 Stocks. Suggested Articles:Goldman Sachs Tech Stocks: Top 12 Stock Picks15 Fastest Growing Fintech Companies In 202310 Healthcare Stocks with Insider BuyingDisclosure: None. Bill Gates Stock Portfolio: August 2023 Update is originally published on Insider Monkey.

Insider Monkey

Bill Gates Stock Portfolio: August 2023 Update

https://finance.yahoo.com/news/bill-gates-stock-portfolio-august-112713302.html

dff51ab5-6b76-308e-a43a-4ebca5659ba3

ECL

Ecolab CEO Christophe Beck doesn't like to call the seemingly endless slew of weather calamities this summer—wildfires in Canada, 120-degree temperatures in Italy, and a tropical storm slamming Los Angeles—an opportunity. But he does concede that these events have added urgency to efforts to contain climate change and are keeping the heat (no pun intended) on his big corporate clients to improve their sustainability records. "It is making climate change more real for people," the Swiss-born CEO says.The company, which began in 1923 in St. Paul, Minn., as Economics Laboratory, has a client roster chock full of Fortune 500 companies, such as Coca-Cola, Walmart, Dow, McDonald's, PepsiCo, and Microsoft. Ecolab, a $14 billion-a-year company, provides industrial cleaners, wastewater treatment, and cooling water treatment products.Beck says clients, also facing public pressure, are hungry for the cost savings that come with more efficient water use. That includes the oil and gas industries, which he says will remain very large for decades, even as renewable energies make up a growing percentage of energy use."Companies realize they can produce oil in more sustainable ways," says Beck, who is not to be confused with Christophe Beck, the film score composer of such movies as Marvel's Ant-Man series.At the same time, a big incentive for his clients is a more prosaic concern: cutting costs. "There is a theory that people are ready to pay more for sustainable products. It's not really true for the masses," says Beck.This interview was edited and condensed for clarity.Fortune: Does this summer of bonkers weather worldwide help Ecolab's business?I would answer yes, but that feels self-serving. It is, however, making climate change more real for people. The wildfires we've seen this year from a human, social, and business perspective are threats that are making climate change even clearer for anyone who thought it was truly not happening. And since we are in the business of helping companies cope with climate change, it's good for business.Story continuesDo you worry that the ESG pushback could reduce corporations' urgency to save water and be better environmental stewards?I don't think so. Take the example of the Paris Agreement. The previous U.S. administration withdrew from it, yet no company has changed its plans. That's because they need water and energy to keep operating. They need natural resources and to procure them in a way that makes business sense. If you produce more or better products with less water and energy, you create less waste, reducing costs and carbon footprint.What industries do you see most ripe for reducing water usage and, therefore, offering Ecolab the biggest opportunities?To put it in perspective, 150 companies use one-third of the world's water resources. You can fit them all in a single room, which is pretty cool because you can collectively change things more quickly. There are two groups of companies. There are those with huge potential, such as oil and gas, and those with less potential but which consumers expect will do more. That second bucket includes food and beverage companies like Coke, Pepsi, Nestlé, et cetera. That's because they're related to agriculture, which is behind 70% of water usage on the planet. They have to be cost-competitive, because while there is a theory that people are ready to pay more for sustainable products, it's not really true for the masses.And there are also companies making microchips rather than potato chips.You have data centers everywhere around the world, and that's growing exponentially. We as an economy will need way more of those for our computers since the large servers use a lot of energy and need to be cooled down. And you need a lot of water for that. As for phones, you need 50 gallons to produce their chip. So, tech companies have huge potential and are making the most progress.You can argue that the oil and gas and paper industries are fading. So, what helps Ecolab grow?Without stepping into a political debate, I think that in the next 30 years, we will need more oil and gas than we use today. Renewable energy is still a small percentage of the total energy production globally, and the energy from fossil fuels will still be the bulk of it. It's turned into a growth opportunity because companies realize they can produce oil more sustainably at a refinery, whereas now, you still have to use more water than oil to make the fuel. We can help these big brands reduce their water usage and carbon footprint. There is also the rise of electric vehicles, for which you need a huge amount of lithium. That comes from mines, and we must use underground water for that. And there is, of course, helping brands like McDonald's, Coca-Cola, Pepsi, Nestlé, and Tyson hit their ESG goals.Almost all of Ecolab's business is products and services for corporations, with virtually nothing for the general consumer. This year, you announced your first-ever suite of cleaning products selling at Home Depot. Is this the beginning of an effort to go after the consumer market?No. This line at Home Depot focuses on the pros or professional contractors. We are always trying to reach new markets and new people. That includes smaller contractors who don't typically buy from us. So two years ago, we approached Ted Decker (CEO of Home Depot) and said, "What can we do here?" As those smaller contractors grow, they become bigger companies, and then they shift to our more traditional model. So it's a new end market for us to capture.Get to know Beck:He's a trained rescue helicopter pilot in his native Switzerland.Beck worked on a space shuttle project for the European Space Agency early in his engineering career.He speaks four languages—English, French, German, and Italian—and a fifth if you include the Swiss-German dialect.This story was originally featured on Fortune.comMore from Fortune: 5 side hustles where you may earn over $20,000 per year—all while working from homeWant more for your money? These 9 savings accounts have rates of 5.01% APYBuying a house? Here's how much to saveThis is how much money you need to earn annually to comfortably buy a $600,000 home

Fortune

The CEO of water treatment company Ecolab doesn’t think fossil fuels are going away anytime soon: ‘We will need more oil and gas than we use today’

https://finance.yahoo.com/news/ceo-water-treatment-company-ecolab-150534967.html

6dc1fb2b-dc22-31be-b96e-6c83303a5d1f

ED

Key InsightsInstitutions' substantial holdings in Consolidated Edison implies that they have significant influence over the company's share priceThe top 25 shareholders own 48% of the company Insiders have bought recently If you want to know who really controls Consolidated Edison, Inc. (NYSE:ED), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 67% to be precise, is institutions. Put another way, the group faces the maximum upside potential (or downside risk).Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of Consolidated Edison. See our latest analysis for Consolidated Edison ownership-breakdownWhat Does The Institutional Ownership Tell Us About Consolidated Edison?Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.We can see that Consolidated Edison does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Consolidated Edison, (below). Of course, keep in mind that there are other factors to consider, too.earnings-and-revenue-growthInstitutional investors own over 50% of the company, so together than can probably strongly influence board decisions. We note that hedge funds don't have a meaningful investment in Consolidated Edison. Our data shows that BlackRock, Inc. is the largest shareholder with 13% of shares outstanding. For context, the second largest shareholder holds about 12% of the shares outstanding, followed by an ownership of 7.3% by the third-largest shareholder.Story continuesOur studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.Insider Ownership Of Consolidated EdisonWhile the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.Our data suggests that insiders own under 1% of Consolidated Edison, Inc. in their own names. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$19m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying. General Public OwnershipThe general public-- including retail investors -- own 32% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.Next Steps:While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for Consolidated Edison (of which 2 can't be ignored!) you should know about.But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

With 67% ownership of the shares, Consolidated Edison, Inc. (NYSE:ED) is heavily dominated by institutional owners

https://finance.yahoo.com/news/67-ownership-shares-consolidated-edison-140019432.html

330f155f-1a46-33a7-aa01-c355725d9200

ED

Consolidated Edison Inc (NYSE:ED) experienced a daily gain of 1.77%, but a 3-month loss of -5.21%. With an Earnings Per Share (EPS) of 6.95, the question arises: is the stock fairly valued? This article provides a comprehensive valuation analysis to answer this question. Read on for an insightful exploration of Consolidated Edison's intrinsic value.Company IntroductionWarning! GuruFocus has detected 5 Warning Signs with ED. Click here to check it out. ED 30-Year Financial DataThe intrinsic value of EDConsolidated Edison, a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R, provides steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The company's earnings are primarily generated from these utilities. With a stock price of $88.34 and a GF Value of $92.94, Consolidated Edison presents an interesting case for valuation analysis.Consolidated Edison (ED): A Balanced Analysis of Its Market ValueUnderstanding GF ValueThe GF Value is a proprietary measure of a stock's intrinsic value, based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates. The GF Value Line provides a snapshot of the fair value at which the stock should ideally trade. If the stock price is significantly above the GF Value Line, it is overvalued, and its future return is likely to be poor. Conversely, if it is significantly below the GF Value Line, its future return will likely be higher.Consolidated Edison's stock appears to be fairly valued based on the GuruFocus Value calculation. With a market cap of $30.50 billion at its current price of $88.34 per share, the long-term return of its stock is likely to be close to the rate of its business growth.Consolidated Edison (ED): A Balanced Analysis of Its Market ValueLink: These companies may deliver higher future returns at reduced risk.Financial StrengthInvesting in companies with low financial strength could result in permanent capital loss. Therefore, a company's financial strength should be carefully reviewed before deciding to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Consolidated Edison has a cash-to-debt ratio of 0.08, ranking worse than 74.53% of 479 companies in the Utilities - Regulated industry. Based on this, GuruFocus ranks Consolidated Edison's financial strength as 4 out of 10, suggesting a poor balance sheet.Story continuesConsolidated Edison (ED): A Balanced Analysis of Its Market ValueProfitability and GrowthCompanies that have been consistently profitable over the long term offer less risk for investors. Consolidated Edison has been profitable 10 times over the past 10 years. Over the past twelve months, the company had a revenue of $15.50 billion and an Earnings Per Share (EPS) of $6.95. Its operating margin is 16.69%, ranking better than 60.48% of 496 companies in the Utilities - Regulated industry. Overall, the profitability of Consolidated Edison is ranked 7 out of 10, indicating fair profitability.One of the most important factors in the valuation of a company is growth. The average annual revenue growth of Consolidated Edison is 4.9%, ranking worse than 65% of 480 companies in the Utilities - Regulated industry. The 3-year average EBITDA growth is 2.3%, ranking worse than 57.99% of 457 companies in the same industry.ROIC vs WACCReturn on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC exceeds the WACC, the company is likely creating value for its shareholders. During the past 12 months, Consolidated Edison's ROIC was 3.3, while its WACC came in at 5.29.Consolidated Edison (ED): A Balanced Analysis of Its Market ValueConclusionIn summary, the stock of Consolidated Edison appears to be fairly valued. The company's financial condition is poor, and its profitability is fair. Its growth ranks worse than 57.99% of 457 companies in the Utilities - Regulated industry. To learn more about Consolidated Edison stock, you can check out its 30-Year Financials here.To find out the high quality companies that may deliver above average returns, please check out GuruFocus High Quality Low Capex Screener.This article first appeared on GuruFocus.

GuruFocus.com

Consolidated Edison (ED): A Balanced Analysis of Its Market Value

https://finance.yahoo.com/news/consolidated-edison-ed-balanced-analysis-153606518.html

8d3ff1a2-eac6-3d85-8a6f-30f8b699557c

EDIT

A month has gone by since the last earnings report for Ligand Pharmaceuticals (LGND). Shares have lost about 8.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Ligand due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Q2 Earnings Beat, Sales Miss EstimatesLigandreported adjusted diluted earnings of $1.42 per share in second-quarter 2023 from continuing operations, beating the Zacks Consensus Estimate of 76 cents. The company reported adjusted earnings of 43 cents in the year-ago quarter.Total revenues of $26.4 million were down 47% from the year-ago quarter’s levels. The downside was due to the absence of COVID-19-related Captisol sales during the quarter. Revenues missed the Zacks Consensus Estimate of $28 million.Quarterly HighlightsRoyalty revenues were up 15% year over year to $20.4 million in the second quarter. The upside was mainly driven by increased royalties from Amgen’s Kyprolis, Jazz Pharmaceuticals’ Rylaze and Merck’s Vaxneuvance.Total Captisol sales were down 82% year over year to $5.2 million in the reported quarter. Ligand reports its Captisol sales separately for core assets and COVID-related sales. Core Captisol sales rose 57% to $5.2 million due to the favorable timing of customer orders. During the quarter, the company did not record any Captisol sales related to COVID-19.Contract revenues were down 74% year over year to $0.7 million in the second quarter, owing to the unfavorable timing of partner milestone events.Cash, cash equivalents and short-term investments amounted to $219.0 million as of Jun 30, 2023, compared with $282.7 million as of Mar 31, 2023.2023 GuidanceLigand revised its guidance for 2023. The company reaffirmed its total revenue guidance of $124-$128 million.Story continuesRoyalty revenues expectations remained unchanged in the $78-$82 million range. The company now expects Captisol sales to generate $24 million (previously: $21 million), while contract revenue is expected to be $22 million (previously: $25 million).The company also increased its expectation for adjusted diluted EPS to $4.85-$5.00, which was expected in the range of $4.60-$4.75. This increased EPS guidance is due to gains from Viking Therapeutics stock sales.The above guidance excludes Captisol sales related to COVID-19 and its impact on gross profit. Management will update investors as and when orders for COVID-19-related products are received.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.The consensus estimate has shifted -50.81% due to these changes.VGM ScoresAt this time, Ligand has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ligand has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerLigand is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Editas Medicine (EDIT), a stock from the same industry, has gained 3.2%. The company reported its results for the quarter ended June 2023 more than a month ago.Editas reported revenues of $2.89 million in the last reported quarter, representing a year-over-year change of -54.6%. EPS of -$0.56 for the same period compares with -$0.78 a year ago.For the current quarter, Editas is expected to post a loss of $0.64 per share, indicating a change of +21% from the year-ago quarter. The Zacks Consensus Estimate has changed -1% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Editas. Also, the stock has a VGM Score of D.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis ReportEditas Medicine, Inc. (EDIT) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?

https://finance.yahoo.com/news/ligand-lgnd-down-8-8-153055826.html

917ae9ae-2093-375c-b7f0-4ba3ca176f15

EDIT

Ultragenyx (RARE) shares rallied 6.1% in the last trading session to close at $41.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks.The sudden rise in the stock price can be attributed to positive investor expectations from the upcoming milestone events for some of the candidates in Ultragenyx's pipeline, due next month. In June 2023, the company reported positive phase II data from its phase II/III Orbit study of UX143 for osteogenesis imperfecta. Additional data from the phase II portion of the study is expected in mid-October. Also in mid-October, RARE is expected to provide an interim program update from its early-mid-stage study of GTX-102 for Angelman syndrome.This biotechnology company is expected to post quarterly loss of $2.05 per share in its upcoming report, which represents a year-over-year change of +15.6%. Revenues are expected to be $110.67 million, up 22% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Ultragenyx, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Ultragenyx belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Editas Medicine (EDIT), closed the last trading session 2.3% lower at $8.91. Over the past month, EDIT has returned 3.2%.Story continuesFor Editas , the consensus EPS estimate for the upcoming report has changed -1% over the past month to -$0.64. This represents a change of +21% from what the company reported a year ago. Editas currently has a Zacks Rank of #3 (Hold).Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportUltragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis ReportEditas Medicine, Inc. (EDIT) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?

https://finance.yahoo.com/news/ultragenyx-rare-soars-6-1-090300591.html

17c29226-15ef-31a4-b72a-d04c111fbb04

EFOI

Conference Call to be Held Today at 11 a.m. ETSolon, Ohio --News Direct-- Energy Focus, Inc.Energy Focus, Inc. (NASDAQ:EFOI), a leader in energy-efficient lighting and control system products for the commercial market and military maritime market (“MMM”), today announced financial results for its second quarter ended June 30, 2023.Second Quarter 2023 Financial Highlights:Net sales of $1.1 million, decreased 28.7% compared to the second quarter of 2022, reflecting a decrease of $0.5 million, or 54.7%, in commercial sales, partially offset by a $0.1 million, or 21.4%, increase in military sales period-over-period. Sequentially, net sales increased by 13.4%, primarily reflecting a $0.1 millionincrease in commercial sales, with military sales remaining flat, as compared to the first quarter of 2023.Gross profit margin of 17.0% increased from 7.4% in the second quarter of 2022, and 1.8% in the first quarter of 2023. The period-over-period increase, as compared to the second quarter of 2022, was driven mainly by a favorable impact from lower fixed costs, offset slightly by an unfavorable impact from the change in inventory reserves. Sequentially, the increase quarter-over-quarter, as compared to the first quarter of 2023, primarily relates to a favorable impact from the change in inventory reserves due to orders received in the second quarter of 2023 that are expected to be fulfilled during the third quarter of 2023.Loss from operations of $1.1 million improved as compared to loss from operations of $2.2 million in the second quarter of 2022, and $1.2 million in the first quarter of 2023.Net loss of $1.2 million, or $(0.42) per basic and diluted share of common stock, compared to a net loss of $2.5 million, or $(2.43) per basic and diluted share of common stock, in the second quarter of 2022. Sequentially, the net loss decreased by $0.2 million compared to a net loss of $1.3 million, or $(0.58) per basic and diluted share of common stock, in the first quarter of 2023.Cash of $1.3 million, included in total availability (as defined under “Non-GAAP Measures” below) of $1.5 million, each as of June 30, 2023, as compared to cash of $52 thousand and $938 thousand and total availability of $107 thousand and $2.5 million as of December 31, 2022 and June 30, 2022, respectively.Subsequent to approval by the Company’s stockholders and pursuant to the ratio approved by the Company’s Board of Directors on June 15, 2023, a 1-for-7 reverse stock split became effective on June 16, 2023 wherein every seven shares of common stock issued and outstanding automatically combined into one validly issued, fully paid and non-assessable share of common stock. No fractional shares were issued as a result of the reverse stock split.Private placement of additional $1.3 million of common stock was completed during the second quarter of 2023.Story continues“We believe the second quarter has been the start of a true turn around for Energy Focus,” said Lesley Matt, Chief Executive Officer. “The arrival of fresh inventory late in the quarter allowed for us to begin showing improvement in both our topline sales and gross profit. As more inventory continues to arrive, we are optimistic to continue this trend. Additionally, we have made changes to our sales team structure to better align with growth and the future. As we march towards increasing revenue by providing customers with innovative energy solution products, we continue to look at ways to improve our overall operation.”Second Quarter 2023 Financial Results:Net sales of $1.1 million for the second quarter of 2023 decreased $0.4 million, or 28.7%, compared to second quarter of 2022 net sales of $1.5 million, primarily driven by a decrease in commercial sales of $0.5 million, or 54.7%, that was partially offset by an increase in MMM product sales of $0.1 million, or 21.4%. MMM sales have increased due to improved sales pipeline as management replaced the head of MMM sales mid-year 2022. The MMM sales cycle is prolonged and started to reverse its negative trend in the middle of the fourth quarter of 2022. Net commercial product sales decreased in the second quarter of 2023 compared to the same period in 2022, primarily due to the lack of availability in high-margin, high-demand commercial products as a result of supply chain interruptions. Sequentially, net sales were up 13.4% compared to $0.9 million in the first quarter of 2023, reflecting a slight increase in commercial sales with the sales in MMM orders flat.Gross profit was $0.2 million, or 17.0% of net sales, for the second quarter of 2023. This compares with gross profit of $0.1 million, or 7.4% of net sales, in the second quarter of 2022. The period-over-period increase in gross profit was driven mainly by a favorable impact from lower fixed costs of $0.2 million, or 15.3% of net sales. The $0.1 million favorable impact from product mix was offset by an unfavorable impact of $0.1 million from lower sales. Additionally, there was an overall net unfavorable impact from the change in inventory reserves of $0.1 million, or 7.5% of net sales, versus the second quarter of 2022, which included a one-time adjustment from a scrap write-off.Sequentially, gross profit of $0.2 million for the second quarter of 2023 compares with gross profit of $17 thousand, or 1.8% of net sales, in the first quarter of 2023. The increase quarter-over-quarter primarily relates to a favorable net impact of approximately $0.1 million, or 8.1% of net sales, related to the change in inventory reserves and favorable impacts of $0.1 million in sales and product mix, together. The change in inventory reserves relates mainly to orders received during the second quarter of 2023 that are expected to be fulfilled during the third quarter of 2023.Adjusted gross margin, as defined under “Non-GAAP Measures” below, was 6.8% for the second quarter of 2023, compared to (5.1)% in the second quarter of 2022, primarily driven by lower fixed costs during the second quarter of 2023 as compared to the second quarter of 2022. Sequentially, this compares to adjusted gross margin of (0.6)% in the first quarter of 2023. The improvement from the first quarter of 2023 was primarily driven by higher variable margins and lower fixed costs in the second quarter of 2023.Operating loss was $1.1 million for the second quarter of 2023, an improvement as compared to an operating loss of $2.2 million in the second quarter of 2022, and an operating loss of $1.2 million in the first quarter of 2023. Net loss was $1.2 million, or $(0.42) per basic and diluted share of common stock, for the second quarter of 2023, compared with a net loss of $2.5 million, or $(2.43) per basic and diluted share of common stock, in the second quarter of 2022. Sequentially, this compares with a net loss of $1.3 million, or $(0.58) per basic and diluted share of common stock, in the first quarter of 2023.Adjusted EBITDA, as defined under “Non-GAAP Measures” below, was a loss of $1.0 million for the second quarter of 2023, compared with a loss of $2.1 million in the second quarter of 2022 and a loss of $1.2 million in the first quarter of 2023. The smaller adjusted EBITDA loss in the second quarter of 2023, as compared to the second quarter of 2022, was primarily due to improved margins and lower operating expenses.Cash was $1.3 million as of June 30, 2023. This compares with cash of $52 thousand and $938 thousand as of December 31, 2022 and June 30, 2022, respectively. As of June 30, 2023, the Company had total availability, as defined under “Non-GAAP Measures” below, of $1.5 million, which consisted of $1.3 million of cash and $0.2 million of additional borrowing availability under its credit facilities. This compares to total availability of $107 thousand as of December 31, 2022 and $2.5 million as of June 30, 2022. Our net inventory balance of $5.3 million as of June 30, 2023 decreased $0.2 million and $1.9 million from our net inventory balance as of December 31, 2022 and June 30, 2022, respectively.Earnings Conference Call:The Company will host a conference call and webcast today, August 10, 2023, at 11 a.m. ET to discuss the secondquarter 2023 results, followed by a Q & A session.You can access the live conference call by dialing the following phone numbers:Toll free 1-877-451-6152 orInternational 1-201-389-0879Conference ID# 13739842The conference call will be simultaneously webcast. To listen to the webcast, log onto it at: https://viavid.webcasts.com/starthere.jsp?ei=1623732&tp_key=af4459857f. The webcast will be available at this link through August 25, 2023. Financial information presented on the call, including this earnings press release, will be available on the investors section of Energy Focus’ website, investors.energyfocus.com.Condensed Consolidated Balance Sheets(in thousands)June 30, 2023December 31, 2022(Unaudited)ASSETSCurrent assets:Cash$ 1,316$ 52Trade accounts receivable, less allowances of $79 and $26, respectively841445Inventories, net5,3045,476Short-term deposits630592Prepaid and other current assets217232Receivable for claimed Employee Retention Tax Credit—445Total current assets8,3087,242Property and equipment, net6076Operating lease, right-of-use asset1,0341,180Total assets$ 9,402$ 8,498LIABILITIESCurrent liabilities:Accounts payable$ 2,908$ 2,204Accrued liabilities116145Accrued legal and professional fees89—Accrued payroll and related benefits268261Accrued sales commissions3276Accrued warranty reserve146183Operating lease liabilities210198Promissory notes payable, net of discounts and loan origination fees1,3352,618Related party promissory notes payable—814Credit line borrowings, net of loan origination fees2841,447Total current liabilities5,3887,946Operating lease liabilities, net of current portion9151,029Total liabilities6,3038,975STOCKHOLDERS' EQUITY (DEFICIT)Preferred stock, par value $0.0001 per share:Authorized: 5,000,000 shares (3,300,000 shares designated as Series A Convertible Preferred Stock) at June 30, 2023 and December 31, 2022Issued and outstanding: 876,447 at June 30, 2023 and December 31, 2022——Common stock, par value $0.0001 per share:Authorized: 50,000,000 shares at June 30, 2023 and December 31, 2022Issued and outstanding: 3,495,924 at June 30, 2023 and 1,406,920* at December 31, 2022—1Additional paid-in capital154,624148,545Accumulated other comprehensive loss(3)(3)Accumulated deficit(151,522)(149,020)Total stockholders' equity (deficit)3,099(477)Total liabilities and stockholders' equity (deficit)$ 9,402$ 8,498* Shares outstanding for prior periods have been restated for the 1-for-7 reverse stock split effective June 16, 2023.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three months endedSix months ended June 30,June 30, 2023March 31, 2023June 30, 202220232022Net sales$ 1,055$ 930$ 1,480$ 1,985$ 3,541Cost of sales8769131,3711,7893,458Gross profit 1791710919683Operating expenses:Product development147154353301856Selling, general, and administrative1,1321,0661,9642,1984,091Total operating expenses1,2791,2202,3172,4994,947Loss from operations(1,100)(1,203)(2,208)(2,303)(4,864)Other expenses (income):Interest expense, net69123260192444Other income(16)——(16)(30)Other expenses147182129Net loss$ (1,167)$ (1,333)$ (2,486)$ (2,500)$ (5,307)Net loss per common share - basic and diluted:Net Loss$ (0.42)$ (0.58)$ (2.43)$ (0.98)$ (5.45)Weighted average shares of common stock outstanding:Basic and diluted*2,7662,3101,0242,539973* Shares outstanding for prior periods have been restated for the 1-for-7 reverse stock split effective June 16, 2023.Condensed Consolidated Statements of Cash Flows(in thousands)(unaudited)Three months endedSix months endedJune 30,June 30,2023March 31,2023June 30,2220232022Cash flows from operating activities:Net loss($1,167)($1,333)($2,486)($2,500)($5,307)Adjustments to reconcile net loss to net cash used in operating activities:Other income————(30)Depreciation88431687Stock-based compensation2326544998Provision for doubtful accounts receivable2129550(4)Provision for slow-moving and obsolete inventories(107)(23)(185)(130)(56)Provision for warranties3(40)51(37)21Amortization of loan discounts and origination fees476291109160Changes in operating assets and liabilities (sources / (uses) of cash):Accounts receivable93(496)184(403)101Inventories(259)562384303754Short-term deposits—(23)47-2359Prepaid and other assets454696460116Accounts payable884(27)(777)857(716)Accrued and other liabilities(152)66(149)(86)(360)Deferred revenue————(268)Total adjustments1,015150(156)1,165(38)Net cash used in operating activities(152)(1,183)(2,642)(1,335)(5,345)Cash flows from investing activities:Acquisitions of property and equipment——(2)—(37)Net cash used in investing activities——(2)—(37)Cash flows from financing activities (sources / (uses) of cash):Proceeds from the issuance of common stock and warrants1,3043,0253,5004,3293,500Offering costs paid on the issuance of common stock and warrants——(334)—(334)Costs related to reverse stock-split(16)——(16)—Principal payments under finance lease obligations————(1)Proceeds from exercise of stock options and employee stock purchase plan purchases——5—5Payments on the 2021 Streeterville Note——(410)—(1,025)Proceeds from the 2022 Streeterville Note——2,000—2,000Payments on the 2022 Streeterville Note—(500)—(500)—Deferred financing costs——(234)—(234)Net payments on proceeds from the credit line borrowings - Credit Facilities(121)(1,093)(1,170)(1,214)(273)Net cash provided by financing activities1,1671,4323,3572,5993,638Net increase (decrease) in cash1,0152497131,264(1,744)Cash, beginning of period30152225522,682Cash, end of period$ 1,316$ 301$ 938$ 1,316$ 938Sales by Product(in thousands)(unaudited)Three months endedSix months endedJune 30,June 30, 2023March 31, 2023June 30, 202220232022Net sales:Commercial$ 442$ 321$ 975$ 763$ 2,109Military maritime products6136095051,2221,432Total net sales$ 1,055$ 930$ 1,480$ 1,985$ 3,541Non-GAAP MeasuresIn addition to the results in this release that are presented in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), we provide certain non-GAAP measures, which present operating results on an adjusted basis. These non-GAAP measures are supplemental measures of performance that are not required by or presented in accordance with U.S. GAAP and, include:total availability, which we define as our ability on the period end date to access additional cash if necessary under our short-term credit facilities, plus the amount of cash on hand on that same date;adjusted EBITDA, which we define as net income (loss) before giving effect to financing charges, income taxes, non-cash depreciation, stock non-cash compensation, accrued incentive compensation, non-routine charges to other income or expense; andadjusted gross margins, which we define as our gross profit margins during the period without the impact from excess and obsolete, in-transit and net realizable value inventory reserve movements that do not reflect current period inventory decisions.We believe that our use of these non-GAAP financial measures permits investors to assess the operating performance of our business relative to our performance based on U.S. GAAP results and relative to other companies within the industry by isolating the effects of items that may vary from period to period without correlation to core operating performance or that vary widely among similar companies, and to assess liquidity, cash flow performance of the operations, and the product margins of our business relative to our U.S. GAAP results and relative to other companies in the industry by isolating the effects of certain items that do not have a current period impact. However, our presentation of these non-GAAP measures should not be construed as an indication that our future results will be unaffected by unusual or infrequent items or that the items for which we have made adjustments are unusual or infrequent or will not recur. Further, there are limitations on the use of these non-GAAP measures to compare our results to other companies within the industry because they are not necessarily standardized or comparable to similarly titled measures used by other companies. We believe that the disclosure of these non-GAAP measures is useful to investors as they form part of the basis for how our management team and Board of Directors evaluate our operating performance.Total availability, adjusted EBITDA and adjusted gross margins do not represent cash generated from operating activities in accordance with U.S. GAAP, are not necessarily indicative of cash available to fund cash needs and are not intended to and should not be considered as alternatives to cash flow, net income and gross profit margins, respectively, computed in accordance with U.S. GAAP as measures of liquidity or operating performance. Reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP are provided below for total availability, adjusted EBITDA and adjusted gross margins, respectively.As of(in thousands)June 30, 2023December 31, 2022June 30, 2022Total borrowing capacity under credit facilities$ 500$ 1,567$ 3,568Less: Credit line borrowings, gross(1)(296)(1,512)(2,015)Excess availability under credit facilities(2)204551,553Cash1,31652938Total availability(3)$ 1,520$ 107$ 2,491(1) Forms 10-Q and 10-K Balance Sheets reflect the Line of credit net of debt financing costs of $12, $65 and $23, respectively.(2) Excess availability under credit facilities - represents difference between maximum borrowing capacity of credit facilities and actual borrowings.(3) Total availability - represents Company’s ‘access’ to cash if needed at point in time.Three months endedSix months endedJune 30,(in thousands)June 30, 2023March 31, 2023June 30, 202220232022Net loss$ (1,167)$ (1,333)$ (2,486)$ (2,500)$ (5,307)Interest69123260192444Other income———(16)(30)Depreciation88431687Stock-based compensation2326544998Other incentive compensation23(28)33(5)28Adjusted EBITDA $ (1,044)$ (1,204)$ (2,096)$ (2,264)$ (4,680)Three Months Ended(in thousands)June 30, 2023March 31, 2023June 30, 2022($)(%)($)(%)($)(%)Net sales$ 1,055$ 930$ 1,480Actual gross profit$ 17917.0 %$ 171.8 %$ 1097.4 %E&O, in-transit and net realizable value inventory reserve changes, net of scrap write-off for inventory reduction(107)(10.1) %(23)(2.5) %(185)(12.5) %Adjusted gross profit (loss)$ 726.8 %$(6)(0.6) %$(76)(5.1) %About Energy FocusEnergy Focus is an industry-leading innovator of sustainable light-emitting diode (“LED”) lighting and lighting control technologies and solutions. As the creator of the first flicker-free LED lamps, Energy Focus develops high quality LED lighting products and controls that provide extensive energy and maintenance savings, as well as aesthetics, safety, health and sustainability benefits over conventional lighting. In 2023, EFOI announced plans to add high efficiency GaN (gallium nitride) power supply products to its product portfolio. Energy Focus is headquartered in Solon, Ohio. For more information, visit our website at www.energyfocus.com.Forward-Looking StatementsForward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “feels,” “seeks,” “forecasts,” “projects,” “intends,” “plans,” “may,” “will,” “should,” “could” or “would” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, capital expenditures, and the industry in which we operate. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Although we base these forward-looking statements on assumptions that we believe are reasonable when made in light of the information currently available to us, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ materially from statements made in or suggested by the forward-looking statements contained in this release. We believe that important factors that could cause our actual results to differ materially from forward-looking statements include, but are not limited to: (i) our need for and ability to obtain additional financing in the near term, on acceptable terms or at all, to continue our operations; (ii) our ability to maintain compliance with the continued listing standards of The Nasdaq Stock Market (iii) our ability to refinance or extend maturing debt on acceptable terms or at all; (iv) our ability to continue as a going concern for a reasonable period of time; (v) our ability to realize synergies with our strategic investor; (vi) instability in the U.S. and global economies and business interruptions experienced by us, our customers and our suppliers, particularly in light of supply chain constraints and other long-term impacts of the coronavirus pandemic; (vii) the competitiveness and market acceptance of our LED lighting and control technologies and products; (viii) our ability to compete effectively against companies with lower prices or cost structures, greater resources, or more rapid development capabilities, and new competitors in our target markets; (ix) our ability to extend our product portfolio into new applications and end markets; (x) our ability to increase demand in our targeted markets and to manage sales cycles that are difficult to predict and may span several quarters; (xi) the timing of large customer orders, significant expenses and fluctuations between demand and capacity as we manage inventory and invest in growth opportunities; (xii) our ability to successfully scale our network of sales representatives, agents, distributors and other channel partners to compete with the sales reach of larger, established competitors; (xiii) our ability to implement plans to increase sales and control expenses; (xiv) our reliance on a limited number of customers for a significant portion of our revenue, and our ability to maintain or grow such sales levels; (xv) our ability to add new customers to reduce customer concentration; (xviii) our ability to attract and retain a new chief financial officer; (xvii) our ability to manage the size of our workforce while continuing to attract, develop and retain qualified personnel, and to do so in a timely manner; (xviii) our ability to diversify our reliance on a limited number of third-party suppliers and development partners, our ability to manage third-party product development and obtain critical components and finished products on acceptable terms and of acceptable quality despite ongoing global supply chain challenges, and the impact of our fluctuating demand on the stability of such suppliers; (xix) our ability to timely, efficiently and cost-effectively transport products from our third-party suppliers by ocean marine and other logistics channels despite global supply chain and logistics disruptions; (xx) the impact of any type of legal inquiry, claim or dispute; (xxi) the macro-economic conditions, including rising interest rates and recessionary trends, in the United States and in other markets in which we operate or secure products, which could affect our ability to obtain raw materials, component parts, freight, energy, labor, and sourced finished goods in a timely and cost-effective manner; (xxii) our dependence on military maritime customers and on the levels and timing of government funding available to such customers, as well as the funding resources of our other customers in the public sector and commercial markets; (xxix) business interruptions resulting from geopolitical actions such as war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, or from health epidemics, or pandemics or other contagious outbreaks; (xxx) our ability to respond to new lighting and control technologies and market trends; (xxxi) our ability to fulfill our warranty obligations with safe and reliable products; (xxxii) any delays we may encounter in making new products available or fulfilling customer specifications; (xxxiii) any flaws or defects in our products or in the manner in which they are used or installed; (xxix) our ability to protect our intellectual property rights and other confidential information, and manage infringement claims by others; (xxx) our compliance with government contracting laws and regulations, through both direct and indirect sale channels, as well as other laws, such as those relating to the environment and health and safety; (xxxi) risks inherent in international markets, such as economic and political uncertainty, changing regulatory and tax requirements and currency fluctuations, including tariffs and other potential barriers to international trade; and (xxix) our ability to maintain effective internal controls and otherwise comply with our obligations as a public company. For additional factors that could cause our actual results to differ materially from the forward-looking statements, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.Contact DetailsInvestor Relations+1 [email protected] Websitehttps://energyfocus.com/View source version on newsdirect.com: https://newsdirect.com/news/energy-focus-inc-reports-second-quarter-2023-financial-results-124017606

News Direct

Energy Focus, Inc. Reports Second Quarter 2023 Financial Results

https://finance.yahoo.com/news/energy-focus-inc-reports-second-130000175.html

d4fc0ae3-57c1-32c7-8ca6-98c592280c66

EFOI

Solon, Ohio --News Direct-- Energy Focus, Inc.Energy Focus, Inc. (NASDAQ: EFOI), a leader in sustainable, energy-efficient LED lighting control systems and products for the commercial, military, maritime and consumer markets, today announced that on August 24, 2023, the Board of Directors (the “Board”) of Energy Focus, Inc. (the “Company” or “Energy Focus”) approved the termination of the Company’s Chief Executive Officer (“CEO”), Lesley Matt, effective immediately. The Board appointed Chiao Chieh Jay Huang to serve as the Company’s new CEO. In line with this decision, Mr. Huang will discontinue his role as Chairman of the Board.Mr. Huang, 48, is the President of Sander Electronics, Inc., which he has served as since 2015 and after holding positions of increasing responsibility since 1997. As an innovative entrepreneur, Mr. Huang has more than 20 years of experience in engineering and management within the LED lighting industry, and he holds over 50 electronic and lighting related patents, including commercial buildings, signages, and medical use. In recent years, Mr. Huang has devoted himself to the development of green energy-related products. In addition to assisting in the development of energy solution and energy storage, he has also assisted several collaborating companies to establish a sustainable governance system. Mr. Huang graduated from St. John's University with outstanding achievements from the Department of Electrical Engineering, where he specialized in microelectronic circuits, computer structure, engineering mathematics, microcomputer applications, system programming, interfacing technology, and electronic manufacturing.There are no family relationships between Mr. Huang and any director or other executive officer of the Company. Other than the transactions between the Company and Sander Electronics, Inc. that have been disclosed in the Company’s prior filings with the Securities and Exchange Commission (the “SEC”), there are no transactions between Mr. Huang or any member of his immediate families and the Company or any of its subsidiaries that would be reportable as a related party transaction under the rules of the SEC. Further, there is no arrangement or understanding between Mr. Huang and any other persons or entities pursuant to which Mr. Huang was appointed as Chief Executive Officer of the Company.Story continuesEnergy Focus has consistently demonstrated a commitment to growth, innovation, and leadership within the industry. As part of our ongoing efforts to align our leadership structure with the evolving demands of the business landscape, the Board has undertaken a comprehensive review of the organization's strategic direction and executive responsibilities. The Board has determined that Mr. Huang’s experience, vision, and strategic acumen make him the ideal candidate to lead the Company as the CEO. The Board firmly believes that his transition to the role of CEO from Chairman will further enhance the Company's position in the market.As part of this transition, the Board has appointed Kin Fu Chen as the Chairman of the Board. Mr. Chen brings a wealth of experience and a deep understanding of Energy Focus’ operations, values, and strategic goals, making him well-suited to guide the Board in its oversight and governance functions. This strategic decision is driven by the desire to leverage Mr. Huang's leadership strengths, experience, and expertise in a manner that best serves Energy Focus’ growth trajectory. By concentrating his efforts as CEO, Mr. Huang will be able to direct his focus toward shaping the Company's operational strategies, driving innovation, and expanding its business horizons.There are no family relationships between Mr. Chen and any director or other executive officer of the Company. There are no transactions between Mr. Chen or any member of his immediate families and the Company or any of its subsidiaries that would be reportable as a related party transaction under the rules of the SEC. Further, there is no arrangement or understanding between Mr. Chen and any other persons or entities pursuant to which Mr. Chen was appointed as Chairman of the Board of the Company.About Energy FocusEnergy Focus is an industry-leading innovator of sustainable light-emitting diode (“LED”) lighting and lighting control technologies and solutions. As the creator of the first flicker-free LED lamps, Energy Focus develops high quality LED lighting products and controls that provide extensive energy and maintenance savings, as well as aesthetics, safety, health and sustainability benefits over conventional lighting. In 2023, EFOI announced plans to add high efficiency GaN (gallium nitride) power supply products to its product portfolio. Energy Focus is headquartered in Solon, Ohio. For more information, visit our website at www.energyfocus.com.Forward-Looking Statements:Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “feels,” “seeks,” “forecasts,” “projects,” “intends,” “plans,” “may,” “will,” “should,” “could” or “would” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, capital expenditures, and the industry in which we operate. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Although we base these forward-looking statements on assumptions that we believe are reasonable when made in light of the information currently available to us, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ materially from statements made in or suggested by the forward-looking statements contained in this release. We believe that important factors that could cause our actual results to differ materially from forward-looking statements include, but are not limited to: (i) our need for and ability to obtain additional financing in the near term, on acceptable terms or at all, to continue our operations; (ii) our ability to refinance or extend maturing debt on acceptable terms or at all; (iii) our ability to continue as a going concern for a reasonable period of time; (iv) instability in the U.S. and global economies and business interruptions experienced by us, our customers and our suppliers, particularly in light of supply chain issues, and related long-term impacts on travel, trade and business operations, as a result of the COVID-19 pandemic; (v) the competitiveness and market acceptance of our LED lighting and control technologies and products; (vi) our ability to compete effectively against companies with lower prices or cost structures, greater resources, or more rapid development capabilities, and new competitors in our target markets; (vii) our ability to extend our product portfolio into new end markets, including consumer products; (viii) our ability to increase demand in our targeted markets and to manage sales cycles that are difficult to predict and may span several quarters; (ix) the timing of large customer orders, significant expenses and fluctuations between demand and capacity as we manage inventory and invest in growth opportunities; (x) our ability to successfully scale our network of sales representatives, agents, distributors and other channel partners to compete with the sales reach of larger, established competitors; (xi) our ability to implement plans to increase sales and control expenses; (xii) our reliance on a limited number of customers for a significant portion of our revenue, and our ability to maintain or grow such sales levels; (xiii) our ability to add new customers to reduce customer concentration; (xiv) our ability to attract and retain a new chief financial officer; (xv) our ability to manage the size of our workforce while continuing to attract, develop and retain qualified personnel, and to do so in a timely manner; (xvi) our reliance on a limited number of third-party suppliers and development partners, our ability to manage third-party product development and obtain critical components and finished products on acceptable terms and of acceptable quality despite ongoing global supply chain challenges, and the impact of our fluctuating demand on the stability of such suppliers; (xvii) our ability to timely, efficiently and cost-effectively transport products from our third-party suppliers by ocean marine and other logistics channels despite global supply chain and logistics disruptions; (xiii) the impact of any type of legal inquiry, claim or dispute; (xix) the macro-economic conditions, including recessionary trends, in the United States and in other markets in which we operate or secure products, which could affect our ability to obtain raw materials, component parts, freight, energy, labor, and sourced finished goods in a timely and cost-effective manner; (xx) our dependence on military maritime customers and on the levels and timing of government funding available to such customers, as well as the funding resources of our other customers in the public sector and commercial markets; (xxi) business interruptions resulting from geopolitical actions such as war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, or from health epidemics, or pandemics or other contagious outbreaks; (xxii) our ability to respond to new lighting and control technologies and market trends; (xxiii) our ability to fulfill our warranty obligations with safe and reliable products; (xxiv) any delays we may encounter in making new products available or fulfilling customer specifications; (xxv) any flaws or defects in our products or in the manner in which they are used or installed; (xxvi) our ability to protect our intellectual property rights and other confidential information, and manage infringement claims made by others; (xxvii) our compliance with government contracting laws and regulations, through both direct and indirect sale channels, as well as other laws, such as those relating to the environment and health and safety; (xxiii) risks inherent in international markets, such as economic and political uncertainty, changing regulatory and tax requirements and currency fluctuations, including tariffs and other potential barriers to international trade; (xxix) our ability to maintain effective internal controls and otherwise comply with our obligations as a public company; and (xxx) our ability to regain and maintain compliance with the continued listing standards of The Nasdaq Stock Market. For additional factors that could cause our actual results to differ materially from the forward-looking statements, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.Contact DetailsEnergy FocusInvestor Relations+1 [email protected] Websitehttps://energyfocus.com/View source version on newsdirect.com: https://newsdirect.com/news/energy-focus-appoints-new-ceo-and-chairman-of-the-board-115635646

News Direct

Energy Focus Appoints New CEO and Chairman of the Board

https://finance.yahoo.com/news/energy-focus-appoints-ceo-chairman-140051822.html

ca72cc59-c311-3a96-b2f6-3f8ed3748900

EFX

It has been about a month since the last earnings report for Fidelity National Information Services (FIS). Shares have lost about 2.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Fidelity National due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Fidelity National Q2 Earnings Beat, '23 View RaisedFidelity National  reported second-quarter 2023 adjusted earnings per share of $1.55, which outpaced the Zacks Consensus Estimate by 4.7%. However, the bottom line declined 10% year over year.Revenues inched up 1% year over year to $3,746 million. The top line beat the consensus mark by 1.2%. The organic revenue growth came in at 2% in the quarter under review.The better-than-expected quarterly results benefited from well-performing Banking and Capital Markets businesses. FIS’ Future Forward enterprise transaction program reaped results in the form of cash savings this quarter. Recurring revenue growth and lower costs aided the second-quarter results. The company also reported a $6.8 billion charge regarding the upcoming separation of the Worldpay Merchant Solutions business.Q2 PerformanceThe cost of revenues of $2,188 million slipped 2.1% year over year, below our model estimate of $2,215.6 million. Selling, general and administrative expenses also declined 4.5% year over year to $1,033 million in the second quarter and remained below our estimate of $1,070.2 million.Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of Fidelity National fell 3% year over year to $1,551 million but beat our estimate of $1,510.1 million. The adjusted EBITDA margin of 41.4% deteriorated 160 basis points (bps) year over year.Inside FIS’ SegmentsRevenues from Banking Solutions improved 1% year over year to $1,702 million in the second quarter, beating our estimate of $1,680.3 million. It was supported by increased recurring revenues from processing volumes, as well as professional services. The organic revenue growth was 2%. Adjusted EBITDA margin of 42.5% deteriorated 200 bps year over year due to the lower-margin revenue mix.Merchant Solutions’ revenues were $1,312 million, which climbed 1% year over year and beat our estimate of $1,290.9 million thanks to higher volumes and eCommerce strength. The organic revenue growth came in at 1%. Adjusted EBITDA margin improved 120 bps year over year to 48.3% due to cost efficiencies.Revenues from Capital Market Solutions increased 6% year over year to $672 million in the quarter under review and beat our estimate of $655.9 million, on the back of recurring revenue growth. The organic revenue growth was reported at 7%. Adjusted EBITDA margin of 50.2% improved 100 bps year over year on the back of solid contribution margins from growing revenues.The Corporate and Other segment’s revenues of $60 million plunged 43% year over year but beat our estimate of $50.1 million.Story continuesBalance Sheet & Cash FlowFidelity National exited the second quarter with cash and cash equivalents of $1,982 million, which fell from $2,188 million at 2022-end. Total assets of $53,574 million decreased from $63,278 million at 2022-end.Long-term debt, excluding the current portion, came in at $13,589 million at the second-quarter end. The figure decreased from $14,207 million as of Dec 31, 2022. The current portion of long-term debt was $785 million while short-term borrowings were $5,144 million.Total equity of $20,273 million declined from the 2022-end level of $27,226 million.In the second quarter of 2023, net cash provided by operations of $1,087 million rose from the $1,024 million figure in the prior-year quarter. FIS generated a free cash flow of $953 million in the second quarter, which jumped from $806 million a year ago.Capital DeploymentFidelity National rewarded $309 million to its shareholders via dividends in the quarter under review.Divestiture of Merchant Solutions Business AnnouncedFIS agreed to divest a 55% stake in its Worldpay Merchant Solutions business in July, to private equity funds managed by GTCR. The deal is likely to close by the first quarter of next year, following which, it will report ownership interest in Worldpay as income from minority interest. Operating results from the unit will be presented as discontinued operations from the third quarter of 2023.Update on Enterprise Transformation ProgramFIS achieved annualized Future Forward cash savings of more than $315 million as of Jun 30, 2023. The company revised its guidance for cash savings of $1 billion by 2024-end.3Q23 ViewRevenues are expected to remain between $3,640 million and $3,690 million, while adjusted EBITDA is estimated to be in the $1,580-$1,625 millionband.2023 GuidanceManagement revised the guidance for net revenues upward, which is expected to be between $14,500 million and $14,631 million compared with the 2022 reported figure of $14,528 million.Adjusted EBITDA is forecasted within $6,025-$6,146 million for 2023, with the margin expected in the range of 41.6-42%.How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended upward during the past month.VGM ScoresAt this time, Fidelity National has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Fidelity National has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerFidelity National is part of the Zacks Financial Transaction Services industry. Over the past month, Equifax (EFX), a stock from the same industry, has gained 4.9%. The company reported its results for the quarter ended June 2023 more than a month ago.Equifax reported revenues of $1.32 billion in the last reported quarter, representing a year-over-year change of +0.1%. EPS of $1.71 for the same period compares with $2.09 a year ago.Equifax is expected to post earnings of $1.78 per share for the current quarter, representing a year-over-year change of +2.9%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%.Equifax has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportFidelity National Information Services, Inc. (FIS) : Free Stock Analysis ReportEquifax, Inc. (EFX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why Is Fidelity National (FIS) Down 2.5% Since Last Earnings Report?

https://finance.yahoo.com/news/why-fidelity-national-fis-down-153133075.html

cd897abd-5659-32ba-af2b-b0d8039ad8b9

EFX

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Equifax Inc. (NYSE:EFX), by way of a worked example.ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. Check out our latest analysis for Equifax How Is ROE Calculated?The formula for ROE is:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for Equifax is:13% = US$529m ÷ US$4.2b (Based on the trailing twelve months to June 2023).The 'return' is the profit over the last twelve months. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.13 in profit.Does Equifax Have A Good ROE?By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. You can see in the graphic below that Equifax has an ROE that is fairly close to the average for the Professional Services industry (15%).roeThat isn't amazing, but it is respectable. Although the ROE is similar to the industry, we should still perform further checks to see if the company's ROE is being boosted by high debt levels. If a company takes on too much debt, it is at higher risk of defaulting on interest payments.How Does Debt Impact ROE?Most companies need money -- from somewhere -- to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first and second cases, the ROE will reflect this use of cash for investment in the business. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.Story continuesCombining Equifax's Debt And Its 13% Return On EquityEquifax clearly uses a high amount of debt to boost returns, as it has a debt to equity ratio of 1.35. While its ROE is pretty respectable, the amount of debt the company is carrying currently is not ideal. Debt does bring extra risk, so it's only really worthwhile when a company generates some decent returns from it.SummaryReturn on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. In our books, the highest quality companies have high return on equity, despite low debt. If two companies have around the same level of debt to equity, and one has a higher ROE, I'd generally prefer the one with higher ROE.Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So you might want to take a peek at this data-rich interactive graph of forecasts for the company.Of course Equifax may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

How Did Equifax Inc.'s (NYSE:EFX) 13% ROE Fare Against The Industry?

https://finance.yahoo.com/news/did-equifax-inc-nyse-efx-120119190.html

4a59dc04-8bea-38db-8383-c42870e42f64

EG

HAMILTON, Bermuda, August 09, 2023--(BUSINESS WIRE)--Everest Group, Ltd. (NYSE: EG), a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions, today announced that it will host an Investor Day at the New York Stock Exchange on Tuesday, November 14, 2023, from 9:30 am to 1:00 pm Eastern Time.Everest’s President and Chief Executive officer, Juan C. Andrade, and members of the senior leadership team will present an update on the Company’s long-term strategic vision.In-person attendance is by invitation only. A live, listen-only webcast will be available on the day of the event.About EverestEverest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.Everest common stock (NYSE: EG) is a component of the S&P 500 index.Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230809915192/en/ContactsMedia: Dawn LauerChief Communications Officer908.300.7670Investors: Matt RohrmannHead of Investor Relations908.604.7343

Business Wire

Everest to Host 2023 Investor Day

https://finance.yahoo.com/news/everest-host-2023-investor-day-201500304.html

68b9db60-9b96-347a-8e58-39fdc6dd2220

EG

HAMILTON, Bermuda, September 08, 2023--(BUSINESS WIRE)--Everest Group, Ltd. announced that its Board of Directors declared an increase in the regular quarterly dividend from $1.65 to $1.75 per common share. This dividend will be payable on or before September 29, 2023 to all shareholders of record as of September 19, 2023.About EverestEverest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.Everest common stock (NYSE: EG) is a component of the S&P 500 index.Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230908141583/en/ContactsMedia: Dawn LauerChief Communications Officer908.300.7670Investors: Matt RohrmannHead of Investor Relations908.604.7343

Business Wire

Everest Group Increases Quarterly Dividend to $1.75

https://finance.yahoo.com/news/everest-group-increases-quarterly-dividend-201500356.html

21f3a76a-af22-3b7c-8cb6-1e5d2c2d2d1a

EGBN

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One company value investors might notice is Eagle Bancorp (EGBN). EGBN is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock holds a P/E ratio of 6.59, while its industry has an average P/E of 8.27. Over the past 52 weeks, EGBN's Forward P/E has been as high as 10.19 and as low as 4.28, with a median of 8.82.Investors should also recognize that EGBN has a P/B ratio of 0.59. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. EGBN's current P/B looks attractive when compared to its industry's average P/B of 1.16. EGBN's P/B has been as high as 1.27 and as low as 0.42, with a median of 1.13, over the past year.Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. EGBN has a P/S ratio of 1.3. This compares to its industry's average P/S of 1.77.Story continuesFinally, our model also underscores that EGBN has a P/CF ratio of 5.03. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 9.96. Within the past 12 months, EGBN's P/CF has been as high as 10.24 and as low as 3.99, with a median of 9.05.Value investors will likely look at more than just these metrics, but the above data helps show that Eagle Bancorp is likely undervalued currently. And when considering the strength of its earnings outlook, EGBN sticks out at as one of the market's strongest value stocks.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEagle Bancorp, Inc. (EGBN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is Eagle Bancorp (EGBN) a Great Value Stock Right Now?

https://finance.yahoo.com/news/eagle-bancorp-egbn-great-value-134011120.html

1cbd0c6e-a01d-3818-ba2f-e77fb1e7c206

EGBN

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term Eagle Bancorp, Inc. (NASDAQ:EGBN) shareholders for doubting their decision to hold, with the stock down 56% over a half decade. And it's not just long term holders hurting, because the stock is down 52% in the last year. More recently, the share price has dropped a further 14% in a month.Since Eagle Bancorp has shed US$51m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics. View our latest analysis for Eagle Bancorp To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.During the unfortunate half decade during which the share price slipped, Eagle Bancorp actually saw its earnings per share (EPS) improve by 5.1% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or possibly, the market was previously very optimistic, so the stock has disappointed, despite improving EPS.Due to the lack of correlation between the EPS growth and the falling share price, it's worth taking a look at other metrics to try to understand the share price movement.The steady dividend doesn't really explain why the share price is down. While it's not completely obvious why the share price is down, a closer look at the company's history might help explain it.You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).Story continuesearnings-and-revenue-growthWe consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. You can see what analysts are predicting for Eagle Bancorp in this interactive graph of future profit estimates.What About Dividends?It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Eagle Bancorp, it has a TSR of -50% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.A Different PerspectiveWhile the broader market gained around 9.3% in the last year, Eagle Bancorp shareholders lost 49% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Eagle Bancorp better, we need to consider many other factors. For instance, we've identified 2 warning signs for Eagle Bancorp (1 is concerning) that you should be aware of.Eagle Bancorp is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

The five-year underlying earnings growth at Eagle Bancorp (NASDAQ:EGBN) is promising, but the shareholders are still in the red over that time

https://finance.yahoo.com/news/five-underlying-earnings-growth-eagle-144140063.html

f844953e-8d88-30f1-a178-19cd005d1212

EGLX

Enthusiast Gaming Inc.Netflix, Enthusiast Gaming, and Metavision to bring new experiences to gamers across digital platformsLOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ: EGLX; TSX: EGLX) and Metavision have collaborated with Netflix to launch its first-ever Fortnite Creative experience for the most popular manga series in history: ONE PIECE, in celebration of the new live-action version streaming globally on Netflix beginning August 31.The in-game experience, created with the new development toolbox ‘Unreal Editor for Fortnite’ (UEFN) in Fortnite Creative, a tool that allows users to design, create and share experiences with other players outside of the traditional ‘Battle Royale’, marks the first time that a streaming service has utilized the platform’s creative capabilities to deliver a bespoke gaming experience to fans.This new toolset, announced by Epic Games at the Gaming Development Conference in San Francisco earlier this year, allows developers to use AAA gaming industry development tools to supercharge their Fortnite experiences with custom assets, audio and visuals allowing assets from the production of shows to be re-created or adapted with incredible detail and accuracy, without requiring a direct Epic Games partnership.Brought to life by Fortnite Creative build team 3D Lab, the ONE PIECE experience was built in collaboration with Enthusiast Gaming and Metavision to reflect three classic ships from the series, and will be centered around a swashbuckling battle between two factions, the ‘Straw Hats’ and the ‘Marines’. Players who drop into the game will be part of either crew, and equipped with swords, flint-knock pistols and cannons, will attempt to destroy their opponent’s ship to be crowned the winner.The new map and gametype will be featured on the September 12th episode of Enthusiast Gaming’s ‘NFL Tuesday Night Gaming’, the first-of-its-kind gaming competition created by Enthusiast Gaming in partnership with the NFL, featuring NFL players & Legends teaming up with top gaming creators to go head-to-head across popular video game titles every week.Story continues“This collaboration with Netflix is an exciting example of how Enthusiast Gaming is creating unique and immersive experiences for brands that are scalable across digital entertainment and gaming platforms,” said Amanda Rubin, EVP, Brand Solutions at Enthusiast Gaming. “NFL Tuesday Night Gaming continues to offer a distinct opportunity to engage diverse communities through shared passions of gaming, sports, and entertainment.”Ashley Lewis, Managing Director at Metavision commented, “We’re super excited to be bringing a cultural heavyweight like ONE PIECE to the Metaverse, where the world can be explored and enjoyed by an entirely new audience. It was particularly inspiring to see how far we could push things with the recently launched UEFN toolset, and it’s safe to say it’s remarkable what can now be achieved on the platform.”Players can enter the experience through Fortnite Discovery tab by entering the code “7374-8187-1871” or heading to https://www.fortnite.com/creative/island-codes/7374-8187-1871This is an independently created Fortnite Creative experience and is not sponsored, endorsed, or administered by Epic Games, Inc.About the Show: ONE PIECEBased on Japan’s highest-selling manga series in history by Eiichiro Oda, ONE PIECE is a legendary high-seas adventure unlike any other. Monkey D. Luffy is a young adventurer who has longed for a life of freedom since he can remember. Luffy sets off from his small village on a perilous journey to find the legendary fabled treasure, ONE PIECE, to become King of the Pirates! But in order to find the ultimate prize, Luffy will need to assemble the crew he’s always wanted before finding a ship to sail, searching every inch of the vast blue seas, outpacing the Marines, and outwitting dangerous rivals at every turn.Starring Iñaki Godoy as Monkey D. Luffy, Mackenyu as Roronoa Zoro, Emily Rudd as Nami, Jacob Romero as Usopp, and Taz Skylar as Sanji, ONE PIECE is a live action pirate adventure created in partnership with Shueisha and produced by Tomorrow Studios and Netflix. Matt Owens and Steven Maeda are writers, executive producers, and showrunners. Eiichiro Oda, Marty Adelstein, and Becky Clements also executive produce. Additional cast includes Vincent Regan, Ilia Isorelýs Paulino, Morgan Davies, Aidan Scott, Langley Kirkwood, Jeff Ward, Celeste Loots, Alexander Maniatis, McKinley Belcher III, Craig Fairbrass, Steven Ward, Chioma Umeala and Michael Dorman.About Enthusiast GamingEnthusiast Gaming is the leading gaming media and entertainment company in North America, building the largest platform for video game enthusiasts and esports fans to connect and compete worldwide. Combining the elements of its five core pillars: creators, content, communities, games, and experiences, Enthusiast Gaming provides a unique opportunity for marketers to create integrated brand solutions to connect with coveted Gen Z and Millennial audiences. Through its proprietary mix of digital media, content and gaming assets, Enthusiast Gaming continues to grow its network of communities, reflecting the scale and diversity of gaming enthusiasts today.PR / Media ContactsEnthusiast Gaming – [email protected] Metavision – [email protected] – [email protected] ContactsEnthusiast Gaming – Alex Macdonald, CFOFNK IR – Rob Fink / Matt Chesler, CFA [email protected] MetavisionMetavision is an award winning studio and creative agency for the Metaverse. They sit at the intersection of virtual worlds and culture, building creative strategy and in-game, immersive experiences for brands and entertainment companies.Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward Looking InformationThis news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast Gaming anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s strategic plans, partnerships and anticipated product expansions.Forward-looking statements are based on assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, including, but not limited to, expectations and assumptions concerning interest and foreign exchange rates; capital efficiencies, cost saving and synergies; growth and growth rates; the success in the esports and media industry; and the Company’s growth plan. While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; the timing and filing of the final base shelf prospectus and corresponding Registration Statement; the potential offering of any Securities by the Company; uncertainty with respect to the completion of any future offering; the ability to obtain applicable regulatory approvals for any contemplated offerings; the ability of the Company to negotiate and complete future funding transactions; adverse industry events; and future legislative, tax and regulatory developments. Readers are cautioned that the foregoing list is not exhaustive. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of Enthusiast Gaming which are available on SEDAR at www.sedar.com. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

GlobeNewswire

Netflix, Enthusiast Gaming, and Metavision Bring Iconic Anime “ONE PIECE” to Life Utilizing Fortnite Creative 2.0

https://finance.yahoo.com/news/netflix-enthusiast-gaming-metavision-bring-110000845.html

3367aa6d-1ca4-3d4c-a40e-35e95cc02a7b

EGLX

Enthusiast Gaming Inc.LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (Nasdaq: EGLX; TSX: EGLX), the leading gaming media and entertainment company in North America, today announced that CFO Alex Macdonald will be attending and presenting at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place in New York City on September 11, 2023.Date: September 11, 2023Presentation Time: 3.00 PM ETPlease contact your H.C. Wainwright sales representative to request a meeting with management at the conference. Investors can also contact the Enthusiast Gaming IR team at [email protected] Enthusiast GamingEnthusiast Gaming is the leading gaming media and entertainment company in North America, building the largest platform for video game enthusiasts and esports fans to connect and compete worldwide. Combining the elements of its five core pillars: creators, content, communities, games, and experiences, Enthusiast Gaming provides a unique opportunity for marketers to create integrated brand solutions to connect with coveted Gen Z and Millennial audiences. Through its proprietary mix of digital media, content and gaming assets, Enthusiast Gaming continues to grow its network of communities, reflecting the scale and diversity of gaming enthusiasts today.Investor ContactsEnthusiast Gaming – Alex Macdonald, CFOFNK IR – Rob Fink / Matt Chesler, CFA [email protected] the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the exchange) accepts responsibility for the adequacy or accuracy of this release.

GlobeNewswire

Enthusiast Gaming to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

https://finance.yahoo.com/news/enthusiast-gaming-participate-h-c-110000291.html

bf2f6e11-9ab3-3081-ad44-86b23bc63ecd

EGP

Investors with an interest in REIT and Equity Trust - Other stocks have likely encountered both Brandywine Realty Trust (BDN) and EastGroup Properties (EGP). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.Brandywine Realty Trust and EastGroup Properties are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that BDN likely has seen a stronger improvement to its earnings outlook than EGP has recently. But this is only part of the picture for value investors.Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.BDN currently has a forward P/E ratio of 4.07, while EGP has a forward P/E of 23.34. We also note that BDN has a PEG ratio of 1.57. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. EGP currently has a PEG ratio of 3.37.Another notable valuation metric for BDN is its P/B ratio of 0.52. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, EGP has a P/B of 3.65.Based on these metrics and many more, BDN holds a Value grade of A, while EGP has a Value grade of F.Story continuesBDN sticks out from EGP in both our Zacks Rank and Style Scores models, so value investors will likely feel that BDN is the better option right now.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBrandywine Realty Trust (BDN) : Free Stock Analysis ReportEastGroup Properties, Inc. (EGP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

BDN or EGP: Which Is the Better Value Stock Right Now?

https://finance.yahoo.com/news/bdn-egp-better-value-stock-154010808.html

b319cf15-0181-3ac7-8acf-535282911ef8

EGP

JACKSON, Miss., Sept. 7, 2023 /PRNewswire/ -- EastGroup Properties, Inc. (NYSE: EGP) (the "Company" or "EastGroup") announced today its recent business activity.EastGroup Properties, Inc. logo. (PRNewsfoto/EastGroup Properties, Inc.)Commenting on the Company's activity, Marshall Loeb, CEO, stated, "We continue to be pleased by both the strength and resiliency of the Sunbelt, shallow bay industrial market. Operationally it's been a positive, steady year in an unsteady capital markets environment. Given the volatility in the capital markets, we continue to opportunistically improve the strength and flexibility of our balance sheet. This strength allows us to make strategic investments such as the ones detailed below."In September, EastGroup acquired Blue Diamond Business Park, which contains two recently developed buildings totaling 255,000 square feet, for approximately $53,000,000. The buildings are located in the Southwest submarket of Las Vegas and are 100% leased. This acquisition increased the Company's ownership in Las Vegas to approximately 1,165,000 square feet, which is currently 100% leased.Also during September, the Company closed on the acquisition of Crossroad Logistics Land for approximately $15,000,000. The parcel is comprised of 44 acres of development land at the intersection of I-4 and I-75 in East Tampa. This site will accommodate the future development of three buildings containing approximately 500,000 square feet.During the third quarter of 2023 to date, EastGroup began construction of two development projects located in Atlanta and Charlotte which will contain approximately 430,000 square feet and have projected total costs of $51,500,000.As of August 31, 2023, EastGroup's portfolio was 98.1% leased and 97.7% occupied. Rental rates on new and renewal leases signed during third quarter to date increased an average of 56.1% on a straight-line basis and 40.1% on a cash basis.During the third quarter of 2023 to date, EastGroup sold 759,650 shares of common stock under its continuous common equity offering program at a weighted average price of $177.71 per share, providing aggregate gross proceeds to the Company of approximately $134,996,000.  Year to date, the Company has sold 2,553,253 shares at a weighted average price of $170.10 per share, providing aggregate gross proceeds to the Company of approximately $434,306,000.Story continuesManagement is scheduled to participate in two upcoming conferences:The 15th Annual Evercore ISI Real Estate Conference on Friday, September 8, 2023Bank of America Securities 2023 Global Real Estate Conference scheduled for Tuesday, September 12, 2023 through Wednesday, September 13, 2023During the conferences, EastGroup executives may discuss the Company's transaction activity, leasing environment, market trends and conditions, financial matters and other business that may be affecting the Company. EastGroup's presentation materials that may be referenced during the conferences are available on the "Investor Relations" page of the Company's website.About EastGroup Properties, Inc.EastGroup, a member of the S&P Mid-Cap 400 and Russell 1000 Indexes, is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in major Sunbelt markets throughout the United States with an emphasis in the states of Florida, Texas, Arizona, California and North Carolina. The Company's goal is to maximize shareholder value by being a leading provider in its markets of functional, flexible and quality business distribution space for location sensitive customers (primarily in the 20,000 to 100,000 square foot range). The Company's strategy for growth is based on ownership of premier distribution facilities generally clustered near major transportation features in supply-constrained submarkets. EastGroup's portfolio, including development projects and value-add acquisitions in lease-up and under construction, currently includes approximately 58.2 million square feet.EastGroup Properties, Inc. press releases are available at www.eastgroup.net.Forward-Looking InformationThe statements and certain other information contained herein, which can be identified by the use of forward-looking terminology such as "may," "will," "seek," "expects," "anticipates," "believes," "targets," "intends," "should," "estimates," "could," "continue," "assume," "projects," "goals" or "plans" and variations of such words or similar expressions or the negative of such words, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These forward-looking statements reflect the Company's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the Company and on assumptions it has made. Although the Company believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that such plans, intentions, expectations, strategies and prospects will be attained or achieved. Furthermore, these forward-looking statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties could cause actual results to differ materially from those projected. These uncertainties include, but are not limited to: international, national, regional and local economic conditions; disruption in supply and delivery chains; construction costs could increase as a result of inflation impacting the costs to develop properties; the competitive environment in which the Company operates; fluctuations of occupancy or rental rates; potential defaults (including bankruptcies or insolvency) on or non-renewal of leases by tenants, or our ability to lease space at current or anticipated rents, particularly in light of the impacts of inflation; potential changes in the law or governmental regulations and interpretations of those laws and regulations, including changes in real estate laws or real estate investment trust ("REIT") or corporate income tax laws, potential changes in zoning laws, or increases in real property tax rates, and any related increased cost of compliance; our ability to maintain our qualification as a REIT; acquisition and development risks, including failure of such acquisitions and development projects to perform in accordance with projections; natural disasters such as fires, floods, tornadoes, hurricanes and earthquakes; pandemics, epidemics or other public health emergencies, such as the coronavirus pandemic; availability of financing and capital, increase in interest rates, and ability to raise equity capital on attractive terms; financing risks, including the risks that our cash flows from operations may be insufficient to meet required payments of principal and interest, and we may be unable to refinance our existing debt upon maturity or obtain new financing on attractive terms or at all;  our ability to retain our credit agency ratings; our ability to comply with applicable financial covenants; credit risk in the event of non-performance by the counterparties to our interest rate swaps; lack of or insufficient amounts of insurance; litigation, including costs associated with prosecuting or defending claims and any adverse outcomes; our ability to attract and retain key personnel; risks related to the failure, inadequacy or interruption of our data security systems and processes; potentially catastrophic events such as acts of war, civil unrest and terrorism; and environmental liabilities, including costs, fines or penalties that may be incurred due to necessary remediation of contamination of properties presently owned or previously owned by us. All forward-looking statements should be read in light of the risks identified in Part I, Item 1A. Risk Factors within the Company's most recent Annual Report on Form 10-K, as such factors may be updated from time to time in the Company's periodic filings and current reports filed with the SEC. The Company assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/eastgroup-properties-announces-recent-business-activity-and-participation-in-upcoming-conferences-301921310.htmlSOURCE EastGroup Properties

PR Newswire

EastGroup Properties Announces Recent Business Activity and Participation in Upcoming Conferences

https://finance.yahoo.com/news/eastgroup-properties-announces-recent-business-201000317.html

13bc8067-e514-3fd0-ba11-03b3f5cf1d1c

EHAB

AREX Capital Management, LPJames T. CorcoranPartnerAndrew RechtschaffenManaging PartnerApplauds Decision to Launch Strategic Alternatives ProcessExpects Requisite Tax Opinion to be Delivered PromptlyRequests Board Refreshment to Boost Shareholder Confidence in Sale ProcessNEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- AREX Capital Management, LP, together with its affiliates, the owners of approximately 4.7% of the shares of Enhabit, Inc. (NYSE: EHAB) (the “Company”), today issued an open letter to the Company’s Board of Directors.The full text of the letter is set forth below:August 14, 2023Via Electronic MailThe Board of DirectorsEnhabit, Inc.6688 N. Central ExpresswaySuite 1300Dallas, TX 75206Attention: Barbara A. Jacobsmeyer, Chief Executive OfficerDear Barbara and Members of the Board:AREX Capital Management, LP and its affiliates (together, “AREX” or “we”), are collectively the beneficial owners of approximately 2.4 million shares of Enhabit, Inc. (“Enhabit” or the “Company”), representing approximately 4.7% of the Company’s common shares outstanding.We were pleased that the Company announced last week that it intends to launch a strategic alternatives process upon receiving a tax opinion that such action would not jeopardize the tax-free treatment of Enhabit’s spin-off. Based on our extensive discussions with tax counsel and our experience investing in spin-offs, we are confident that this opinion can be obtained promptly. We eagerly await the Company’s confirmation that it has received the requisite tax opinion and has formally launched a strategic alternatives process over the next few weeks. We will view any delay with severe skepticism.We were simultaneously disappointed by Enhabit’s second quarter performance and revised 2023 outlook. In addition to the issues that the Company has been encountering operationally, we were again struck by the magnitude of its unallocated home office expenses, which are now roughly equivalent to its overall EBITDA guidance. While we do not intend to discuss the Company’s consistently underwhelming results or investor communications here, it seems manifestly clear that the appropriate path forward for the Company is a sale.Story continuesShareholders must have full confidence in Enhabit’s Board of Directors (the “Board”) to conduct a fulsome, robust, and value-maximizing strategic alternatives process. Candidly, we do not believe that the Board, as currently constituted, enjoys such confidence. While there is no reason to relitigate the circumstances that resulted in Enhabit’s spin-off, there was a perception at that time that the Encompass board was reluctant to sell Enhabit. We cannot help but observe that five of those same Encompass directors are now on Enhabit’s Board. This lingering perception, along with the Company’s overall poor performance since it became a standalone public company, has raised legitimate shareholder concerns about the effectiveness of the Board and whether it is truly focused on fulfilling its fiduciary obligations. Such sentiment adds unhelpful uncertainty to a strategic alternatives process.In the same vein, we were disappointed when the Company recently informed us that it would not be accepting either of our proposed directors, and that it did not anticipate adding any in the near future. We presented the Company with two skilled healthcare executives with direct insight into working with payers—one of whom has broad home health operations experience—and yet our highly qualified candidates each received a single perfunctory interview with a third-party recruiter. In fact, we doubt that they were ever given serious consideration. The Company is correct that there should be no net additions to its Board, as Enhabit already carries a bloated home office cost burden and has too many directors for a company of its size.1 However, in light of shareholder apprehension concerning the Board as well as the Company’s commitment to replace at least four of the legacy Encompass directors by the 2024 Annual Meeting of Stockholders, we are shocked by the Board’s unwillingness to accelerate its transition by adding two directors who would contribute valuable operational perspective during the strategic alternatives process.As the Company embarks upon this critical journey to realize Enhabit’s considerable strategic value, we believe that the Company should take steps to bolster shareholder confidence in the Board. One obvious solution would be the acceleration of the legacy Encompass director retirements, which would help to alleviate any investor concerns that the disappointing reasoning or outcome associated with the Encompass process might reappear. While our director candidates could immediately add value and should be considered as replacements, it is not essential that the legacy Encompass directors be replaced, as an eight-person Board seems more appropriate for a company of Enhabit’s size and might facilitate better decision-making during the strategic alternatives process.In closing, we applaud the Board’s decision to initiate a strategic alternatives process, and we are confident (and believe that other investors concur) that Enhabit’s strategic value significantly exceeds its current valuation. Moreover, our diligence suggests that there are many well-capitalized strategic and financial buyers interested in acquiring the Company. It seems to us that the only way that shareholders might not realize this strategic value would be if the process were not conducted in an appropriate and sincere manner. If this happens, and if the process fails to yield the proper outcome for shareholders, we will review all options at our disposal to ensure that the Board is held accountable.Best regards,Andrew RechtschaffenAndrew RechtschaffenManaging PartnerJames T. CorcoranJames T. CorcoranPartnerAbout AREXAREX Capital Management, LP is a value-oriented investment firm based in New York City. AREX takes a long-term, opportunistic approach to investing and focuses primarily on publicly traded companies with significant, unrealized potential.Media ContactValerie Toomey, Chief Operating OfficerAREX Capital Management, LP(646) [email protected] According to the EY Center for Board Matters, the average S&P SmallCap 600 company has 8.9 directors.Photos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/a6e4c362-2f4b-4495-a7fb-d7607ca11c52https://www.globenewswire.com/NewsRoom/AttachmentNg/5dea6925-8688-407e-8570-ef1bf4e5953c

GlobeNewswire

AREX Capital Issues Letter to Board of Directors of Enhabit, Inc.

https://finance.yahoo.com/news/arex-capital-issues-letter-board-130000144.html

2196a66e-a0b1-3873-a343-0557b9618d1c

EHAB

DALLAS, August 23, 2023--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today announced that it has satisfied the conditions in its Tax Matters Agreement ("TMA"), dated June 30, 2022, with Encompass Health Corporation to conduct a review of strategic alternatives and has formally initiated such process. As part of this process, the board of directors will consider a wide range of options for the Company including, among other things, a potential sale, merger or other strategic transaction. Certain transactions involving the company remain subject to additional conditions in the TMA, including securing an additional tax opinion with respect to the specific transaction, satisfactory to Encompass Health in its sole and absolute discretion, that such proposed transaction would not jeopardize the tax-free treatment of the spin-off of Enhabit.The Company issued the following statement:"Enhabit is a leader in a valuable industry, providing a better way to care where patients prefer to receive their care. The Enhabit board and management team are aligned in their belief that the best way to enhance value for stockholders is to comprehensively review the Company’s strategic alternatives, including a potential sale of Enhabit. We will pursue the pathway that enhances value for our stockholders and ensures we can continue to deliver exceptional care to our patients."There can be no assurance the Company’s strategic alternatives process will result in Enhabit pursuing any particular transaction or other strategic outcome or that any such transaction will satisfy the remaining conditions in the TMA. The Company has not set a timetable for completion of this process, and it does not intend to disclose further developments unless and until it determines further disclosure is appropriate or necessary.AdvisorGoldman Sachs & Co. LLC is serving as financial advisor to Enhabit.Story continuesAbout Enhabit Home Health & HospiceEnhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 108 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.Forward-looking statementsStatements contained in this press release which are not historical facts, such as those relating to our initiation of a strategic alternatives review process focused on enhancing shareholder value, our consideration of potential strategic transactions, including a potential sale, merger or other strategic transaction, and other future events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking information speaks only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from our present expectations include, but are not limited to, the outcome of our strategic alternatives review, the volatility and uncertainty in the capital markets for home health and hospice companies and the availability of financing to any potential strategic partner, the availability of suitable third parties with which to conduct any strategic transaction, our ability to satisfy the remaining conditions under the TMA, and if a definitive agreement for a transaction is signed with another party, whether the conditions to closing are satisfied, including any necessary regulatory or other approvals. Our Form 10-K and subsequent quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.View source version on businesswire.com: https://www.businesswire.com/news/home/20230823702650/en/ContactsInvestor contact Jordan [email protected] 469-860-6061Media contact Andy Brimmer / Adam PollackJoele Frank, Wilkinson Brimmer Katcher212-355-4449

Business Wire

Enhabit Home Health & Hospice Confirms Exploration of Strategic Alternatives to Enhance Stockholder Value

https://finance.yahoo.com/news/enhabit-home-health-hospice-confirms-205100731.html

36e472ca-3fa1-3216-bd0f-311d4e60c644

EHC

Molina Healthcare, Inc. MOH gains from improved premium revenues, growth in Medicaid and Medicare membership as well as a commendable financial position. A favorable earnings per share (EPS) outlook for 2023 reinforces investors’ confidence in the stock.Top Zacks Rank & Upbeat Price PerformanceMolina Healthcare currently carries a Zacks Rank #2 (Buy).The stock has gained 11.6% in the past six months against the industry’s 0.4% decline. The Zacks Medical sector inched up 0.6% and the S&P 500 composite has risen 14.2% in the same time frame.Zacks Investment ResearchImage Source: Zacks Investment ResearchFavorable Style ScoreMOH carries an impressive Value Score of A. Value Score helps find stocks that are undervalued. Back-tested results have shown that stocks with a favorable Value Score in combination with a solid Zacks Rank are the best investment bets.Robust ProspectsThe Zacks Consensus Estimate for Molina Healthcare’s 2023 earnings is pegged at $20.66 per share, indicating growth of 15.3% from the prior-year reported figure. The consensus mark for revenues stands at $33.1 billion, implying a rise of 3.4% from the year-ago reported number.The consensus mark for 2024 earnings is pegged at $23.44 per share, suggesting an improvement of 13.5% from the 2023 estimate. The same for revenues stands at $38.2 billion, hinting at a 15.7% increase from the 2023 estimate.Impressive Earnings Surprise HistoryMOH’s bottom line outpaced estimates in each of the trailing four quarters, the average surprise being 7.18%.Solid Return on EquityThe return on equity for Molina Healthcare is currently 35.9%, which is higher than the industry’s average of 24.7%. The figure substantiates the company’s efficiency in utilizing shareholders’ funds.Valuation: Cheaply PricedPrice-to-earnings (P/E) is one of the multiples used for valuing healthcare stocks.  MOH has a reading of 13.75 compared with the health maintenance organization industry’s forward 12-month P/E ratio of 16.34. It is quite evident that the stock is currently undervalued.Story continuesA Strong EPS View for 2023Management forecasts adjusted EPS to be a minimum of $20.75, which suggests 16% growth from the 2022 figure.Key Business TailwindsRevenues of Molina Healthcare continue to benefit on the back of an expanding customer base, which it earns through distributing cost-effective Medicaid and Medicare plans across different U.S. communities. The strength of such plans often fetches contract wins from time to time, which is another means to boost membership growth.One of the recent contract wins of Molina Healthcare this August was receiving a Medicaid managed care contract from the New Mexico Human Services Department. Needless to say, such contract wins, which result in membership growth, fetch improved premiums, which remains the most significant contributor to a health insurer’s top line.An aging U.S. population belonging to the medically vulnerable group is likely to sustain the solid demand for MOH’s Medicare plans, which is primarily meant to cater to individuals aged 65 years or above. Also, premium revenues improved 3.9% year over year in the first half of 2023, attributable to higher Medicaid and Medicare membership.A series of acquisitions undertaken over the years have expanded the capabilities, diversified revenue streams and solidified the geographical footprint of Molina Healthcare. Molina Healthcare announced plans to buy Brand New Day and Central Health Plan of California in June 2023 in a bid to bolster its Medicare presence across California and enhance its position in the evolving home health market.The health insurer also resorts to tactical cost-cutting measures, which aid margins. A strong financial standing is of dire need to pursue business investments and that’s exactly the case with MOH. Growing cash reserves and solid cash-generating abilities bear testament to the same. It generated operating cash flows of $1.4 billion in the first half of 2023, which surged 91.9% year over year.Other Stocks to ConsiderSome other top-ranked stocks in the Medical space are Option Care Health, Inc. OPCH, Encompass Health Corporation EHC and Penumbra, Inc. PEN, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Option Care Health’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and matched the mark once, the average beat being 57.02%. The consensus estimate for OPCH’s 2023 earnings suggests 71.1% surge, while the same for revenues indicates growth of 8.4% from the respective year-ago reported figures.The consensus estimate for OPCH’s 2023 earnings has moved 51.1% north in the past 60 days. Shares of Option Care Health have gained 8.6% in the past six months.Encompass Health’s earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 14.04%. The consensus estimate for EHC’s 2023 earnings indicates a rise of 19% from the year-ago reported figure.The consensus estimate for EHC’s 2023 earnings has moved 6.3% north in the past 30 days. Shares of Encompass Health have gained 28% in the past six months.Penumbra’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 94.24%. The consensus estimate for PEN’s 2023 earnings is pegged at $1.75 share, which indicates a nearly 11-fold increase from the prior-year reported figure. The same for revenues indicates growth of 25.2% from the year-ago reported figure.The Zacks Consensus Estimate for PEN’s 2023 earnings has moved 7.4% north in the past 30 days. Shares of Penumbra have inched up 1.4% in the past six months.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportMolina Healthcare, Inc (MOH) : Free Stock Analysis ReportPenumbra, Inc. (PEN) : Free Stock Analysis ReportEncompass Health Corporation (EHC) : Free Stock Analysis ReportOption Care Health, Inc. (OPCH) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Factors That Make Molina Healthcare (MOH) an Attractive Bet Now

https://finance.yahoo.com/news/factors-molina-healthcare-moh-attractive-184000132.html

c3794107-884d-3979-87e7-35d1aad5b0b0

EHC

For Immediate ReleaseChicago, IL – September 5, 2023 – Today, Zacks Equity Research discusses DaVita Inc. DVA, Encompass Health Corp. EHC, Option Care Health, Inc. OPCH and RadNet, Inc. RDNT.Industry: Outpatient/Home HealthcareLink: https://www.zacks.com/commentary/2143657/4-stocks-to-buy-in-a-booming-outpatient-home-health-industryThe pandemic altered the nature and dynamics of the healthcare industry. The Zacks Medical - Outpatient and Home Healthcare industry, after struggling with lower outpatient clinic visits and inability to provide quality home healthcare, has gradually shifted to digital healthcare treatment. In the past few years, there has been a significant rise in demand for telemedicine-focused online medical and artificial intelligence (AI)-powered technology services.Post-pandemic, many healthcare companies that were traditionally not technology-based transformed to survive in the market. Per a report by Grand View Research, the global healthcare analytics market was valued at $35.3 billion in 2022 and is expected to expand at a CAGR of 21.4% between 2023 and 2030. Another factor prompting these MedTech players to embrace digital healthcare is the skyrocketing healthcare costs.On a positive note, rising dependence on telehealth and AI is likely to help the industry thrive in the near term. DaVita Inc., Encompass Health Corp., Option Care Health, Inc. and RadNet, Inc. are likely to gain from the prospects.Industry DescriptionThe industry comprises companies that offer ambulatory care in an outpatient setting or at home. They use advanced medical technologies for diagnosis, treatment and rehabilitation services. The players include operators of HMO medical centers, kidney dialysis centers and other outpatient care centers. After navigating a tough pandemic era, the payers and providers have been seeing steady growth on the back of innovation in services. This buoys optimism about prospects over the next few years, although persistent inflation in consumer prices could dent the outlook.Story continuesThe potential for scaling up innovation, prompted by the pandemic's pressure on the healthcare system, is an added plus. Also, the acceleration of value-based care models and the increasing application of technology across the healthcare industry are likely to continue in the long run.Major Trends Shaping the Future of the Outpatient and Home Healthcare IndustryCost Effectiveness: The primary advantage of outpatient clinics is cost-effectiveness. Outpatient medical care clinics do not retain patients for long hours (overnight) or charge exorbitantly. Modern-day outpatient clinics offer a broad spectrum of treatment and diagnostic options and even minor surgical procedures. Financial incentives like health plans and government program payment policies supporting services in lower-cost care settings have also been driving outpatient care.Additionally, with value-based models of care steadily emerging as the future of healthcare, the shift from fee-for-service (FFS) to alternative payment models (APM) is an ongoing parallel trend. FFS will be crucial to care organizations as a benchmark through which providers can assess APM.AI's Dominant Role: AI has been a roaring success in healthcare. It is no wonder that it has taken the outpatient and home healthcare space by storm. Outpatient companies prefer bots and automated techniques for managing health information. With the help of AI, hospitals have been achieving better outcomes, with patients receiving more efficient and personalized care. The outpatient industry has been generating huge profits from Electronic Health Records and ePrescriptions.The most visible area where AI can make a significant difference is in mental healthcare at home. Addressing the most prevalent mental health conditions among home care patients —depression, anxiety and dementia — is essential to improve overall patient well-being. In recent years, complex machine learning algorithms have become capable of analyzing large datasets of patient information, including clinical and social diagnoses. These systems can alert caregivers regarding potential triggers or warning signs of mental health deterioration.Dependence on Telehealth: The pandemic caused a decline in outpatient clinic visits where home healthcare providers struggled to offer quality care due to the risk of exposure to the virus. Though the impact of the pandemic has been far-reaching, it has accelerated healthcare innovation. Home healthcare can gain from the benefits provided by Medicare (and several other payers) that comprise a broad range of services that can be delivered in a patient's home, including post-operative and chronic wound care.Home healthcare has seen a surge in the utilization of the telehealth platform in response to the pandemic. With the rise in elderly population and the increasing costs of in-person health care, the demand for home-based health care will emerge. People with chronic illnesses and disabilities also require home-based care.The rising demand for remote patient monitoring (RPM) has considerably driven the demand for wearable technology to monitor patient's health. Although wearables have been popular for several years, their integration with AI has recently increased their popularity immensely and has become a powerful home healthcare tool. AI technology-powered RPM enables healthcare firms to provide consistent patient care without occupying space in their hospitals and facilities, thus reducing overcrowding.Staffing Shortages: The U.S. healthcare industry has been experiencing a severe shortage of workers at every level, worsened by the COVID-19 pandemic. Among support personnel, there is a laxity of home health aides. The increasing international migration of health workers may aggravate health workforce shortfalls, especially in low-income and lower-middle income countries. Another reason for the acute staffing shortage is high burnout due to physical, emotional and mental exhaustion. Thus, these overworked employees are leaving the profession at an accelerating rate.Healthcare staffing shortages lead to poor patient outcomes that can include hospital-acquired infections, patient falls and increased probabilities of death. With a lesser number of staff available in hospital settings for patient care, there has been a gradual shift toward home healthcare for non-critical patients who can be monitored remotely.Zacks Industry RankThe Zacks Medical - Outpatient and Home Healthcare industry falls within the broader Zacks Medical sector. It carries a Zacks Industry Rank #41, which places it in the top 16% of nearly 250 Zacks industries.The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates bleak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.Before we present a few outpatient home health stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture.Industry's Stock Market PerformanceThe industry has underperformed both its sector and the Zacks S&P 500 composite in the past year.The industry has declined 1.9% over this period against the S&P 500's rise of 14.9%. The broader sector has declined 0.4% in the same time frame.Industry's Current ValuationOn the basis of the forward 12-month price-to-earnings (P/E), commonly used for valuing medical stocks, the industry is currently trading at 19X compared with the S&P 500's 19.5X and the sector's 22.2X.Over the last five years, the industry has traded as high as 24.9X and as low as 16.6X, with the median being at 19.5X.4 Outpatient and Home Healthcare Stocks to Add Right NowEncompass Health: Encompass Health, the owner and operator of inpatient rehabilitation hospitals in the United States, reported its second-quarter 2023 results in August. The company saw a robust uptick in its overall top line, primarily driven by increased volumes. It also recorded growth in total discharge, including same-store growth, during the period. Net revenue per discharge growth was also seen. Management also increased Encompass Health's 2023 guidance to reflect its strong first-half results and updated expectations for the year's balance.EHC currently sports a Zacks Rank of 1 (Strong Buy).The Zacks Consensus Estimate for Encompass Health's 2023 earnings suggests growth of 18.9%. The company's return on equity (ROE) of 18.3% compares favorably with the industry's 6.9%.Option Care Health: Option Care Health is a renowned independent provider of home and alternate site infusion services. In July, the company announced its second-quarter 2023 results, where it registered a solid uptick in its net revenues. At the time of the earnings release, Option Care Health confirmed that it had terminated its earlier-announced merger agreement with Amedisys, Inc. and received cash payment on behalf of Amedisys.OPCH sports a Zacks Rank of 1. You can see the complete list of today's Zacks #1 Rank stocks here.For this Bannockburn, IL-based company, the Zacks Consensus Estimate for 2023 revenues suggests growth of 8.4%. The same for earnings indicates an increase of 71.1%.The company's ROE of 17.3% compares favorably with the industry's 6.9%.RadNet: RadNet is a renowned provider of freestanding, fixed-site outpatient diagnostic imaging services through a network of owned or operated outpatient imaging centers. Last month, RadNet announced its second-quarter 2023 results, where it registered a solid uptick in its net revenues. Excluding revenues from its AI reporting segment, revenues from the Imaging Centers reporting segment were also strong.The company's aggregate procedural volumes and same-center procedural volumes also increased year over year in the reported quarter.Management also confirmed that RadNet is currently experiencing increasing enrollment as it rolls out its Enhanced Breast Cancer Detection program.RDNT flaunts a Zacks Rank of 1.For this Los Angeles, CA-based company, the Zacks Consensus Estimate for 2023 revenues suggests growth of 12.1%. The same for earnings indicates a surge of 130%.The company's historical cash flow growth of 19.4% compares favorably with the industry's 10.4%.DaVita: DaVita, a renowned global comprehensive kidney care provider, reported its second-quarter 2023 results in August. The company registered an uptick in its overall top line and dialysis patient service revenues during the period. The upside in total U.S. dialysis treatments during the quarter was also recorded. The opening of several dialysis centers within the United States and overseas was also seen.DVA carries a Zacks Rank of 2 (Buy).For this Denver, CO-based company, the Zacks Consensus Estimate for 2023 revenues suggests growth of 2.1%. The same for earnings indicates an increase of 9.4%. The company's ROE of 60.7% compares favorably with the industry's 6.9%.Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.See Stocks Free >>Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.Media ContactZacks Investment Research800-767-3771 ext. [email protected]://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDaVita Inc. (DVA) : Free Stock Analysis ReportRadNet, Inc. (RDNT) : Free Stock Analysis ReportEncompass Health Corporation (EHC) : Free Stock Analysis ReportOption Care Health, Inc. (OPCH) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and RadNet

https://finance.yahoo.com/news/zacks-industry-outlook-highlights-davita-115400482.html

d1b03657-1f6e-3b82-b4cd-a1a3e9834b42

EIX

NORTHAMPTON, MA / ACCESSWIRE / September 6, 2023 / Edison InternationalFostering better career opportunities for underrepresented talent has never been more important, and it requires strategic investment in the right workplace policies and programs. In 2022, SCE expanded on previous successes and launched new initiatives:Developed a new training module on leading with inclusion. In 2023, we are also rolling out an interactive education entitled "Creating a Culture of Inclusion" that will be available to all employees. This education will be led by the DEI team and other trained facilitators. OUs will be encouraged to utilize this education in furtherance of their DEI plans and overall business goals.Expanded the voluntary career coaching program to nonrepresented3 employees enterprisewide, after a successful pilot with BRGs in 2021. We also introduced speed coaching events on select topics to offer greater career support to those who are interested. Results indicate that employees who met with a coach received a job offer more often than those who had not met with a coach when applying for competitive positions within the company.Expanded Talent Accelerator Development program to a broader group. This program provides mentorship, advocacy and increased visibility toparticipants with the objective of enhancing leadership capabilities and career development opportunities. Of the five participants from the first cohort who completed the program in July 2022, two were promoted. In addition, three participants from the first cohort were selected for team lead roles within the companywide Catalyst5 initiative. Of the seven participants in the second cohort who will complete the program in July 2023, one has already been promoted to a director position, and two have taken lateral moves in key areas of the business.Working with team members from all backgrounds provides such a tremendous benefit to SCE and its culture. The work that we do each day is more fulfilling when our culture is inclusive."MUHAMMAD (MO) AL-AHMARPrincipal Manager, Asset Management & Wildfire Safety, SCEStory continuesEdison International also invests in education and training that provides employees with skills and resources to integrate DEI into their day-to-day interactions and decisions. In 2022, DEI elements were introduced in the following new course offerings:Emotional Intelligence (EQ) Empathy vs. SympathyEQ Building Stress ToleranceEQ Leading with OptimismMyers Briggs Type Indicator (MBTI): Practical Applications for Leaders trainingMBTI Your Style Under StressMBTI Your Style and Decision MakingIn 2023, we are investing in leaders to develop a workforce capable of implementing Pathway 2045, SCE's analysis of the necessary steps for California to achieve its greenhouse gas emissions-reduction goals, including storing and delivering clean energy, electrifying transportation and buildings, and carbon capture. We will accomplish this by providing them with the leadership knowledge, skills and capabilities that will pass on to the next generation of SCE employees.Edison International company values; the Edison International leadership model; diversity, equity, inclusion and belonging; and safety leadership will be standalone courses and embedded into learning. The program will incorporate tools to boost performance, improve organizational dynamics and increase leadership power and influence in order to maximize leadership impact.Ongoing SCE programs used to build DEI skills among employees in 2022 include:Illuminate: a new-employee orientation that has DEI interwoven throughout the four-hour virtual courseEmpower: a one-year leadership training and mentoring program that teaches new leaders about Edison International's values and provides tools to practice inclusive leadership dailyLeadership Learning Journeys: including assessments that provide personalized learning paths to develop value-oriented leadersListening to Our EmployeesWe undertake a variety of initiatives to promote a culture of honest feedback and open dialogue. This includes quarterly pulse surveys of all Edison International and SCE employees.Each quarter, a stratified sample of employees are surveyed for their thoughts on what's going well and where the company can improve - resulting in feedback solicited from each employee once annually. The survey is administered by an external vendor to ensure confidentiality and anonymity. It covers important topics such as inclusion, trust and job satisfaction. In 2022, results show we are trending upwardsin key categories such as respect, work and comfortably voicing one's opinion. As in 2021, surveys indicate there is room for improvement in the areas of recognition, collaboration and career growth and development for all employees. Each of these areas is being addressed through initiatives contained in OU DEI Action Plans.Listening to employee sentiment is critical to our commitment to transparency and accountability in creating a diverse and inclusive work environment. In this way, we build and promote a culture where people feel free to speak up, and we identify those areas where we can continue to improve."NATALIE K. SCHILLING | Senior Vice President and Chief Human Resources Officer, Edison International and SCE87% of employees say they are proud to work at Edison International85% of employees say they are treated with respect at work83% of employees say their job makes good use of their skills and abilities82% of employees say they have a favorable level of pride, passion and commitment toward their job and Edison International79% of employees say they are confident in Edison International's strategy and see the link between their work and the strategyView the full Edison International 2022 Diversity, Equity & Inclusion Report.View additional multimedia and more ESG storytelling from Edison International on 3blmedia.com.Contact Info:Spokesperson: Edison InternationalWebsite: https://www.3blmedia.com/profiles/edison-internationalEmail: [email protected]: Edison InternationalView source version on accesswire.com: https://www.accesswire.com/781141/edison-international-2022-diversity-equity-inclusion-report-increasing-development-opportunities

ACCESSWIRE

Edison International 2022 Diversity, Equity & Inclusion Report: Increasing Development Opportunities

https://finance.yahoo.com/news/edison-international-2022-diversity-equity-134000187.html

c86600ec-7197-3319-999c-cff4057a3b82

EIX

Edison International’s EIX systematic long-term capital investment strategy to strengthen its infrastructure will further enhance its service reliability.However, this Zacks Rank #3 (Hold) company’s substantial wildfire-related expenses act as a headwind.TailwindsSouthern California Edison (SCE) incurred a capital expenditure of $5.7 billion in 2022 and forecasts capital expenses of $43.5 billion during the 2023-2028 period. Of the total expenses, $35.5 billion has been allotted for the traditional investment that focuses on expanding its distribution and transmission facilities and generating more electricity. SCE expects to make additional CPUC capital expenditures in the range of $5.3-$6.8 billion between 2024 and 2025.The company expects strong rate base growth of nearly 6-8% through the 2023-2028 period, which could cause earnings to witness a CAGR of 5-7% during 2025-2028.California remains committed to reducing its greenhouse gas (GHG) emissions and has set goals to lower the same by 40% from the 1990 level within 2030 and by 85% from the same baseline within 2045. SCE anticipates meeting California's requirements through 2045 and believes that this goal can be achieved most economically through electrifying vehicles.SCE is currently working with nearly 200 sites to potentially support approximately 4,000 medium and heavy-duty vehicles. To support system reliability, SCE is investing $1.0 billion in utility-owned storage capacity as well as contracting for substantial new clean energy resources.HeadwindsMultiple factors have contributed to increased wildfire activity and damage from wildfires across SCE's service territory and California. Through Dec 31, 2022, Edison International and SCE recorded total pre-tax charges of $8.8 billion related to the 2017/2018 Wildfire/Mudslide events. The company incurred after-tax net charges to earnings worth $4.7 billion through Jun 30, 2023, in relation to the Wildfire/Mudslide events.Story continuesStocks to ConsiderSome better-ranked stocks from the same sector are Vistra Corp. VST, sporting a Zacks Rank #1 (Strong Buy), and FirstEnergy Corporation FE and Atmos Energy Corp. ATO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for VST’s 2023 earnings per share (EPS) indicates an increase of 205.8% from the previous year’s reported number. The same for sales indicates a year-over-year increase of 46.2%.FE’s long-term (three to five years) earnings growth rate is 6.45%. The Zacks Consensus Estimate for FE’s 2023 EPS indicates an increase of 5% from the previous year’s reported number.ATO’s long-term earnings growth rate is 7.25%. It delivered an average earnings surprise of 2.4% in the previous four quarters.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEdison International (EIX) : Free Stock Analysis ReportFirstEnergy Corporation (FE) : Free Stock Analysis ReportAtmos Energy Corporation (ATO) : Free Stock Analysis ReportVistra Corp. (VST) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Edison International (EIX) to Gain From Long-term Investments

https://finance.yahoo.com/news/edison-international-eix-gain-long-114000445.html

eef5c2a8-8527-3d3e-9392-fc44ec23d716

EKSO

Ekso Bionics (EKSO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.71%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $0.31 per share when it actually produced a loss of $0.33, delivering a surprise of -6.45%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Ekso Bionics , which belongs to the Zacks Medical - Instruments industry, posted revenues of $4.7 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 8.12%. This compares to year-ago revenues of $3.47 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Ekso Bionics shares have added about 5% since the beginning of the year versus the S&P 500's gain of 18.9%.What's Next for Ekso Bionics?While Ekso Bionics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Story continuesAhead of this earnings release, the estimate revisions trend for Ekso Bionics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.29 on $4.28 million in revenues for the coming quarter and -$1.27 on $16.06 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, TransMedics (TMDX), has yet to report results for the quarter ended June 2023. The results are expected to be released on August 3.This medical technology company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +63.4%. The consensus EPS estimate for the quarter has been revised 15.6% higher over the last 30 days to the current level.TransMedics' revenues are expected to be $41.8 million, up 103.7% from the year-ago quarter.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEkso Bionics Holdings, Inc. (EKSO) : Free Stock Analysis ReportTransMedics Group, Inc. (TMDX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

https://finance.yahoo.com/news/ekso-bionics-ekso-reports-q2-212514773.html

cdf6c056-2467-3eca-b518-3615640fb819

EKSO

ParticipantsJason C. Jones; COO; Ekso Bionics Holdings, Inc.Jerome Wong; Corporate Controller, Corporate Secretary & CFO; Ekso Bionics Holdings, Inc.Scott G. Davis; CEO & Director; Ekso Bionics Holdings, Inc.Sean Lee; Equity Research Associate; H.C. Wainwright & Co, LLC, Research DivisionUnidentified ParticipantPresentationOperatorHello, and welcome to the Ekso Bionics Q2 2023 Financial Results Conference Call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, Matt Steinberg with Finn Partners. Please go ahead, Matt.Unidentified ParticipantThank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jason Jones, Chief Operating Officer; and Jerome Wong, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the second quarter of 2023. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that will include forward-looking statements within the meaning of the Federal Securities Laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during the call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations, are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. Ekso disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections, our regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise, we speak only as of today, July 27, 2023. And I will now turn the call over to Ekso Bionics CEO, Scott Davis.Story continuesScott G. DavisThank you, Matt, and thank you to everyone for joining us today. We are very pleased with our second quarter results, most notably a record number of EksoHealth device bookings and strong revenue growth of 36% year-over-year, driven by the ongoing performance of our EksoNR, the positive contributions from our Ekso Indego products and continued solid execution of our team. We are making tremendous progress in reaching more patients across the continuum of care. Ekso has taken an approach of using our technology and rehabilitative programs to follow patients from post-acute to outpatient care and onto continued home and community use. This helps differentiate us in the industry and provides our patients with more options for use of technology in their recovery process. We believe this differentiating strategy gives us access to a sizable addressable market. Specifically, we believe the VA alone with its programs around the Ekso Indego Personal provides us a market opportunity of more than $300 million. Additionally, with the full Indego product line, our reach now expands to outpatient facilities that total almost 53,000 centers domestically, along with wellness centers, which is an emerging market for us that total approximately 31,000 across the U.S. Our commercial and marketing teams are hard at work to drive greater awareness as we seek to penetrate these large markets. In the second quarter, we booked a total of 44 EksoHealth devices, a quarterly record. This includes devices within the EksoNR and Ekso Indego product lines. Among these bookings was another significant multiunit order from an integrated delivery network, or IDN, for 12 of our EksoNR devices. This represents the second straight quarter of a sizable booking number with a large IDN customer. We believe that our customers are seeing firsthand how our cutting-edge devices elevate the standard of care for neuro rehabilitation. Our research suggests that post-acute care centers gain clear benefits with our EksoNR and Ekso IndeGo devices in the form of positive patient outcomes, a differentiated and more efficient offering and better economic value. Furthermore, we are leveraging our current customer base to heighten awareness for individuals who can benefit from the use of Ekso Indego Personal. These adoption drivers are among the reasons our commercial team is generating strong demand from new and existing network operators, putting us in a position to reach a significantly larger patient population. Internationally, we're pleased to have reported a strong booking quarter, particularly in Europe. One exciting deal of note is through a distributor in Hungary that resulted in a 6-unit EksoNR deal. The strength in Europe underscores our investment in indirect partnerships in the region. In APAC, we secured our first Ekso Indego booking. We continue to these regions as important growth drivers in the years to come. Turning to an update on the progress with our industrial product line, Ekso Works. During the second quarter, as we previously mentioned, we continued focusing on a different go-to-market strategy placing increased emphasis on EVO and its placement into large industrial settings where we believe there is an addressable market opportunity of approximately $5 billion. This refocus takes time with a longer sales cycle, but I'm pleased to report subsequent to quarter end, we won a competitive bid with a global automotive leader and have a number of other promising opportunities in our pipeline. During the quarter, we also shipped our first EVO from our new contract manufacturer, which brings us a better pricing structure. Looking ahead, our Ekso Works commercial team is focused on targeting large customers and increasing engagement to drive demand and ensure the success and safety of our customers' workforce. Another exciting development at the end of the quarter was the recently updated 2024 home health prospective payment system rate from the centers for Medicare and Medicaid services or CMS with a newly proposed rule that is relevant for our business and our patients. This rule would [cut of] a long-standing Medicare definition of race to provide clarification on the scope of the Medicare Part B benefit for leg, arm, back and neck braces. And as a result, we classify certain exoskeleton-type devices as braces for Medicare payment purposes. This is a positive step in facilitating the potential for Medicare coverage of personal exoskeletal such as [RXO] Indego Personal for qualified patients as a lump sum reimbursement. We fully support the codifying of the proposal to further enhance potential access for Medicare beneficiaries and look forward to providing updates around this proposed rule in coming quarters. Overall, we are encouraged by our performance, highlighted by record quarter results of revenues and bookings securing multiunit orders with large network operators and inroads we are making in large markets across the continuum of care. Driven by the strength of our commercial team and newly expanded portfolio, we look forward to bringing our life-changing solutions to a greater number of patients in the worldwide. Now I will turn the call over to our Chief Operating Officer, Jason Jones.Jason C. JonesThank you, Scott. Within operations, we continue to execute on our mandate to reduce our cash burn and have a number of related initiatives underway. Among these are improving processes and efficiencies tightening OpEx and cost controls and optimizing inventory. That said, our operating expenses did increase in the quarter on a year-over-year basis. This is in line with our expectations due to the costs associated with HMC or Human Motion Control integration. On the inventory front, since the second half of 2022, we have carried higher than optimal inventory to mitigate production risks due to pervasive supply chain disruptions. .While not completely back to normal, our component lead time are much more predictable than they have been in past quarters. In response to these improvements, we are working diligently to optimize our inventory levels to free up additional working capital. The integration of HMC continues to progressively. From a product perspective, all former HMC products are now fully integrated into our portfolio, which now covers a broad portion of the continuum of care for rehabilitation and mobility. As a result, our production and revenue potential are significantly higher. The former HMC team is also now fully utilizing our combined operational systems, which we are continually working to improve. In addition, the process to combine our engineering and quality systems is well underway with a target completion of mid-2024. I look forward to providing additional updates as the year progresses. I will now turn the call over to Jerome Wong, who will discuss our second quarter 2023 financial results.Jerome WongThank you, Jason. Now on to a summary of our second quarter 2023 financial results. Ekso generated second quarter 2023 revenue of $4.7 million compared to $3.5 million for the second quarter of 2022, an increase of 36%. This increase was comprised of a $1.5 million increase in EksoHealth revenue, partially offset by a $200,000 decrease in EksoWorks. In the quarter, EksoWorks revenue was affected by delays from our transition to our contract manufacturer. .Gross profit for the second quarter was $2.3 million, representing a gross margin of approximately 48% compared to a gross profit of $1.6 million and a gross margin of 47% for the same period in 2022. The 37% overall increase in gross profit was driven by a sharp increase in EksoHealth device sales. The increase in gross margin was primarily due to lower device costs. Operating expenses for the second quarter were $6.5 million compared to $4.9 million for the second quarter of 2022. During the second quarter of 2023, the company incurred increased expenses related to the acquisition and integration of HMC, severance expense and an increase in marketing activities. Net loss for the second quarter was $4.2 million or $0.31 per basic and diluted share compared to a net loss of $3 million or $0.23 per basic and diluted share for the same period in 2022. Turning to our 2023 1st half results. Revenue increased $2.8 million or 46% to $8.8 million for the 6 months ended June 30, 2023 compared to $6 million in the same period of 2022. The increase in revenue was primarily driven by an increase in EksoHealth device sales of $3.6 million. Gross profit for the 6 months ended June 30, 2023, was $4.3 million, representing a gross margin of 48% compared to gross profit of $2.9 million for the same period in 2022 representing a gross margin of 47%. The overall increase in gross margin was primarily due to lower device costs. Operating expenses for the first 6 months of 2023 were $13 million compared to $10.3 million for the same period in 2022. The increase in operating expenses was primarily related to the acquisition and integration of HMC, severance expense and marketing costs. Net loss applicable for the first 6 months of 2023 was $8.6 million or $0.64 per basic and diluted share compared to net loss of $7.6 million or $0.59 per basic and diluted share for the same period in 2022. Cash used in operating activities in the first half of 2023 was $7.1 million, down from $8.5 million in the year ago period. As of June 30, 2023, the company had a cash balance of $13.3 million. Please see our 10-Q filed earlier today for further details regarding the quarter. Operator, you may now open the line for questions.Question and Answer SessionOperator(Operator Instructions) Our first question today is coming from Sean Lee from H.C. Wainwright.Sean LeeCongratulations on a great quarter. My first question is on the Indego. It's nice to hear that the product is going well and adoption is increasing. I was wondering if you can provide a bit more color on -- how much of the -- how much is Indego contributing to the overall increase in revenue that we've seen in the last quarter? And where do you see it going for the rest of the year?Scott G. Davis.Okay. Thank you for your question, Sean. Appreciate it. This is Scott Davis. With the Indego devices, Ekso considers these devices as part of our EksoHealth bookings. So generally speaking, we contain those within that category. However, within that family of products, the Ekso Indego therapy and Ekso Indego-NR are typically used by clinics for patient rehabilitation. And the Ekso Indego Personal is used by individuals for home and community health use. So in Q2, our home and community health segment of the Indego product line represented in the neighborhood of 20% of our revenue overall. And if we talk specifically about our legacy EksoNR product and strip out the Indego, we are seeing year-over-year growth even within that product line alone. So Indego was certainly a contributor to our grade numbers in Q2.Sean LeeGreat. That was very helpful. In the prepared remarks, you also mentioned that you guys want to bid with the auto manufacturer for Ekso Works. Assuming whether you can provide some more details on that.Scott G. DavisWell, we're really excited about the win with the auto -- in the auto industry. We booked an initial order from that. However, in the quarter due to some supply chain challenges in late delivery of our [EBOs] we were unable to fulfill those in the quarter, but we carry those as backlog into Q3. And we continue to have additional development in that category as well with new customers coming into our forecast and pipelines.Sean LeeMy final question is on the margin side. You mentioned the margin increased the last quarter because of lower device prices. So I was wondering whether we can see that trend continue for the rest of the year?Scott G. DavisSure. We continue to work to improve operational efficiencies. And we are, as a result, seeing lower costs in our supply chain. So it is a trend that we are constantly working towards. Jason Jones, would you like to maybe shed a little more light on that? .Jason C. JonesYes. I guess I would just say that we are not satisfied with our current margin level. We think it should be higher. I don't think we're in a position to forecast is going to be higher, but that's a focus of ours along with reducing our inventory. So that's how it operates. But I don't think we're in a position to forecast higher numbers in the future yet.OperatorWe reach end of our question-and-answer session. I'd like to turn the floor back over to Scott for any further closing comments. .Scott G. DavisAll right. Thank you, Kevin. And to everyone, we are very proud of the progress we made so far this year, highlighted by our quarterly record number of EksoHealth bookings and revenue. Our commercial team continues to generate new demand by strengthening our relationships with top network operators. We're generating new multiunit orders and combined with the strength of our sales team and our expanded product portfolio now reaching across the continuum of care. We believe that we are well positioned to sustain this momentum into the second half of 2023 and beyond. We look forward to providing additional updates throughout the year. Thank you all. Have a great day. .OperatorThank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.

Thomson Reuters StreetEvents

Q2 2023 Ekso Bionics Holdings Inc Earnings Call

https://finance.yahoo.com/news/q2-2023-ekso-bionics-holdings-104521983.html

826febd2-0c66-36d7-bdf8-44bd30159f38

EL

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, we'll use ROE to better understand The Estée Lauder Companies Inc. (NYSE:EL).Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. Check out our latest analysis for Estée Lauder Companies How Is ROE Calculated?Return on equity can be calculated by using the formula:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for Estée Lauder Companies is:16% = US$1.0b ÷ US$6.4b (Based on the trailing twelve months to June 2023).The 'return' is the amount earned after tax over the last twelve months. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.16.Does Estée Lauder Companies Have A Good Return On Equity?One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As you can see in the graphic below, Estée Lauder Companies has a higher ROE than the average (13%) in the Personal Products industry.roeThat's clearly a positive. Bear in mind, a high ROE doesn't always mean superior financial performance. A higher proportion of debt in a company's capital structure may also result in a high ROE, where the high debt levels could be a huge risk . To know the 4 risks we have identified for Estée Lauder Companies visit our risks dashboard for free.How Does Debt Impact Return On Equity?Virtually all companies need money to invest in the business, to grow profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. That will make the ROE look better than if no debt was used.Story continuesEstée Lauder Companies' Debt And Its 16% ROEEstée Lauder Companies does use a high amount of debt to increase returns. It has a debt to equity ratio of 1.28. There's no doubt its ROE is decent, but the very high debt the company carries is not too exciting to see. Investors should think carefully about how a company might perform if it was unable to borrow so easily, because credit markets do change over time.ConclusionReturn on equity is one way we can compare its business quality of different companies. Companies that can achieve high returns on equity without too much debt are generally of good quality. All else being equal, a higher ROE is better.But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So you might want to check this FREE visualization of analyst forecasts for the company.Of course Estée Lauder Companies may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Should We Be Delighted With The Estée Lauder Companies Inc.'s (NYSE:EL) ROE Of 16%?

https://finance.yahoo.com/news/delighted-est-e-lauder-companies-110020343.html

63fbae04-0932-3a9e-9876-32555b45c0e3

EL

Over the past year, many The Estée Lauder Companies Inc. (NYSE:EL) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. Check out our latest analysis for Estée Lauder Companies Estée Lauder Companies Insider Transactions Over The Last YearIn the last twelve months, the biggest single sale by an insider was when the Executive Group President, Jane Hudis, sold US$2.0m worth of shares at a price of US$202 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$157. So it may not shed much light on insider confidence at current levels.Estée Lauder Companies insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!insider-trading-volumeFor those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.Does Estée Lauder Companies Boast High Insider Ownership?Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Estée Lauder Companies insiders own about US$7.0b worth of shares (which is 12% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.Story continuesWhat Might The Insider Transactions At Estée Lauder Companies Tell Us?There haven't been any insider transactions in the last three months -- that doesn't mean much. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Estée Lauder Companies insider transactions don't fill us with confidence. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 4 warning signs for Estée Lauder Companies you should be aware of, and 2 of these are concerning.But note: Estée Lauder Companies may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Estée Lauder Companies Insiders Sold US$4.2m Of Shares Suggesting Hesitancy

https://finance.yahoo.com/news/est-e-lauder-companies-insiders-140024425.html

6e478419-6a93-300b-a74b-1cc6467cf06f

ELAN

GREENFIELD, Ind., September 05, 2023--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 and Tuesday, September 12, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday at 4:15 p.m. ET.A live audio webcast will be available in the "Events and Presentations" section of Elanco’s investor website. A replay will be available for approximately 30 days.ABOUT ELANCOElanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.comView source version on businesswire.com: https://www.businesswire.com/news/home/20230905910565/en/ContactsInvestor Contact:Katy Grissom(317) [email protected] Contact:Colleen Parr Dekker(317) [email protected]

Business Wire

Elanco to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

https://finance.yahoo.com/news/elanco-participate-morgan-stanley-21st-210000049.html

3d51e0fa-1814-3691-80b2-89b3661149c6

ELAN

GREENFIELD, Ind., September 07, 2023--(BUSINESS WIRE)--Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced that the first shipments of Varenzin™-CA1 (molidustat oral suspension), conditionally approved by U.S. Food and Drug Administration (FDA) as the first and only treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD), are shipping to veterinary clinics around the country. Anemia from CKD can dramatically affect a cat’s existence, making them lethargic, reducing their appetite, and even leading to a rapid heart rate and difficulty breathing in severe cases. According to the FDA, CKD-related anemia is a complication that often contributes to death or euthanasia of affected cats due to poor quality of life.i The challenges of current therapy to address this devastating condition often include inconvenient and extra-label use of a human drug."Varenzin-CA1 is the first drug to receive conditional approval for use in cats, providing access to a novel medicine for our feline companions suffering from nonregenerative anemia due to CKD," said the FDA Center for Veterinary Medicine, upon conditionally approving the product. "Additionally, this is the first drug for cats under expanded conditional approval, a pathway to the marketplace that encourages development of innovative treatments and increases the options for treating animals with uncommon conditions, serious or life-threatening diseases, or diseases without existing or adequate therapies."CKD-related anemia stops cats’ bone marrow from producing enough red blood cells to replace the older or damaged red blood cells that are naturally removed from the blood, resulting in the inability for oxygen to be carried from the lungs throughout the body. CKD is common among mature and senior cats, occurring in about 15-30% of feline patients over 12 years old. Anemia is a common finding in over half of all CKD-diagnosed cats.ii However, prior to Varenzin-CA1, less than one-third of anemic cats received treatment.iii This latest innovation from Elanco addresses an unmet need for this chronic condition in mature cats and furthers Elanco’s feline portfolio aimed at keeping cats healthy throughout their lives, especially as they age.Story continues"Chronic kidney disease is not curable, so veterinarians and pet owners are focused on improving quality of life and slowing disease progression in affected cats," said Dr. Melinda Wood, Specialty Consulting Veterinarian at Elanco. "Varenzin-CA1 is an innovative, needle-free oral suspension option for cats that can be given at-home – no in-clinic injections needed. This innovation sets a new standard of care for cats suffering from the debilitating effects of this disease. It represents a paradigm shift in the early-treatment of CKD-related anemia and helps CKD cats feel more like their feline selves."In a series of studies, Varenzin-CA1 was shown to have a reasonable expectation of efficacy in managing anemia in CKD cats. By day 28, 50% of cats given Varenzin-CA1 had increased their red blood cell count, and by day 56, 75% of cats had increased their red blood cell count, improving the ability to deliver necessary oxygen and nutrients to their bodies.As a leader in feline care, Elanco has focused on bringing cutting edge products, like Varenzin-CA1, to market, in an effort to address challenges for pet owners and veterinarians, while improving the wellbeing of pets. This latest technology adds to Elanco’s existing feline portfolio, including Elura® (capromorelin oral solution) for cats, the only FDA-approved treatment specifically designed for the management of weight loss in cats with CKD. These products are helping to improve the lives of older cats and reducing the burden of care for their owners as they age."The bond with our pets only deepens over time," says Dr. Wood. "Unfortunately, it’s not uncommon for aging cats to be diagnosed with conditions that steal their personalities and make it hard for their owners to provide ongoing care. Elanco is uniquely offering products to address these later-stage health challenges, so cat owners no longer have to accept a sub-optimal existence for their mature and senior pets."This conditional approval reinforces Elanco’s commitment to pioneering solutions in the underserved chronic disease state and feline market through a growing portfolio of treatment options. For more information, visit https://my.elanco.com/us/campaign/varenzin.Varenzin-CA1 IndicationVarenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.Varenzin-CA1 Important Safety InformationFor oral use in cats only. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use. In case of accidental ingestion, seek medical advice immediately. Women who are pregnant or may become pregnant should administer the product with caution. Varenzin-CA1 should not be administered to cats that are pregnant, lactating or intended for breeding or to cats with known hypersensitivity to molidustat. Use with caution in cats with a history of seizures and in cats predisposed to thromboembolic disease. Hematocrit (HCT) or packed cell volume (PCV) levels should be monitored regularly as polycythemia may result from use of Varenzin-CA1. Varenzin-CA1 has not been evaluated in cats less than 1 year of age. The most common adverse reactions included vomiting, increases in systolic blood pressure and mild transient increase in serum potassium. Click here for full prescribing information.Elura Indication:Elura is indicated for management of weight loss in cats with chronic kidney disease.Elura Important Safety Information:For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Click here to see Elura product label for full prescribing information.ABOUT ELANCOElanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose™– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.i FDA Conditionally Approves First Drug for Anemia in Cats with Chronic Kidney Disease | FDAii Chalhoub S, et al. Anemia of renal disease: what it is, what to do and what's new. J Feline Med Surg. 2011;13(9):629-40.iii Boyd LM, et al. Survival in cats with naturally occurring chronic kidney disease (2000-2002). J Vet Intern Med. 2008;22:1111-17Elura, Varenzin, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. @2023 Elanco or its affiliates.PM-US-23-0888View source version on businesswire.com: https://www.businesswire.com/news/home/20230907527480/en/ContactsElanco Investor Contact: Katy Grissom (317) 273-9248 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected]

Business Wire

Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

https://finance.yahoo.com/news/elanco-launches-varenzin-ca1-molidustat-201500022.html

72d9a6a3-0b8c-3618-9b9e-6364981dcabc

ELF

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about e.l.f. Beauty (ELF) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.e.l.f. Beauty currently has an average brokerage recommendation (ABR) of 1.73, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 13 brokerage firms. An ABR of 1.73 approximates between Strong Buy and Buy.Of the 13 recommendations that derive the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 53.9% and 15.4% of all recommendations.Brokerage Recommendation Trends for ELFBroker Rating Breakdown Chart for ELFCheck price target & stock forecast for e.l.f. Beauty here>>>While the ABR calls for buying e.l.f. Beauty, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.Story continuesZacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is ELF a Good Investment?In terms of earnings estimate revisions for e.l.f. Beauty, the Zacks Consensus Estimate for the current year has increased 0.2% over the past month to $2.37.Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for e.l.f. Beauty. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, the Buy-equivalent ABR for e.l.f. Beauty may serve as a useful guide for investors.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reporte.l.f. Beauty (ELF) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is e.l.f. Beauty (ELF) a Buy as Wall Street Analysts Look Optimistic?

https://finance.yahoo.com/news/e-l-f-beauty-elf-133006673.html

905fb815-90d9-37ef-aabf-593a0d5821cc

ELF

e.l.f. Beauty (ELF) closed the most recent trading day at $136.04, moving -1.31% from the previous trading session. This move lagged the S&P 500's daily gain of 0.14%. At the same time, the Dow added 0.22%, and the tech-heavy Nasdaq gained 0.09%.Heading into today, shares of the cosmetics company had gained 3.48% over the past month, outpacing the Consumer Staples sector's loss of 4.48% and the S&P 500's loss of 1.27% in that time.Wall Street will be looking for positivity from e.l.f. Beauty as it approaches its next earnings report date. The company is expected to report EPS of $0.58, up 61.11% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $196.08 million, up 60.26% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.37 per share and revenue of $817.55 million. These totals would mark changes of +42.77% and +41.24%, respectively, from last year.Investors should also note any recent changes to analyst estimates for e.l.f. Beauty. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.21% higher. e.l.f. Beauty currently has a Zacks Rank of #2 (Buy).Valuation is also important, so investors should note that e.l.f. Beauty has a Forward P/E ratio of 58.23 right now. This represents a premium compared to its industry's average Forward P/E of 30.5.Story continuesMeanwhile, ELF's PEG ratio is currently 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Cosmetics stocks are, on average, holding a PEG ratio of 2.89 based on yesterday's closing prices.The Cosmetics industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 206, putting it in the bottom 19% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow ELF in the coming trading sessions, be sure to utilize Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reporte.l.f. Beauty (ELF) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

E.l.f. Beauty (ELF) Stock Sinks As Market Gains: What You Should Know

https://finance.yahoo.com/news/e-l-f-beauty-elf-215016819.html

ee837fd7-5600-3859-8a0e-e5a2770a4733

ELMD

NEW PRAGUE, Minn., August 08, 2023--(BUSINESS WIRE)--Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2023 fourth quarter and year ended June 30, 2023, on Tuesday, August 22, 2023 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International).The live conference call webcast will be accessible in the Investor Relations section of Electromed’s web site and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1625050&tp_key=e81a566324For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13740145. Additionally, an online replay will be available in the Investor Relations section of Electromed’s web site at: http://investors.smartvest.com/.About Electromed, Inc.Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230808749538/en/ContactsBrad Nagel, Chief Financial Officer(952) [email protected] Cavanaugh, Investor RelationsICR Westwicke(617) [email protected]

Business Wire

Electromed, Inc. Schedules its Fourth Quarter Fiscal 2023 Financial Results Conference Call for August 22, 2023 at 5:00 p.m. ET

https://finance.yahoo.com/news/electromed-inc-schedules-fourth-quarter-200500611.html

32771edc-7c68-3862-a468-4a42dfe9827f

ELMD

--Record Annual Revenue---- Fourth Quarter Revenue Increased 21% Year-Over-Year; Full Year Revenue Increased 15% --NEW PRAGUE, Minn., August 22, 2023--(BUSINESS WIRE)--Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2023") and full year ("FY 2023") ended June 30, 2023.Q4 FY 2023 Financial HighlightsNet revenue increased 21% to a record $13.6 million in Q4 FY 2023, from $11.3 million in Q4 of the prior year.Operating income totaled $1.5 million in Q4 FY 2023, compared to $0.5 million in Q4 FY 2022.Net income was $1.0 million for the quarter, or $0.12 per diluted share, compared to $0.4 million, or $0.04 per diluted share, in Q4 FY 2022.Cash as of June 30, 2023, was $7.4 million.FY 2023 Financial HighlightsNet revenue increased 15% year over year to $48.1 million, from $41.7 million, during the fiscal year ended June 30, 2023 ("FY 2023").Operating income totaled $4.0 million, a 35% increase compared to $3.0 million in FY 2022.Net income totaled $3.2 million, or $0.36 per diluted share, compared to $2.3 million, or $0.26 per diluted share, in FY 2022."Fiscal year 2023 was pivotal for Electromed," said Jim Cunniff, President and Chief Executive Officer. "The team delivered exceptional results, including record revenues of $13.6 million in the fourth quarter, a 21% year-over-year growth rate and over $48 million for the fiscal year, despite facing headwinds from the expiration of the CMS waiver and macro supply chain disruptions. The team made strides on our key strategic milestones, most importantly launching the next generation SmartVest Clearway device, a sleeker, lighter-weight, user-friendly device, and the first new HFCWO technology to be introduced to the market in years. We continue to invest in our commercial organization and direct-to-consumer marketing efforts as we march toward greater market penetration and adoption. The operating leverage generated by these investments is clear in our annual results."Story continuesFiscal 2024 Strategic PrioritiesMr. Cunniff continued, "As I step into the role of President and Chief Executive Officer, I am grateful for the solid foundation created by Kathleen Skarvan, former President and Chief Executive Officer, and current Board Chair. Looking into Fiscal Year 2024, we will continue to execute against Electromed’s four strategic pillars: continued thoughtful sales force expansion; direct to consumer and direct to physician marketing; infrastructure to support anticipated sales growth which includes operational and manufacturing excellence; and finally, we will continue to add to the body of clinical evidence to further support HFCWO therapy as an efficacious therapy for bronchiectasis. We believe that bronchiectasis is under-recognized and under-diagnosed, but we believe this is changing and we are poised to capture increased diagnoses and subsequent prescriptions. I am confident that our continued attention to these strategic pillars will accelerate topline growth, improve our operating margin, and in turn increase shareholder value."Q4 FY 2023 ReviewNet revenue in the fourth quarter of the Company’s fiscal year ending June 30, 2023 ("fiscal 2023") increased 20.8% to $13.6 million, from $11.3 million in the fourth quarter of the Company’s fiscal year ended June 30, 2022 ("fiscal 2022"), primarily driven by 22.8% growth in the home care business which benefitted from an increase in direct sales representatives, increased sales representative productivity driven by increased clinic access and patient flow and our sales team refining their selling process and clinic targeting methodology. Field sales employees totaled 55, of which 46 were direct sales, at the end of the fourth quarter of fiscal 2023, compared to 52 at the end of the fourth quarter of fiscal 2022, of which 43 were direct sales. Sales force productivity continued to improve during the quarter allowing us to achieve home care revenue per direct sales rep of $945,000 for FY 2023, on the high end of the target of $850,000 to $950,000.Distributor revenue decreased 41.2% to $0.2 million in the fourth quarter of fiscal 2023 from $0.4 million in the same period in fiscal 2022, primarily due to the timing of purchases of one of our key distribution partners. Institutional revenue increased 29.0% to $0.6 million in the fourth quarter of fiscal 2023, and international revenue increased 30.2% to $0.1 million in the fourth quarter of fiscal 2023.Gross profit in the fourth quarter of fiscal 2023 increased to $10.5 million, or 76.8% of net revenues, from $8.1 million, or 72.0% of net revenues, in the fourth quarter of fiscal 2022, as rising raw material and shipping costs were offset by higher Medicare allowable pricing, increased operational efficiencies and fixed cost leverage on higher revenue.Operating income totaled $1.5 million in the fourth quarter of fiscal 2023, compared to $0.5 million in the fourth quarter of fiscal 2022. The higher operating income was driven by increased revenue in the fourth quarter of fiscal 2023.Net income for the fourth quarter of fiscal 2023 was $1.0 million, or $0.12 per diluted share, compared to $0.4 million, or $0.04 per diluted share, in the fourth quarter of fiscal 2022.FY 2023 SummaryNet revenue for the full year was $48.1 million led by Homecare revenue which increased by $5.9 million or 15.6%, to $44.0 million in fiscal 2023 compared to fiscal 2022. The revenue increase compared to fiscal 2022 was primarily due to increases in referrals and approvals. The increase in referrals was primarily due to an increase in direct sales representatives, increased sales representative productivity driven by increased clinic access and patient flow, our sales team refining their selling process and clinic targeting methodology, and benefits of the CMS waiver on the non-commercial Medicare portion of our home care revenue. Additionally, we benefitted from a Medicare allowable rate increase that took effect on January 1, 2023. Annual Medicare rate increases for our device are linked closely to changes in the Urban Consumer Price Index.The CMS waiver benefited the non-commercial Medicare portion of our home care revenue by increasing the number of referrals and the approval percentage for previously non-covered diagnoses. We believe that our ongoing sales team execution, along with the expected return to pre-COVID-19 levels of patient face-to-face engagement with physicians and clinic access for our sales team mitigated the Q4 homecare revenue impact of the CMS waiver expiration on May 11, 2023.Institutional revenue increased by $0.4 million, or 25.3%, in fiscal 2023 compared to fiscal 2022. Institutional revenue includes sales to hospitals and rental companies. The revenue increase was due to increased capital purchases and stronger consumable volumes compared to fiscal 2022, as hospitals resumed utilization of HFCWO protocols after reducing utilization early in the COVID-19 pandemic.Home care distributor revenue increased by $0.1 million, or 9.8%, in fiscal 2023 compared to fiscal 2022. The revenue increase in fiscal 2023 was due to increased demand from one of our primary home care distribution partners. We began selling to a limited number of home medical equipment distributors during our fiscal year ended June 30, 2020, who in turn sell our SmartVest System in the U.S. home care market.International revenue decreased by $0.1 million, or 18.6%, in fiscal 2023 compared to fiscal 2022. International revenue growth is not currently a primary focus for us, and our corporate resources are focused on supporting and maintaining our current distributors.Gross profit increased to $36.5 million in fiscal 2023, or 76.0% of net revenues, from $31.4 million or 75.5% of net revenues, in fiscal 2022. The increase in gross profit was primarily related to increases in domestic home care revenue including the Medicare allowable rate increase that took effect in January 2022.Selling, general and administrative ("SG&A") expenses were $31.6 million in fiscal 2023, representing an increase of $4.5 million or 16.5% from $27.1 million in fiscal 2022. The increase in SG&A expenses was primarily related to increased payroll and other compensation related expenses as a result of increased headcount.R&D expenses decreased by $0.4 million, or 32.4%, to $0.9 million in fiscal 2023 compared to $1.3 million in fiscal 2022. The decrease in the current year was primarily due to reduced professional consulting costs associated with our next generation platform development activities.Net income for fiscal 2023 was $3.2 million, or $0.36 per diluted share, compared to net income of $2.3 million, or $0.26 per diluted share, in fiscal 2022. The increase in current year net income was primarily due to stronger home care and distributor revenue growth.As of June 30, 2023 Electromed had $7.4 million in cash, $24.1 million in accounts receivable, and no debt, for a working capital of $29.7 million, and shareholders’ equity of $37.7 million.Conference CallCompany management will host a conference call on August 22 at 5:00 p.m. Eastern Time to discuss the results.Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed’s web site and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1625050&tp_key=e81a566324For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13740145. Additionally, an online replay will be available in the Investor Relations section of Electromed’s web site at: http://investors.smartvest.com/.About Electromed, Inc.Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.Cautionary StatementsCertain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "potential," "should," "will," and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the duration, extent and severity of the Covid-19 pandemic, including its effects on our business, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking statements," as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.Source: Electromed, Inc.Electromed, Inc.Condensed Balance Sheets June 30, 2023 June 30, 2022AssetsCurrent AssetsCash and cash equivalents$7,372,000$8,153,000Accounts receivable (net of allowances for doubtful accounts of $45,000)24,130,00021,052,000Contract assets487,000286,000Inventories4,221,0003,178,000Prepaid expenses and other current assets1,577,0001,870,000Total current assets37,787,00034,539,000Property and equipment, net5,672,0004,568,000Finite-life intangible assets, net605,000599,000Other assets161,000120,000Deferred income taxes1,581,0001,538,000Total assets$45,806,000$41,364,000Liabilities and Shareholders' EquityCurrent LiabilitiesAccounts payable$1,372,000$1,261,000Accrued compensation3,018,0002,742,000Income tax payable336,00051,000Warranty reserve1,378,0001,256,000Other accrued liabilities1,949,0001,840,000Total current liabilities8,053,0007,150,000Other long-term liabilities86,00041,000Total liabilities8,139,0007,191,000Commitments and ContingenciesShareholders' EquityCommon stock, $0.01 par value per share, 13,000,000 shares authorized;8,555,238 and 8,475,438 shares issued and outstanding, respectively86,00085,000Additional paid-in capital18,788,00018,308,000Retained earnings18,793,00015,780,000Total shareholders' equity37,667,00034,173,000Total liabilities and shareholders' equity$45,806,000$41,364,000Electromed, Inc.Condensed Statement of OperationsThree Months EndedJune 30Twelve Months EndedJune 302023202220232022(Unaudited)(Unaudited)Net revenues$13,612,000$11,268,000$48,067,000$41,659,000Cost of revenues3,162,0003,152,00011,548,00010,217,000Gross profit10,450,0008,116,00036,519,00031,442,000Operating expensesSelling, general and administrative8,658,0007,309,00031,595,00027,114,000Research and development298,000315,000916,0001,356,000Total operating expenses8,956,0007,624,00032,511,00028,470,000Operating income1,494,000492,0004,008,0002,972,000Interest income (expense), net41,0005,00078,00025,000Net income before income taxes1,535,000497,0004,086,0002,997,000Income tax expense502,000116,000920,000692,000Net income$1,033,000$381,000$3,166,000$2,305,000Income per share:Basic$0.12$0.05$0.37$0.27Diluted$0.12$0.04$0.36$0.26Weighted-average common shares outstanding:Basic8,511,6328,427,4048,463,6848,471,320Diluted8,723,7008,735,1548,700,8338,768,703Electromed, Inc.Condensed Statements of Cash FlowsFor the Years Ended June 30,20232022Cash Flows From Operating ActivitiesNet income$3,166,000$2,305,000Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation550,000503,000Amortization of finite-life intangible assets63,000125,000Share-based compensation expense708,000976,000Deferred income taxes(43,000)(489,000)Changes in operating assets and liabilities:Accounts receivable(3,078,000)(4,020,000)Contract assets(201,000)107,000Inventories(1,033,000)(1,072,000)Prepaid expenses and other current assets202,000(1,322,000)Income tax receivable285,000(237,000)Accounts payable and accrued liabilities420,0002,170,000Accrued compensation276,000268,000Net cash provided by (used in) operating activities1,315,000(686,000)Cash Flows From Investing ActivitiesInvestment in property and equipment(1,648,000)(1,425,000)Investment in finite-life intangible assets(68,000)(100,000)Net cash used in investing activities(1,716,000)(1,525,000)Cash Flows From Financing ActivitiesIssuance of common stock upon exercise of options83,000-Taxes paid on stock options exercised on a net basis(310,000)(77,000)Repurchase of common stock(153,000)(1,448,000)Net cash used in financing activities(380,000)(1,525,000)Net (decrease) increase in cash(781,000)(3,736,000)Cash And Cash EquivalentsBeginning of period8,153,00011,889,000End of period$7,372,000$8,153,000View source version on businesswire.com: https://www.businesswire.com/news/home/20230822410095/en/ContactsBrad Nagel, Chief Financial Officer(952) [email protected] Cavanaugh, Investor RelationsICR Westwicke(617) [email protected]

Business Wire

Electromed, Inc. Announces Fiscal 2023 Fourth Quarter and Full Year Financial Results

https://finance.yahoo.com/news/electromed-inc-announces-fiscal-2023-200500410.html

fa139f87-b128-330e-8d7c-a95ee768b8ed

ELTX

Elicio Therapeutics Inc.BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET.A live webcast of the presentation will be accessible to registered attendees via the company’s Events page. An archived replay will be available on-demand for 30 days following the event.About Elicio TherapeuticsElicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.Cautionary Note on Forward-Looking StatementsCertain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding Elicio’s planned clinical programs, statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and the expected participation and presentation at upcoming conferences; and therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to Elicio’s plans to research, develop and commercialize its current and future product candidates.Story continuesNew factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the current report on Form 8-K that was filed with the SEC on June 2, 2023 and Elicio’s periodic reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.Media ContactGloria GasaaturaLifeSci [email protected]+1 646-970-4688Investor Relations ContactHeather DiVecchiaElicio [email protected]+1 857-209-0153

GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

https://finance.yahoo.com/news/elicio-therapeutics-present-h-c-120000092.html

8a8b6bd2-dc4c-30a7-b186-1e34337cd9fe

ELTX

Elicio Therapeutics Inc.Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutationsThis $2.6 million grant is an addition to the $2.8 million that GIRF awarded Elicio in September 2022BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has been awarded a $2.6 million grant from the GI Research Foundation in Chicago to fund research for two therapeutic cancer vaccines, ELI-007 and ELI-008. This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022. Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations. Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.Elicio has achieved several critical milestones in the development of both vaccines: (1) AMP-vaccine design and validation of manufacturing feasibility, (2) validation of robust in vivo immunogenicity and (3) execution of CMC, regulatory and clinical strategic planning for IND planning. This additional funding will help support the completion of all manufacturing, regulatory and clinical preparation needed to continue to move ELI-007 and ELI-008 forward. The grant will enable Elicio to pursue initial patient clinical assessment.“We’re pleased to have this additional funding from the GI Research Foundation for these two cancer vaccine programs that we believe can fill a significant unmet need for patients living with a variety of solid tumors. BRAF V600E mutations are present in 40% of melanoma, 10% of colon cancer and 2% of lung cancer while mutations in p53 are found in approximately 30% of patients with solid tumors,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio. “Prior studies of immune responses in patients with tumors known to express these mutant antigens have shown spontaneous generation of antigen-specific T cells capable of anti-tumor effector function. AMP-peptide vaccines targeting these antigens have the potential to expand and mature tumor-specific T cells through enhanced delivery and immune stimulation in draining lymph nodes to generate tumor-specific immunity capable of eliminating tumor tissue.”Story continuesChristopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio, added, “This is another important milestone for the company during this exciting year where we’ve gone public and announced initial positive Phase 1 data for our lead cancer vaccine candidate, ELI-002, in mKRAS-driven tumors. The AMP platform is an ideal vehicle for cancer vaccine development because it allows us to leverage the lymph node’s role as the ‘schoolhouse’ of the immune system to educate T cells on how to identify and eliminate these aggressive cancers. We’re honored to work with the GI Research Foundation on our joint mission to provide an additional potential tool for the treatment arsenal of cancers with BRAF and p53 mutations.”David T. Rubin, M.D., Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago and the GI Research Foundation’s Senior Scientific Advisor, added, “The GI Research Foundation is dedicated to raising awareness and supporting innovative research in digestive diseases, which includes the Foundation’s special initiative focused on cancer. We’re proud to support Elicio as they move their unique approaches into the clinic, and we look forward to this ongoing line of research.”About the Amphiphile PlatformOur proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies.Our AMP platform, originally developed at the Massachusetts Institute of Technology, or MIT, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.The Amphiphile platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, we have observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.About Elicio TherapeuticsElicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.About the GI Research FoundationIn 1961, the GI Research Foundation was founded by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology, who devoted his life to medicine, teaching, and patient care. Since then, in partnership with University of Chicago Medicine Digestive Diseases Center and with gifts from generous donors, the Foundation has given millions to support research to improve treatments for digestive diseases and discover prevention pathways and cures.Cautionary Note on Forward-Looking StatementsCertain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding Elicio’s planned clinical programs, including planned clinical trials, the potential of Elicio’s product candidates, Elicio’s expectations that the funds received from the GI Research Foundation will advance the development of its product candidates; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s ability to reach additional milestones and progress the development of ELI-007 and ELI-008; the potential of AMP-peptide vaccines; Elicio’s plans to develop and commercialize its product candidates, including ELI-002; the timing of initiation of Elicio’s planned clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Elicio’s product candidates; Elicio’s commercialization, marketing and manufacturing capabilities and strategy; Elicio’s ability to identify additional products or product candidates with significant commercial potential; and Elicio’s ability to use the funds received from the GI Research Foundation to successfully advance the development of its product candidates.New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the current report on Form 8-K that was filed with the SEC on June 2, 2023 and Elicio’s periodic reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.Media ContactGloria GasaaturaLifeSci [email protected] 646-970-4688Investor Relations ContactHeather DiVecchiaElicio Therapeutics [email protected]

GlobeNewswire

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

https://finance.yahoo.com/news/elicio-therapeutics-receives-2-6-120000387.html

40f42a81-7e2e-3b97-b38d-e7626f0010c6

ELV

A Deep Dive into the Dividend Profile of Elevance Health Inc (NYSE:ELV)Elevance Health Inc(NYSE:ELV) recently announced a dividend of $1.48 per share, payable on 2023-09-22, with the ex-dividend date set for 2023-09-07. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's deep dive into Elevance Health Inc's dividend performance and assess its sustainability.What Does Elevance Health Inc Do?Warning! GuruFocus has detected 7 Warning Signs with BLK. Click here to check it out. High Yield Dividend Stocks in Gurus' PortfolioThis Powerful Chart Made Peter Lynch 29% A Year For 13 YearsHow to calculate the intrinsic value of a stock?Elevance Health (formerly known as Anthem) remains one of the leading health insurers in the U.S., providing medical benefits to 48 million medical members as of December 2022. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.Unraveling Elevance Health Inc's Dividend Performance and SustainabilityA Glimpse at Elevance Health Inc's Dividend HistoryElevance Health Inc has maintained a consistent dividend payment record since 2011. Dividends are currently distributed on a quarterly basis. Elevance Health Inc has increased its dividend each year since 2011. The stock is thus listed as a dividend achiever, an honor that is given to companies that have increased their dividend each year for at least the past 12 years.Below is a chart showing annual Dividends Per Share for tracking historical trends.Story continuesUnraveling Elevance Health Inc's Dividend Performance and SustainabilityBreaking Down Elevance Health Inc's Dividend Yield and GrowthAs of today, Elevance Health Inc currently has a 12-month trailing dividend yield of 1.23% and a 12-month forward dividend yield of 1.34%. This suggests an expectation of increase dividend payments over the next 12 months.Over the past three years, Elevance Health Inc's annual dividend growth rate was 17.00%. Extended to a five-year horizon, this rate decreased to 14.10% per year. And over the past decade, Elevance Health Inc's annual dividends per share growth rate stands at an impressive 14.50%.Based on Elevance Health Inc's dividend yield and five-year growth rate, the 5-year yield on cost of Elevance Health Inc stock as of today is approximately 2.38%.Unraveling Elevance Health Inc's Dividend Performance and SustainabilityThe Sustainability Question: Payout Ratio and ProfitabilityTo assess the sustainability of the dividend, one needs to evaluate the company's payout ratio. The dividend payout ratio provides insights into the portion of earnings the company distributes as dividends. A lower ratio suggests that the company retains a significant part of its earnings, thereby ensuring the availability of funds for future growth and unexpected downturns. As of 2023-06-30, Elevance Health Inc's dividend payout ratio is 0.21.Elevance Health Inc's profitability rank, offers an understanding of the company's earnings prowess relative to its peers. GuruFocus ranks Elevance Health Inc's profitability 8 out of 10 as of 2023-06-30, suggesting good profitability prospects. The company has reported positive net income for each of year over the past decade, further solidifying its high profitability.Growth Metrics: The Future OutlookTo ensure the sustainability of dividends, a company must have robust growth metrics. Elevance Health Inc's growth rank of 8 out of 10 suggests that the company's growth trajectory is good relative to its competitors.Revenue is the lifeblood of any company, and Elevance Health Inc's revenue per share, combined with the 3-year revenue growth rate, indicates a strong revenue model. Elevance Health Inc's revenue has increased by approximately 17.20% per year on average, a rate that outperforms than approximately 66.67% of global competitors.The company's 3-year EPS growth rate showcases its capability to grow its earnings, a critical component for sustaining dividends in the long run. During the past three years, Elevance Health Inc's earnings increased by approximately 10.30% per year on average, a rate that outperforms than approximately 68.75% of global competitors.Lastly, the company's 5-year EBITDA growth rate of 13.30%, which outperforms than approximately 60% of global competitors.Next StepsWith a consistent dividend payment history, a robust growth rate, and a sustainable payout ratio, Elevance Health Inc presents an attractive prospect for dividend-focused investors. Its strong profitability and growth metrics further bolster the case for its dividend sustainability. However, like any investment, it is crucial to conduct thorough research and consider the broader market dynamics before making a decision.GuruFocus Premium users can screen for high-dividend yield stocks using the High Dividend Yield Screener.This article first appeared on GuruFocus.

GuruFocus.com

Unraveling Elevance Health Inc's Dividend Performance and Sustainability

https://finance.yahoo.com/news/unraveling-elevance-health-incs-dividend-110327193.html

67b14653-2fbc-3c89-b0b1-166ec1e27811

ELV

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Elevance Health (NYSE:ELV). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. View our latest analysis for Elevance Health How Fast Is Elevance Health Growing?The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Over the last three years, Elevance Health has grown EPS by 5.4% per year. While that sort of growth rate isn't anything to write home about, it does show the business is growing.Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Not all of Elevance Health's revenue this year is revenue from operations, so keep in mind the revenue and margin numbers used in this article might not be the best representation of the underlying business. Elevance Health maintained stable EBIT margins over the last year, all while growing revenue 11% to US$166b. That's progress.You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart.Story continuesearnings-and-revenue-historyFortunately, we've got access to analyst forecasts of Elevance Health's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.Are Elevance Health Insiders Aligned With All Shareholders?Since Elevance Health has a market capitalisation of US$105b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at US$134m. This comes in at 0.1% of shares in the company, which is a fair amount of a business of this size. This should still be a great incentive for management to maximise shareholder value.Does Elevance Health Deserve A Spot On Your Watchlist?One positive for Elevance Health is that it is growing EPS. That's nice to see. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Now, you could try to make up your mind on Elevance Health by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Here's Why We Think Elevance Health (NYSE:ELV) Is Well Worth Watching

https://finance.yahoo.com/news/heres-why-think-elevance-health-120037011.html

fc3fb261-3cbb-3642-a32e-c009daabf0c0

ELVN

Enliven Therapeutics, Inc.Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024Strong balance sheet, closing the quarter with $278 million in cash, cash equivalents and marketable securitiesBOULDER, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.“We are pleased with the continued progress this quarter across our parallel lead programs,” said Sam Kintz, MBA, Enliven’s Co-founder, President and Chief Executive Officer. “The Phase 1 trials of ELVN-001 and ELVN-002 are advancing through dose escalation, and we look forward to reporting initial proof of concept data for both programs in 2024. Our team is focused on executing these clinical trials and enthusiastic to show their potential to help patients with CML and HER2-driven cancers.”Recent Business Highlights and Upcoming MilestonesResearch and Development HighlightsELVN-001 and ELVN-002: Patient enrollment and dose escalation continue to progress in the Phase 1 clinical trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) (NCT05304377) and the Phase 1 clinical trial evaluating ELVN-002 in patients with solid tumors with HER2 alterations (NCT05650879). Initial safety and efficacy data from the Phase 1a trials are expected to be reported in 2024.Pipeline: Selected a product candidate for the Company’s third program, with more information to be disclosed in 2024. Enliven continues to actively pursue multiple additional early-stage discovery programs.Second Quarter 2023 Financial ResultsCash Position: As of June 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $277.9 million.Research and development (R&D) expenses: R&D expenses were $15.2 million for the second quarter of 2023, compared to $7.9 million for the second quarter of 2022. General and administrative (G&A) expenses: G&A expenses for the second quarter of 2023 were $5.0 million, compared to $1.1 million for the second quarter of 2022. Net Loss: Enliven reported a net loss of $16.7 million for the second quarter of 2023, compared to a net loss of $8.9 million for the second quarter of 2022.Story continuesAbout Enliven TherapeuticsEnliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.Forward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)) concerning Enliven and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Enliven, as well as assumptions made by, and information currently available to, management of Enliven. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of, and plans and expectations regarding, Enliven’s programs, including ELVN-001, ELVN-002, Enliven’s third program and its early-stage discovery programs; the expected timing of initial results for ELVN-001 and ELVN-002; the expected timing of disclosure of more information on Enliven’s third program; and statements by Enliven’s Co-founder, President and Chief Executive Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of Enliven; the significant net losses incurred since its inception; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, product candidates; the outcome of preclinical testing and early clinical trials for product candidates and the potential for the results of clinical trials to differ from preclinical, preliminary, initial or expected results; the risk of significant adverse events, toxicities or other undesirable side effects; Enliven’s limited resources;  Enliven’s ability to obtain additional capital to finance its operations; the decision to develop or seek strategic collaborations to develop Enliven’s current or future product candidates in combination with other therapies and the related costs associated with running combination trials; Enliven’s lack of experience in developing a product candidate through commercialization; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven’s patent protection; developments relating to Enliven’s competitors and its industry, including competing product candidates and therapies; reliance on third parties, including contract manufacturing organizations and contract research organizations; general economic and market conditions; and other risks and uncertainties, including those more fully described in Enliven’s filings with the Securities and Exchange Commission (SEC), including additional risks which may be found in the section entitled “Risk Factors” in Enliven’s Annual and Quarterly Reports on Form 10-K and 10-Q filed with the SEC and in Enliven’s future reports to be filed with the SEC. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.Contact:Enliven Investors & Media:Argot [email protected] Therapeutics, Inc.Selected Condensed Consolidated Financial Information(in thousands, except per share data)(unaudited)           Statements of Operations  Three Months Ended June 30,  Six Months Ended June 30,      2023   2022   2023   2022  Operating expenses:          Research and development  $15,183  $7,937  $27,063  $14,996  General and administrative   4,951   1,079   9,489   2,698  Total operating expenses   20,134   9,016   36,552   17,694  Loss from operations   (20,134)  (9,016)  (36,552)  (17,694) Other income (expense), net   3,413   127   5,107   136  Net loss  $(16,721) $(8,889) $(31,445) $(17,558) Net loss per share, basic and diluted  $(0.41) $(2.86) $(1.05) $(5.87) Weighted-average shares outstanding, basic and diluted   40,961   3,104   29,862   2,991             Balance Sheets    June 30, December 31,       2023   2022  Assets     Current assets:     Cash, cash equivalents and marketable securities $277,865  $75,536  Prepaid expenses and other current assets  5,310   2,217  Total current assets  283,175   77,753  Property and equipment, net  867   890  Operating lease right-of-use assets  475   626  Deferred offering costs  524   3,975  Restricted cash  54   54  Other long-term assets  3,406   —  Total assets $288,501  $83,298  Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)     Current liabilities:     Accounts payable $2,843  $3,438  Accrued expenses and other current liabilities  6,304   6,277  Total current liabilities  9,147   9,715  Long-term liabilities  360   659  Total liabilities  9,507   10,374  Convertible preferred stock  —   149,749  Stockholders' equity (deficit)  278,994   (76,825) Total liabilities, convertible preferred stock and stockholders' equity (deficit) $288,501  $83,298             

GlobeNewswire

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

https://finance.yahoo.com/news/enliven-therapeutics-reports-second-quarter-200500489.html

d7fe405a-3498-3dae-b07f-018057fa3ab8

ELVN

Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech stocks.Biotech companies are involved in the study of organisms, cells and biological systems to develop products, applications and treatments.These companies are deep into research and development and could spend millions to research products in hopes of a scientific breakthrough and regulatory approvals.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut it’s not easy. If you invest in biotech stocks, you have to be comfortable with the idea that your company could live or die with the success or failure of a single drug or product.That means that the industry is affected not only by the results of clinical trials but also by regulatory decisions, which could take months.But if your company hits, the results can be life-changing for investors and patients who benefit from the new treatment or product.I’ve used the Portfolio Grader to identify some top-rated biotech stocks that are worth a look at today. If you are eager to enter the sector, this is an excellent place to start.ANI Pharmaceuticals (ANIP)Hands with puppet string and a red and green candlestick stock chart.Source: ShutterstockLocated in Minnesota, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures and markets branded and generic prescription medications. It has dozens of successful products on the market.Currently, the company is focusing on building a purified franchise cortrophin gel, a medication injected under the skin or muscle to treat autoimmune and inflammatory conditions.It’s also working on expanding and strengthening its generic medications business.So far, business is going well. Second-quarter earnings were $116.55 million in revenue and earnings per share of $1.28, beating analysts’ estimates of $99.86 million in revenue and EPS of 67 cents.ANIP stock is up 50% this year and has an “A” rating in the Portfolio Grader.Story continuesImmunoGen (IMGN)Biotechnology stocks, biomedical stocksSource: aslysun / Shutterstock.comImmunoGen (NASDAQ:IMGN) is a biotech company developing antibody-drug conjugate technology to combat cancer. ADCs are cancer-killing toxins attached via a biodegradable linker to a specific antibody.ImmunoGen works on finding the correct combination of cancer targets, antibodies, payloads and linkers to develop effective ADCs that a cancer patient can tolerate.It currently has an ovarian cancer drug, Elahere, to market, and several other drugs in various stages of development. One of those tests also involves Elahere, which got positive results in May as a second potential treatment for cancer.Earnings for the second quarter were sales of $83.15 million, which beat analysts’ estimates of $46.6 million. But the company’s still losing money, as its EPS was a loss of 2 cents per share.But investors aren’t concerned, and you shouldn’t be either. IMGN stock is up 180% this year and has an “A” rating in the Portfolio Grader.Wave Life Sciences (WVE)half of a double helix molecule of DNASource: ShutterstockWave Life Sciences (NASDAQ:WVE) is a clinical-stage RNA medicine company developing treatments for conditions such as muscular dystrophy and Huntington’s disease.RNA therapeutics involve using ribonucleic acid molecules as agents to treat diseases, either through messenger RNA (mRNA), small interfering RNA (siRNA) or microRNA (miRNA).RNA drugs are interesting from an investor’s perspective because the treatments can be developed and produced quickly, as it was for the development of Covid-19 vaccines.Wave Life Sciences currently has two drugs in clinical Phase 1 or 2 testing and says it’s “on the cusp” of moving the industry’s first RNA editing therapeutic candidate to clinical testing.Considering the company’s deep into the testing and development phase and doesn’t have products to bring to market yet, the stock is volatile. But the company is building momentum and was added to the Russell 2000 and Russell 3000 indices in June.WVE stock has an “A” rating in the Portfolio Grader.Enliven Therapeutics (ELVN)Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotechSource: shutterstock.com/Romix ImageEnliven Therapeutics (NASDAQ:ELVN) is a biotech company in Boulder, Colorado, working on cancer treatments.Its research involves developing kinase inhibitors to block overactive proteins that trigger abnormal cell behavior and growth.Its most advanced candidate is in Phase 1 clinical trials. ELVN-001 is a potential treatment for patients who have chronic myeloid leukemia. It’s also testing a drug to potentially treat non-small cell lung cancer.ELVN stock jumped earlier this year when it completed a savvy move – it closed a merger with Boston rare disease specialist Imara after that company had two Phase 2B trials fail. By buying the distressed stock and raising $165 million from institutional investors to fund research, Enliven acquired some assets on the cheap.ELVN stock is up 328% this year and has an “A” rating in the Portfolio Grader.Nuvalent (NUVL)DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT StockSource: CI Photos / Shutterstock.comNuvalent (NASDAQ:NUVL) is also focused on cancer treatments. The company develops small molecules to overcome resistance, minimize adverse events, address brain metastases, and drive more durable patient responses.It has two drug candidates in clinical trials to treat non-small cell lung cancer and other solid tumors. With $431 million in financing in hand, the company says it has a cash runway into the second half of 2025. The company reported a net loss of $29.1 million in the second quarter, with nearly $26 million coming from research and development expenses.However, investors are bullish on the stock. The price nearly reached $50 per share earlier this summer, and even after a modest pullback is up 46% this year.NULV stock has an “A” rating in the Portfolio Grader.Eli Lilly and Company (LLY)Eli Lilly (LLY) sign on corporate building with blue sky in backgroundSource: shutterstock.com/Michael ViEli Lilly and Company (NASDAQ:LLY) is a major pharmaceutical company in Indianapolis. The drugmaker has high hopes for two drugs that could bring windfalls to investors.First, there’s donanemab, a treatment for Alzheimer’s disease that could get approval from the Food and Drug Administration in the next year. Then there’s tirzepatide, sold under the brand name Mounjaro to treat type 2 diabetes. Lilly is asking the FDA to approve the drug as a treatment for obesity. If approved, the change could mean $25 billion in annual revenues.Lilly is also on a growth spurt. It recently announced plans to buy Versanis Bio, which is developing treatments for cardiometabolic diseases, for $1.925 billion. And it just closed its acquisition of Dice Therapeutics, which expands Lilly’s immunology portfolio.LLY stock is up 44% this year and gets an “A” rating in the Portfolio Grader.Novo Nordisk (NVO)Novo Nordisk logo on a corporate buildingSource: joreks / Shutterstock.comNovo Nordisk (NYSE:NVO) is a Danish pharmaceutical company that focuses on developing treatments for diabetes.Diabetes affects an estimated 537 million adults around the world, and that number is expected to rise to 643 million by 2030.But a significant catalyst for Novo Nordisk is interest in its weight loss drug, Wegovy. The drug is so popular that doctors often report shortages and then prescribe another Novo Nordisk drug, Ozempic, as an alternative.Wegovy is already available in the U.S. and Denmark, but Novo Nordisk is now introducing it in Germany, making it the first launch of the drug into a large European market. Investors should be excited about the potential of other European Union countries opening their doors to Wegovy.NVO stock is up 35% this year and has an “A” rating in the Portfolio Grader.On the date of publication, Louis Navellier had long positions in NVO. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today.More From InvestorPlaceMusk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.ChatGPT IPO Could Shock the World, Make This Move Before the AnnouncementIt doesn’t matter if you have $500 or $5 million. Do this now.The post 7 A-Rated Biotech Stocks for Your August Buy List appeared first on InvestorPlace.

InvestorPlace

7 A-Rated Biotech Stocks for Your August Buy List

https://finance.yahoo.com/news/7-rated-biotech-stocks-august-104049290.html

59fae3c6-22fe-3921-a4ef-c0804e1c4e10

ELYM

Eliem Therapeutics, Inc.SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process.As part of this process, Eliem will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. There can be no assurance that its exploration will result in Eliem pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. Eliem has not set a timetable for completion of this evaluation process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary.As of June 30, 2023, the Company had a preliminary unaudited amount of approximately $102.6 million in cash, cash equivalents and investments in marketable securities.About Eliem Therapeutics, Inc. Eliem Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. https://eliemtx.com/Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical and therapeutic potential of Eliem’s product candidates and strategic alternatives. Words such as “excited,” “advance,” “look forward,” “believe,” “potential,” “will,” “on track,” “expects,” “opportunity,” “continues,” “plans,” “runway,” “initiate,” “anticipated,” “support,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Eliem's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: Eliem’s ability to successfully pursue a strategic alternative transaction on attractive terms, or at all ; and other factors discussed under the caption "Risk Factors" in Eliem's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023. This filing is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Eliem expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Eliem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Story continuesInvestorsChris Brinzey ICR [email protected] CoulterVerge [email protected]

GlobeNewswire

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

https://finance.yahoo.com/news/eliem-therapeutics-announces-plans-explore-104500296.html

9a9d936e-1292-3428-a330-d6356cfbd602

ELYM

Eliem Therapeutics ELYM announced that it has completed a review of its business encompassing the status of its programs, resources and capabilities as part of its reorganization efforts. To this extent, the company has decided to halt its Kv7 development program in treating pain, epilepsy and depression.Per Eliem, the potential strategic alternatives may include, but are not limited to, an acquisition, merger, business combination or other transaction under its evaluation process. In the event of Eliem pursuing a transaction, the company refrained from giving its shareholders any assurance that such a transaction will be completed on attractive terms.ELYM has not provided any anticipated date of completion of its evaluation process. Additionally, the company is reluctant to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary.The stock of the company gained about 6% on Thursday, in response to the news. Year to date, shares of Eliem have lost 18.8% compared with the industry’s 1% decline.Zacks Investment ResearchImage Source: Zacks Investment ResearchWe would like to remind the investors that in February 2023, the company announced pausing further development of ETX-155, a novel GABAA receptor, positive allosteric modulator neuroactive steroid. This pausing of the ETX-155 program was intended to re-prioritize Eliem’s pipeline to focus on its high-potential preclinical Kv7 program, which has now been halted as well.Eliem has completed phase I studies on ETX-155 in the treatment of major depressive disorder (MDD), with the potential to also pursue development in epilepsy. ETX-155 is currently phase II ready for MDD. During the early-stage study, it was observed that the 60 mg dose strength of ETX-155 demonstrated an encouraging pharmacokinetic, safety and tolerability profile. However, the board of the company decided to discontinue further investment in the MDD program stating that the current market conditions are not in favor of the company or its stockholders at the time.Story continuesELYM had also announced cutting its workforce by around 55% in the first half of 2023, as part of the reorganization process.Eliem Therapeutics, Inc. Price and ConsensusEliem Therapeutics, Inc. Price and ConsensusEliem Therapeutics, Inc. price-consensus-chart | Eliem Therapeutics, Inc. QuoteZacks Rank and Stocks to ConsiderEliem currently has a Zacks Rank #3 (Hold).Some better-ranked stocks from the same industry are EQRx EQRX, FibroGen FGEN and AlloVir ALVR, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 90 days, the Zacks Consensus Estimate for EQRx’s 2023 loss per share has narrowed from 58 cents to 56 cents. During the same period, the estimate for EQRx’s 2024 loss per share has remained unchanged at 65 cents. Year to date, shares of the company have lost 21.2%.EQRX beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average earnings surprise of 16.58%.In the past 90 days, the Zacks Consensus Estimate for FibroGen’s 2023 loss per share has narrowed from $2.75 to $2.59. During the same period, the estimate for FibroGen’s 2024 loss per share has narrowed from $2.16 to $1.82. Year to date, shares of the company have plunged 86.1%.FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average earnings surprise of 4.67%.In the past 90 days, the Zacks Consensus Estimate for AlloVir’s 2023 loss per share has narrowed from $1.90 to $1.80. During the same period, the estimate for ALVR’s 2024 loss per share has narrowed from $1.98 to $1.89. Year to date, shares of the company have declined 35.5%.ALVR beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.78%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportFibroGen, Inc (FGEN) : Free Stock Analysis ReportAlloVir, Inc. (ALVR) : Free Stock Analysis ReportEliem Therapeutics, Inc. (ELYM) : Free Stock Analysis ReportEQRx, Inc. (EQRX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

https://finance.yahoo.com/news/eliem-elym-explore-strategic-options-111700029.html

3f11aa5c-3896-334b-9d3c-49425e03788c

EMBC

Embecta Corp.'s (NASDAQ:EMBC) investors are due to receive a payment of $0.15 per share on 13th of September. This makes the dividend yield 2.9%, which will augment investor returns quite nicely.While the dividend yield is important for income investors, it is also important to consider any large share price moves, as this will generally outweigh any gains from distributions. Embecta's stock price has reduced by 32% in the last 3 months, which is not ideal for investors and can explain a sharp increase in the dividend yield. Check out our latest analysis for Embecta Embecta's Payment Has Solid Earnings CoverageIf the payments aren't sustainable, a high yield for a few years won't matter that much. The last payment made up 72% of earnings, but cash flows were much higher. In general, cash flows are more important than earnings, so we are comfortable that the dividend will be sustainable going forward, especially with so much cash left over for reinvestment.The next year is set to see EPS grow by 134.6%. If the dividend continues on this path, the payout ratio could be 31% by next year, which we think can be pretty sustainable going forward.historic-dividendEmbecta Is Still Building Its Track RecordIt's not possible for us to make a backward looking judgement just based on a short payment history. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself.Dividend Growth Potential Is ShakyInvestors could be attracted to the stock based on the quality of its payment history. Unfortunately things aren't as good as they seem. Embecta's earnings per share has shrunk at 52% a year over the past three years. Dividend payments are likely to come under some pressure unless EPS can pull out of the nosedive it is in. On the bright side, earnings are predicted to gain some ground over the next year, but until this turns into a pattern we wouldn't be feeling too comfortable.Story continuesIn SummaryOverall, it's nice to see a consistent dividend payment, but we think that longer term, the current level of payment might be unsustainable. In the past, the payments have been unstable, but over the short term the dividend could be reliable, with the company generating enough cash to cover it. Overall, we don't think this company has the makings of a good income stock.Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. Just as an example, we've come across 5 warning signs for Embecta you should be aware of, and 2 of them shouldn't be ignored. Is Embecta not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

https://finance.yahoo.com/news/embectas-nasdaq-embc-dividend-0-100848178.html

325ecac8-b739-35e1-b2e8-0ec53aeea659

EMBC

Embecta Corp.PARSIPPANY, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Healthcare Conference in New York on Tuesday, September 12, 2023 at 2:55 p.m. ET.Audio webcast of the chat event will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.CONTACTSInvestors:Pravesh KhandelwalVP, Head of Investor Relations551-264-6547Contact IRMedia: Christian GlazarSr. Director, Corporate Communications 908-821-6922 Contact Media Relations

GlobeNewswire

embecta to Participate at the Morgan Stanley 21st Annual Healthcare Conference

https://finance.yahoo.com/news/embecta-participate-morgan-stanley-21st-210000437.html

f133b384-0c0b-3f66-80b8-8f363d87e892

EMN

The stock of Eastman Chemical Co (NYSE:EMN) experienced a daily loss of 4.77%, and a 3-month gain of 0.55%. Its Earnings Per Share (EPS) stands at 5.86. With these figures in mind, the question arises: Is the stock modestly undervalued? This article aims to provide a comprehensive analysis of Eastman Chemical Co's valuation. Read on to gain valuable insights into the company's financial health and future prospects.Company IntroductionWarning! GuruFocus has detected 8 Warning Signs with EMN. Click here to check it out. EMN 30-Year Financial DataThe intrinsic value of EMNEstablished in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical Co has evolved into a global specialty chemicals company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. Over the years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings. With a current stock price of $81.86 per share and a GF Value of $110.44, Eastman Chemical Co appears to be modestly undervalued.Eastman Chemical Co (EMN)'s True Worth: A Comprehensive Analysis of Its Market ValueUnderstanding GF ValueThe GF Value is a unique measure that calculates the intrinsic value of a stock based on historical multiples, a GuruFocus adjustment factor, and future business performance estimates. The GF Value Line on our summary page provides an overview of the fair value at which the stock should ideally be traded. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. Conversely, if it is significantly below the GF Value Line, its future return will likely be higher.Eastman Chemical Co's stock shows signs of being modestly undervalued according to the GF Value. The stock's fair value is estimated based on historical multiples, an internal adjustment based on past business growth, and analyst estimates of future business performance. At its current price of $81.86 per share, Eastman Chemical Co has a market cap of $9.70 billion, indicating that the stock is modestly undervalued.Story continuesAs Eastman Chemical Co is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth.Eastman Chemical Co (EMN)'s True Worth: A Comprehensive Analysis of Its Market ValueLink: These companies may deliver higher future returns at reduced risk.Financial StrengthCompanies with poor financial strength pose a high risk of permanent capital loss to investors. To avoid this, it's crucial to review a company's financial strength before deciding to purchase shares. Both the cash-to-debt ratio and interest coverage of a company are excellent indicators of its financial strength. Eastman Chemical Co has a cash-to-debt ratio of 0.08, ranking worse than 90.44% of 1475 companies in the Chemicals industry. The overall financial strength of Eastman Chemical Co is rated 5 out of 10, indicating fair financial health.Eastman Chemical Co (EMN)'s True Worth: A Comprehensive Analysis of Its Market ValueProfitability and GrowthInvesting in profitable companies carries less risk, especially if they have demonstrated consistent profitability over the long term. Companies with high profit margins typically offer better performance potential than those with low profit margins. Eastman Chemical Co has been profitable for 10 years over the past 10 years. During the past 12 months, the company had revenues of $9.80 billion and Earnings Per Share (EPS) of $5.86. Its operating margin of 10.78% is better than 68.45% of 1474 companies in the Chemicals industry. Overall, GuruFocus ranks Eastman Chemical Co's profitability as strong.Growth is a crucial factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long-term stock performance of a company. A faster-growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Eastman Chemical Co is 8.2%, ranking worse than 53.76% of 1421 companies in the Chemicals industry. The 3-year average EBITDA growth rate is 1.6%, ranking worse than 67.15% of 1312 companies in the Chemicals industry.ROIC vs WACCOne can evaluate a company's profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). ROIC measures how well a company generates cash flow relative to the capital it has invested in its business. WACC is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC exceeds the WACC, the company is likely creating value for its shareholders. During the past 12 months, Eastman Chemical Co's ROIC was 7.76 while its WACC came in at 8.73.Eastman Chemical Co (EMN)'s True Worth: A Comprehensive Analysis of Its Market ValueConclusionIn summary, the stock of Eastman Chemical Co (NYSE:EMN) shows every sign of being modestly undervalued. The company's financial condition is fair, and its profitability is strong. However, its growth ranks worse than 67.15% of 1312 companies in the Chemicals industry. To learn more about Eastman Chemical Co stock, you can check out its 30-Year Financials here.To find out the high-quality companies that may deliver above-average returns, please check out GuruFocus High Quality Low Capex Screener.This article first appeared on GuruFocus.

GuruFocus.com

Eastman Chemical Co (EMN)'s True Worth: A Comprehensive Analysis of Its Market Value

https://finance.yahoo.com/news/eastman-chemical-co-emn-true-233251275.html

0a9edf01-72fe-326a-8bd0-c972e6818f63

EMN

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of learning-by-doing, we'll look at ROE to gain a better understanding of Eastman Chemical Company (NYSE:EMN).ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. Check out our latest analysis for Eastman Chemical How To Calculate Return On Equity?The formula for return on equity is:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for Eastman Chemical is:13% = US$709m ÷ US$5.4b (Based on the trailing twelve months to June 2023).The 'return' is the income the business earned over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.13 in profit.Does Eastman Chemical Have A Good ROE?One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. The image below shows that Eastman Chemical has an ROE that is roughly in line with the Chemicals industry average (14%).roeThat isn't amazing, but it is respectable. Although the ROE is similar to the industry, we should still perform further checks to see if the company's ROE is being boosted by high debt levels. If so, this increases its exposure to financial risk. You can see the 3 risks we have identified for Eastman Chemical by visiting our risks dashboard for free on our platform here.The Importance Of Debt To Return On EquityCompanies usually need to invest money to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt required for growth will boost returns, but will not impact the shareholders' equity. That will make the ROE look better than if no debt was used.Story continuesCombining Eastman Chemical's Debt And Its 13% Return On EquityEastman Chemical clearly uses a high amount of debt to boost returns, as it has a debt to equity ratio of 1.03. While its ROE is pretty respectable, the amount of debt the company is carrying currently is not ideal. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it.SummaryReturn on equity is useful for comparing the quality of different businesses. Companies that can achieve high returns on equity without too much debt are generally of good quality. If two companies have the same ROE, then I would generally prefer the one with less debt.Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So you might want to take a peek at this data-rich interactive graph of forecasts for the company.If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

With A Return On Equity Of 13%, Has Eastman Chemical Company's (NYSE:EMN) Management Done Well?

https://finance.yahoo.com/news/return-equity-13-eastman-chemical-143914955.html

df171f84-60de-3b61-ade9-a5b659643b6e

EMR

ST. LOUIS, Sept. 6, 2023 /PRNewswire/ -- Emerson (NYSE: EMR) today announced President and Chief Executive Officer, Lal Karsanbhai, and Chief Financial Officer, Mike Baughman, will present at the Morgan Stanley Laguna Conference on Wednesday, September 13th at 12:20 p.m. Eastern Time, 11:20 a.m. Central Time.Emerson (PRNewsfoto/Emerson)The audio will be webcast and archived on Emerson's website at www.Emerson.com/investors.About Emerson Emerson (NYSE: EMR) is a global technology and software company providing innovative solutions for the world's essential industries. Through its leading automation portfolio, including its majority stake in AspenTech, Emerson helps hybrid, process and discrete manufacturers optimize operations, protect personnel, reduce emissions and achieve their sustainability goals. For more information, visit Emerson.com.Emerson uses our Investor Relations website, www.Emerson.com/investors, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.Contacts InvestorsColleen Mettler (314) 553-2197CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/emerson-to-present-at-the-morgan-stanley-laguna-conference-301919797.htmlSOURCE Emerson

PR Newswire

Emerson to Present at the Morgan Stanley Laguna Conference

https://finance.yahoo.com/news/emerson-present-morgan-stanley-laguna-200500191.html

0cb4ff8d-99ee-3d64-b35e-9d7d6c048e81

EMR

It has been about a month since the last earnings report for EnerSys (ENS). Shares have added about 6.9% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is EnerSys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Enersys Beats on Q1 Earnings, Revenues Miss MarkEnersys reported first-quarter fiscal 2024 (ended Jul 2, 2023) adjusted earnings (excluding 29 cents from non-recurring items) of $1.89 per share, which surpassed the Zacks Consensus Estimate of $1.80. The bottom line surged 64.4% year over year due to lower cost of sales.Enersys’ total revenues of $908.6 million missed the Zacks Consensus Estimate of $953 million. The top line inched up 1.1% year over year due to a 9% increase in price/mix. Organic sales in the quarter decreased 8%.Segmental DiscussionThe Energy Systems segment’s sales (accounting for 46.7% of total sales) were $424.6 million, up 3.9% year over year. This compares with the Zacks Consensus Estimate of $467.50 million. Segmental revenues increased due to higher pricing, partly offset by lower volumes in Europe and Asia. Foreign currency translation had a negative impact of 1%, while organic revenues decreased 7%.The Motive Power segment generated revenues of $350.8 million (accounting for 38.6% of total sales), down 4.6% year over year. The Zacks Consensus Estimate for segmental revenues was $341.31 million. The downside was due to a 14% decrease in organic sales, partly offset by an 8% increase in pricing. Acquisitions contributed 1% to segmental revenues, while foreign currency translation had an adverse impact of 1%.The Specialty segment’s sales were $133.2 million (accounting for 14.7% of total sales), up 8.7% year over year. The Zacks Consensus Estimate for the same was $132.07 million. A 7% increase in pricing/mix and a 1% rise in organic volume contributed to the higher segmental revenues. Foreign currency translation had a favorable impact of 1%.Story continuesMargin ProfileIn the reported quarter, EnerSys' cost of sales decreased 7.6% year over year to $587.20 million. Gross profit in the quarter increased 29.5% year over year to $240.3 million, while the gross margin increased 580 basis points (bps) year over year to 26.4%.Operating expenses increased 13.8% year over year to $144.6 million. Adjusted operating earnings surged 65.4% year over year to $107.2 million. The margin increased 460 bps year over year to 11.8%.Balance Sheet and Cash FlowAt the end of the first quarter of fiscal 2024, EnerSys had cash and cash equivalents of $258.34 million compared with $346.67 million at the end of fiscal 2023. Long-term debt (net of unamortized debt issuance costs) was $907.77 million compared with $1,042 million at the fiscal 2023-end.EnerSys generated net cash of $74.95 million from operating activities in the fiscal first quarter against $71.89 million used in the year-ago period. Capital expenditure totaled $16.09 million compared with $23.01 million in the previous year’s period.In first-quarter fiscal 2024, ENS rewarded its shareholders with a dividend payout of $7.17 million, up nearly 1% year over year.Fiscal Q2 GuidanceFor the second quarter of fiscal 2024, EnerSys expects adjusted earnings of $1.77-$1.87 per share. The Zacks Consensus Estimate for the same stands at $7.67. Gross margin is expected to be 25-27%. The company expects capital expenditures of approximately $120 million.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed an upward trend in estimates review.VGM ScoresCurrently, EnerSys has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise EnerSys has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.Performance of an Industry PlayerEnerSys belongs to the Zacks Manufacturing - Electronics industry. Another stock from the same industry, Emerson Electric (EMR), has gained 4.1% over the past month. More than a month has passed since the company reported results for the quarter ended June 2023.Emerson Electric reported revenues of $3.95 billion in the last reported quarter, representing a year-over-year change of -21.2%. EPS of $1.29 for the same period compares with $1.38 a year ago.For the current quarter, Emerson Electric is expected to post earnings of $1.29 per share, indicating a change of -15.7% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the last 30 days.Emerson Electric has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEnersys (ENS) : Free Stock Analysis ReportEmerson Electric Co. (EMR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why Is EnerSys (ENS) Up 6.9% Since Last Earnings Report?

https://finance.yahoo.com/news/why-enersys-ens-6-9-153028964.html

7dace326-ab04-35f7-b158-644fef3df449

ENB

Enbridge just inked a deal to expand its exposure to natural gas. Investors sold the shares, but should you step in to buy?Continue reading

Motley Fool

Is Enbridge Stock a Buy?

https://finance.yahoo.com/m/d17537cc-b879-3b2a-a394-28c31469f688/is-enbridge-stock-a-buy-.html

d17537cc-b879-3b2a-a394-28c31469f688

ENB

CALGARY, AB, Sept. 8, 2023 /CNW/ - Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge or the Company) today announced it has closed its previously announced public offering (the Offering) of common shares by a syndicate of underwriters led by RBC Capital Markets and Morgan Stanley, together with BMO Capital Markets, CIBC Capital Markets, National Bank Financial Markets, Scotiabank, TD Securities as joint bookrunners. Enbridge issued 102,913,500 common shares inclusive of 13,423,500 common shares issued pursuant to the full exercise of the underwriters' over-allotment option. Gross proceeds from the Offering are approximately CDN$4.6 billion.Enbridge intends to use the net proceeds from the Offering to finance a portion of the aggregate cash consideration payable for the purchase of local distribution company gas utilities in the United States from Dominion Energy, Inc. (the Acquisitions), the details of which were announced in a news release issued by Enbridge on September 5, 2023.The exercise of the over-allotment option by the underwriters reduces, and further de-risks, Enbridge's future financing requirements to fund the Acquisitions.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.A copy of the Canadian Prospectus and the Canadian Prospectus Supplement is available on SEDAR+ (http://www.sedarplus.ca) and a copy of the U.S. Prospectus and U.S. Prospectus Supplement is available on the SEC website (http://www.sec.gov). You can request copies of the Canadian Prospectus and Canadian Prospectus Supplement from RBC Dominion Securities Inc., 180 Wellington Street West, 8th Floor, Toronto, ON M5J 0C2, Attention: Distribution Centre, or via telephone: 1-416-842-5349, or via e- mail at [email protected] and the U.S. Prospectus and U.S. Prospectus Supplement from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, Attention: Equity Syndicate, phone: 877-822-4089, Email: [email protected] or Morgan Stanley & Co. LLC - Attn: Prospectus Department - 180 Varick Street, 2nd Floor - New York, NY 10014.Story continuesAbout Enbridge Inc. At Enbridge, we safely connect millions of people to the energy they rely on every day, fueling quality of life through our North American natural gas, oil or renewable power networks and our growing European offshore wind portfolio. We're investing in modern energy delivery infrastructure to sustain access to secure, affordable energy and building on two decades of experience in renewable energy to advance new technologies including wind and solar power, hydrogen, renewable natural gas and carbon capture and storage. We're committed to reducing the carbon footprint of the energy we deliver, and to achieving net zero greenhouse gas emissions by 2050. Headquartered in Calgary, Alberta, Enbridge's common shares trade under the symbol ENB on the Toronto (TSX) and New York (NYSE) stock exchanges.Forward Looking StatementsThis news release contains both historical and forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements have been included to provide potential investors with information about Enbridge. This information may not be appropriate for other purposes. Forward-looking statements are typically identified by words such as "anticipate", "believe", "estimate", "expect", "forecast", "intend", "likely", "plan", "project", "target" and similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements included in this news release include, but are not limited to, statements with respect to the following: the use of proceeds of the Offering and the purchase of local distribution company gas utilities in the United States from Dominion Energy, Inc. Although Enbridge believes these forward-looking statements are reasonable based on the information available on the date such statements are made and processes used to prepare the information, such statements are not guarantees of future events and readers are cautioned against placing undue reliance on forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual events to differ materially from those expressed or implied by such statements.Enbridge's forward-looking statements are subject to risks and uncertainties, including, but not limited to the possibility that the Acquisitions do not close when expected, or at all, because required regulatory approvals and other conditions to closing are not received or satisfied on a timely basis, and those other risks and uncertainties disclosed in Enbridge's other filings with Canadian and United States securities regulators. The impact of any one risk, uncertainty or factor on a particular forward-looking statement is not determinable with certainty as these are interdependent and Enbridge's future course of action depends on management's assessment of all information available at the relevant time. Except to the extent required by applicable law, Enbridge assumes no obligation to publicly update or revise any forward-looking statements made in this news release or otherwise, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements, whether written or oral, attributable to Enbridge or persons acting on its behalf, are expressly qualified in their entirety by these cautionary statements.FOR FURTHER INFORMATION PLEASE CONTACT:Enbridge Inc. - MediaEnbridge Inc. - Investment CommunityJesse SemkoRebecca MorleyToll Free: (888) 992-0997Toll Free: (800) 481-2804Email: [email protected]: [email protected] original content:https://www.prnewswire.com/news-releases/enbridge-announces-the-closing-of-cdn4-6-billion-common-equity-offering-inclusive-of-underwriters-over-allotment-301921952.htmlSOURCE Enbridge Inc.CisionView original content: http://www.newswire.ca/en/releases/archive/September2023/08/c9927.html

CNW Group

Enbridge Announces the Closing of CDN$4.6 Billion Common Equity Offering Inclusive of Underwriters' Over-Allotment

https://finance.yahoo.com/news/enbridge-announces-closing-cdn-4-123800373.html

72019365-a8f7-3f9a-a5bb-57cc75d109f4

ENPH

Enphase Energy (ENPH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this solar technology company have returned -10.4%, compared to the Zacks S&P 500 composite's -1.3% change. During this period, the Zacks Solar industry, which Enphase Energy falls in, has lost 9.7%. The key question now is: What could be the stock's future direction?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.For the current quarter, Enphase Energy is expected to post earnings of $1.10 per share, indicating a change of -12% from the year-ago quarter. The Zacks Consensus Estimate has changed -6% over the last 30 days.The consensus earnings estimate of $5.05 for the current fiscal year indicates a year-over-year change of +9.3%. This estimate has changed -1% over the last 30 days.Story continuesFor the next fiscal year, the consensus earnings estimate of $6.73 indicates a change of +33.3% from what Enphase Energy is expected to report a year ago. Over the past month, the estimate has changed -1.7%.With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Enphase Energy.The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSRevenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.For Enphase Energy, the consensus sales estimate for the current quarter of $574.46 million indicates a year-over-year change of -9.5%. For the current and next fiscal years, $2.73 billion and $3.2 billion estimates indicate +17% and +17.2% changes, respectively.Last Reported Results and Surprise HistoryEnphase Energy reported revenues of $711.12 million in the last reported quarter, representing a year-over-year change of +34.1%. EPS of $1.47 for the same period compares with $1.07 a year ago.Compared to the Zacks Consensus Estimate of $726.94 million, the reported revenues represent a surprise of -2.18%. The EPS surprise was +15.75%.The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.Enphase Energy is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Enphase Energy. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportEnphase Energy, Inc. (ENPH) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Enphase Energy, Inc. (ENPH) is Attracting Investor Attention: Here is What You Should Know

https://finance.yahoo.com/news/enphase-energy-inc-enph-attracting-130009632.html

e85a778c-6640-34ce-9d95-71c1985908b7

ENPH

The U.S. is installing panels fast, too—so many that solar power is expected this year to account for more than half of new electricity capacity for the first time ever. None has fallen from grace quite as hard as Enphase Energy (ticker ENPH), which entered the year on a six-year winning streak that included two years when the stock more than quintupled. High interest rates and more-stringent rules for solar panels in California have scared off potential customers and led to uncertainty in the industry.Continue reading

Barrons.com

Buy This Beaten-Down Solar Stock. Shares Could Jump 80%.

https://finance.yahoo.com/m/f7169d9a-bc9b-3f71-9bcb-c7621062a0c2/buy-this-beaten-down-solar.html

f7169d9a-bc9b-3f71-9bcb-c7621062a0c2

ENSG

The Ensign Group, Inc.SAN JUAN CAPISTRANO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of Ashley River Healthcare, a 125-bed skilled nursing facility located in Charleston, South Carolina, and The Reserve Healthcare and Rehabilitation, a 135-bed skilled nursing facility located in Hanahan, South Carolina. These acquisitions were effective September 1, 2023 and will be subject to a long-term, triple net lease.“We are very excited for our continued growth in South Carolina,” said Barry Port, Ensign's Chief Executive Officer. “These buildings present a great geographical and strategic fit within this particular market,” he added.Adam Willits, President of Hopewell Healthcare LLC, Ensign’s South Carolina-based subsidiary, added “We can’t wait to work with the wonderful caregivers at each of these facilities as we seek to meet and exceed the clinical, emotional and social needs of the residents and families we are honored to serve.”These acquisitions bring Ensign's growing portfolio to 295 healthcare operations, 26 of which also include senior living operations, across thirteen states.  Ensign subsidiaries, including Standard Bearer, now own 112 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.About Ensign™The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 295 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.Story continuesContact InformationThe Ensign Group, Inc., (949) 487-9500, [email protected]: The Ensign Group, Inc.

GlobeNewswire

The Ensign Group Acquires Two Skilled Nursing Facilities in South Carolina

https://finance.yahoo.com/news/ensign-group-acquires-two-skilled-100000446.html

9e218096-0fa7-3993-9264-3ff6e4cfec77

ENSG

The Ensign Group, Inc. ENSG recently purchased the operations of two skilled nursing facilities in South Carolina. The transactions, which are subject to a long-term, triple net lease, were effective since September 1 of this year.The first facility named Ashley River Healthcare is equipped with 125 beds and is situated in the Charleston city of South Carolina. Meanwhile, the second one, which is located in Hanahan city of the state, comprises 135 beds and is named The Reserve Healthcare and Rehabilitation.The recent move enables Ensign Group to work closely with the team of caregivers at each of the acquired facilities. This, in turn, equips the clinical and operational squad of ENSG to gain in-depth knowledge about the local communities, which prove to be of great use in bringing about better health outcomes.Such acquisitions are also a means to solidify the healthcare portfolio of Ensign Group, upgrade capabilities as well as strengthen its U.S. foothold. The latest acquisition takes its portfolio’s healthcare operations count to 295 spanning across 13 U.S. states, out of which 26 can also be listed as senior living operations. Subsidiaries of ENSG (which also involve Standard Bearer) presently own 112 real-estate assets.Increasing the count of skilled nursing facilities within its portfolio may boost the revenues of the Skilled Services segment, which is the most significant contributor to its overall revenues. The unit provides skilled nursing and senior living services, physical, occupational and speech therapies as well as other rehabilitative and healthcare services.Ensign Group follows an aggressive inorganic growth strategy and multiple buyouts pursued throughout the year bear testament to this fact. Management keeps an eye on detecting opportunistic real-estate buyouts. It also aims to lease solid and struggling skilled nursing, assisted living and other healthcare-linked businesses across the United States.Story continuesThis August, Ensign Group purchased the real estate and operations of two skilled nursing facilities, Belmont Terrace and Puget Sound Transitional Care, in Washington. Simultaneously, it also acquired the real estate of a post-acute care retirement campus situated in the state, which is equipped with licensed skilled nursing beds and independent living units. On the very same day, ENSG also purchased the real estate and operations of a skilled nursing facility named Rehabilitation and Nursing Center of the Rockies in Colorado.Shares of Ensign Group have gained 1.5% in the past three months against the industry’s 9.3% decline. ENSG currently carries a Zacks Rank #3 (Hold).Zacks Investment ResearchImage Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks in the Medical space are Surgery Partners, Inc. SGRY, ANI Pharmaceuticals, Inc. ANIP and Medpace Holdings, Inc. MEDP. While Surgery Partners sports a Zacks Rank #1 (Strong Buy), ANI Pharmaceuticals and Medpace carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.Surgery Partners’ earnings surpassed estimates in three of the last four quarters and missed the mark once, the average beat being 269.64%. The Zacks Consensus Estimate for SGRY’s 2023 earnings is pegged at 73 cents per share, which indicates an increase of nearly five-fold from the year-ago reported figure. The consensus mark for revenues indicates growth of 8.7% from the year-ago reported figure. The consensus mark for SGRY’s 2023 earnings has moved 2.8% north in the past seven days.The bottom line of ANI Pharmaceuticals outpaced estimates in each of the trailing four quarters, the average surprise being 91.56%. The Zacks Consensus Estimate for ANIP’s 2023 earnings is pegged at $3.73 per share, which indicates an increase of nearly three-fold from the year-ago reported figure. The consensus mark for ANIP’s 2023 earnings has moved 10% north in the past 30 days.Medpace’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.28%. The Zacks Consensus Estimate for MEDP’s 2023 earnings indicates a rise of 15.3% from the year-ago reported figure. The consensus mark for revenues suggests an improvement of 27.8% from the year-ago reported figure. The consensus mark for MEDP’s 2023 earnings has moved 2.1% north in the past 30 days.Shares of ANI Pharmaceuticals and Medpace have gained 25.6% and 19.2%, respectively, in the past three months. However, the Surgery Partners stock has declined 10.7% in the same time frame.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis ReportThe Ensign Group, Inc. (ENSG) : Free Stock Analysis ReportSurgery Partners, Inc. (SGRY) : Free Stock Analysis ReportMedpace Holdings, Inc. (MEDP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina

https://finance.yahoo.com/news/ensign-group-ensg-pursues-facility-180800688.html

49b4b569-c2b6-3d6f-8765-ec8064842e17

ENSV

Enservco9th consecutive quarter of YOY revenue growth, continued improvement in profit metricsQ2 revenue up 8% year over year to $3.7 million from $3.5 millionQ2 adjusted EBITDA improves to $1.0 million loss from $1.6 million lossSix-month revenue up 5% year over year to $12.6 million from $12.0 millionSix-month adjusted EBITDA loss of $14,000 vs. loss of $1.4 millionCompany continues to de-lever balance sheet, reducing long-term debt to $4.6 million from $7.6 million since 2022 year-end and from $36 million at peak debt in 2019Cross River Partners converts more than $1.3 million in convertible debt to equity in second quarterLONGMONT, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Enservco Corporation (NYSE American: ENSV), a diversified national provider of specialized well-site services to the domestic onshore conventional and unconventional oil and gas industries, today reported financial results for its second quarter and six-month period ended June 30, 2023.“We are pleased to report continued growth momentum, highlighted by our ninth consecutive quarter of year-over-year revenue growth,” said Rich Murphy, Executive Chairman. “In what is traditionally one of our two slower, off-season quarters, we grew revenue by 8% year over year on the strength of a 147% increase in completion services, which more than offset a 7% decline in production services. Similarly, our six-month revenue increased by 5% year over year as completion services grew 12% and offset a 2% decline in production services. It is worth noting that the decline in revenues within production services for both the second quarter and six months was primarily related to our decision to exit our North Dakota operations, but that decline was substantially offset by significant gains within the more profitable Texas operations.“We also continued to drive improvements in profit metrics,” Murphy added. “Adjusted EBITDA improved by $0.5 million and $1.3 million for the three and six-month periods, respectively, reflecting enhanced segment profitability and substantial cost reductions at the SG&A level. Net loss in the second quarter improved by $1.4 million, reflecting higher revenue and the positive impact of cost reductions. The six-month net loss was higher year over year due to the Company recognizing a $4.3 million gain on debt extinguishment in the same period last year. Absent that one-time gain, this year’s six-month net loss would have shown solid improvement year over year.Story continuesMurphy added, “We continued to focus on debt reduction in the second quarter and are pleased to report that Cross River Partners converted approximately $1.3 million in convertible debt to equity in the period. That transaction, combined with the sale of non-revenue-generating surplus equipment, contributed to a further decline in total long-term debt to $4.6 million from $7.6 million at 2022 year-end and from a high of $36 million in 2019 when the Company began its debt reduction program. We expect to further de-lever our business over time while focusing on growing our core business and adding new revenue streams.”Second Quarter ResultsRevenue in the second quarter increased 8% year over year to $3.7 million from $3.5 million due to a 147% increase in completion services, which offset a 7% decline in production services revenue.Adjusted EBITDA in the second quarter improved by approximately $0.5 million to a loss of $1.0 million compared to a loss of $1.6 million in the same quarter last year.Net loss in the second quarter improved by $1.3 million to ($2.6 million), or ($0.14) per basic and diluted share, versus ($3.9 million), or ($0.34) per basic and diluted share, in the same quarter last year. The reduced net loss was attributable to a combination of higher revenue and cost reductions across the business, including a 43% decrease in sales, general and administrative expense in the quarter.Six Month ResultsRevenue through six months increased 5% year over year to $12.6 million from $12.0 million. The increase was attributable to 12% growth in completion services, partially offset by a 2% decline in production services.Adjusted EBITDA through six months improved by $1.3 million to ($14,000) from ($1.4 million) over the same period last year.Net loss through six months was ($3.6 million), or ($0.22) per basic and diluted share, compared to ($0.8 million), or ($0.07) per basic and diluted share, in the same period last year when the Company booked a non-recurring $4.3 million gain on debt extinguishment. As in the second quarter, the Company achieved meaningful cost reductions at both the operating and corporate levels through six months.Conference Call InformationManagement will hold a conference call to discuss these results on Tuesday, August 15 at 9:00 a.m. ET. The call will be accessible by dialing 877-545-0523 (973-528-0016 for international callers). Access code 173030. A telephonic replay will be available through August 29, 2023, by calling 877-481-4010 (919-882-2331 for international callers) and entering the Replay ID # 48952. To listen to the webcast, participants should go to the Enservco website at www.enservco.com and link to the “Investors” page at least 10 minutes early to register and download any necessary audio software. A replay of the webcast will be available until September 15, 2023. The webcast also is available here: https://www.webcaster4.com/Webcast/Page/2228/48952About EnservcoThrough its various operating subsidiaries, Enservco provides a range of oilfield services, including hot oiling, acidizing, frac water heating, and related services. The Company has a broad geographic footprint covering seven major domestic oil and gas basins and serves customers in Colorado, Montana, New Mexico, North Dakota, Oklahoma, Pennsylvania, Ohio, Texas, Wyoming, West Virginia, Utah, Michigan, Illinois, Florida, and Louisiana. Additional information is available at www.enservco.com.*Note on non-GAAP Financial Measures This press release and the accompanying tables include a discussion of EBITDA and Adjusted EBITDA, which are non-GAAP financial measures provided as a complement to the results provided in accordance with generally accepted accounting principles ("GAAP"). The term "EBITDA" refers to a financial measure that we define as earnings (net income or loss) plus or minus net interest taxes, depreciation and amortization. Adjusted EBITDA excludes from EBITDA stock-based compensation and, when appropriate, other items that management does not utilize in assessing Enservco’s operating performance (as further described in the attached financial schedules). None of these non-GAAP financial measures are recognized terms under GAAP and do not purport to be an alternative to net income as an indicator of operating performance or any other GAAP measure. We have reconciled Adjusted EBITDA to GAAP net loss in the Consolidated Statements of Operations table at the end of this release. We intend to continue to provide these non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of these non-GAAP financial measures will provide consistency in our financial reporting.Cautionary Note Regarding Forward-Looking StatementsThis news release contains information that is "forward-looking" in that it describes events and conditions Enservco reasonably expects to occur in the future. Expectations for the future performance of Enservco are dependent upon a number of factors, and there can be no assurance that Enservco will achieve the results as contemplated herein. Certain statements contained in this release using the terms "may," "expects to," “should,” and other terms denoting future possibilities, are forward-looking statements. The accuracy of these statements cannot be guaranteed as they are subject to a variety of risks, which are beyond Enservco's ability to predict, or control and which may cause actual results to differ materially from the projections or estimates contained herein. Among these risks are those set forth in Enservco’s annual report on Form 10-K for the year ended December 31, 2022, and subsequently filed documents with the SEC. Forward looking statements in this news release that are subject to risk include the ability to further de-lever the business. It is important that each person reviewing this release understand the significant risks attendant to the operations of Enservco. The Company disclaims any obligation to update any forward-looking statement made herein.Contact:Mark PattersonChief Financial OfficerEnservco [email protected]

GlobeNewswire

Enservco Corporation Reports 2023 Second Quarter Financial Results

https://finance.yahoo.com/news/enservco-corporation-reports-2023-second-200100808.html

bc9c8b29-2629-39cd-b12d-b451a23e2384